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Abstract 
Malaria kills almost half a million people every year and is a huge public health burden 
particularly in Sub-Saharan Africa. The current first line treatment is very effective but is 
threatened by the drug resistance that has been seen in the many effective compounds that 
have come before it. Consequently, there is a real need to develop new and novel compounds 
that target multiple stages of the parasite life cycle, as failure of our first line treatment could 
be devastating. Cell signalling pathways regulate essential events in the parasite lifecycle and as 
such, components of these pathways are potential targets for parasite disruption. The cyclic 
nucleotide and Ca2+ signalling cascades have essential functions at multiple stages in the parasite 
life cycle and often show overlap in their roles. This means that inhibition of one such pathway 
may disrupt the other. The relationship between 3’-5’-cyclic guanosine monophosphate and Ca2+ 
signalling is investigated here using Ca2+ assays on both schizont and gametocyte stages using a 
combination of genetic and pharmacological approaches. Results indicate that zaprinast-
induced Ca2+ release through PDE inhibition is dependent upon PKG and in schizonts occurs via 
inositol triphosphate. Gametogenesis is an essential lifecycle event leading to transmission. The 
PDE PfPDE has been implicated in this event, however little is known about this enzyme. Using 
a PfPDE-ko line and the generation of a HA-tagged PfPDE line using the CRISPRCas9 gene 
editing system, this project seeks to confirm whether PfPDE is essential for gametogenesis and 
to understand more about the role that this protein plays in this event. This includes its cellular 
localisation, cyclic nucleotide specificity and its role in Ca2+ mobilisation, an event essential to 
the later stages of gametogenesis. The role of PfPDE in erythrocyte-infected gametocyte 
deformability is also investigated and the phenotype of a PfPDE-ko line is dissected. This 
information will eventually aim to determine whether PfPDE would be a good transmission-
blocking target. Of particular interest to this thesis are compounds that would prevent 
transmission because currently the only licenced antimalarial to target transmission stages is 
Primaquine. A combination of a transmission-blocking agent with one that will inhibit asexual 
replicating stages would both alleviate clinical symptoms while preventing transmission.  PDEs 
have already been identified and used as effective drug targets in humans. A small panel of Pfizer 
PDE inhibiters that have shown good activity in asexual blood stages has been tested against the 
gametocyte stages and this has led to the identification of a human PDE inhibitor that not only 
kills asexual blood stages in the low nM range, but also one that can kill gametocyte stages at 
similar concentrations. In addition to this, the mode of action of this compound has been 
determined.  
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Chapter 1 
Introduction 
 
1.1  Malaria 
 
Malaria is a blood borne febrile illness resulting from a bite by a female Anopheles mosquito 
carrying apicomplexan parasites of the genus Plasmodium. The genus Plasmodium includes five 
different species of parasite that are known to infect humans. The most clinically relevant of 
these is P. falciparum. In 2015, 99 % of all estimated deaths from malaria were a result of P. 
falciparum infection[2]. 5 % of P. falciparum cases result in a severe form of the disease. 
Asymptomatic cases of P. falciparum do occur, but this is not as common an occurrence as with 
P. vivax[3]. P. vivax is the most widespread of the five species and although it is rarely fatal, 
malaria caused by infection of this species is still a major public health problem due to the 
morbidity it causes particularly in endemic areas and relapse of disease can occur with vivax 
infection due to dormant forms in the liver.  
P. ovale and P. malariae malaria infections are less common and the disease they cause is of less 
clinical importance. P. knowlesi however, has the potential to cause severe disease in part due 
to its short 24-hour life cycle, which can quickly result in high parasitemias. This species is often 
mis-diagnosed as the benign P. malaria[4], and in certain parts of South east Asia, P. knowlesi is 
the dominant cause of malaria particularly in areas where other malaria species are diagnosed 
and treated effectively[5]. Due to the clinical importance of P. knowlesi, this can result in poor 
case management and improper treatment[6].  
 
The clinical symptoms of malaria are caused by the asexual erythrocytic stage parasites that 
replicate in the bloodstream of the vertebrate host. This results in lysis and subsequent loss of 
host erythrocytes and a build-up of parasite derived waste products inside host erythrocytes, 
which are released into the blood stream. The host’s immune system responds to this by 
activating immune cells such as macrophages, which release cytokines, and other soluble factors 
thus contributing to clinical symptoms of the disease, notably fever [7],[8]. As observed by Golgi 
between 1886 and 1892, the characteristic symptom of periodic fever in malaria infection 
correlates with the lysis of erythrocytes and subsequent release of merozoites into the blood 
stream which induces an immune response leading to fever and other clinical symptoms [7].  
The symptoms of malaria are many and varied depending on the severity and stage of disease, 
the patient profile and the species of Plasmodium causing the infection. Symptoms of 
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uncomplicated malaria include; fever, chills, nausea, sweats, vomiting, cough, abdominal pain, 
diarrhoea, headache and muscle aches, all common symptoms of a wide range of infectious 
diseases including the early symptoms of Ebola, influenza and other viral infections. As such, 
Malaria can often be diagnosed too late only when symptoms of severe disease manifest. Severe 
infection can lead to acute respiratory distress syndrome, which is an inflammatory reaction in 
the lungs, acute kidney failure and cerebral malaria, which can result in seizures, coma or other 
neurological abnormalities. If not treated soon enough (before 24 hours after onset of clinical 
symptoms) severe P. falciparum malaria may and does in many cases lead to death[8]. 
The incubation period of Plasmodium species ranges from 7 days to 30 days. P. falciparum 
generally establishes a clinical infection quicker that the other species, with P .malariae often 
presenting with a longer incubation period[8]. P. malariae can also cause latent infections, which 
have been known to last for many years in some people. However, this species rarely causes 
serious disease[9]. P. vivax and P. ovale differ from the other species in that they have the ability 
to remain dormant in the liver [10],[11]. This stage of the lifecycle known as the hypnozoite stage 
derived from the Greek words hypnos for sleep and zoon for animal is a challenge to target with 
drugs and as yet primaquine is the only licenced antimalarial that kills these stages[12].  
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1.1.1. A brief history of malaria 
 
Malaria has plagued the world for centuries. Records of this disease can be found in ancient 
Chinese text and symptoms of malaria had been described by Hippocrates[13]. The term Malaria 
is derived from the Italian for ‘bad air’ as disease had long been associated with swampy areas. 
Malaria was first identified as a parasitic blood disease in 1880 when a French army surgeon, 
Charles Louis Alphonse Laveran observed what we now know as asexual blood stage forms in 
the blood of one of his patients. He named this parasite Oscillaria malariae. Laveran was not 
only successful in identifying that malaria is caused by a parasite found in the bloodstream, but 
he also observed that these parasites destroyed the blood cells of the host and produced 
particles of black pigment, known today as haemozoin, the product of haemoglobin digestion 
by the parasite, but identified by Laveran as ‘melanins’; particles associated with the disease 
which were only observed in patients suffering from malaria. Studies by Laveran on these 
‘melanins’ led to his discovery of the parasite[14]. Following Laveran’s discovery, observations 
by the Italian neurosurgeon Camillo Golgi on periodicity of fevers identified that not only was 
there more than one form of this disease (one with a tertian pattern (2-day intervals between 
fevers) and the other with a quartan pattern (3-day intervals between fevers) of fever), but that 
these fever patterns corresponded with schizont rupture and release of merozoites into the 
blood stream. Golgi also observed that different forms of the disease resulted in different 
numbers of merozoites being released[15].  
It was not until 1897, nearly 20 years after Laveran first discovered the malaria parasite, that it 
was demonstrated that this disease could be transmitted by mosquitoes. This was discovered 
by a British Army officer Ronald Ross who achieved transmission between birds[16]. However a 
connection of the disease to stagnant water had been known for some time, with the Romans 
using drainage programmes to control the disease, and scientists, including Laveran and Patrick 
Manson[17], hypothesising a role for the mosquito in facilitating this disease. Ross not only 
identified that this parasite could also infect birds and that the disease could be transmitted 
between birds via a mosquito vector, but he was the first to identify the oocyst stage in the 
mosquito mid gut[16]. A couple of years later, the role of the mosquito vector was confirmed 
further by the successful infection of two volunteers in London who were infected by 
mosquitoes fed previously on a malaria patient in Rome and sent over to the UK for the 
study[18].  
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1.1.2 The life cycle of Plasmodium falciparum 
 
                       The liver and asexual blood stages 
 
The life cycle of P. falciparum in the human host begins with the bite of an infected mosquito. 
While taking a blood meal, infectious sporozoites residing in the salivary glands can be 
introduced into the skin. These motile forms make their way to the bloodstream via the 
sinusoidal barrier of liver cells[19] to finally invade hepatocytes. Parasites then undergo 
schizogony, finally rupturing to release merozoites into the blood stream. Merozoites quickly 
invade host erythrocytes marking the start of asexual blood stage infection, the part of the life 
cycle responsible for the clinical symptom of malaria. Successful invasion leads to the 
development of ring stage forms. These early trophozoite stages mature into the ‘feeding’ 
trophozoite stages and the presence of parasite derived proteins such as P. falciparum epithelial 
membrane protein I (PfEMP1) on the host erythrocyte surface marks the switch from circulation 
in the blood stream to sequestration in the microvasculature of internal organs[20]. Trophozoite 
stages consume a large amount of haemoglobin with the formation of the waste product 
haemozoin, appearing as a large golden brown pigment in the food vacuole[21]. Haemozoin can 
be easily observed in Giemsa-stained blood films and the presence of this pigment can be used 
to separate early ring stages from mature asexual forms (section 2.2.B of methods). As 
trophozoite stages mature, they transport more parasite derived proteins to the erythrocyte 
surface and host erythrocyte membrane modifications by the parasite become more apparent, 
one such example is the increased permeability of host erythrocytes which allows parasites to 
obtain more nutrients from outside of the infected cell[21]. The start of nuclear division in the 
parasites marks the maturation of trophozoite stages into schizonts. Malaria parasites replicate 
their DNA by a process known as schizogony. This consists of a series of nuclear divisions to 
produce up to 32 daughter merozoites (this number varies depending upon the strain and 
species of parasite). Once nuclear division has occurred, individual merozoites are formed and 
retained within individual membranes. Schizonts then undergo the tightly regulated process of 
egress. Both the parasitophorous vacuolar membrane and the erythrocyte membranes rupture 
releasing fully mature (and competently invasive) merozoites into the blood stream. At this 
point, no longer hidden from the immune system, these invasive blood stages are now briefly 
open to attack by the host immune system. Merozoites rapidly invade new erythrocytes and the 
asexual cycle begins again (see Figure 1.1). This cycle varies between species and between 
strains of the different species, but for P. falciparum this cycle takes ~48 hours and corresponds 
to the characteristic fever peaks observed every 48 hours in malaria infected individuals. 
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Figure 1.1. The full life cycle of Plasmodium falciparum  
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                       Sexual commitment and insect stage development 
 
In order for the parasite to be transmitted to a mosquito, a small proportion of asexual stage 
parasites must commit to develop into the male and female sexual precursor cells known as 
gametocytes (see Figure 1.1). The process of this ‘switch’ from the asexual blood cycle to the 
sexual cycle and the subsequent development and maturation of these sexual stages to mature 
transmissible forms is known as gametocytogenesis. These mature forms are obligatory for 
transmission to the mosquito vector and thus essential for the survival and propagation of the 
malaria parasite and for disease. In P. falciparum infections, gametocytes are detectable after 
the asexual stages have established an infection in the blood stream of the human host. This is 
in part due to the long maturation period of P. falciparum gametocytes, which take 9-10 days to 
develop. There are many possible factors contributing to the ‘decision’ to switch to a 
transmission stage and cell signalling pathways may be involved in this process of 
gametocytogenesis. This will be discussed further in the cell signalling section of the 
introduction.  
 
There are five morphologically distinct gametocyte stages (I-V) the last of which are mature male 
and female gametocytes primed for transmission to the mosquito vector [22],[23]. The non-
mature forms (stages I to IV) sequester in the bone marrow and are able to develop to maturity 
while avoiding splenic clearance [24]. Evidence suggests that these early stages exhibit a ‘stiff’ 
phenotype which is maintained by regulation of cAMP signalling[25] (this will be discussed 
further in the cell signalling section). The mature stages (Stage V) on the other hand, are distinct, 
crescent-shaped cells which circulate in the blood stream and can be taken up in the blood meal 
of a feeding mosquito. Once gametocytes reach full maturity (stage V) they become deformable. 
This change in phenotype coincides with their release from the bone marrow. This allows these 
transmission stages to transverse through the splenic slits while circulating in the host 
bloodstream, therefore avoiding spleen retention and thus clearance from the host circulation. 
On entering the mosquito mid gut, the dramatic change in environment and the reduction in 
temperature combined with the presence of a mosquito factor, xanthurenic acid (XA), (or a rise 
in pH in in vitro studies) triggers the cells to respond by ‘rounding up’ and emerging from the 
host erythrocyte. The mosquito factor inducing gametogenesis was identified as XA in 1998 by 
two separate groups. Billker et al[26] who carried out high-performance liquid chromatography 
(HPLC), high-voltage paper electrophoreses (HVPE), mass spectrometry (MS) and chemical 
derivatization assays on Anopheles stephensi pupae and activity assays using a read out of 
exflagellation events on P. berghei gametocyte stages, and Garcia et al[27], who used high 
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resolution electrospray MS from Anopheles stephensi mosquito tissue extracts, complemented 
by in vitro activity assays on P. gallinaceum and P. falciparum. On entering the mosquito midgut, 
emerged female macrogametes remain morphologically relatively unchanged. Males on the 
other hand exhibit a spectacular display known as exflagellation whereby the gametocyte 
undergoes 3 rounds of DNA replication and mitotic division producing 8 flagellated motile 
microgametes within 15 minutes which detach from the residual body and seek out the female 
macrogamete allowing fertilization to take place. This process of gametocyte ‘activation’, is 
known as gametogenesis and is by definition the ‘formation of gametes’. Several studies have 
highlighted an important role for cell signalling, in the process of gametogenesis and this will be 
discussed later on in this report. Fertilization results in the formation of a zygote, which then 
develops into a motile ookinete, which transcends the mosquito gut wall followed by 
development into an oocyst. Once mature, oocysts rupture releasing many thousands of 
sporozoites into the salivary glands; these are transmitted to a human host when the mosquito 
takes a blood meal. Sporozoites establish an infection in the hepatocytes of the human host. 
This marks the first phase of human infection. However, there is some debate as to whether 
sporozoite infection of the skin is in fact the first phase of human infection rather than invasion 
of liver cells[28].    
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1.1.3     Key interventions  
 
WHO estimated the number of recorded malaria cases in 2015 to have been 212 million,  a 22 
% decline since 2000[2]. A large proportion of this reduction in incidence can be attributed to 
malaria control interventions, namely the use of insecticide-treated bed nets [29] and still hugely 
important, but of a lesser impact over the last 5 years, the use of artemisinin based combination 
therapy[29] and indoor residual spraying[29]. However, despite this achievement in reduction 
of incidence, the number of people at risk of contracting malaria still remains high (3.2 
billion)[29], as does the number of deaths per year attributed to this disease, which was 
estimated by WHO to be 429,000 in 2015[2]. The complex life cycle of the malaria parasite 
makes this a difficult disease to control and as such, the fight against this ancient disease must 
involve a combination of several key interventions not one alone. 
 
 
 
                        1.1.3.A. Malaria diagnosis 
 
Malaria is a deadly but treatable disease and if detected early, within 24 hours of onset of clinical 
symptoms (WHO) and treated in a timely fashion with the first line drug of choice, the mortality 
and serious complications of this disease can be prevented. Quick and affordable diagnosis and 
education of both health care professionals and patients, enables better case management and 
means that antimalarials are only used for those who actually have the disease promoting better 
treatment practices thus helping to prevent the spread of resistance. The WHO now 
recommends ‘prompt malaria diagnosis either by microscopy or malaria Rapid Diagnostic Test 
(RDT) in all patients with suspected malaria before treatment is administered’ (WHO).  
 
 
 
                        1.1.3.B. Malaria vaccine development 
 
The complex life cycle of the malaria parasite (Figure 1.1), coupled with its successful strategies 
enabling it to evade the host’s immune system, poses huge challenges for the host in defeating 
the invading parasite. It does, however, present more targets for vaccine design and 
development. The ability of radiation-attenuated sporozoites to induce immunity has been 
recognised since the 1970’s with protection being observed in both humans[30] and mice[31]. 
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This demonstration that an immune response could be induced against malaria in addition to 
observations that individuals can develop progressive natural immunity with time[32],[33], 
subsequently lead to important work on vaccine development. Despite the challenges to these 
projects, there has been recent progress with several candidates in the pipeline.  
The most promising malaria vaccine candidate to date is the RTS,S/AS01 vaccine, which has been 
30 years in the making and was initially developed by GlaxoSmithKline (GSK) in 1987 in 
collaboration with the Walter Reed Army Institute of research and more recently, PATH Malaria 
Vaccine Initiative (MVI). This pre-erythrocytic subunit vaccine targets the circumsporozoite 
protein (CSP) of P. falciparum, a protein that is presented on the surface of the sporozoite and 
is expressed by early liver stages. This vaccine candidate showed encouraging results in phase 3 
clinical trials [34],[35]. However, the efficacy of this vaccine is limited with vaccine efficacy 
ranging from 25 % to 55 % in African children and as a result, this vaccine is still in the pipeline 
awaiting further clinical trials. 
Other approaches include whole parasite sporozoite vaccines that involve challenge with 
aseptic, purified, radiation-attenuated P. falciparum sporozoites that have been cryopreserved 
(PfSPZ). This vaccine approach is was well tolerated and has shown 100 % protection against 
challenge with malaria infection ten weeks post vaccination[36]. However, achieving high 
enough yields of irradiated sporozoites to support mass production of such a vaccine is a huge 
challenge. 
Other vaccine targets include blood stage specific proteins such as apical membrane antigen-1 
(AMA1)[37], merozoite surface proteins MSP1, MSP2 and MSP3[38],[39],[40], erythrocyte-
binding antigen-175 (EBA175)[41], serine repeat antigen 5 (SERA5)[42] and reticulocyte-binding 
protein homologue (PfRh5)[43]. Blood stage vaccines are aimed at preventing invasion and 
therefore preventing clinical disease. However, these vaccine candidates are highly expressed 
on the surface of merozoites and exhibit high genetic diversity. This allows the parasite to escape 
attack by the host immune system and may also allow the parasite to evade vaccine-induced 
immunity[44]. 
Transmission blocking vaccines target antigens on the surface of gametes, zygotes and ookinetes 
with the aim of preventing development in the mosquito midgut. However a limitation to 
transmission blocking vaccines is that antigens used for inducing a transmission blocking 
response are not presented naturally to the host immune system. This means that the immune 
system will be unable to provide a natural boosting effect as a result of vaccination and this will 
be a likely limit to vaccine efficiency[35] . 
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                        1.1.3.C. Targeting the vector 
 
One of the most successful tools used for the fight against malaria in the last 15 years has been 
the distribution, increased access and increased use of insecticide treated bed nets (ITNs). WHO 
have estimated that use of ITNs has contributed greatly to the 18 % global decline in malaria 
cases estimated between 2000 and 2015[29]. This has been due to the impact of vector control 
being recognised through important research[45],[46] and subsequent effective 
implementation of vector control strategies as a result of this work. This ITN-led reduction in 
incidence can be attributed to an increased access to bed nets, coupled with a better 
understanding and use of bed nets in infected areas, with an increase of people sleeping under 
ITNs[2]. This reduction in incidence highlights that a simple action such as sleeping under a bed 
net can significantly reduce the burden of this disease and protect lives. 
Indoor residual spraying (IRS) has been used as a vector control method against malaria as well 
as other vector borne diseases for many years with huge success and has proven instrumental 
to vector control. The insecticide dichloro-diphenyl-trichloroethane (DDT) was synthesized by a 
German student in 1874. However, the beneficial insecticidal properties of this compound were 
not known at the time and were not identified until many years later in 1939. This work, carried 
out by Swiss Scientist Paul Muller was fundamental to contributing to vector control and gained 
him the Nobel prize for medicine in 1948 (Nobel prize.org). Despite the progress seen with 
insecticide use, as with antimalarials, resistance has been observed and threatens to reverse the 
positive impact that this intervention has had on malaria control efforts[47],[48]. 
 
 
                       1.1.3.D.  Targeting the parasite: Drug treatment and prophylaxis 
 
In the fight against malaria, effective chemotherapy is essential, particularly for severe cases of 
the disease. With the current treatments, prophylaxis and interventions available, and with the 
often encountered issues with access to antimalarials not considered, malaria can be both 
prevented and treated easily. Treatments are currently effective, however, they do not inhibit 
transmission, and infected individuals are still able to transmit the parasite to the mosquito 
vector after clinical symptoms have ceased. Resistance has also emerged against all classes of 
antimalarials currently available excluding the artemisinin combination therapies (ACTs). 
However, slower parasite clearance times and an increased rate of treatment failure have been 
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observed for these drugs in Asia and recently in Africa[49], with some people calling this 
phenomenon resistance and others claiming that it is not and as such, there is some debate as 
to whether this is the start of emerging resistance. However, despite differing opinions, the 
slower clearance times remain a grave concern and the loss of this highly effective current 
treatment would be devastating to the fight against this disease. There is therefore need for 
new drugs that will target both the clinically relevant asexual blood stages and the transmission 
stages of this parasite, and particularly ones that would be active against all species in case the 
artemisinins fail.  
 
Quinine 
The naturally occurring compound quinine is an alkaloid compound isolated from the bark of 
the cinchona tree. This drug can now be made synthetically and in addition to exhibiting 
antimalarial properties, has also anti-inflammatory and analgesic effects. The medicinal benefits 
of cinchona bark were discovered hundreds of years ago when it was used in traditional 
medicine by native Peruvian Indians as a treatment for fever [50]. In fact, originally referred to 
as Peruvian bark, it was renamed in the 1700s after the countess of Chinchon was treated for a 
fever with this bark and was cured of her symptoms. It was successfully used as a first line 
treatment until the introduction of synthetic antimalarials in the 1920s [50]. Due to the toxicity 
of this drug, it is no longer used as a first line treatment. However, it is often used as a second 
line treatment in severe disease and is currently an important treatment for malaria in 
pregnancy particularly in the first trimester [50]. Quinine is also used to treat the related 
parasites of the Babesia species, which cause babesiosis. 
 
 
Antifolates 
Antifolates are synthetic compounds used to treat malaria infection and are subdivided into 
class I antifolates and class 2 antifolates by those that inhibit the parasite enzyme 
dihydropteroate synthase (DHPS) and those that inhibit the parasite enzyme dihydrofolate 
reductase (DHFR) respectively[51]. Combination of these two classes results in a synergistic 
effect so they are often used together[51]. Proguanil was the first compound of this class of 
antimalarials discovered. It is an inhibitor of DHFR and the partner drug to atovaquone in the 
drug combination used extensively as prophylaxis in travellers known as Malarone[51]. 
Chloroproguanil is synthesised by adding a chlorine group to the phenyl ring of proguanil. Both 
proguanil and chloroproguanil are metabolised into an active metabolite. Another class 2 
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antifolate is pyrimethamine, which was synthesised in the late 1940s and is another inhibitor of 
parasite DHFR. It is often used in combination with the DHPS inhibitor sulphadoxine. Although 
no longer widely used due to resistance, this combination is still often used for the intermittent 
prevention treatment of malaria during pregnancy (IPTp).  
 
Quinoline antimalarials 
The 4-aminoquinoline chloroquine was discovered in 1934 by the German Hans Andersag and 
originally named resochin[52]. It was used routinely as the first line treatment against P. 
falciparum infection, and was of particular value in 1955 to the WHO, who embarked on a global 
malaria eradication programme which also used the insecticide dichloro-diphenyl-
trichloroethane (DDT) [53]. However, resistance of P. falciparum to chloroquine was confirmed 
in South East Asia in 1960[54] and as a consequence, this drug is no longer used to treat P. 
falciparum infections in areas where resistance has been recorded. It is however, still routinely 
used to treat P. vivax blood stage infections, and this treatment is still efficacious in most areas. 
Resistance to chloroquine is thought to be due to mutation in the pfcrt gene and in some cases 
in the gene for pfmdr1[51]. The related compound Mefloquine has also been subject to 
resistance. This may be correlated with mutations in the pfmdr1 gene. However, this has not 
been confirmed[51]. 
 
Artemisinins and the artemisinin derivatives 
The herb Artemisia annua, also known as sweet wormwood, has been used in traditional 
Chinese medicine for centuries. Tea made from this plant was often used to treat fevers and it 
wasn’t until the mid-20th century, 1971 in fact, that the active ingredient of sweet wormwood, 
or Qinghao as it was historically known, was isolated from this plant by Chinese scientists. This 
compound, artemisinin, proved to be a very efficient antimalarial and derivatives of it 
(Dihydroartemisinin (DHA), Artemether and Artesunate) are also very potent and effective drugs 
against malaria [55]. This important work gained the Chinese scientist Youyou Tu a Nobel Prize 
in 2015. As a result, since being licensed, Artemisinin combination therapy (ACT) has been the 
standard first line treatment for P. falciparum blood stage infection and is a very effective and 
widely used treatment regime which is effective against blood stage infections of all five species 
of malaria. However there has been some so-called resistance reported for artemisinin. 
Artemisinin resistance is defined by WHO as delayed parasite clearance following treatment 
with an artesunate monotherapy or with an artemisinin-based combination therapy (ACT)[56]. 
A slower clearance time is not necessarily an indication of resistance to artemisinin and may in 
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some cases reflect resistance to the partner drug. However, artemisinin resistance has been 
associated with a mutation in the propeller domain of the K13 (Kelch13, PF3D7_1343700) 
gene[56]. This can be used as a molecular marker to monitor the spread of artemisinin resistance 
as this mutation has been strongly correlated with reduced parasite clearance times. This has 
already been seen in Thailand, Vietnam, Cambodia and Myanmar. This emergence of resistance 
may be a result of one or more factors such as poor compliance, use of monotherapies, and 
substandard treatments[57]. Artemisinins are metabolised very quickly in the human body and 
as a result, the current regime is to treat the patient for three consecutive days. This highlights 
how poor compliance could promote resistance to the artemisinin component of the 
combination therapy used. Slow parasite clearance has been associated with increased presence 
of gametocytes. This is a concern as it facilitates a selective transmission advantage amongst 
drug resistant parasites[58]. To prevent the issues associated with fast metabolism of 
artemisinins, they must be partnered with a drug from a different class that has a longer half-
life such as lumefantrine, mefloquine, amodiaquine, proguanil and 
sulphadoxine/pyrimethamine. 
The observation of slow clearance with ACTs had prompted a need to investigate new targets 
and alternative drugs to treat malaria. Access to ACTs is also an issue, although the number of 
children under 5 years of age being treated with ACTs has increased (from less than 1 % in 2005 
to 30 % in 2015)[2] and the proportion of ACTs used over alternative antimalarials for treatment 
of children has also increased in favour of ACT use. The recent identification of four imported 
cases of pfk13-independent treatment failure of artemether-lumefantrine in the UK[59] is a 
concern and emphasises the importance of identifying genetic markers in order to monitor the 
efficacy of this precious first line treatment.  
 
 
Gametocytocidal compounds 
Antimalarials that target asexual stages do not generally kill mature gametocyte stages. In fact, 
some compounds have even been documented to facilitate the production of gametocytes. 
Chloroquine was shown to stimulate a 5-fold increase in gametocytogenesis in P. falciparum in 
vitro[60]. This followed previous in vivo work on the murine species P. chabaudi which indicated 
an earlier peak of gametocytemia in mice treated with drug (pyrimethamine, quinine and 
mefloquine) 5 days post infection[61]. The combination drug sulphadoxine/pyrimethamine 
known as Fansidar, appeared to induce an almost 5-fold increase in P. falciparum gametocyte 
production in patients treated with this drug compared to those treated with chloroquine[62], 
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while others can kill the early gametocyte stages but not the late transmissible ones and vice 
versa. Artemisinin and its derivatives kill early stage gametocytes (I-III) but not mature stages. 
This reduces transmission efficiency but does not inhibit transmission as mature gametocytes 
still circulate in the blood stream[63]. As a result, drugs currently used to treat malaria will 
alleviate clinical symptoms but the individual will still be infectious to mosquitoes and therefore 
have the potential to spread disease.  
Blocking transmission of malaria is an essential part of controlling this devastating disease. 
Developing new antimalarial compounds that target both the asexual blood stages that are 
responsible for the morbidity and mortality caused by malaria and at the same time killing 
gametocyte stages would both alleviate clinical symptoms and prevent the infection being 
passed on from the infected individual to other people. In the fight against malaria such a drug 
would be an invaluable weapon. However, there remains the concern that drugs targeting both 
the asexual stages and transmission stages of the life cycle would exhibit the same issues with 
the development of resistance and some argue that a transmission-only drug that targets the 
non replicating gametocyte stages would greatly reduce the selection for resistance. Such a 
drug, however, would not alleviate clinical symptoms but would be a good candidate for 
prophylaxis.     
 
Primaquine (8-aminoquinoline) 
The only available licenced drug that can kill mature P. falciparum gametocyte stages is the 8-
aminoquinoline primaquine. This drug is hugely valuable as not only does it kill mature P. 
falciparum gametocytes, but it is also the only currently available drug that targets the P. vivax 
liver stages, including hypnozoites and as such is the only drug currently available to treat 
relapses.  
Primaquine is currently used to treat vivax and ovale malaria, is used for prophylaxis and is also 
given as a single dose of between 0.5 mg/kg and 0.75 mg/kg to target the gametocyte stages[64]. 
However, primaquine cannot generally be used to treat people with G6PD (glucose-6-phosphate 
dehydrogenase deficiency), a common disorder in Africa and in some parts of Asia [65] as it 
results in severe haemolytic anaemia in persons deficient for this enzyme [66]. Aging 
erythrocytes become more and more G6PD deficient as they age. Oxidant haemolysis is a 
common effect of primaquine treatment but usually causes limited haemolysis in patients who 
have the normal enzyme. The health consequence of this limited haemolysis is outweighed by 
the treatment benefit in these patients and haemolysis tends to be much less severe than that 
caused by the malaria infection itself. However patients with G6PD are much more at risk of 
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severe haemolysis with subsequent anaemia, because although they produce the enzyme, it is 
unstable and degrades more rapidly thus resulting in higher levels of oxidant haemolysis of older 
erythrocytes which are more vulnerable to damage by oxidants and so more susceptible to 
lysis[12]. In these patients, treatment with primaquine can be life threatening and may lead to 
severe haemolysis and haemoglobinuric renal failure and in such cases the treatment efficiency 
does not outweigh the dangerous effect of the drug. Although there have been tests developed 
to identify people with G6PD deficiency, there is no current quick and simple test to identify the 
level of risk, it is therefore still too dangerous to treat with primaquine particularly in some areas 
of the globe where the more severe genetic variants are more common[12]. This has limited the 
use of this antimalarial despite it being a very valuable and unique compound in regards to its 
gametocytocidal and hypnozoitocidal activity. There is therefore a need to develop new 
compounds that target these stages of the lifecycle. The design of compounds that prevent 
transmission formed part of a proposal published by Medicines for Malaria Venture (MMV) in 
2013[67], which outlined a list of target candidate profiles (TCP) and target product profiles 
(TPP). The aim of this was to provide a framework to channel research and development of 
antimalarial compounds in order to optimise malarial control efforts. An updated list published 
in 2016[68] includes molecules that clear asexual blood stages and with activity against 
hypnozoites (mainly P. vivax), hepatic schizonts, gametocytes and the insect vector[68].  
 
Antibiotics 
Several antibiotic compounds have been shown to be active against malaria parasites. A number 
of these compounds show differing modes of action to currently used antimalarials. This means 
that cross-resistance should not occur and these drugs have the potential to be good partner 
drugs in combination with current antimalarials. These compounds target the parasite 
apicoplast[69]. A large focus has been on two families of antibiotics, the tetracyclines and 
macrolides. Doxycycline is a synthetic tetracycline antibiotic originally developed in the 1960s 
by Pfizer Inc, but its potential as antimalarial compound wasn’t discovered until the early 
1970s[70]. Doxycycline has been shown to prevent the expression of apicoplast genes resulting 
in parasites devoid of functioning apicoplasts in the following cycle[71]. This compound can be 
used as a preventative measure in people travelling to malaria endemic areas[72]. Doxycycline 
exhibits slow acting activity against blood schizont stages and also shows partial efficacy against 
liver stages. When combined with another antimalarial compound exhibiting fast action against 
schizont stages, this treatment is very effective at preventing malarial infection[72]. 
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The antimalarial quinolone Ciprofloxacin also causes formation of an abnormal apicoplast and a 
resulting delayed death of parasites[71]. It has been shown to have the ability to increase the 
anti-malarial activity of Primaquine[73]. However ciprofloxine has shown some off target 
toxicity[74].  
Clindamycin is the semisynthetic derivative of the antimicrobial agent, Lincomycin[74]. 
Clindamycin is thought to target the apicoplast[74] and has been shown to be active against 
several apicomplexan parasites including Toxoplasma[75] and P. falciparum[76]. Most 
antibiotics present with a delayed activity and in studies with arithromycin, ciprofloxacin, 
clindamycin and docycycline on P. falciparum asexual blood stages, compounds appeared to be 
relatively inactive initially. However, a delayed death phenotype was observed and this was 
attributed to the progeny of treated parasites inheriting abnormal apicoplasts, leading to cell 
death and a subsequent inability of parasites to fully mature[68]. This emphasises a need for 
appropriate and faster acting partner drugs for these compounds when used in the treatment 
of malaria. 
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1.2 Cell signalling 
 
The life cycle of P. falciparum is extremely complex. Tightly regulated and timely interactions 
between components of cell signalling cascades are likely required in order for the parasite to 
develop through all stages of its lifecycle and to successfully infect the host and transmit to the 
mosquito vector. Huge progress has been made in understanding signal transduction pathways 
in mammalian systems and although this knowledge has helped facilitate understanding in 
protozoan systems, there is still much more to learn and work on cell signalling in protozoans 
such as P. falciparum is still in its infancy. This has in part been due to the huge differences 
between mammalian and protozoan signalling pathway components, and due to a lack of 
reagents and the difficulties associated with growth and manipulation of the organisms both at 
the cellular and genetic level. 
Signalling pathways are initiated when a stimulus is detected by a cell. This is followed by the 
coordination of an appropriate response. The presence of an external stimulus generally, but 
not always, involves the interaction of a molecule with its receptor on the surface of the cell. 
This interaction activates the receptor, which can then induce intracellular changes in 
concentrations of downstream secondary messengers. Changes in the concentrations of these 
secondary messengers amplify the original signal and activate downstream effector proteins 
leading to an appropriate and timely cellular response.  
Several types of secondary messenger signalling pathways exist. In P. falciparum, previous 
research has shown that cyclic nucleotide and Ca2+ signalling are both important pathways 
involved in coordinating many cellular functions essential to the parasite life cycle. There is often 
an overlap of these two signalling pathways in several important stages of the parasite lifecycle 
and as such, a relationship between these two signalling pathways is thought to often occur. The 
following will from this point focus specifically on cyclic nucleotide and Ca2+ signalling in the 
context of the Plasmodium lifecycle. Specific interest will be focused towards such signalling 
interactions in the sexual stage of the life cycle but with additional reference to cyclic nucleotide 
signalling and Ca2+ signalling in other organisms in particular mammalian systems. 
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1.2.1 Cyclic nucleotide signalling 
Cyclic nucleotide signalling regulates a wide range of cellular events in many different organisms. 
Ranging from regulation of heart function[77] and olfaction in mammals[78] to bacterial 
phytopathogenesis[79]. Cyclic nucleotide signalling has been well documented in mammalian 
systems with recognition that dysregulation of this signalling pathway leads to the pathology of 
a wide range of diseases and as such, components of this pathway have long since been 
recognised as good drug targets. Studies have also highlighted an essential role for this pathway 
in infectious organisms including apicomplexans such as T. gondii where it regulates gliding 
motility, invasion[80], cellular differentiation[81], gene expression and proliferation[82] and in 
Eimeria where inhibition of the cyclic nucleotide signalling pathway inhibits growth[83]. With 
relevance to this project, Plasmodium species require cyclic nucleotide signalling to regulate 
several key phases of their complex life cycle.  
The cyclic nucleotide signalling cascade involves several key components that interact with each 
other in a systematic and highly organised manner to regulate downstream effector molecules 
that will vary depending upon the cellular response required and the initial signal. As such, this 
pathway can be activated by a range of different signals and can regulate many cellular 
responses across a diverse range of organisms and in a temporal and spatial manner. In 
mammalian cells, cyclic nucleotide signalling is predominantly initiated by activation of 
membrane bound G protein-coupled receptors (GPCRs), which can have both a stimulatory and 
inhibitory effect on levels of cyclic nucleotides. However, as yet, there has been no evidence of 
genes encoding GPCRs in Plasmodium species. The key components of this pathway include the 
secondary messengers 5’-cyclic adenosine monophosphate (cAMP) and 3’-5’-cyclic guanosine 
monophosphate (cGMP). Levels of these secondary messengers are regulated by the opposing 
action of two classes of enzymes, firstly, their synthesis by adenylyl cyclase (AC) and guanylyl 
cyclase (GC) respectively and secondly, their hydrolysis by a family of enzymes known as 
phosphodiesterases (PDEs). These secondary messengers activate their specific downstream 
effector molecules: cAMP activates PKA and cGMP activates PKG. Once activated these effector 
proteins can phosphorylate downstream target proteins leading to the desired cellular response 
(see Figure 1.2).  
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Figure 1.2: Schematic of the basic cyclic nucleotide cascade. To initiate the cascade, a stimulus 
is detected; in mammalian cells this is often by a receptor interaction on the cell surface. The 
stimulus could act on the cyclase or PDE and results in changes in levels of the cyclic nucleotides 
(CNs) cAMP and/or cGMP. These are regulated by opposing actions of cyclases and PDEs. 
Increased levels of CNs leads to activation of downstream effector proteins, the main ones being 
PKA and PKG for cAMP and cGMP respectively. PKA and PKG then phosphorylate downstream 
target proteins leading to a cellular response.  
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1.2.1.A. The key players in cyclic nucleotide signalling 
The regulators: Phosphodiesterases (PDEs) and cyclases (GCs and ACs)  
PDEs and cyclases are important signalling enzymes that work in a tightly coordinated 
partnership to regulate levels of cGMP and cAMP. Guanylyl cyclases convert guanosine-5’-
triphosphate (GTP) to cyclic guanosine-3’,5’-monophosphate (cGMP) and adenylyl cyclases 
convert adenosine triphosphate (ATP) to 3’,5’-cyclic adenosine monophosphate (cAMP). PDEs 
are enzymes that hydrolyse the cyclic phosphate bond in cAMP and/or cGMP to produce the 
inactive products 5’-AMP and 5’-GMP respectively. These essential enzymes are good potential 
drug targets and in fact, in mammalian systems, these enzymes and in particular the PDEs have 
been used as drug targets to treat a range of health problems from sildenafil citrate that targets 
mammalian PDE5[84] to treat erectile dysfunction[85],[86] to the mammalian GC-C inhibitor 
linaclotide used to treat irritable bowel syndrome[87]  and the mammalian PDE 4 inhibitor 
roflumilast-a to treat chronic obstructive pulmonary disease[88].  
 
Adenylyl cyclases 
Mammalian adenylyl cyclases 
Adenylyl cyclases (ACs) are ubiquitous and important signalling enzymes. Mammalian ACs fall 
under the large category of class III cyclases which also contains all mammalian GCs[89].  The 
ten identified mammalian ACs exhibit differing tissue expression patterns and regulation and 
can be categorised into two main types, a single soluble isoform (sAC) first identified by Buck 
and colleagues in 1999 [90] which is expressed in many tissue types and can be directly activated 
by Ca2+ and bicarbonate[91],[92] and the nine better characterised and earlier identified 
heterotrimeric G protein-regulated membrane associated isoforms (tmAC)[93]. Mammalian 
tmACs have a short cytoplasmic amino acid terminus followed by two regions of six 
transmembrane domains separated by a catalytic domain. The second transmembrane domain 
is followed by a second catalytic domain[94]. The activity of mammalian tmACs is for the most 
part regulated by interaction of hormones and neurotransmitters with G protein-coupled 
receptors[95]. sACs lack the transmembrane domains that tmAC have but have the two catalytic 
domains which are located at the N-terminus of the protein connected by a linker[96]. The active 
site of these enzymes is formed by interaction between conserved catalytic residues in each of 
the two catalytic domains (C1 and C2), which in the active state of the enzyme, interact forming 
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a homodimer [96]. Conversion of ATP to cAMP only occurs when these two homologous 
cytoplasmic domains combine. Prior to interaction the domains are catalytically inactive[97]. 
TmACs have been associated with processes such as cardiac myocyte function[98] and brain 
functions[93]. The soluble isoform has been associated amongst other functions with 
apoptosis[99], glucose induced insulin release[100] and control of prostrate cell 
proliferation[101]. The latter two roles indicate sAC to be a potential drug target in diseases such 
as prostate cancer and diabetes. Unlike tmACs, which are restricted to the cell membrane, sACs 
are able to localise to different areas of the cell depending on where cAMP regulation needs to 
occur[102]. This temporal and spatial distribution adds to the complexity of cAMP signalling and 
means that multiple AC isoforms can be expressed at any one time and can play different 
functions in a cell. This reflects the diversity and complexity of cyclic nucleotide signalling.  
Plasmodium adenylyl cyclases 
Genes encoding two ACs (PfACα and PfACβ) have been identified in the P. falciparum genome. 
Unlike Plasmodium GCs, these are distinct from each other. However, both show similarity in 
their catalytic domains to mammalian soluble ACs[103]. PfACα is predicted to be bifunctional 
and is thought to contain a predicted voltage-gated potassium channel domain suggesting that 
this enzyme may be sensitive to changes in the membrane potential and involved in ion 
conduction across the membrane[104],[105],[106]. It has a predicted structure of 6 
transmembrane domains and a single carboxyl-terminal catalytic domain with amino acid 
residues required for substrate binding[106]. This differs from the currently less characterised 
PfACβ, which has no predicted transmembrane domains and two sAC-like AC catalytic domains. 
Unlike PfACβ, PfACα has been heterlogously expressed and characterised[105]. Transcripts 
appear at high levels in gametocyte stages suggestive of a role for this cyclase in the sexual stage 
of the parasite life cycle[106]. In further support of this, higher PKA activity has been reported 
in the gametocyte producing line LE5 compared to the non-producing line T9/96[107]. Like 
PfGCβ, the PfACα gene is intron rich[106]. A role for this cyclase in liver sporozoites has also 
been indicated[108]. PfACβ mRNA on the other hand is highly expressed in asexual blood stages 
(plasmodb.org) indicative of a role for this cyclase in the asexual erythrocytic stage of the life 
cycle. In fact, to date, unlike PfACα, attempts to produce a PfACβ knockout line have been 
unsuccessful, highly indicative of an essential role in asexual blood stages. However, with the 
current ever advancing genetic techniques, a conditional knockout may not be far away and this 
would advance studies into the role of this cyclase. PfACβ mRNA transcript levels increase in the 
trophozoite stage reaching a rapid peak during schizogony[109],[110]. This corresponds to 
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pharmacological data demonstrating that mammalian soluble AC inhibitors (thought to target 
PfACβ) are most effective 24-31 hours post invasion[111]. The same study also revealed a 
significant pH sensitivity of this cyclase leading to the prediction that PfACβ may act as a pH 
sensor for the parasite while it resides in the host erythrocyte. 
 
Guanylyl cyclases 
Mammalian guanylyl cyclases 
In 1969, guanylyl cyclase (GC) was first identified in mammalian systems as being one of the 
enzymes responsible for cGMP regulation[112],[113]. Since then genes encoding eleven 
mammalian GCs (mGCs) have been identified. Four of the eleven are soluble mGCs subunits 
termed α1, α2, β1 and β2 respectively. These exist as a heterodimers[114], each composed of 
one large α subunit and one small β subunit, are activated by nitric oxide[115] and require heme 
for activity[116],[117]. They are located in most tissues including the brain, lung and 
kidney[118],[119]. The remaining seven genes encode membrane-associated mGCs[119]. All 
encode functional proteins that have distinct structural and biochemical properties from the 
soluble forms apart from two (mGC-D and mGC-G), which are pseudogenes. mGC-A through to 
mCG-E exist as homodimers with the exception of mGC-C which exists as a homotrimer[119]. 
Unlike soluble mGCs, membrane-associated mGCs are activated by peptides[119] and require 
dimerization for activity[119]. The topology of all transmembrane mGC’s consists of a ligand 
binding domain located extracellularly, suggestive of a receptor function for this domain, 
followed by a short transmembrane region containing two transmembrane domains and an 
intracellular catalytic domain responsible for cGMP synthesis[120]. Mg2+ or Mn2+ are required 
during GC synthesis to stabilise the negative charge of the molecule[94],[121]. Disruption of 
mGCs can lead to many diseases including irritable bowel syndrome in the case of mGC-C 
disruption and congestive heart failure, as is the case for mGC-A disruption[122] and as such, 
mGCs are already targets for several inhibitors[87],[123].  
Plasmodium guanylyl cyclases 
The genome of P. falciparum encodes two large guanylyl cyclases, PfGCα with a predicted 
molecular mass of 496kDa and PfGCβ with a predicted molecular mass of 370kDa[124],[125]. 
These cyclases are thought to be bifunctional[124] and the genes that encode them are located 
on different chromosomes[124]. The PfGCβ gene is located on chromosome 13 and is 
characterised by 13 introns, 12 of which are located in the ATPase-encoding area of the gene 
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whereas the PfGCα gene located on chromosome 11 is not subject to intron disruption[124]. In 
Plasmodium species guanylyl cyclases are predicted to be integral membrane proteins with 12 
transmembrane domains in the cyclase region and a further 10 in the predicted type IV ATPase 
(flippase) domain[124]. Significant GC activity has been identified in membrane preparations of 
P. falciparum mature gametocytes[126] indicating a possible membrane localisation of one or 
both of the P. falciparum GCs. Compared to mammalian cyclases, Plasmodium cyclases exhibit 
unusual topological and structural features[125]. Both have an identical predicted topology with 
a paired C-terminal catalytic domain, which resembles mammalian G protein-dependent ACs 
with two catalytic domains each preceded by a region of six transmembrane helices[124] and 
an N-terminal P-type ATPase-like domain.  
Both PfGCα (PF3D7a_1138400) and PfGCβ (PF3D7a_1360500) mRNA expression have been 
detected in the asexual blood stages, gametocytes and sporozoite stages of P. 
falciparum[127],[110]. However, PfGCα mRNA expression is highest in asexual blood stage 
schizonts stages, whereas PfGCβ mRNA expression, although high in schizonts, is also high in 
gametocyte stages and sporozoites[110],[124] . This is supported by RT PCR data on P. berghei 
which identifies PbGCα as the dominant cyclase in mixed asexual samples and PbGCβ as being 
additionally transcribed in enriched gametocytes[128]. This evidence reflects a likely stage 
specific role for these two GCs and in fact, evidence has pointed to a role for PbGCβ in ookinete 
motility. P. berghei parasites devoid of PbGCβ exhibited severely compromised ookinete 
motility[129],[128]. These data were also indicative that at the ookinete stage PbGCα is unable 
to compensate for lack of PbGCβ. This knock out line was able to undergo gametogenesis 
indicating that PbGCβ is not essential for this process to occur. These data were consistent with 
a similar study in P. falciparum which showed a significantly reduced enzyme activity in a PfGCβ 
ko line but normal levels of gametogenesis[130]. Ability to knock PfGCβ out in this study was 
also indicative that this GC is not essential for the asexual blood stages or for gametocytogenesis 
or gametogenesis. Attempts to knock PfGCα out on the other hand have historically been 
unsuccessful[128],[130], supportive of an essential role for this cyclase in asexual blood stages.  
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Phosphodiesterases 
 
Mammalian phosphodiesterases 
The PDE family of enzymes hydrolyse the 3’phosphoester bond of cAMP and/or cGMP. In 
mammals there are 11 different families of PDEs named PDE1 to PDE11 that are classified 
according to the substrates that they degrade. Whether they degrade cAMP specifically (PDE4, 
PDE7 and PDE8), cGMP specifically (PDE2, PDE5, PDE6 and PDE9), or whether they are dual 
specific as is the case for human PDE3, PDE10 and PDE11[131],[132]. Dual specific enzymes also 
differ in their preference for either cGMP or cAMP[132]. Each of the 11 gene families give rise 
to multiple isozymes resulting in more than 50 proteins. This in part is due to alternate 
splicing[132]. Mammalian PDEs (mPDEs) have two distinct domains, firstly an N-terminal 
regulatory domain, which as its name implies, is responsible for the regulatory function of the 
protein. This regulatory function differs between the PDE families due to the varying domain 
composition. Most mPDEs contain domains essential for kinase recognition and 
phosphorylation, ligand binding and domains required for dimerization. Some mPDEs (PDE2, 
PDE5, PDE6, PDE10 and PDE11) can be regulated by a cyclic nucleotide via an allosteric GAF 
(cGMP-activated PDEs adenylyl cyclase and Fh1A) domain located in the N-terminal region to 
activate them to then hydrolyse another cyclic nucleotide. An example of this is the mPDEs in 
the heart that are regulated by cGMP leading to cAMP hydrolysis[133]. PDE 1 is unique in that 
its N-terminus contains calmodulin binding domains. PDE1, PDE3, PDE4, PDE5 and PDE10 have 
phosphorylation sites in their regulatory domain. Other differing regulatory and structural 
features include Per-ARNT-Sim (PAS) domains (which can bind small molecules and in a signalling 
system can function as a signalling sensor or play a role in protein-protein interactions), 
upstream conserved regulatory domains (UCR), transmembrane domains and anchoring 
domains (see figure 1.3).  
PDEs are metal ion-dependent and require one zinc ion and an additional currently unknown 
metal ion, thought to be magnesium, for catalysis. The Zn2+ binding site is located in the catalytic 
domain, which is conserved and is also involved in cyclic nucleotide recognition and substrate 
binding. As such, this domain is important for pharmacological targeting. The domain is 
composed of 16 alpha helices made up of 3 sub domains. Differences in this binding pocket and 
the differing properties of mammalian PDEs reflect the different PDE drug targets[134]. Most 
isoforms are expressed in multiple tissues for example, PDE2 is expressed in the adrenal gland, 
heart, lung, liver, platelets, and endothelial cells, PDE5 is expressed in the lung, platelets, smooth 
muscle, heart, endothelial cells and the brain, and PDE8 is expressed in the testes, eye, liver, 
41 
 
skeletal muscle, heart, kidney, ovary, brain, T lymphocytes and the thyroid. PDE 6 differs from 
all other mammalian PDEs as it is less widely distributed and is only present in the rods and 
cones of the retina[135] and the pineal gland[136]. PDE3 and PDE4 constitute the majority of 
cAMP regulatory activity[132].  
Mammalian PDEs have long been acknowledged to be good drug targets to treat a multitude of 
diseases resulting from an imbalance in cyclic nucleotide signalling required to regulate normal 
cellular processes. A well known example of a drug that targets a human PDE is sildenafil citrate 
more commonly known as Viagra. This compound and a related compound tadalafil target PDE5 
to increase vasodilation for the treatment of erectile dysfunction[86]. Sildenafil citrate was 
originally developed to treat heart disease and is still used to treat pulmonary arterial 
hypotension[137]. However, due to homology between mammalian PDEs, adverse side effects 
can sometimes be associated with drug treatment. In regards to treatment with Viagra, blue 
vision is sometimes experienced due to the additional targeting of PDE6 which shows homology 
to PDE5, a PDE that is highly concentrated in the retina and involved in retinal photo-
transduction[138]. Inhibitors such as roflumilast that targets PDE4 also often result in poor 
tolerance due to undesirable side effects[139]. However, as a whole, these drugs are generally 
well tolerated. 
Comparison of the catalytic domains of Plasmodium PDEs and human PDEs led researchers to 
hypothesise that the PDE1, PDE5 and PDE9 isoforms showed most similarity to Plasmodium 
PDEs[140] . This has allowed more of a focus for the design of small molecules targeting 
Plasmodium PDEs as the structures of compounds aimed at targeting Plasmodium PDEs can be 
designed based on the structure of known active PDE1, PDE5 and PDE9 inhibitors.  
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Figure 1.3. Schematic of the structure and domain organisation of the 11 Human PDE families[1]  
 
 
Plasmodium phosphodiesterases 
There are four cyclic nucleotide PDE enzyme paralogues encoded in the P. falciparum genome 
(PfPDEα-δ), which show similarity to their human homologues. 13 of the 16 amino acid residues 
found to be conserved across the mammalian PDE families are conserved also in Plasmodium 
PDEs[140]. The mammalian amino acids involved in metal binding are also conserved in the 
Plasmodium PDEs[141]. The catalytic domain of Plasmodium PDEs shows some similarities to 
the catalytic domain of human PDEs and shares the HD(X2)H(X4)N binding pocket signature[141], 
although the catalytic domain of Plasmodium PDEs is thought to be divergent enough from that 
of humans to be a target for drug discovery efforts. All Plasmodium PDEs are thought to be 
integral membrane proteins as the N-terminal domain contains 4 to 6 predicted transmembrane 
domains and PDE activity has been shown to be associated with parasite membrane fractions 
but not the soluble fraction[141]. Expression of these enzymes in Plasmodium is 
developmentally regulated at the mRNA level  (Plasmo DB) and research indicating roles for 
these enzymes at different stages of the parasite life cycle is supportive of this (Drought LD & 
Flueck CH unpublished)[130],[128],[142]. Plasmodium PDE active sites show most similarity to 
mammalian PDEs 1, 5 and 9 and modelling work has indicated that cGMP can bind to all PfPDEs 
leading to the hypotheses that Plasmodium PDEs are more likely to be better at hydrolysing 
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cGMP than cAMP[140]. The catalytic domain of the Plasmodium PDEs closely resemble that of 
mammalian PDEs[141].  
 PfPDEα and PfPDEβ 
PfPDEα encoded by the gene PF3D7_1209500 has a predicted size of 115 kDa and is expressed 
in blood stages but at relatively low levels (see Figure 1.4)[143],[141],[25]. Two splice variants 
of the gene have been identified, PfPDEαA which is predicted to have 6 transmembrane domains 
in the N-terminus and PfPDEαB which is predicted to have 4[141]. The gene is located on 
chromosome 12[141]. The catalytic region is located at the C terminus[141] and catalytic activity 
of PfPDEα has been demonstrated by heterologous expression and this PDE is thought to be 
cGMP specific[141],[143]. In further support of this, a knock out line was observed to have 20 % 
lower cGMP-PDE activity but cAMP-PDE activity remained unchanged[141]. There is evidence to 
suggest that the PfPDEα catalytic domains of both splice variants are intracellular[141]. This is 
also predicted to be the case for PfPDEγ. Interestingly, this is thought not to be the case for the 
other two Plasmodium PDEs which are predicted to have their catalytic domains exposed to the 
lumen of the parasitophorous vacuole but this has not been demonstrated biochemically[141]. 
This different topology between the Plasmodium PDEs may in some part explain the differing 
roles of these PDEs in the cell[141]. Deletion of PfPDEα demonstrated that it is not essential 
during the asexual blood stage of the lifecycle[141]. It is thought that at least one other PDE is 
expressed at this life cycle stage[143],[141] and that it is likely to be dual specific. A likely 
candidate is PfPDEβ (PF3D7_1321500) which has a predicted size of 133 kDa, as it is highly 
expressed in asexual stages (see Figure 1.5)[141],[25]. Attempts to knock out PfPDEβ have until 
recently, historically been unsuccessful suggesting that it is essential in erythrocytic stages and 
in fact, mRNA levels of all PDEs in asexual stages indicate that both PfPDEα and PfPDEβ are 
expressed in asexual stages and this, together with data indicating that that PfPDEα is not 
essential at that stage and that its absence is unlikely to be compensated for by another PDE, 
has indicated that PfPDEβ is likely to be the predominant PDE in asexual stages[141]. In support 
of this, a recent conditional knockout system has been developed and used to demonstrate an 
essential role for PfPDEβ in P. falciparum blood stage replication (Laura Drought, PhD Thesis, 
2014). Work using this knockout line has indicated the phenotype affects merozoite invasion 
and very early ring stage development (Christian Flueck, LSHTM, unpublished). Dual specificity 
of PfPDEβ has been confirmed using PDE assays on immunoprecipitated protein from asexual 
blood stages (Laura Drought, PhD Thesis, 2014). [141]. The PfPDEβ protein shows a similar 
topology to that of PfPDEαA with 6 transmembrane helices at the N-terminus and a catalytic 
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domain located at the C-terminus[141]. The gene encoding PfPDEβ is located on chromosome 
13[141]. Evidence suggests that PfPDEα does not affect gametocytogenesis as parasites lacking 
this PDE switch to the gametocyte stages efficiently with a resulting gametocytemia (my 
observations, unpublished) and sexual stages appear to grow and develop normally to maturity 
indicating that this PDE does not play an essential role in sexual stage switching or gametocyte 
growth and development. PfPDEα has been detected in mature gametocyte stages. 
Interestingly, in a proteomic analysis of P. falciparum gametocytes, more protein was detected 
in mature male gametocytes than mature females, suggesting a possible sex-specific function of 
PfPDEα. The only other PfPDE detected at the protein level in this study was PfPDEδ, which was 
identified at similar levels in both sexes, although slightly higher in females (17.8 % females to 
5.9 % males), [144]. Although PfPDEα appears dispensable for both asexual and sexual blood 
stage growth and development, it is expressed at the mRNA level in both stages and at the 
protein level in sexual stages, therefore a role for PfPDEα in mature gametocytes in vivo cannot 
be ruled out. No data are available on the insect stages so there may be a possible role for 
PfPDEα at these stages. Future conditional knockout studies involving PfPDEα/PfPDEβ may shed 
some light on a possible compensatory role for PfPDEα.  
 
 
 
 
 
 
 
 
Figure 1.4. Detection of PfPDEα mRNA levels in P. falciparum parasite stages. Detection of 
PfPDEα mRNA in 7 life cycle stages of 3D7 by illumina sequencing. Measured as transcript levels 
of fragments per kilo base of exon model per million mapped reads (FPKM)[144].  
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Figure 1.5. Detection of PfPDEβ mRNA levels in P. falciparum parasite stages. Detection of 
PfPDEβ mRNA in 7 life cycle stages of 3D7 by illumina sequencing. Measured as transcript levels 
of fragments per kilo base of exon model per million mapped reads (FPKM)[145].  
 
 
PfPDEγ 
PfPDEγ (PF3D7_1321600) is a 92 kDa protein that has been associated with sporozoite 
formation[142], (Cathy Taylor, PhD thesis, 2007). Its mRNA has been detected at low levels in 
asexual blood stages[141],[25] and in gametocyte stages[145] (see Figure 1.6). This PDE has also 
been shown to be expressed in P. yoelii blood stages at a low level and at higher levels in the 
sporozoite stages[142]. The gene encoding PfPDEγ is located immediately adjacent to PfPDEβ 
on chromosome 13 but on the opposite strand[141]. The PfPDEγ protein consists of 6 
transmembrane helices located at the N-terminal with a C-terminal catalytic domain[141]. 
Deletion of this PDE has been achieved in P. falciparum, P. berghei and P. yoelii[142], (Cathy 
Taylor, PhD Thesis, 2007). Parasite lines lacking PfPDEγ appear to grow and develop normally 
through the asexual blood cycle indicating that this PDE is not essential at this stage of the life 
cycle[130]. A knockout line of PfPDEγ was able to maintain the ability to switch from the asexual 
blood cycle to the sexual stage of the lifecycle and appeared to exhibit normal 
gametocytogenesis and gametogenesis indicative that PfPDEγ is not essential for the switch to 
the sexual cycle or for the growth and development of gametocytes to mature stages or for 
gametocyte activation (Cathy Taylor, PhD Thesis, 2007)[130]. PbPDEγ and PyPDEγ mutants also 
exhibit normal asexual growth and development and gametocyte initiation and development 
appeared unaffected, as seen in the P. falciparum line[142], (Cathy Taylor, PhD Thesis, 2007). 
These mouse models also showed that the oocyst development and development to the 
sporozoite stage was normal in the absence of PDEγ. However, in a study on P. yoelii, deletion 
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of PyPDEγ was shown to render sporozoites non-motile and unable to invade the salivary glands 
of the mosquito vector. P. yoelii sporozoites also exhibited elevated levels of cGMP. These data 
indicate an essential role for PfPDEγ in maintaining levels of cGMP required for sporozoite 
motility and subsequent salivary gland invasion in the mosquito vector, processes critical for 
transmission [142]. These data is supported by work on P. berghei, which showed high numbers 
of ookinetes and oocysts in a PbPDEγ-ko line, but very low number of sporozoites. Furthermore, 
in bite back assays (mosquitoes infected with the PbPDEγ-ko line were allowed to feed on 
uninfected mice), no transmission was seen suggesting that this line shows a defect in sporozoite 
production and infectivity (or invasion of liver cells).  Although the exact cyclic nucleotide 
specificity of PfPDEγ is currently unknown, the highly elevated levels of cGMP observed in 
sporozoite stages are indicative that PyPDEγ hydrolyses cGMP. This was further supported by 
addition of the cGMP-specific inhibitor zaprinast that ablated sporozoite motility [142]. Levels 
of cAMP were not measured in this study and although the absence of PfPDEγ in P. falciparum 
stage V gametocytes did not appear to affect levels of cAMP or cGMP with levels comparable to 
the wildtype (Cathy Taylor, PhD Thesis, 2007), cAMP hydrolytic activity at the sporozoite stage 
cannot be ruled out and cAMP is known to be involved in sporozoite motility[146]. Interestingly, 
an RNA-Seq analysis of sporozoites of the PyPDEγ knock out line revealed greatly reduced 
transcript abundance of PyPDEγ as expected. However, levels of PyPDEδ and PyPDEβ transcripts 
were increased whereas levels of PyPDEα remained the same[142]. This may indicate a 
compensatory role for PyPDEδ and PyPDEβ when PyPDEγ is absent, although this is not enough 
to reverse the effect on sporozoite motility seen when PyPDEγ is absent.  
 
Figure 1.6. Detection of PfPDEγ mRNA levels in P. falciparum parasite stages. Detection of 
PfPDEγ mRNA in 7 life cycle stages of 3D7 by illumina sequencing. Measured as transcript levels 
of fragments per kilo base of exon model per million mapped reads (FPKM)[144].  
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PfPDEδ 
PfPDEδ (PF3D7_1407500 Plasmo DB) is a 97 kDA protein with a predicted topology of 6 
transmembrane helices located at the N-terminus followed by a catalytic domain[141]. The gene 
encoding PfPDEδ is located on chromosome 14. There is evidence using a PfPDEδ-ko line that 
this PDE appears to be essential for the process of gametogenesis to occur[130]. This is discussed 
in more detail in section 1.2.4 (p63). PbPDEδ has also been shown to regulate levels of cGMP in 
order to facilitate ookinete gliding through a PfPKG-dependent signalling pathway in P. 
berghei[128]. PfPDEδ mRNA is not expressed in asexual stages but is expressed at a high level in 
gametocyte stages[25] (Figure 1.7[144]). In a PfPDEδ-ko line, cGMP levels appeared elevated, 
reflected by a 50 % reduction in cGMP-PDE activity[130]. cAMP-PDE activity did not appear to 
be affected in this line suggesting that PfPDEδ may hydrolyse cGMP specifically[130]. However, 
later work on gametocyte-infected erythrocyte deformability has suggested a role for PfPDEδ in 
regulating levels of cAMP (although this may indirect). In this study, an increase in cAMP levels 
was observed in both stage II and stage V PfPDEδ-ko gametocytes compared to a wildtype 
line[25]. Given this information, a dual specific role for this enzyme cannot be ruled out. Given 
the striking level of PfPDEδ mRNA detected in mature gametocyte stages (Figure 1.7) and the 
evidence that this PDE is likely to be essential for the process of gametogenesis[130], this 
Plasmodium PDE is an interesting protein to study further and will be a dominant topic of this 
thesis. More evidence is needed to confirm the substrate specificity of PfPDEδ and its cellular 
localisation and as yet there are no data demonstrating that this PDE is actually present at the 
protein level in gametocyte stages (although given what we know so far, it is predicted to be). 
More investigation is required into the role of this PDE in the process of gametogenesis.  
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Figure 1.7. Detection of PfPDEδ mRNA levels in P. falciparum parasite stages. Detection of PfPDEδ mRNA 
in 7 life cycle stages of 3D7 by illumina sequencing. Measured in RNA-seq expression units as transcript 
levels of fragments per kilobase of exon model per million mapped reads (FPKM)[144].  
 
 
The cyclic nucleotides: cGMP and cAMP 
The cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and 3’-5’-cyclic guanosine 
monophosphate (cGMP) are tightly regulated by the opposing actions of ACs and GCs 
respectively to synthesise them and by PDEs to hydrolyse them. The functions of cyclic 
nucleotides are mediated mostly by their respective effector kinases. In mammals, cGMP has 
additional cellular targets apart from PKG: cGMP-specific PDEs and cGMP-gated channels[147]. 
However, in Plasmodia there is currently only one known downstream effector protein for 
cGMP, PKG. In mammalian systems, although PKA is the main effector protein for cAMP, cyclic 
nucleotide-gated ion channels[148] and the exchange protein guanine nucleotide exchange 
factor (EPAC)[149] are also directly activated by cAMP. In mammals, there are two isoforms of 
EPAC that both contain a conserved cAMP-binding domain and bind cAMP with high affinity. 
This binding of cAMP to EPAC results in the direct activation of Ras-like small GTPases (Rap 1 
and Rap 2) and plays an important role in signalling events required for the regulation of 
neurotransmitter release, Insulin secretion, cardiovascular function and cancer cell proliferation 
amongst other functions [150],[151].   
In Plasmodium species, known effector proteins of cAMP include the main effector PKA. EPAC 
has also been shown to be regulated by cAMP in Plasmodium and although divergent from 
mammalian EPAC, shares the putative cAMP binding sites[152]. 
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cAMP was first identified as a signalling molecule in the 1950s prior to the identification of 
cGMP[153] where it was implicated in hormone-induced phosphorylation of proteins involved 
in the heart, liver, skeletal muscle and brain tissue[153]. cGMP was discovered in 1963 when it 
was isolated from rat urine[155]. It was subsequently demonstrated in 1969 that it is synthesised 
from guanosine triphosphate (GTP) by the enzyme guanyl cyclase (also known as guanylyl 
cyclase)[112]. 
In mammalian systems cross talk can occur between the cAMP and cGMP signalling pathways. 
An example of such cross-talk is the cGMP regulated PDE2-mediated hydrolysis of cAMP in the 
human heart[133]. cGMP can also competitively inhibit the hydrolysing activity of cAMP-
PDEs[133]. This demonstrates the complexity of cyclic nucleotide signalling.  
cAMP and cGMP regulate multiple cellular functions often in the same cell and as such signalling 
pathways involving these cyclic nucleotides must be tightly regulated and targeted to ensure the 
specificity of the required response. One of the ways that cells achieve this is to structurally and 
functionally restrict components of the signalling cascade by compartmentalising the proteins 
that regulate levels of cyclic nucleotides and effector proteins that are activated by cyclic 
nucleotides[156]. This allows components of the required signalling pathway only to be able to 
come into contact with each other to complete the signalling cascade when required. This can 
be achieved by spatial and temporal distribution of signalling components as well as targeting 
of proteins into complexes and the targeted localisation of components that restrict them to 
specific intracellular domains at very specific times. 
In plasmodium cAMP signalling has been implicated in many important cellular processes 
including gametocyte-infected erythrocyte deformability[25], sporozoite migration through 
hepatocytes[108], cell cycle regulation[157], and merozoite invasion[152]. Similarly, cGMP also 
plays an essential roles across the parasite life cycle including late liver stage development[158], 
sporozoite invasion of mosquito salivary glands[142], gametogenesis[159], blood stage 
schizogony and invasion[160].  
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The effector proteins: cGMP-dependent protein kinase (PKG) and cAMP-dependent protein 
kinase (PKA)  
Protein kinases phosphorylate target proteins by transferring a gamma phosphatase from ATP 
phosphoryl groups to specific serine, threonine or tyrosine amino acids in the target 
protein[161]. This action can be reversed by protein phosphatases such as calcineurin that 
remove the phosphoryl groups[162]. Protein kinases such as PKA and PKG are involved in a range 
of different functions across a diverse array of organisms.  
 
Protein kinase G (PKG) 
Mammalian PKG 
Human PKG is found in many parts of the body including, the brain, smooth muscle and platelets 
and was first isolated and purified from the human adrenal cortex in 1982[163]. Two types of 
mammalian PKG exist which are encoded by different genes, a 76 kDa soluble form (PKG I) which 
has two isoforms and a 87 kDa membrane bound form[164]. Mammalian PKG is structurally 
similar to PKA. However, it exists as a homodimer that has two distinct domains, a regulatory 
domain located at the N-terminus which contains two cGMP binding sites and a catalytic domain 
located at the C-terminus that binds substrates and Mg2+ /ATP[147]. Cyclic GMP interacts with 
PKG by binding to allosteric sites in the regulatory domain of PKG. This induces a conformational 
change resulting in exposure of the active site allowing phosphorylation of PKG substrate 
proteins to occur[165],[166]. The two binding sites of PKG I exhibit differing affinity for cGMP 
binding[167]. 
Plasmodium PKG 
PKG has been identified in apicomplexans including E. tenella, T. gondii and P. 
falciparum[83],[168],[164]. P. falciparum expresses a single PKG, PfPKG (Pf3D7_1436600), a 
97.5kDa protein consisting of a C-terminal catalytic domain and an N-terminal regulatory 
domain, characterised by Deng and colleagues in 2002[164]. Unlike mammalian PKGs, PfPKG is 
thought to exist as a monomer. cGMP binding to the regulatory domain of P. falciparum PKG 
has been determined by crystallography[169]. This protein kinase exhibits some structural 
similarities to mammalian PKG; however, it contains an additional two cGMP binding sites 
making a total of four, the last of which was shown to be degenerate[170]. PfPKG is activated 
on binding to cGMP (in Eimeria, cGMP must be bound to all 3 functional cGMP binding domains 
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in order for full activation of the kinase[171],[170]) and its activation subsequently leads to 
cellular responses essential to parasite survival and life cycle progression including 
gametogenesis [159], ookinete gliding [128], late liver stage development[158], blood stage 
schizogony [160], merozoite invasion[172] and merozoite egress [173]. This protein kinase is the 
only known effector protein of cGMP in Plasmodium and phosphoproteomic analysis has 
indicated that it can phosphorylate many substrates[172]. PKG-dependent phosphorylation can 
lead to the mobilisation of an important signalling molecule, Ca2+. PKG has been shown to be 
important for regulating the Ca2+ levels required for gametogenesis[159], P. berghei ookinete 
motility[174] and P. falciparum egress[175],[174]. As well as proteins involved in cell signalling, 
other targets of PKG include proteins involved in protein export, chromatin regulation, invasion, 
egress and transcriptional regulation amongst others[172]. Interestingly, studies of the P. 
falciparum phosphoproteome also indicated a possible feedback mechanism whereby the 
enzymes regulating the levels of cGMP could be phosphorylated by PfPKG therefore possibly 
allowing PfPKG to contribute to regulating cGMP hydrolysis and synthesis and therefore its own 
activation. There was also evidence to suggest that PfPKG may phosphorylate PfACβ indicating 
possible crosstalk between the cAMP and cGMP signalling pathways[172]. Such cross talk and 
feedback mechanism are seen in mammalian systems. 
Investigation into PfPKG expression and subcellular localisation in blood stages suggested a 
cytosolic localisation, with some endoplasmic reticulum (ER) overlap. PfPKG was also shown to 
associate with the peripheral membrane fraction in subcellular fractionation experiments[176]. 
Mammalian PKG is able to translocate to the nucleus where it can regulate gene 
expression[177]. However, as yet there has been no evidence that Plasmodium PKG can do this 
and in fact, the sequencing of mRNA from ookinetes of a gcβ P. berghei knock out mutant did 
not show any difference in gene expression compared to a wildtype control, indicating that in P. 
berghei ookinetes, there is no indication that PbPKG can control transcription[174]. 
Apicomplexan PKGs differ from their mammalian orthologues at an important site adjoining the 
ATP-binding pocket [164],[83]. This makes them of particular interest as drug targets because 
compounds specifically targeted to apicomplexan PKG will act upon the parasite without 
disrupting host PKG. One such compound, the trisubstituted pyrrole 4-[2-(4-fluorophenyl)-5-(1-
methylpiperidine-4- yl)-1H pyrrol-3-yl] pyridine; Compound 1 (C1), was developed by Merck as 
a treatment for Eimeria infection in chickens[83]. This compound, which is an ATP-competitive 
inhibitor, was subsequently shown to target apicomplexan PKG and exhibited activity against 
several apicomplexan parasites including E. tenella, T. gondii [178] and P. falciparum [179],[160]. 
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A transgenic line resistant to C1 and the more potent C2 (4-[7-](dimethylamino)methyl]-2-(4-
fluorophenyl)imidazo[1,2-α]pyridine-3-yl]pyrimidin-2-amine))[180] has been developed[159]. 
In this gatekeeper mutant, (PfPKGT618Q), a key threonine residue in the gatekeeper position of 
PfPKG has been replaced by an amino acid with a more bulky side chain (glutamine) rendering 
this line resistant to C1 and C2. These compounds can no longer bind to the ATP binding site of 
the enzyme. This line in combination with the PKG inhibitors C1 and C2 is a valuable tool for 
confirming the specific involvement of PfPKG in cellular events and to confirm that PKG is the 
primary target of the inhibitors in a particular cellular event[159]. These inhibitors have proved 
invaluable for functional studies on PKG[178]. C1 and C2 (Figure 1.8) although potent inhibitors 
of PKG, can target other kinases. One known non-PKG target for these compounds is the 
homologue of PfCDPK4 in T. gondii TgCDPK1[181]. A more specific PKG inhibitor (MRT00207065) 
has now been developed that has an IC50 of 160 nM in a PKG assay and an EC50 of 2.1 nM in a 72 
hour P. falciparum growth assay and does not show any off-target effects when used at 
appropriate concentrations. 
  
 
Figure 1.8. Chemical structures of C1 (4-[2-(4-fluorophenyl)-5-(1-methylpiperidine-4- yl)-1H 
pyrrol-3-yl] pyridine)[182] and C2 (4-[7-](dimethylamino)methyl]-2-(4-fluorophenyl)imidazo[1,2-
α]pyridine-3-yl]pyrimidin-2-amine)[181]. 
 
Protein Kinase A (PKA) 
Mammalian PKA exists as a heterotetramer complex composed of two catalytic subunits (PKA-
C) that bind to two regulatory subunits (PKA-R). Mammalian cells encode three isoforms of the 
catalytic subunit and four isoforms of the regulatory subunit[183]. The regulatory subunits are 
responsible for cellular localisation, which is achieved by association with A-kinase anchoring 
 Compound 1  (C1) Compound 2  (C2) 
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proteins (AKAPs) which facilitate an association of the regulatory domain with other cellular 
components such as membrane associated proteins[184]. Both regulatory subunits contain two 
cAMP binding sites. When cAMP binds to the regulatory subunits of PKA it results in a 
conformational change in protein structure whereby the complex containing the catalytic and 
regulatory subunits dissociates. This releases the active catalytic subunit and enables it to 
phosphorylate target substrates[185],[186],[187]. PKA is subdivided into two classes depending 
on which regulatory subunit the protein contains. Type I PKA contains RI subunits whereas type 
II PKA contains RII regulatory subunits. The regulatory subunits exhibit differing affinity to cAMP 
binding and as such, the response to changing cAMP levels differs depending on which PKA 
isoform is present[185]. Differing tissue expression and therefore distribution of the different 
isoforms of the catalytic and regulatory subunits of PKA mean that PKA can mediate diverse cell 
signalling responses[183].  
The regulatory subunit of PKA has also been characterised in P. falciparum[187]. PfPKA activity 
has been detected in P. falciparum asexual blood stages and shows higher activity in schizont 
stages. Addition of the PKA inhibitor H89 blocks parasite growth[188]. However, it is unclear 
whether the PKA target is host or parasite derived as this inhibitor targets both and the IC50 for 
the human orthologue is much lower than that for the parasite PKA[189]. The domain allowing 
AKAP association, which is responsible for localisation and PKA function in mammals, is absent 
in Plasmodium (Baker et al; in press). 
A homologue of the catalytic subunit of PKA has been identified in all plasmodium 
species[190],[183],[188] and is encoded by a single gene which has been cloned and 
characterised[188]. This gene is developmentally regulated[188] with higher levels detected in 
asexual blood stages than sexual stages initially indicating that PKA may not play a role in 
gametocyte stages. However, PfPKA activity detected in gametocytes has been shown to be 
higher in gametocyte producing strains than non-gametocyte producing strains suggesting that 
in contrast to previous reports PKA may play a role in sexual stages[107], and in fact, recent work 
on gametocyte deformability[25] has identified a role for this protein kinase in sexual stages. 
PKA phosphorylation of downstream substrates is known to regulate several key parasite 
processes. PKA is required for P. berghei sporozoite motility and liver cell invasion[108] and for 
P. falciparum erythrocyte invasion where it is required to phosphorylate the parasite adhesin 
apical membrane antigen 1 (AMA1)[191],[192]. PKA has also been implicated in modulation of 
anion conductance in the host erythrocyte cell membrane in order to facilitate movement of 
nutrients required by the parasite into the infected cell[187]. PKA has recently been implicated 
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in P. falciparum merozoite invasion and ring formation (Christian Flueck, unpublished). A role 
for PKA in gametocyte-infected erythrocyte deformability has been identified. Regulation of 
levels of PKA are required for gametocytes to remain non-deformable while sequestering in the 
bone marrow (high PKA levels) and for mature gametocytes to become deformable once they 
are released into the peripheral circulation (low PKA levels)[25]. A phosphoproteome study 
suggested that phosphorylation events by PKA play an important role in P. falciparum schizont 
stages[193]. This same study also identified the merozoite glidosome motor proteins, myosin A, 
GAP45 and CDPK1, as potential substrates for PKA in P. falciparum[193]. 
In infected erythrocytes there is both host and parasite PKA present[188]. It is therefore not 
clear whether these parasite functions are a result of the host PKA, parasite PKA or both. This 
can complicate studies using pharmacological agents as tools to investigate the role of PKA in 
parasites as there is no chemical genetic tool available unlike for PKG. 
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1.2.2 Calcium (Ca2+) signalling 
Ca2+ signalling in mammals 
Calcium (Ca2+) is a ubiquitous intracellular signalling molecule that operates across a diverse 
range of organisms to regulate many different cellular functions ranging from organisation of 
cell polarity in plants [194] to muscle contraction in mammals [195]. Levels of Ca2+ in the cell are 
tightly regulated by stimulated release from internals stores, which increases the levels of Ca2+ 
in the cytoplasm. In mammals, Ca2+ levels in the cytoplasm are restored back to basal levels by 
removal into internal stores by pumps and exchangers. High levels of Ca2+ can be toxic to 
cells[196] so removal of Ca2+ is important to maintain Ca2+ gradients across cell membranes and 
to avoid prolonged elevated levels of Ca2+ in the cytosol. Sarcoendoplasmic reticulum Ca2+ 
ATPases (SERCA pumps) are P type ATPases that pump Ca2+ from the cytoplasm back into the ER 
by exchanging protons for two Ca2+ ions per ATP hydrolysed[161]. Similarly plasma membrane 
Ca2+ ATPases (PMCA pumps) pump Ca2+ out of the cytoplasm into the extracellular space by 
exchanging one Ca2+ ion for one ATP. Mammalian cells also use Na+/ Ca2+ exchangers that 
exchange one Ca2+ ion for three Na+ ions. The inward movement of Na+ ions into the cell from 
the extracellular environment drives the movement of Ca2+ ions out of the cytoplasm[161]. In 
response to environmental cues and cell signalling cascades, Ca2+ ions are released from cellular 
stores such as the endoplasmic reticulum by Ca2+ channels such as inositol trisphosphate (IP3) 
receptors and ryanodine receptors. Both are large channels located in the endoplasmic 
reticulum (ER) membrane and Ca2+ mobilisation out of the ER is thought to mainly occur through 
these two receptors. Ryanodine receptors are opened by changes in levels of Ca2+ whereas IP3 
channels are activated by interaction with signalling molecules such as inositol (1,4,5)-
trisphosphate (IP3)[161]. IP3 is a secondary messenger produced by the hydrolysis of the 
phosphatidylinositol lipid, phosphatidylinositol (4,5)-bisphosphate (PI(4,5)P2) by phospholipase 
C (PLC). PI(4,5)P2 is a product of (PI4P) phosphorylation by the PIP5 kinase which is derived from 
the phosphorylation of phosphatidyl-1D-myo-inositol (PI) by the PI4 kinase (Figure 1.9). The 
generation of IP3 is mediated by lipid kinases and leads to mobilisation of Ca2+ from the ER. 
 In mammalian cells three isoforms of ryanodine receptor exist. These have different tissue 
distribution with RYR1 being expressed in skeletal muscle, RYR2 in cardiac muscle and RYR3 
which has a wider tissue distribution being found at low levels in several tissue types including 
the brain[197]. However, to date homologues of both the IP3 and ryanodine receptors have not 
been identified in Plasmodium although there is evidence that they might exist through studies 
using pharmacological approaches[198],[199],[200].  
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Figure 1.9: Schematic depicting the generation of IP3 leading to Ca2+ mobilisation from the ER. 
Following an upstream signal, PI is phosphorylated by the lipid kinase PI4K to produce PI4P. The 
lipid kinase PIP5K then phosphorylates PI4P producing the phosphatidylinositol lipid PI(4,5)P2, 
which undergoes hydrolysis by PI-PLC to produce the secondary messengers IP3 and DAG. In 
mammalian cells IP3 binds to its associate receptor on the ER membrane. Activation of the 
receptor leads to the mobilisation of Ca2+ out of the ER store and into the cytosol. This leads to 
the required downstream signalling response. 
  
Ca2+ acts as a second messenger by binding to effector molecules. This often results in a change 
in the charge and/or shape of the protein and acts to regulate its function. The change in charge 
of some proteins when binding to the positive Ca2+ ion can allow them to translocate from the 
cytoplasm to the membrane[161]. Many proteins involved in Ca2+ signalling pathways such as 
protein kinase C (PKC) and phosphoinositide 3-kinase (PI3K) contain a domain known as a C2 
domain that can bind Ca2+ ions and promote association with the plasma membrane[161] where 
they can interact with other signalling proteins and molecules. This allows spatial regulation of 
signalling molecules and acts to bring proteins into contact with their substrates. Binding of Ca2+ 
ions requires specific binding domains and one of the most common protein binding motifs is 
the EF hand domain. These domains capture Ca2+ ions between negatively charged oxygen 
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atoms within a loop of the helix-turn-helix structure and the affinity for Ca2+ can vary greatly 
between proteins [161]. 
In mammalian cells, calmodulin is an important signalling protein that is regulated by Ca2+. 
Calmodulin is a small protein that amplifies the Ca2+ signal. The second messenger nucleotides 
cADPR and NAADP are important for controlling the release of Ca2+ from cellular Ca2+ stores. In 
plants, the phytohormone abscisic acid (ABA) acts to induce cADPR production, which results in 
Ca2+ mobilisation. Interestingly, this plant hormone is also present in the apicomplexan parasite 
T. gondii, where it governs the decision of the parasite to develop either to a dormant stage or 
to switch to lytic growth, and addition of exogenous ABA can trigger egress of T. gondii in a PKG-
dependent manner, indicating that cADPR plays a role in the regulation of Ca2+ in this 
organism[201]. Although T. gondii is closely related to Plasmodium species, there has been no 
indication that ABA induced cADPR regulated Ca2+ pathways are present in Plasmodium. 
However an inhibitor of ABA synthesis fluridone, which is a registered pesticide has been shown 
to be active against malaria[202].  
Ca2+ signalling in Plasmodium 
Ca2+ signalling in apicomplexans is not well understood. However, Ca2+ is known to regulate 
many key events in apicomplexan parasites, including motility, development and protein 
secretion. Although several of the features of the Ca2+ signalling machinery found in mammals 
remain conserved in Plasmodium, there are many which are not, such as the classical 
mammalian Ca2+ effector proteins PKC and Ca2+-/calmodulin-dependent protein kinases and the 
ER Ca2+ receptors for ryanodine and IP3. A SERCA Ca2+ ATPase has been identified in Plasmodium 
as has a Ca2+/H+ exchanger. However, as yet no PMCA has been identified[203]. As seen in other 
organisms, in plasmodia levels of Ca2+ are tightly regulated. Unlike in mammals, however, 
calcium release in Plasmodium leads to activation of a family of calcium-dependent protein 
kinases (CDPKs). These kinases are key signalling molecules in plants, protozoa and fungi but are 
absent in humans which makes them an attractive therapeutic target in apicomplexans. These 
effector proteins bind calcium and are subsequently activated due to a change in conformation 
allowing the kinase to phosphorylate its substrates [204] [205]. The EF hand domain appears to 
be conserved in Plasmodium with around twenty proteins identified as containing this domain 
feature[206]. Plasmodium as with other apicomplexans, encodes an array of CDPKs. Several of 
these have been shown to play important roles in the life cycle of this parasite. PfCDPK1 is 
expressed in all blood stages and is localised to the plasma membrane. It is thought to play an 
important role in invasion through discharge of micronemes [207]. It has been shown by 
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phosphoproteomics to be a direct cellular target of PfPKG[172]. PfCDPK2 is transcribed in late 
trophozoite stages, PfCDPK3 is expressed in ookinetes and has been shown to be important for 
ookinete gliding motility [208], [209]. PfCDPK4 has been shown to play an important role in 
regulating gametogenesis and is therefore important for transmission [210], and PfCDPK5 is 
expressed in P. falciparum blood stages and is essential for merozoite egress and acts 
downstream of PKG[175]. PfCDPK7 shows highest levels of transcription in ring stages. 
Disruption of the gene encoding PfCDPK7 results in ablated development from the ring stages 
to trophozoite stages and fewer progeny generated from each subsequent schizont leading to 
an overall reduced growth rate[211]. 
The mitochondria [212], ER, food vacuole[213] and acidocalcisomes [214] are all reported 
intracellular Ca2+ stores in apicomplexans [198]. The ER is thought to be a major Ca2+ store in 
Plasmodium[213].  
In P. falciparum, Ca2+ mobilization has been strongly implicated in the late stages of 
gametogenesis[159],[215] , in cell cycle development and progression [216], [198],[174] , in 
ookinete gliding motility and invasion of the mosquito midgut [209],[208],[174], sporozoite 
development and invasion [217],[218] and gamete formation [210], [210],[174]. The wide range 
of key events regulated by Ca2+ emphasises its critical importance as a signalling molecule in P. 
falciparum. Ca2+ must interact with many signalling and other downstream molecules in a timely 
and precise fashion, in order for the parasite to develop, survive and propagate. 
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1.2.3. Cell signalling in the asexual blood stages 
 
Cell signalling in merozoite egress 
 
Release of infectious merozoites from host erythrocytes is an essential step in the propagation 
of P. falciparum in the blood stream. This process must be tightly regulated in order for 
merozoites to be released only when they are fully mature and competent to invade new blood 
cells. Premature schizont rupture results in the release of merozoites which will not invade. This 
is seen in zaprinast-induced egress in which schizonts rupture in a PfPKG-dependent manner but 
merozoites are unable to invade new erythrocytes[173]. cGMP signalling has been shown to be 
essential for egress. Addition of the PKG inhibitor C1 to P. falciparum schizonts resulted in a 
block in schizont rupture which was not observed in parasites of the C1 insensitive line 
PfPKGT618Q[160]. Mechanical shearing of C1-blocked schizonts resulted in merozoites that were 
invasively incompetent[175].  
In order for schizont rupture and subsequent merozoite egress to occur, a protease cascade 
must be activated. A key player in this cascade is the subtilisin-family serine protease PfSUB1, 
which is expressed late in schizont maturation[219],[173]. PfSUB1 is stored in specialised 
organelles called exonemes from which it is released into the parasitophorous vacuole 
space[220]. PfSUB1 proteolytically processes several proteins required for egress, one of which 
is the protein serine-repeat antigen 5 (SERA5)[220]. SERA5 is expressed abundantly in the 
parasitophorous vacuole of mature schizonts and appears to be indispensable for parasite 
growth[221]. Antibodies against SERA5 block egress[222]. PfSUB1 has been shown to be 
refractory to deletion in blood stages identifying it as an essential protease in asexual blood 
stages[220].  
Inhibition of PfSUB1 results in a block in processing of SERA5, which also correlates with a block 
in egress and also invasion[220],[223]. In P. falciparum, PfSUB1 also cleaves merozoite surface 
protein 1 (PfMSP1). During normal egress the cleaved forms of both MSP1 (shed from the 
merozoite surface) and SERA5 are shed into the surrounding medium. PfSUB1-mediated 
proteolytic processing of PfMSP1 can be blocked by addition of C1[175]. C1 and C2 also block 
proteolytic processing of SERA5 and PKG inhibition was shown to have no effect on PfSUB1 
expression in the cell or for its maturation[173]. Instead, inhibition of PfPKG by C1 and C2 was 
shown to block the discharge of exonemes and micronemes and this block was shown to be 
reversible by removal of C1 or C2[173]. This observation explained the previous finding that 
mechanically ruptured PfPKG inhibited parasites produced non-invasive merozoites[175]. This 
can be explained by the fact that these merozoites have not been exposed to PfSUB1, which 
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stays trapped in exonemes due to PKG inhibition[173]. Addition of the PDE inhibitor zaprinast 
to mature schizonts induces premature egress and a rapid discharge of micronemes and 
exonemes and proteolytic processing of both PfMSP1 and PfSERA5[173]. Zaprinast also induced 
a translocation of the protein PfAMA1 (from micronemes) onto the surface of schizonts, this was 
inhibited by C1 treatment and was observed in both mature (segmented) schizonts and 
immature (non-segmented) schizonts[173].  
Prior to blood stage egress a steady increase in cytoplasmic free Ca2+ occurs [224]. This was 
shown to be independent of external Ca2+ but dependent upon internal Ca2+ stores, as chelation 
with EGTA did not inhibit this Ca2+ release whereas the membrane-permeable chelator BAPTA-
AM did. Furthermore, addition of the Ca2+ ionophore A23187 induced egress[224]. The related 
apicomplexan parasite T. gondii also requires mobilisation of Ca2+ for egress. Artificial 
stimulation of Ca2+ release using A23187 or ionomycin triggers microneme secretion and this 
process is blocked by disruption of Ca2+ release. This chelation of parasite Ca2+ also prevents T. 
gondii egress[225]. There is evidence that IP3 is involved in mediating the Ca2+ response in T. 
gondii[226]. Ryanodine and caffeine (an agonist of ryanodine receptor Ca2+ release)  also 
induced Ca2+ indicating that there may be a RYR-like receptor in T. gondii[226].  
In P. falciparum, CDPK5 is present at the protein level in schizonts and invasive merozoites[110]. 
A conditional knock down line of CDPK5 using a destabilising domain system revealed an 
essential role for this protein in regulating merozoite egress[175]. Degradation of the CDPK5 
protein using the DD system resulted in a block in egress. However, this block in egress differed 
to that seen with PfPKG inhibition in that the CDPK5 block occurred downstream of PfSUB1 
mediated proteolytic processing as processing of both PfSUB1 and PfMSP1 were unaffected by 
the absence of CDPK5[175], whereas inhibition of PKG results in a block in the proteolytic 
processing of PfSUB1 substrates. The schizont block as a result of CDPK5 disruption also differed 
from that caused by PKG inhibition in terms of invasiveness of merozoites. Merozoites from 
schizonts derived from sheared CDPK5-deficient blocked schizonts were able to invade 
normally[175], whereas mechanically sheared C2 blocked schizonts were not[175]. However, 
removal of the C2 block releases invasive merozoites if allowed to egress naturally.  
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Cell signalling in merozoite invasion 
 
Once merozoites are released into the harsh environment of the host bloodstream, they must 
quickly invade new erythrocytes in order to develop into ring stage forms and to develop 
through the subsequent asexual blood stage forms.  
The first step of invasion involves an initial recognition of and contact with the erythrocyte. This 
primary contact is of low affinity and reversible[227]. Initial attachment is followed by 
reorientation of the parasite to bring its apical end into contact with the host erythrocyte 
membrane. This allows for a stronger interaction. The apical membrane protein 1 (AMA1) is 
translocated to the merozoite surface prior to invasion[227] and is essential for invasion[228]. 
Use of specific antibodies against PfAMA1 did not block the initial attachment but prevented 
reorientation of the parasite[229]. PfAMA1 has also been shown to be essential for invasion of 
T. gondii[230], where it is thought to be involved in forming the initial apical interaction and also 
in the regulation of rhoptry secretion[230]. 
Once the initial attachment has occurred, the parasite can start the process of entering the host 
cell. This entry involves the formation of a tight junction and the parasite is propelled forward 
by the action of an actin-myosin motor[231]. AMA1 is a key protein involved in formation of the 
tight junction[232]. The serine protease SUB2, which is released from micronemes at the apical 
end of the merozoites, acts to induce removal of the merozoite surface coat in a process known 
and ‘shedding’[233]. During the process of invasion, the tight junction moves from the apical 
end of the parasite, which forms the initial attachment, to the posterior end of the parasite. As 
this occurs, a parasitophorous vacuole is formed enabling the parasite to reside within the host 
cell but in a compartment in which it has favourable conditions to survive. A possible role for 
PfPDE in erythrocyte invasion has been elucidated. Parasites devoid of PfPDE exhibited 
greatly reduced invasion and ring forms appeared to be unable to develop (Christian Flueck, 
LSHTM, unpublished). 
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1.2.4. Cell signalling in gametocytogenesis  
 
Unlike the initiation of gametogenesis which requires a well-documented trigger resulting from 
the transition between the vertebrate host and mosquito vector, what makes a parasite decide 
to make the earlier transition from the asexual replication cycle to the transmission stages is 
presently not well understood. Very little is known about the signalling pathways involved in 
gametocytogenesis, although there are several factors that have come to light over the years 
and more recently, evidence of an epigenetic factor that is an important mediator of this 
process[234]. 
It has been known for some time that ‘stress’ is one such factor leading to the induction of 
gametocytogenesis in vitro. The use of spent medium to stress asexual cultures has been shown 
to result in the production of gametocytes[235]. Variations of this method are currently used as 
the ‘gold standard’ to produce gametocytes for in vitro studies. This observation that spent 
medium can trigger gametocytogenesis supports a hypothesis that the switch from the asexual 
cycle is one that allows the parasite to exit the increasingly unfavourable conditions of the host 
and to leave before host death occurs. However, the observation that P. vivax gametocytes 
appear early on in infection, sometimes prior to the observation of asexual stages calls this 
‘stress’ hypothesis into question. However, stress induced initiation of gametocytogenesis in 
vitro may be different from what happens in vivo. The reason that P. falciparum gametocytes 
appear much later in the blood stream of the human host than the other human Plasmodium 
species could be due to their long maturation period (~10 days), and the ability of the immature 
stages to sequester means that P. falciparum gametocytes are only observed in the blood once 
they have fully matured. Despite this, the fact remains that in vitro stress can stimulate 
gametocytogenesis so must be an important factor at least in vitro when considering what 
initiates this process. However, the cell signalling pathways involved in this response to stress 
are currently unknown. There have been several other studies highlighting alternative in vitro 
triggers for gametocytogenesis. Carter et al, observed that lysed erythrocytes resulted in the 
formation of gametocytes[236]. Host reticulocytes have also been associated with increased 
gametocytemia[237] , as have host hormones such as steroids[238], [239]. Interestingly, P. 
chabaudi parasites converted to a much higher proportion of gametocytes when taken from 
their natural host, a mouse, and injected into a rat[240]. A publication in 1980[241] suggested a 
role for cAMP in the switch to gametocytes and data demonstrated that addition of cAMP to an 
asexual ring stage culture of P. falciparum resulted in nearly 100 % of asexual stages switching 
to gametocyte stages, although, this has yet to be replicated efficiently. However, prior to this 
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study in 1979, Hertelendy et al, described an increase in cAMP production in erythrocytes 
infected with P. berghei compared to uninfected erythrocytes[242]. Caffeine[243] and 8-bromo-
cAMP[237], both of which inhibit the action of mammalian cAMP-PDEs, have both been 
reported to enhance the production of gametocytes. In addition to this, a comparison of a 
gametocyte producing and a non-gametocyte producing P. falciparum clone linked the loss of 
gametocyte-producing ability to a decrease in cAMP-dependent protein kinase activity[107], 
Indicating a possible role for cyclic nucleotide signalling in gametocytogenesis. In further support 
of this, PfACα is highly expressed in gametocyte stages[106] suggesting that PKA may play a role 
at this stage of the life cycle. 
Recent studies have uncovered an epigenetic factor that regulates gametocyte induction leading 
many to believe that the switch from the asexual stages to the sexual stages is a stochastic event. 
The transcription factor PfAP2-G was identified in 2014 as an epigenetically regulated master 
switch of gametocytogenesis. It is encoded by a member of the ApiAP2 gene family. In asexual 
blood stages, this gene appears to be epigenetically regulated[244],[245] and spontaneously 
activated[246]. ApiAP2 proteins are major transcriptional regulators in Plasmodium and have 
been shown to regulate several key developmental stages including liver stage 
development[247], ookinete formation[248] and sporozoite development[249]. However, until 
recently no link to the gametocyte stages had been seen and the use of both forward and reverse 
genetic approaches demonstrated a role for AP2G in gametogenesis and this has sparked a huge 
interest in this protein[250]. The early gametocyte markers Pfg 14,744, Pfs16 and Pfg 27/25 were 
all found in lower abundance in a PfAp2-g mutant line[250]. Furthermore, this mutant lost the 
ability to produce gametocytes completely, indicating that it directly activates the transcription 
of the early gametocyte genes required for gametocytogenesis. Interestingly two gametocyte 
non-producer clonal lines derived from 3D7a (F12 and A4) were found to have mutations in the 
Pfap2-g gene (Pf3D7_1222600, Plasmo DB). No other mutations associated with gametocyte 
formation were found in these lines and in particular, no disruptions in the sub telomeric region 
of chromosome 9 were found, the deletion of which has historically been known to be 
associated with gametocytogenesis[251]. Higher abundance of PfAP2-G transcripts was 
detected by RT-PCR in a high gametocyte producing clonal line (3D7B) compared to the lesser 
producer 3D7A[250]. HA tagging of PfAP2-G has indicated that this protein localises to the 
nuclear region[250].  
It is not clear at which point in the asexual cycle gametocytogenesis is initiated, however, 
evidence has pointed to the switch occurring prior to the formation of segmented schizonts. In 
1989, Bruce et al, used antibodies against the gametocyte specific marker Pfg 27/25 and the 
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specific asexual marker MSA2 to show that in plaques obtained from erythrocyte monolayers, 
in a single segmented schizont all merozoites were either sexually committed or not[252]. In 
support of this, in PfAP2-G expressing schizonts, all merozoites in one schizont stained positive 
for PfAP2-G[250]. Interestingly, the work of Smith et al[253], showed that of those parasites that 
had committed to the sexual cycle, all merozoites from a single schizont were either all male or 
all female gametocytes.  
 
A biased sex ratio in P. falciparum has already been identified and the ratio leans in favour of 
females. This female favoured sex ratio likely compensates for the fact that when gametogenesis 
occurs male gametocytes will produce 8 gametes whereas females will only produce one. 
Therefore more females are required to facilitate fertilisation efficiency. However, sex ratios do 
vary between strains and species[254]. In P. falciparum sex specificity can be distinguished by 
microscopy at stage V by Giemsa stain and earlier at stage III using the female sex specific 
antibody Pf377 which highlights the higher number of osmiophilic bodies found in female 
gametocytes[255]. From stage III, females exhibit an increasing number of Golgi vesicles, 
mitochondria and ribosomes[23]. To specifically identify male gametocytes, -tubulin II can be 
used. Females stain blue with Giemsa due to the presence of a higher density of ribosomes. In 
contrast, males tend to stain more pink in colouration using Giemsa. Nuclear size also differs 
between the sexes with females presenting with a smaller nucleus than males[256].  
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1.2.5. Cell signalling in gametogenesis 
 
In P. falciparum, fully mature male and female stage V gametocytes circulating in the blood 
stream are primed for activation in the mosquito. This means that on entering the mosquito 
midgut they are ready for the process of gametogenesis to occur immediately. It’s likely 
therefore that the components of the cell signalling pathways required for gametogenesis in the 
mosquito are already present in mature gametocytes circulating in the host bloodstream. In 
order for this process to be regulated efficiently and to avoid premature activation of 
gametocytes, processes and cell signalling cascades required for gametogenesis to be initiated 
in the mosquito vector must not be activated in the mammalian host. If this were to occur, 
transmission efficiency would be reduced due to premature initiation of gametogenesis leading 
to formation of gametes too early and prior to uptake of a blood meal. The key to this timely 
regulation of this switch to gametogenesis lies in the essential environmental and chemical 
triggers specifically induced by conditions in the mosquito vector, which are absent in the human 
host. Mature gametocytes may circulate in the blood stream for several days arrested in the G0 
phase of the cell cycle until eventually they may be taken up by a feeding mosquito taking a 
blood meal. This sudden and dramatic change in environment from the 37 ° C of the human host 
to the lower temperature of the vector, coupled with the presence of a mosquito-derived factor 
(and/or an increase in pH in in vitro settings), is known to initiate the process of gametogenesis. 
The pH change required in vitro to initiate gametogenesis along with a temperature decrease is 
bicarbonate-ion-dependent and requires a switch from pH 7.4 to between pH 8.0 and pH 
8.3[257].  On exposure to the air, a decrease in the concentration of carbonic acid caused by loss 
of CO2 from the blood is thought to result in this pH increase. The pH must be above pH 7.8 for 
exflagellation to be induced in a bicarbonate ion-dependent manner. Having observed that the 
pH of a blood meal rarely increases above this value and usually lies between pH 7.5 and pH 
7.6[26], it was discovered through mosquito feeding assays using medium devoid of bicarbonate 
that a mosquito derived factor, uncharacterised at the time and named mosquito exflagellation 
factor (MEF)[26] or Gametocyte activating factor (GAF)[258] initiated gametogenesis in 
combination with the essential decrease in temperature in vitro rather than by a bicarbonate 
ion-dependent increase in pH[26]. This mosquito derived factor was later identified by HPLC and 
mass spectrometry to be a negatively charged small acidic substance and was shown to be the 
already identified tryptophan by-product of the ommochrome pathway in insects, xanthurenic 
acid (XA)[26]. The ommochrome pathway in insects is required for the synthesis of eye pigment. 
Using insect mutants which do not produce XA as a by-product it was demonstrated that MEF is 
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a product of the ommochrome pathway as homogenates of these mutants did not show MEF 
activity whereas wildtype homogenates did[26]. This was further confirmed by the fact that the 
mosquito vector responsible for malaria transmission, A. gambiae, uses this pathway and 
previous work prior to the discovery that MEF was in fact XA indicated MEF activity in mosquito 
heads[26]. XA can be found in mammalian serum at low concentrations[259], however, 
concentrations this low do not support exflagellation at blood meal pH and will only result in 
exflagellation between a narrow pH window. Addition of >3 M XA to serum expanded this pH 
window thus increasing the likelihood of exflagellation occurring. This demonstrated that on 
transitioning to the mosquito in a blood meal, the presence of a higher concentration of XA than 
already present in the mammalian blood, could along with a small rise in pH and a temperature 
decrease, facilitate the process of gametogenesis[26].  
With the use of increasingly sophisticated genetic and pharmacological tools, we are gaining 
more and more insight into the signalling pathways involved in the process of gametogenesis. 
However there is still much more that needs to be learned and although it is clear what the 
environmental signal for gametogenesis is, it is currently still unknown whether there is a 
receptor interaction at this initiation point and if so, what the receptor for XA is. The exact 
sequence of signalling events following the initial XA signal and identification of all the 
components involved in the signalling events regulating gametogenesis still remains unclear. 
However, the importance of certain signalling molecules is now apparent. XA coupled with a 
reduction in temperature can be used in vitro to stimulate gametogenesis. Studies using 
pharmacological and genetic tools have highlighted an important role for Ca2+ in this 
process[260], [210]. In fact, addition of XA to P. berghei gametocytes induces a rapid release of 
Ca2+. This XA-induced Ca2+ release was gametocyte-specific and was not observed in mixed 
asexual stage preparations[210]. P. falciparum gametocytes were able to round up, and 
emergence was greatly reduced in the absence of Ca2+ as shown by studies using XA to induce 
gametogenesis in the presence of the intracellular Ca2+ chelator BAPTA-AM[159]. This study 
indicates that Ca2+ is not required for the early stages of gametogenesis to occur. The later stages 
of gametogenesis, specifically the male-specific process of exflagellation, do on the other hand 
require the presence of the Ca2+. P. berghei gametocytes stimulated with XA in the presence of 
100 M BAPTA-AM were unable to exflagellate[210]. P. falciparum gametocytes were also 
unable to exflagellate in the absence of Ca2+ [159]. The essential role for Ca2+ in gametogenesis 
suggested the involvement of Ca2+-dependent effector molecule. This led to the discovery that 
the Ca2+-dependent protein kinase 4 (CDPK4) was required for exflagellation to occur. Regulation 
by CDPK4 was shown to be induced by XA and also by a rise in pH. A knockout of PbCDPK4 in P. 
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berghei eliminated exflagellation completely and cells were still able to round up and 
emerge[210]. The requirement for CDPK4 only in the exflagellation stage of gametogenesis 
indicated a male-specific role for this kinase and in fact, CDPK4 is predominantly expressed in 
male stages (plasmodb.org). Further study into the specific role of pbCDPK4 in exflagellation 
revealed a role in regulating cell cycle progression in activated male gametocytes. In pbCDPK4 
ko male parasites, no increase in DNA content was observed on stimulation with XA, this was in 
contrast to wildtype cells in which the DNA content of males increased by a factor of 5.5. In 
addition to this, the formation of axonemes and mitotic spindles, which usually occurs in 
microgametes on addition of XA, was inhibited in the knockout line[210]. More recent work in 
P. berghei gametocytes by Fang et al, has shown that CDPK4 plays a role in several distinct events 
of male gametogenesis and in a temporal manner. Within the first 30 seconds of gametocyte 
activation, and downstream of Ca2+ mobilisation, a myristoylated form of CDPK4 is activated by 
Ca2+ and phosphorylates the effector protein SOC1 (substrate of CDPK4 1) this leads to the 
recruitment of a complex containing MCM2-7/Cdt1 onto the ORC1-5/Cdc6 complex. This 
initiates the first of three rounds of DNA replication required for males gametocytes. This Ca2+-
activated myristoylated isoform of CDPK4 also plays another role independently of pre-complex 
loading and the subsequent first genome replication, by phosphorylating another effector 
protein, SOC2 (substrate of CDPK4-2). This is required to complete the first mitosis and for 
mitotic spindle formation. A non-myristoylated isoform of CDPK4 phosphorylates SOC3. This is 
down stream of all other processes required for male gametogenesis and is required for flagella 
motility[215]. 
Work by Kawamoto et al, also demonstrated an essential role for Ca2+ in exflagellation, this study 
also indicated that nitroprusside, a GC activator, enhanced exflagellation, as did 3-isobutyl-1-
methylxanthine (IBMX), an inhibitor of both cAMP and cGMP, whereas, the GC inhibitor N-
methyl-hydroxylamine prevented exflagellation. This indicated a role for both Ca2+ and cGMP in 
the later stages of gametogenesis. However, a pharmacological induced increase in cAMP did 
not affect exflagellation levels in this study, suggesting that gametogenesis is cGMP-dependent 
but not cAMP-dependent[260]. In support of this, studies using the cGMP-PDE inhibitor 
zaprinast have shown a role for cGMP signalling in gametogenesis. Increasing concentrations of 
zaprinast stimulated rounding up and exflagellation in a dose-dependent manner independently 
of XA, suggesting a role for cGMP in this process[159]. This led to the question of whether PKG 
was involved. Addition of the PKG inhibitor C1 to XA induced and zaprinast-induced gametocytes 
inhibited rounding up and subsequent exflagellation of gametocytes indicating an essential role 
for this signalling molecule in both XA and zaprinast-induced gametogenesis[159]. This was 
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verified further by the development of a P. falciparum line with insensitivity to C1. This 
PfPKGT618Q gatekeeper mutant line was able to round up when stimulated with either XA or 
zaprinast both in the presence and absence of C2 indicating that the reversal of XA or zaprinast-
induced rounding up and emergence observed in the wild type when C2 was added was in fact 
PKG-specific[159]. This work showed that PKG is the primary target of C1 and C2 and also that 
PKG has an essential role in gametogenesis/gametocyte activation. However, whilst C1 and C2 
blocked exflagellation, this was also blocked in the PfPKGT618Q gatekeeper mutant indicating that 
another C1/C2 sensitive kinase must have a role in this later stage of gametogenesis[159]. In 
fact, there is evidence that TgCDPK1 is sensitive to C1[181]. In support of a role for cGMP 
signalling in gametogenesis, Muhia et al, measured cGMP levels as an indication of GC activity 
in mature P. falciparum gametocyte membrane preparations. They showed an increase in cGMP 
levels on addition of XA and concluded that XA could stimulate GC activity[126]. These assays 
were carried out in the presence of the non-selective cyclic nucleotide PDE inhibitor theophylline 
indicating that any increase in cGMP levels observed were not due to a reduction in PDE activity 
(however, this inhibitor has since been shown to be relatively inactive against Plasmodium PDEs 
with a > 100 μM activity against C-terminal catalytic domain produced in E. coli compared to a 
3.8 μM activity for zaprinast [143]). To further support GC involvement, authors showed that 
cGMP increases were dependent upon Mg2+ or Mn2+, which have been previously shown to be 
required for GC activity in other organisms.  
PDE activity has also been implicated in the process of gametogenesis.  Lines in which PfPDEδ 
had been disrupted showed elevated cGMP levels and a reduced rounding up at stage V and 
more strikingly, the majority of parasites failed to emerge from the host erythrocyte; these data 
suggest that the absence of PfPDEδ in this line leads to aberrant cGMP hydrolysis leading to 
increased levels of this cyclic nucleotide in gametocytes stages and as a consequence 
gametogenesis is disrupted[130]. Interestingly, Taylor et al[130], indicated that there is likely to 
be another cGMP-PDE in addition to PfPDEδ active in gametocyte stages as residual PDE activity 
seen in the PfPDEδ knockout line was more sensitive to the cGMP-PDE specific inhibitor 
zaprinast than PfPDEδ[130]. Interestingly, deletion of PbPDEδ in P. berghei does not lead to 
aberrant gametogenesis but rather affects the later insect stages[128] suggesting either 
differences between murine and human malaria parasites, or that unlike in P. falciparum, 
another PDE may be able to compensate for the absence of PbPDEδ and maintain cGMP at levels 
that allow gametogenesis to occur. Unlike P. falciparum lines lacking PfPDEδ, P. berghei 
parasites undergo normal gametogenesis and fertilisation takes place leading to the formation 
of ookinetes. However, it is at this stage in the parasite life cycle that disruption occurs due to 
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the absence PfPDEδ. Deletion of PbPDEδ results in a phenotypic change in ookinetes which 
impairs their ability to penetrate the mid gut epithelium leading to greatly reduced mosquito 
transmission[128]. This morphological change is reflected by ookinetes rounding up and is 
accompanied by breakdown of the inner membrane complex (IMC), a process that usually 
occurs later in the lifecycle at the point of oocyst formation once ookinetes have completed their 
transit through the midgut wall. Addition of the PKG inhibitor C1 was shown to reverse the 
ookinete phenotype in the PbPDEδ-ko line, indicating that the phenotype observed in the 
mutant line was due to disrupted levels of cGMP as a result of the absence of PbPDEδ.  This 
phenotype is suggestive of a possible premature initiation of cellular events caused by aberrant 
cGMP signalling. Interestingly, this premature rounding up is what would be expected to occur 
in mature gametocytes of the PfPDEδ-ko line; however instead what is seen is a partial block in 
rounding up and a complete block in egress (this will be investigated in chapter 4). 
 
1.2.6. A relationship between calcium (Ca2+) signalling and PKG  
There is a clear symmetry between the role of PfPKG at various stages of the lifecycle and the 
role of Ca2+ release. Several cGMP-regulated signalling events appear to be dependent upon Ca2+ 
mobilisation from internal stores.  
In P. berghei, PKG acts to maintain Ca2+ at levels required for ookinete gliding motility and 
sporozoite invasion of hepatocytes has been shown to require both PKG and CDPK4 [218]. PKG 
also controls levels of Ca2+ required for merozoite egress and activation of gametogenesis in 
both P. berghei and P. falciparum. It is thought that PKG induces calcium release through 
phosphoinositide metabolism and activation of PLC. This results in the production of IP3 (and 
DAG) from PIP2. Increased IP3 production leads to displacement of Ca2+ from internal stores and 
as a subsequence, the induction of several critical stages of the malarial lifecycle [174]. 
PfPKG-induced rounding up of gametocytes appears to be independent of Ca2+ release [159]; 
however, in both P. berghei and P. falciparum, induction of exflagellation requires both cGMP 
and the release of Ca2+ suggesting that the later stages of gametogenesis are dependent on both 
signalling molecules and that a relationship exists between the two [210] [260] [174].  
Gamete and merozoite egress can be blocked using the Ca2+ chelator BAPTA-AM. It can also be 
inhibited by PfPKG inhibitors and stimulated by zaprinast. This is reflective of an essential role 
for both Ca2+ and PKG in parasite egress. The observation that the PDE inhibitor zaprinast in P. 
falciparum can reverse this BAPTA-AM-induced egress block was suggested to reflect an 
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enhanced Ca2+ mobilisation induced by zaprinast in schizont stages which was able to overcome 
the activity of BAPTA-AM allowing egress to still occur in the presence of Ca2+  chelation (rather 
than indicating that PfPKG acts downstream of Ca2+ release which is not thought to be the case)  
[173]. 
 
1.3. Introduction summary 
The complex life cycle of P. falciparum makes malaria a very difficult disease to control. 
However, as a result of malaria control interventions particularly in the last 5 years, this ancient 
disease has gone from being the number one killer among children to the fourth highest cause 
of death in sub-Saharan African children[29]. Despite this accomplishment, malaria still remains 
a serious threat to the lives of adults and children, particularly in sub-Saharan Africa with the 
shocking reality that this disease currently kills a child every 2 minutes and remains a huge public 
health problem globally. Although our current first line treatments are good, eventual resistance 
is a real threat and if the development of new compounds with novel targets does not evolve 
fast enough, the consequence could be catastrophic and reverse efforts over the last 15 years, 
which have seen a downward trend in cases. Efforts must continue in the search to develop new 
antimalarial drugs preferably with different targets to succeed in the arms race against this 
organism. To achieve this, we must understand more about the cell signalling pathways involved 
in critical events of the parasite life cycle.  The development of molecules that specifically target 
essential and conserved parasite proteins that play critical roles in cell cycle events such as 
schizogony and gametogenesis, and preferably compounds that target more than one part of 
the parasite life cycle, would be invaluable to the drug discovery effort. Cyclic nucleotide 
signalling in Plasmodium is essential for many stages in the parasite life cycle including cell cycle 
progression of asexual blood stages which cause the clinical symptoms of malaria and for 
transmission from the human host to the mosquito vector and as such, this is an attractive 
pathway to direct research efforts. Although not a priority in the past, targeting of the 
transmission stages of malaria is now seen as an important contribution to the fight against this 
ancient disease. The aims and objectives of this thesis are outlined below and seek to 
understand more about the role of cyclic nucleotide signalling and Ca2+ mobilisation in 
schizogony and gametogenesis and to investigate the possible gametocytocidal activity of 
compounds that target parasite PDEs. 
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Aims and objectives 
 
 To explore the relationship between PfPKG and Ca2+ mobilisation in P. falciparum 
schizont stages and mature gametocytes with the aim to determine the PfPKG-
specificity of the zaprinast-induced Ca2+ response in mature schizonts and both the 
zaprinast-induced and XA-induced Ca2+ responses in mature gametocytes. 
 
 To investigate the biological effects of both pharmacological and genetic disruption of 
PDEs in P. falciparum gametocytes, with the aim to identify the effect of PDE absence on 
three important events in gametogenesis; rounding up, emergence and Ca2+ 
mobilisation. 
 
 To dissect the two phenotypes of the PfPDE-ko gametocytes which exhibit non-
deformability and an inability to round up. With the aim to identify whether PfPDE is 
required for XA-induced rounding up and emergence by using a PKA inhibitor to remove 
the PKA-induced ‘stiff’ phenotype. 
 
 To design and create a PfPDE triple HA tagged line and to use it to determine PfPDE 
localisation in mature gametocyte stages. 
 
 To pull down PfPDE-HA protein from the PfPDE triple HA tagged line and to use the 
material to carry out PDE assays with the aim to determine the cyclic nucleotide 
specificity of PfPDE. 
 
 To identify compounds with gametocydal activity from a panel of PDE inhibitors 
developed by Pfizer and to investigate the mode of action of candidates showing 
gametocyte inhibition from the screen. 
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Chapter 2 
Materials and Methods 
 
2.1. Parasite preparation 
2.1.1. P. falciparum parasite culture 
2.1. A. P. falciparum asexual stage culture 
Cultures of P. falciparum NF54[261], PfPDEγ-ko and PfPDEδ-ko lines (Cathy Taylor PhD Thesis 
2007), PfPDE-ko line (Christian Flueck, LSHTM), PfPKGT618Q (Louisa McRobert, LSHTM)[159], 
PfPKG-DD (kindly provided by Dr Manoj Duraisingh and Jeffrey Dvorin) and 3D7a [262] were 
grown and propagated using an adapted version of the Trager and Jensen method of P. 
falciparum culture[263]. Parasites were maintained in RPMI-1640 (Sigma) supplemented with 
(0.02 mg/ml) hypoxanthine (Sigma), 5 mg/ml Albumax II (Invitrogen), 2 mg/ml glucose (Sigma) 
and 0.3 mg/ml L-glutamine (Sigma) from here on referred to as culture medium (CM) or 
complete media and maintained in A+ human erythrocytes (whole blood, National Blood 
Service, Colindale) to a final haematocrit of between 1 % and 5 % and at parasitemias ranging 
from 0.5 % to 20 %. Cells were incubated at 37  C̊ in 5 % CO2 (BOC) while shaking at 60 RPM 
(Eppendorf new Brunswick S41i CO2 shaking incubator). In order to monitor growth and 
development of cultures, thin blood smears were made on glass slides (VWR) and stained with 
Giemsa (see section 2.1.C). 
 
2.1.B. P. falciparum gametocyte initiation and culture 
Spent culture medium (sCM) was removed from a high ring stage culture (8 % to 10 % 
parasitemia) and the culture then ‘stressed’  by addition of the sCM added back onto the culture 
in a ratio of 1:3 (10 ml sCM plus 20 ml new CM) (see 2.1.A for culture for culture media 
components). Cultures were incubated overnight at 37  C̊ with 5 % CO2 (BOC). On day 2, cultures 
should appear as stressed late stage cultures. Blood smears of cultures were prepared in the 
morning, stained with Giemsa and examined by light microscopy (as described in section 2.1.C) 
to determine the level of stress. This was evaluated by comparing morphology of stressed cells 
to that of normal healthy cells of the same stage.  Cultures were purified using a Percoll gradient 
(section 2.2.C). Very fresh whole blood (A+ preferred dependent on availability but other blood 
groups used as required) taken no more than 2 days prior (LSHTM blood service) was washed in 
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RPMI-1640 (Sigma) twice to remove all other blood components, leaving erythrocytes only and 
diluted in RPMI-1640 to a 50 % haematocrit. Washed blood was added to the purified schizont 
pellet to give a resulting parasitemia of ~ 3-5 % schizonts. Cultures were either stressed again 
using spent CM as described above or received a culture media change depending upon the level 
of stress observed previously by light microscopy. Cells were incubated overnight while shaking 
(60 RPM) at 37  C̊ in the presence of a modified gas mixture 3 % CO2/1 % O2/N2 200 bar (BOC) 
from now on referred to as ‘gametocyte gas’. On day 3 cultures were examined by Giemsa 
smear. Cultures are expected to be high ring stage cultures at this point and a certain proportion 
should have committed to gametocytogenesis. Cultures above 5 % parasitemia were split into 
separate flasks and fresh RBC’s added to make a parasitemia of ~ 5 % and a haematocrit of 0.5 
% -1 %. After this point no erythrocytes were added to cultures for the remainder of the 
procedure. From this point onwards, until maturity at stage V, all cultures were continually 
maintained at 37  C̊ and received daily culture medium changes using a hot plate. Culture 
medium used was the same as described above but with an addition of 11.6 mg/ml N-Acetyl-D-
Glucosamine (Sigma) to prevent asexual stage invasion. Cultures were gassed with gametocyte 
gas and incubated at 37  C̊.  
 
2.1.C. Preparation and Giemsa staining of thin blood films  
Parasite samples were pelleted by centrifugation at 8000 rpm for 30 seconds. The supernatant 
was removed to leave a haematocrit of ~ 50 - 80 %. ~ 5 l of sample was placed on a glass slide 
(VWR) using a Gilson pipette. A second glass slide was used to smear the sample across the slide. 
Samples were air dried at room temperature for ~ 2- 5 minutes then fixed in 100 % methanol 
(VWR). A 1:10 dilution of Giemsa R66 (Gurr-Azur-Eosin-methylene blue, VWR) was prepared in 
tap water. Slides were laid face down on a tray and Giemsa solution injected underneath using 
a syringe with a blunt ended needle. Slides were left to stain for 15-20 minutes. Once stained, 
slides were washed gently in tap water and left to air dry. Samples were viewed by light 
microscopy (Leitz LaborLux 8) using a x100 oil immersion lens. Counts were carried out using a 
24 mm diameter miller square graticule (Pyser-SGI Ltd) to determine percentage parasitemia 
and the stage composition of cultures. 
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2.2  P. falciparum synchronisation and purification 
 
2.2.A. P. falciparum sorbitol synchronisation of early asexual stages 
Asexual blood stage cultures were synchronized using a method of (5 %) sorbitol (Sigma) 
treatment to remove all late stage asexual parasites leaving only ring stages. Parasite lines were 
cultured as indicated in section 2.1.A to a mostly ring stage parasitemia. Cultures were pelleted 
by centrifugation for 2 minutes at 500 xg. 5 % sorbitol (2.5 g of sorbitol (Sigma) added to 50 ml 
of purified water) pre-warmed to 37  C̊ was added to the pellet in a ratio of 1:6 (6 ml sorbitol to 
1 ml parasite pellet). Samples were incubated for 10 min at room temperature then washed in 
pre-warmed RPMI-1640 (Sigma) followed by centrifugation at 500 xg for 2 min. This wash step 
was repeated to ensure all sorbitol had been removed. Samples were maintained at 37  C̊ in 5 % 
CO2 (BOC) in line with the asexual stage culture methods indicated in section 2.1.A.  
 
2.2.B. P. falciparum magnetic purification of mature asexual stages and gametocyte stages 
Parasite lines were cultured as indicated in section 2.1.A to a predominantly schizont 
parasitemia, or were induced to produce gametocyte stage culture as indicated in section 2.1.B. 
Cultures were pelleted at 500 xg for 2 minutes (in a centrifuge pre-warmed to 37  C̊ for 
gametocyte samples). The supernatant was removed and samples prepared to a ~10 % 
haematocrit using warm RPMI. The MACS cell separation column type CS (Miltenyl Biotec) was 
attached to the magnet and washed through with warm RPMI to wet the column (at this point 
onwards the column was not allowed to run dry). The parasite sample was loaded on top of the 
column and the regulator adjusted to allow a flow rate of ~2 drops per second. The sample was 
allowed to run through the column into a 50 ml tube (if early stages were not needed to be kept, 
this sample was discarded), after which, warm RPMI was flushed through the column at a flow 
rate of ~ 4 drops per second to remove all unbound material from the column. Once the flow 
through ran clear, the column was removed from the magnet and 20-30 ml of warm RPMI added 
and the regulator opened fully to allow all bound material to wash off the column. Flow through 
was collected in a 50 ml tube and pelleted by centrifugation at 500 xg for 2 minutes (in a 
centrifuge pre-warmed to 37  C̊ for gametocyte samples). The pellet should be purified late 
asexual stage parasites or stage II-V gametocytes (all stages containing haemozoin) and should 
contain no uninfected erythrocytes. Parasite samples were either used for further experiments 
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or put back into culture (see section 2.1.A) with fresh erythrocytes (for late asexual stages) and 
culture medium. 
 
2.2.C. P. falciparum Percoll purification of mature asexual stages and gametocytes 
Asexual stage cultures were synchronized using a method of (70 %) Percoll (90 ml Percoll 
(Sigma), 10ml 10x RPMI (1.04 g), 13.3 % sorbitol (3.724 g) in 1x phosphate buffered saline (PBS) 
(28 ml)) gradient to separate mature stage asexual parasites from early stages. Cultures were 
pelleted by centrifugation at 500 xg for 2 minutes. The supernatant was removed and the cell 
pellet layered gently onto 3 ml of Percoll pre-warmed to 37  C̊. The Percoll gradient was 
centrifuged at 2500 xg for 10 minutes with no brake. The mature stage layer of cells containing 
purified mature stages located at the top of the gradient was removed and placed into 6 ml of 
pre-warmed RPMI-1640 (Sigma) and pelleted by centrifugation for 2 minutes at 500 xg to wash. 
Purified parasites were either used or placed back into culture with fresh erythrocytes (see 
section 2.1.A) and were incubated while shaking (60 RPM) at 37  C̊ to allow invasion to occur. 
The lower fraction of the Percoll gradient consisting of early asexual stages and uninfected 
erythrocytes was either discarded or synchronized further using sorbitol treatment (see section 
2.2.A). To separate gametocyte stages from uninfected erythrocytes (all stages from stage II will 
be retained in the upper fraction), the above protocol was used and gametocytes were 
maintained at 37  C̊ at all times during this process. 
 
2.2.D. P. falciparum Compound 2 synchronisation of mature asexual stages 
Compound 2 (C2) blocks schizont egress (see section 1.3 of introduction for more details) and 
as such can be used to synchronise asexual blood stage cultures by allowing parasites to 
accumulate at the mature segmented schizont stage. Removal of C2 releases the block and 
allows egress within a short time period.  To achieve highly synchronous cultures with a tight 
window of under 4 hours, asexual stage cultures were synchronised using a method of 
compound 2 (C2) (4-{7-{(dimethylaminp)methyl}-2-(4-fluorphenyl)imidazo{1.2-a]pyridine-3-
yl}pyrimidin-2-amine gifted from Merck & Co., Inc) block combined with the methods of sorbitol 
treatment and Percoll gradient (sections 2.2.A and 2.2.C respectively). Predominantly ring stage 
cultures of a high parasitemia (5 %- 10 %) were treated with sorbitol to remove all late stage 
parasites and incubated in fresh culture medium (section 2.1.A) over night at 37  C̊. Parasites 
were monitored the next day by Giemsa stained smears (section 2.1.C). Once parasites 
76 
 
developed into segmented schizonts they were purified on a Percoll gradient (section 2.2.C). 
Purified parasites were put into pre-warmed culture medium and when schizonts appeared 
segmented they were incubated with (1 µM to 2 µM) C2 at a haematocrit of <0.5 %. A small 
control sample of un-blocked parasites was removed prior to addition of C2 to monitor schizont 
rupture. Parasites were incubated with C2 at 37  C̊ in 5 % CO2 until most of the parasites in the 
control sample had ruptured. Parasite were incubated with C2 for no longer than 6 hours to 
avoid loss of parasites due to toxicity. Once incubated, parasites were washed once in pre-
warmed RPMI-1640 (to remove the C2 and to release the schizont block) and immediately put 
into 25 ml of pre-warmed culture medium with fresh RBCs (volume depending upon the size of 
the schizonts pellet and desired resulting ring stage parasitemia). Cells were incubated while 
shaking (60 RPM) at 37  C̊ in 5 % CO2 for 2 hours, after which an additional Percoll gradient was 
performed to remove any un-ruptured schizonts from the sample. The lower ring fraction was 
washed once in pre-warmed RPMI and a sorbitol treatment carried out to ensure removal of 
late stages in the early stage sample. Cells were either used or put into culture (as described in 
section 2.1.A) and allowed to grow to the required stage.  
 
 
2.3.  Parasite sample preparation 
 
2.3.A. Parasite sample preparation for immunoblotting and Immunoprecipitation 
Parasite samples were purified by Percoll gradient as described in sections 2.2.C and 2.2.D. 
Purified parasite pellets were re-suspended in 0.15 % saponin (Sigma-Aldrich) containing a 
cocktail of protease inhibitors- (1x protease inhibitor cocktail (inhibits a broad spectrum of 
cysteine, serine and metalloproteases and calpains, Roche), 2 mM EDTA and 1 mM PMSF 
(inhibits serine proteases and the cysteine protease papain, Sigma-Aldrich) to a ratio of 1:4 or 
less. Samples were incubated on ice for 5 minutes and vortexed intermittently until the whole 
pellet appeared lysed. Lysed samples were pelleted in a micro centrifuge at 8000 rpm for 30 
seconds and then washed once in 1 % PBS (80 g NaCl, 2 g KCl, 14.4 g Na2HPO4, 2.4 g KH2PO4 in 
1L H2O) containing the same protease inhibitors as described above. Samples were snap frozen 
in a dry ice and ethanol (100 %) bath then stored at - 80  C̊ until use. 
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2.3.B. Lipid extraction for electrospray-mass spectrometry 
Sample preparation for electrospray mass spectrometry was carried out at LSHTM in 
collaboration with Mathieu Brochet (Sanger institute). P. falciparum schizonts were 
synchronised using a combination of MACS purification (section 2.2.B) and sorbitol treatment 
(section 2.2.A). Lipids were extracted from 50 µl packed cell volume purified schizonts per 
replicate. Samples were washed in 1x PBS then suspended in 100 µl 1x PBS and transferred to a 
glass tube. A chloroform:methanol mix was prepared to a ratio of 1:2. 375 µl of this mix was 
added to cells to lyse them. Samples were vortexed thoroughly for 15 minutes. 125 µl CHCL3 
(chloroform) and 125 µl H2O were added in order to make samples biphasic. This was followed 
by centrifugation at 1,000 xg for 5 minutes at room temperature. The lower phase was carefully 
removed from samples and transferred to a new glass vial and dried under nitrogen (BOC).  In 
preparation for mass spectrometry (carried out by collaborator Terry K Smith at the university 
of St Andrews), lipids were dissolved in a 1:2 chloroform:methanol mix and  
acetonitrile:propanol:water (6:7:2). Samples were analysed and phospholipids identified by 
collaborators (Terry K Smith at the university of St Andrews) using a triple quadrupole mass 
spectrometer with a Nano electrospray source (Absceix 4000 QTrap). Phospholipid peak identity 
was verified using the LIPID MAPS (Nature Lipidomics gateway-www.lipidmaps.org). 
 
 
2.3.C. Ring stage parasite sample preparation for transfection 
Parasites were grown to a high ring stage parasitemia using an adapted version of the Trager 
and Jensen method as indicated in section 2.1.A and synchronised using a method of sorbitol 
treatment (Section 2.2.A) to remove late asexual parasite stages followed by a Percoll treatment 
the following day when parasites were segmented schizont stages (section 2.2.C). Fresh RBCs 
taken no more than 2 days prior (LSHTM blood service) were added to purified schizont stages 
and cells incubated while shaking (60 RPM) at 37  C̊ in 5 % CO2 for 2 hours to give a high ring 
stage culture of 5 % to 10 % parasitemia. An additional Percoll gradient was then performed to 
remove any un-ruptured schizonts from the sample. The lower ring fraction was washed once 
in pre-warmed RPMI and parasites were put back into CM at 37  C̊ in 5 % CO2 until required.  
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2.4. Fluorescence techniques 
 
2.4.A. Calcium release assay 
This assay was developed by Christine Hopp (LSHTM) and relies on the cell permeable, labelled 
calcium indicator Fluo-4-AM (Sigma, M22426). The AM ester allows access into the cell through 
membranes. Once in the cytoplasm, the AM ester gets cleaved, trapping the Fluo-4 inside the 
cell. Pharmacological treatments can then be used to release Ca2+ from internal stores into the 
cytoplasm. Fluo-4 will specifically bind Ca2+ ions and upon doing so will fluoresce. Levels of 
fluorescence can be measured as an indirect indicator of calcium release. 
Changes in the levels of intracellular free Ca2+ were measured using Fluo-4-AM loaded 
segmented schizonts or mature gametocytes which had been cultured as previously indicated 
in sections 2.1.A and 2.1.B of these methods. Parasites were purified by Percoll gradient (as 
described in sections 2.2.C and 2.2.D) and pelleted by centrifugation for 2 min at 500 xg. 
Parasites were re-suspended in warm 10x Ringer Buffer (122.5 mM NaCl, 5.4 mM KCl, 0.8 mM 
MgCl2, 11 mM HEPES, 10 mM D-Glucose, 1 mM NaH2PO4) to 1-2x108 parasites/ml (25 l pcv 
parasites per 1 ml Ringer buffer). 2 µl of 5 mM Fluo-4-AM was added per 1 ml of parasite 
preparation. Cells were incubated in the dark with Fluo-4-AM at 37°C for 45 min. Cells were then 
washed twice in warm Ringer buffer and incubated for 20 min to allow for de-esterification of 
the AM ester. This was followed by a further two washes. The pellet was re-suspended in Ringer 
buffer at 1-2x108 parasites/ml and plated out on the bottom half of a 96 well plate. Test 
compounds were diluted from DMSO stock concentrations to the required working 
concentration and transferred to the top half of the plate (dilutions were calculated to result in 
a final dilution in the well of 1:20 resulting in addition of 5 l of compound per well).  The 
excitation of the cells (bottom half of the plate) was measured at 488 nm using a SPECTRAmax 
M3 microplate fluorimeter (Molecular Devices) at 20 second intervals for a period of 3 minutes 
to achieve a baseline read (Figure 2.1). The plate was removed from the plate reader onto heat 
blocks and the cells rapidly transferred onto the test compounds using a multi-channel pipette. 
The plate was placed back in the plate reader and read for a further 5 minutes at 20 second 
intervals at the same excitation (see blue arrow in Figure 2.1). Levels of free internal Ca2+ were 
compared to the baseline read measured immediately prior to the addition of a test reagent.  
Data for test compounds were analysed in Microsoft Excel in reference to a DMSO control (0.5 
%), a buffer only control and an ionophore control A23187 (20 µM in DMSO, Sigma). A23187 
increases levels of Ca2+ in intact cells by allowing Ca2+ ions to cross cell membranes which are 
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usually impermeable to them. This allows a large unspecific release of Ca2+ from internal stores 
and can therefore be used as a positive control in Ca2+ release assays. Results are presented in 
this report as percentage of ionophore control or Ca2+ release in relative fluorescence units 
(RFU).  
 
 
Figure 2.1. Representative graph depicting measurement of levels of Ca2+ with time in the Ca2+ release 
assay. Test samples (green) are compared to an ionophore control (Blue). Fluorescence of the DMSO 
control (red) and the baseline values for each samples (time points 00:00 to 02:40) are deducted from 
post read (time points 03:20 to 08:00) test sample values.  
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2.4.B. Immunofluorescence assay (IFA) 
 
 General protocol 
Late stage schizonts or gametocyte stages were purified by Percoll gradient as described in 
section 2.2.C and 2.2.D. The purified suspension was pelleted by centrifugation for 2 minutes at 
8000 rpm. Cells were re-suspended to roughly 50 % haematocrit and thin blood films prepared 
on glass slides (VWR). Samples were left to air dry for 2 hours or overnight. To make the wells, 
2 circles of roughly 0.5 cm to 1 cm in diameter were drawn on each slide using a hydrophobic 
wax pen (Sigma). Slides were placed in a slide box and were fixed by either method A: 4 % 
formaldehyde diluted in PBS from a 16 % stock concentration (Thermo scientific), with or 
without 0.001 % glutaraldehyde (Sigma) for 30 minutes at room temperature then rinsed in 1 x 
PBS. Or method B: fixed in cold methanol (VWR) (-20 °C) for 2 minutes then left to air dry. Slides 
were then permeabilised in 0.1 % Triton (x100 Sigma) for 10 minutes at room temperature 
followed by a 1x PBS wash. Slides were blocked in 3 % bovine serum albumin (BSA), (diluted in 
1x PBS, Sigma) overnight at 4°C. The following day, the required primary antibodies were diluted 
to the required concentration in BSA. Slides were removed from the 3 % BSA and all areas dried 
excluding the wells which remained wet at all times. ~50-100 µl of the primary antibody was 
pipette onto each well and mixed. Samples were incubated with the primary antibody for 1 hour 
at room temperature. Slides were then washed briefly with 1x PBS then shaken gently in fresh 
1x PBS at room temperature for 30 minutes with three 1x PBS buffer changes at 10 minute 
intervals. The same process was repeated for the secondary antibody. After the final PBS wash, 
the slides were dried. One drop of Hydromount containing DAPI (1.5 µg/ml Dapi in glycerol 
based mounting medium Vectarlabs) was placed onto a coverslip and the coverslip placed gently 
over the sample with the hydromount situated on top of the wells. The coverslip was pressed 
gently onto the slide and the edges sealed with nail varnish.  
Unless stated otherwise, samples were viewed using an EVOS FL cell imaging system (Thermo 
Fisher Scientific), which uses LED light cubes to deliver fluorophore excitation, and a Sony ICX445 
monochrome CCd camera. -HA antibody coupled to Alexa Fluor 594 was detected at an 
excitation of 585/29 nm and an emission peak of 624/40 nm, -HA antibody coupled to -rat 
biotin coupled to Alexa Fluor 488 conjugated streptavidin was detected at an excitation of 
470/22 nm and an emission peak of 510/41 nm. WGA-TR was imaged using 592 nm excitation: 
615 emission. Hoechst 33342 was imaged at 347 nm excitation and 483 emission. 
Images were analysed using Adobe photoshop elements. 
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Immunofluorescence assay: Band 3 rounding up and emergence of gametocytes 
Gametocytes were cultured as described in section 2.1.B and purified by Percoll gradient 
(section 2.2.D). Parasites were kept at 37 °C using a heat block. The purified parasite sample was 
mixed with uninfected erythrocytes to a ratio of roughly 2:1 (parasites:erythrocytes) and diluted 
in warm complete media (see section 2.1.A) to a final volume of 100 µl per sample. Test 
compounds were added to 1.5 ml tubes (Star lab) to give a final concentration of 10 µM or 30 
µM XA, 2 µM C2, 1 µM MRT00207065, 100 µM zaprinast and 10 µM PF9. Control tubes contained 
0.5 % DMSO. 100 l of parasite sample was added to each tube and samples incubated for 30 
minutes at room temperature. Samples were then washed once in warm RPMI followed by 
removal of the supernatant to leave a final haematocrit of ~50 %. Samples were smeared on 
glass slides and left to air dry for at least 2 hours. Samples were fixed in cold methanol and the 
general IFA protocol was followed as indicated above.  The -human Band 3 antibody (Abcam, 
Mouse monoclonal), which recognises specifically the cytoplasmic amino acid terminal of the 
integral erythrocyte glycoprotein Band 3, was diluted 1:5000 in BSA. The secondary antibody 
used to identify Band 3 binding (Molecular Probes goat anti mouse Alexa Flour 594) was diluted 
to 1:1000 in BSA. Slides were read using a confocal microscope (Zeiss LSM 510 laser scanning 
confocal microscope). DAPI was imaged at wavelength 405nm using laser diode and rhodamine 
at 594 nm using a HeNe 1 laser and images were analysed using Zeiss LSM image browser. 
 
Immunofluorescence Assay: PDE δ-NF54 triple HA tag line: HA detection 
Plasmodium falciparum gametocytes of the PfPDE-HA transgenic line (see chapter 6 for details 
of the line) and an NF54 control were initiated and cultured as described in section 2.1.B to stage 
IV/V gametocyte stages and purified by Percoll gradient (See section 2.2.D). Parasites were kept 
at 37 °C continually using a heat block, and were prepared to a haematocrit of ~ 50- 80 % then 
smeared on glass slides and left to air dry for at least 2 hours. Samples were fixed in 4 % 
formaldehyde (diluted in 1x PBS from a 16 % stock, Thermo Scientific) and the general IFA 
protocol was followed as indicated above. -HA antibody (High affinity rat monoclonal, stock 
100 µg/ml, Roche) was diluted 1:100 in BSA and incubated for 1 hour followed by a wash step 
as indicated in the general protocol. Two conditions were used; the first was addition of the 
secondary antibody (Alexa Fluor 594 goat α-rat, Invitrogen), diluted to 1:1000 in BSA and 
incubated for 1 hour followed by a wash step. The second was the addition of biotinylated goat 
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α-rat IgG (1:200, vector labs Inc, Lot Z032). This was incubated for 1 hour at room temperature 
followed by 3 1x PBS wash steps as indicated in the general IFA method. This was followed by 1 
hour incubation at room temperature with Alexa Fluor 488 conjugated streptavidin (diluted 
1:500, vectorlabs inc, Lot Z032). This was followed by 3 1x PBS wash steps. IFA samples were 
prepared for microscopy as indicated in the general IFA section (above).  
Note: For detection of ERD2, α-ERD2 (rabbit) diluted 1:1000 was followed by goat α-rabbit Alexa 
Fluor 594. 
 
Immunofluorescence Assay: Wheat germ agglutinin rounding up and emergence of 
gametocytes 
Wheat germ agglutinin (WGA) is a lectin that binds to sialic acid and N-acetylglucosaminyl 
residues. When conjugated to a fluorescent probe, it can be used to visualise the erythrocyte 
membrane by fluorescent microscopy.  Gametocytes were initiated and cultured as indicated in 
section 2.1.B and purified by Percoll gradient (See section 2.2.D). Parasites were kept at 37 °C at 
all times using a heat block. Gametocyte stages do not purify efficiently with a 60 % Percoll 
gradient, with ~ 20 % of erythrocytes remaining in the sample. Uninfected erythrocytes are 
required in the sample to identify effective erythrocyte labelling. If the uninfected erythrocytes 
portion of the sample was lower than 5 % it was adjusted to ~ 5-20 % by addition of fresh 
uninfected erythrocytes. Purified parasite pellets were diluted in warm CM (see section 2.1.A) 
to ~ 1-5 % haematocrit (HC). For DNA staining of live parasites 20 μM Hoechst 33342 (Cell 
Signalling Technology, diluted from 10 mg/ml stock in DMSO, stored in the dark) was added to 
parasite samples and incubated for 45 minutes at 37 °C (in the dark). Wheat germ agglutinin (5 
μg/ml, diluted from stock: 1 mg/ml in H20) conjugated to Texas red (excitation/emission maxima 
~595/615 nm (WGA-TR) (Thermo Fisher Scientific)) was added to parasite samples and 
incubated for a further 15 minutes at 37 °C in the dark. Samples were washed 3x in warm RPMI-
1640 and fresh CM added to the pellet to make a HC of ~ 1- 5 %. Test compounds were made to 
a working concentration of 1 µM MRT00207065 and 10 µM PF9 from DMSO stocks. Parasite 
samples were separated into three tubes (DMSO, PF9 and PF9 + MRT00207065) to a volume 
required to make a final drug dilution of 1:20 (5 l of compound added per 100 l of parasite 
samples). DMSO (0.05 %) was added to the control sample. Samples were incubated with 
compounds for 20 minutes at room temperature in the dark. Samples were washed once in 
warm RPMI-1640 (Sigma) followed directly by addition of 1 % formaldehyde diluted in 1x PBS 
(Thermo Fisher Scientific) containing 0.001 % glutaraldehyde (Sigma Aldrich) and incubated for 
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30 minutes to fix the cells. Samples were pelleted at 8000 xg for 30 seconds. The supernatant 
was removed and discarded leaving a pellet of ~ 60 -80 % HC and 2-5 l of the pellet dropped 
onto a glass slide and a cover slip placed on top. The coverslip was sealed with nail varnish to 
prevent it drying up and the slide turned over to allow the cells to settle onto the coverslip. 
Images were taken (as indicated in the general protocol using an Evos FL microscope). The 
number of emerged (Hoechst 33342 staining but no WGA-TR staining) and non-emerged cells 
(Hoechst staining and WGA-TR staining) were counted from images. Bright field images were 
also taken of each sample to identify a morphological change from a crescent shape to a rounded 
form. 
 
2.4.C. Luciferase Assay: Gametocyte viability assay       
Bioluminescence is the emission of light from a living organism and involves a reaction in which 
a luciferase enzymes catalyses the oxidation of a specific substrate (in this case D-luciferin), this 
releases protons in the visible light spectrum which can be measured. This method can be used 
to quantitatively assess the viability of a parasite culture. The transgenic line 3D7elo1-pfs16-
CBG99 (green emitting luciferase, 537 nm) kindly provided by Grazia Camarda and Pietro 
Alano[264] expresses the enzyme luciferase (CBG99 from the click beetle, Pyrophorus 
plagiophthalamus) under the control of the sexual stage specific pfs16 gene promoter. This 
means that only gametocyte stages will express the enzyme. Synchronised gametocyte cultures 
of this line at early or late stages were used in gametocyte viability assays as described below to 
assess the stage specificity of pharmacological compounds by bioluminescence. 
This line was used to measure the viability of gametocytes after addition of several possible 
gametocytocidal candidates. To achieve either an immature stage culture (Stages II to III) or a 
mature sexual stage culture (Stage V), parasites were induced and cultured as specified in 
section 2.1.B to either stage II or stage IV/V. Samples were prepared to a 2 % gametocytemia at 
1 % haematocrit in complete CM. 
The test compounds (PF9, PF10, PF11, PF12 and PF14) were diluted from a DMSO stock solution 
of 20 mM (in DMSO) into CM to a concentration of double the final concentration required and 
a 1:3 serial dilution for each compound in triplicate was carried out across the plate resulting in 
a final volume of 100 µl of test compound per well (10 μM, 3.33 μM, 1.11 μM, 0.37 μM, 0.123 
μM, 0.041 μM, 0.013 μM, 0.0045 μM). The following controls were included in this assay: 0.5 % 
DMSO, no D-luciferin and uninfected erythrocyte control. 100 µl of parasite suspension was 
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added to each well excluding the erythrocyte only control wells. The plate was incubated for 48 
hours at 37 °C in 1 % O2/3 %CO2/N2 200 bar. 
Citrate buffer (developed by Cevenini et al[264]), was prepared using a combination of two 
solutions, 25.5 ml solution A (0.1 M citric acid monohydrate, Sigma Aldrich) + 74.5 ml solution B 
(0.1M trisodium citrate dehydrate, Sigma Aldrich) and adjusted to pH 5.4. This buffer was used 
to prepare 1 mM D-luciferin (Beetle Luciferin Potassium salt, Promega, Lot 0000153923, 50 mg, 
Ref E1602 MW 318.4). After the 48 hour incubation, 100 μl of 1 mM D-luciferin was added to 
each well excluding the Luciferase free control and the bioluminescence read immediately on a 
Spectramax M3 plate reader (Molecular Devices). Determination of the number of viable cells 
was measured in relative fluorescent units and is determined by quantification of ATP. Data 
were collected in Softmax Pro and analysed in GraphPad, Prism. 
 
2.4.D. Live cell confocal microscopy 
Gametocytes were initiated and cultured as indicated in section 2.1.B and purified by MACS 
purification (section 2.2.B). Parasites were kept at 37 °C at all times using a heat block. Purified 
samples were pelleted by centrifugation for 30 seconds at 8000 rpm and re-suspended in warm 
10x Ringer Buffer (122.5 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl2, 11 mM HEPES, 10 mM D-Glucose, 
1 mM NaH2PO4) to 1-2x108 parasites/ml. 2 µl of 5 mM Fluo-4-AM was added per 1 ml of parasite 
preparation. Cells were incubated with Fluo-4-AM at 37°C for 45 min. Cells were then washed 
twice in warm Ringer buffer and incubated for 20 min to allow for de-esterification followed by 
a further two washes. Samples were resuspended in complete CM (section 2.1.A) to a 
haematocrit of ~ 50 %. 10 μl of sample was loaded onto a Poly-lysine (Sigma Aldrich) coated 
coverslips in a small petri dish (PELCO, Ted Pella Inc). Cells were incubated for 2 minutes to 
enable binding to the cover slip. Cells were viewed by confocal microscopy (Zeiss LSM 510 laser 
scanning confocal microscope) and imaged in real time with sequential pictures taken 1 ms apart 
to produce multiple frames. After ~ 5/10 seconds, 5 l XA was added to the sample to make a 
final concentration of 30 M. Changes in fluorescence before and after addition of XA were 
observed and captured in real time. Green imaging read at a wavelength of 488 nm using an 
argon laser. 
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2.5.  Gametocyte assays 
 
2.5.A. Identifying the effect of PF9 on PKA-inhibited PfPDE-ko gametocytes  
Stage V gametocytes of the PfPDEko transgenic line (see chapter 6) and 3D7a wildtype 
parasites were purified on a Percoll gradient (see section 2.2.D) and mixed with uninfected 
erythrocytes to obtain a gametocytemia of between 2 % and 5 % (parasite samples with a 
parasitemia higher than 2 % were not purified).  Samples were diluted in gametocyte culture 
media (section 2.1.B) to achieve a 0.5 % to 1 % haematocrit (referred to from here on as parasite 
preparation). The PfPDE-ko transgenic line was split into eight samples in a 24 well plate to a 
total culture volume of 1 ml per well at a final haematocrit of 2 %. DMSO (0.05 %) was added to 
two control samples. KT5720 was added to wells to make duplicates of the following final 
concentrations; 10 M, 5M and 1M. Concentrations of KT5720 were calculated to result in 
the same volume of all drug samples added to each well. 1 M of MRT00207065 was added to 
one of each of the two duplicates give the following samples: DMSO, DMSO + 065, KT5720 10 
M, KT5720 10 M + 065, KT5720 5 M, KT5720 5 M + 065, KT5720 1 M, KT5720 1 M + 065. 
The 3D7a control sample was split into 4 samples and KT5720 was added to a final concentration 
of 10 M, 5 M and 1 M. 0.05 % DMSO was added to the last sample. All samples were 
incubated for 3 hours at 37  C̊ / 5 % CO2 (BOC). After incubation, each of the PfPDE-ko transgenic 
line samples was split into two. PF9 was added to one of each of the duplicates to a final 
concentration of 10 M. The equivalent percentage of DMSO was added to the other duplicate 
of each sample. Samples were incubated at room temperature for 20 minutes. All (PfPDEko 
and 3D7a) samples were then pelleted by centrifugation at 8000 rpm for 30 seconds. The 
supernatant was removed to leave a final haematocrit of ~ 80 %. Blood films were prepared and 
stained with Giemsa as indicated in section 2.1.C. Numbers of stage IV/V gametocytes, rounded 
parasites and abnormal forms were counted by light microscopy as described in section 2.1.C. 
Samples were counted in duplicate and analysed in Excel. Graphs and statistics for each sample 
were generated in GraphPad, Prism.  
 
2.5.B. Identifying the effect of XA on PKA-inhibited PfPDE-ko gametocytes  
Stage V gametocytes of the PfPDEko transgenic line and 3D7a wildtype line were prepared as 
indicated in section 2.5.A. The PfPDE-ko transgenic line was split into two samples (to a final 
volume of 100 l per sample). DMSO (0.05 %) was added to one of the PfPDE-ko samples and 
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to the 3D7a sample. KT5720 was added to the remaining PfPDEko sample to a final 
concentration of 5 M. Samples were incubated for 12 hours at 37  C̊ / 5 % CO2 (BOC). After 
incubation, each sample was split into duplicates. XA was added to one of each of the duplicates 
to a final concentration of 30 M. The equivalent percentage of DMSO was added to the other 
duplicate of each sample. Samples were incubated at room temperature for 30 minutes. All 
samples were then pelleted by centrifugation at 8000 rpm for 30 seconds, the supernatant was 
removed to leave a final haematocrit of ~ 80 %. Blood films were prepared and stained with 
Giemsa as indicated in section 2.1.C. Numbers of crescent shaped gametocytes and rounded 
parasites were counted by light microscopy. Samples were counted in duplicate and percentage 
parasitemia values generated using Excel. Graphs and statistics for each sample were generated 
in GraphPad, Prism.  
 
2.5.C. PF9 dose response assay 
Stage V gametocytes of the PfPDEko transgenic line and 3D7a wildtype line were initiated and 
cultured to stage V as described in section 2.1.B. Stage V gametocytes were purified on a Percoll 
gradient (see section 2.2.D) and mixed with uninfected erythrocytes to obtain a gametocytemia 
of 1 % to 3 % depending upon the number of gametocytes (parasite samples with a parasitemia 
higher than 2 % were not purified).  Samples were diluted in gametocyte culture media (section 
2.1.B) to achieve a 0.5 % to 1 % haematocrit. Samples were then incubated for 12 hours  at 37 
 C̊ / 5 % CO2 (BOC) with 0.2 M, 2 M or 20 M PF9 or with < 1 % DMSO (control), all in the 
presence and absence of C2 (2 M).  After incubation, all samples were pelleted by 
centrifugation at 8000 rpm for 30 seconds, the supernatant was removed to leave a final 
haematocrit of ~ 80 %. Blood films were prepared and stained with Giemsa as indicated in 
section 2.1.C. Numbers of crescent shaped gametocytes and abnormal forms were counted by 
light microscopy. Samples were counted in triplicate and percentage parasitemia values 
generated using Excel. Graphs and statistics for each sample were generated in GraphPad, Prism. 
Images of samples were generated using an Olympus BX51 light microscope with an Olympus 
SC30 camera. 
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2.5.D. PF9 time course assay 
Stage V gametocytes of the 3D7a wildtype line were initiated and cultured to stage V as 
described in section 2.1.B. Stage V gametocytes were purified on a Percoll gradient (see section 
2.2.D) and mixed with uninfected erythrocytes to obtain a gametocytemia of 1 % to 4 % 
depending upon the number of gametocytes (parasite samples with a parasitemia higher than 
2 % were not purified).  Samples were diluted in gametocyte culture media (section 2.1.B) to 
achieve a 0.5 % to 1 % haematocrit. Samples were split into 10 samples of 100 l each in 
eppendorf tubes and kept in a heat block at 37  C̊. PF9 (final concentration 10 M) was added 
to 5 of the samples and < 1 % DMSO to the other 5 samples. Samples were incubated for 30 
minutes at 37  C̊.  Every 5 minutes blood films were prepared from one PF9 sample and one 
DMSO control sample as follows; samples were pelleted by centrifugation at 8000 rpm for 30 
seconds, the supernatant was removed to leave a final haematocrit of ~ 80 %. Blood films were 
prepared and stained with Giemsa as indicated in section 2.1.C. Numbers of crescent shaped 
gametocytes or rounded forms were counted by light microscopy. Samples were counted in 
triplicate and percentage parasitemia values generated using Excel. Graphs and statistics for 
each sample were generated in GraphPad, Prism. Images of samples were generated using an 
Olympus BX51 light microscope with an Olympus SC30 camera. 
 
2.5.E. Rounding up assay 
Stage V gametocytes were initiated and cultured to stage V as described in section 2.1.B. 
Gametocytes were purified on a Percoll gradient (see section 2.2.D) and mixed with uninfected 
erythrocytes to obtain a gametocytemia of 1 % to 4 % depending upon the number of 
gametocytes (parasite samples with a parasitemia higher than 2 % were not purified).  Samples 
were diluted in gametocyte culture media (section 2.1.B) to achieve a 0.5 % to 1 % haematocrit. 
Mature gametocyte samples were treated with test compounds for a designated period of time 
(see individual experiments for more specific assay conditions). In all assays unless stated 
otherwise, treated samples were then pelleted by centrifugation at 8000 rpm for 30 seconds, 
the supernatant was removed to leave a final haematocrit of ~ 80 %. Blood films were prepared 
and stained with Giemsa as indicated in section 2.1.C. Numbers of crescent shaped gametocytes 
or rounded forms were counted by light microscopy. Samples were counted in triplicate and 
percentage parasitemia values generated using Excel. Graphs and statistics for each sample 
were generated in GraphPad, Prism.  Images of samples were generated using an Olympus BX51 
light microscope with an Olympus SC30 camera. 
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2.5.F. Microsphiltration assay 
This assay uses a microsphere matrix to mimic splenic retention. A matrix was prepared using 
calibrated metal microspheres of two different size distributions (5 to 15 µm diameter and 15- 
to 25 µm diameter) made up of the following percentage of metals: 96 % tin, 3 % silver and 0.5 
% copper (Industrie des Poudres Spheriques). Gametocyte samples were cultured as described 
in section 2.1.B to produce synchronous stage V gametocyte cultures. Samples were prepared 
to a parasitemia of 1 % to 5 %. Gametocyte cultures under 1 % were purified by MACS separation 
(see section 2.2.B) and diluted to the required percentage parasitemia using uninfected 
erythrocytes. Gametocytes were suspended in warm complete medium or RPMI-1640 to 1- 5 % 
haematocrit and perfused through the microsphere matrix at a flow rate of 60 mL/h using an 
electric pump (Syramed sp6000, Arcomed Ag). This was followed by 5 ml of complete medium 
to wash. Both the upstream and downstream samples were collected and blood smears 
prepared as described in section 2.1.C. Parasitemia of samples was determined by counts (2000 
erythrocytes counted per sample) of Giemsa stained blood films. 
 
 
2.5.G. Phosphodiesterase activity assay 
This assay was developed by Laura Drought (Laura Drought, PhD Thesis, 2014) and is based on a 
scintillation proximity assay (SPA). This is a bead-based assay technology used to detect and 
quantify radioactivity and was adapted to measure the PDE activity of a protein sample. When 
a 3H radioisotope decays it will release  particles. The distance that these  particles travel 
through an aqueous solution is dependent upon their energy. If the  particle is in close enough 
proximity to the SPA bead it will stimulate the stimulant within the bead (in the case of the assay 
this is yttrium (YSi)). This will generate light that can be detected using a scintillation counter. If 
the radioactive molecule does not come into close enough proximity to the SPA bead, the  
particles will have insufficient energy to reach the bead and no light will be emitted. 
Laura Drought has adapted this assay using SPA beads with an YSi core (Perkin Elmer, 
RPNQ0150). This assay relies on the fact that the cyclic nucleotides cAMP and cGMP are unable 
to bind to the SPA beads but when hydrolysed by a PDE, the linear nucleotide products 5’AMP 
or 5’GMP will bind SPA beads in the presence of zinc sulphate by an ion chelation mechanism. 
Higher levels of PDE hydrolysis will result in more binding and the light detected can be 
measured and quantified. PDE assays were carried out on immunoprecipitated HA tagged 
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PfPDE and immunoprecipitated HA tagged PfPDE protein (see section 2.7.C for 
immunoprecipitation method). 
 
PDE Assay on immunoprecipitated HA-tagged PfPDE and HA-tagged PfPDE 
Assays were conducted in a flexible 96 well plate (Perkin Elmer, 1450-401) in a final volume of 
100 l.  90 l of immunoprecipitated (IP) sample diluted in 1x PDE assay buffer (10x buffer 
contains 17 mM EGTA, 500 mM Tris-HCL, 83 mM MgCl2) was added per well.  Test samples were 
added to the appropriate wells (PF9, 5M and 200nM, and XA, 1M and 10M, stock solutions 
prepared in DMSO and working concentrations diluted in PDE assay buffer). The no-compound 
sample was diluted 1:10 in PDE assay buffer from the concentrated IP sample. [3H] cyclic 
nucleotides were diluted to 500nM in 1ml. To start the reaction, 10 l of either [3H]-cAMP or 
[3H]-cGMP [3H]cyclic nucleotide (Perkin Elmer cAMP-NET275250UC, cGMP-NET337250UC 
diluted in 1x PDE assay buffer) was added to wells. Samples were incubated for one hour at 37 
 C̊. To terminate the reaction, 50 l of resuspended SPA beads (reconstituted to 20 mg/ml in 
distilled H2O) were added to each well. The plates were sealed with plateseal (Perkin Elmer), 
briefly shaken and then incubated for a further 20 minutes at room temperature to allow the 
beads to settle. Scintillation was measured using a Wallac 1450 MicrobetaTM scintillation counter 
(Perkin Elmer). Each well was counted for 30 seconds. Data was analysed in Excel and graphs 
generated in GraphPad, Prism. 
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2.6. Molecular techniques 
 
2.6.A. Transformation of competent E.coli cells: General method 
A method of artificial transformation is used to introduce recombinant DNA into chemically 
competent bacterial cells. Unless stated otherwise, the following method was used; plasmid 
DNA was added to chemically competent E. coli cells and incubated on ice for 30 minutes 
followed by a heat shock treatment in a water bath at 42   C̊ for 45 seconds. Samples were then 
placed on ice for 2 minutes followed by addition of 0.9 ml pre warmed SOC recovery medium (2 
% tryptone, 0.5 % yeast extract, 10 mM NaCl, 2.5 mM KCL, 10 mM MgCL2 and 20 mM glucose). 
Samples were placed on a shaker at 225 rpm at 37   C̊ for 1 hour after which they were diluted 
1:10 with SOC medium. SOC medium was spread on an agar plate containing either ampicillin at 
a concentration of 100 g per ml or Kanamycin at a concentration of 30 µg/ml. Plates were 
incubated over night at 37   C̊. The following day colonies were picked from the agar plate and 
each put into Luria-Bertani (LB) broth (1 % tryptone, 0.5 % yeast extract, 1 % NaCL and 1.5 % 
agar) containing an antibiotic. Samples were incubated over night at 225 rpm at 37   C̊. 
For amplification of the plasmid containing the synthetic gene DH5α E. coli cells were used. 
Antibiotic used was kanamycin. After the last step described above DNA from competent cells 
was extracted as described in section 2.6.D. 
For amplification of the PL6--HA plasmid XLI0 Gold E. coli cells were used. Antibiotic used was 
Ampicillin. After the last step described above, further colonies were picked and put into SOC 
medium containing ampicillin and incubated over night at 225 rpm at 37   C̊.  Mini preps were 
carried out on all samples (see method below). 
 
2.6.B. Mini prep for extraction of DNA  
The miniprep procedure is based on alkaline lysis of the bacterial cells. In the presence of high 
salt, DNA from lysed cells is then absorbed onto a silica membrane. This can then be eluted to 
produce a purified DNA sample. A QIAprep®spin mini prep kit (Qiagen, Lot 27104) was used to 
purify the DNA and the method followed as indicated by the manufacturer’s instructions. DNA 
content was measured in each sample by nanodrop.  
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2.6.C. Restriction digest  
Restriction digest of PDE-HA and PL6 plasmids 
The method of restriction digest uses specialist enzymes (restriction endonucleases) that will 
selectively cut at specific DNA sequences to produce fragments which can be separated on an 
agrose gel to determine size. This method is used to prepare DNA for analysis or other processing 
such as ligation, which requires the generation of compatible ends to allow insertion of the 
required sequence of DNA into a compatible plasmid. 
The method of restriction digest was used to firstly remove the synthetic gene from the plasmid 
in which it arrived and then to cut the PL6 plasmid in order to ligate the synthetic gene into it. 
Further restriction digests were then carried out throughout the construction process of the 
plasmid to ensure that the synthetic gene has inserted into the PL6 plasmid correctly. In all 
instances unless stated otherwise, a mastermix was prepared made up of the required 
restriction enzymes, PCR grade water and restriction digest buffer. Digestion preparations were 
prepared by adding plasmid samples to the mastermix followed by incubation at 37   C̊ for 1.5 
hours. Digested samples were run on a 1 % agrose gel at 100V/13w/137MA for 1 hour to 
determine fragment sizes. All restriction endonucleases were supplied by Fermentas or New 
England Biolabs and in all instances restriction digest buffer was prepared unless stated 
otherwise as follows: (10x CutsmartTM Buffer #B77045 with added bovine serum albumin (BSA), 
diluted in 1x PBS, Sigma). 
 
2.6.D. DNA fragment clean up 
PDE-Delta-HA and PL6 fragment DNA clean up  
A miniElute®reaction clean up kit (Qiagen 28204) was used to clean up the DNA of digested 
plasmids. And the method was followed as per the supplier’s instructions. Samples were eluted 
in 10 µl elution buffer. 
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2.6.E. DNA fragment ligation 
PDE-Delta-HA and PL6 fragment ligation (to ligate synthetic gene into PL6 plasmid) 
DNA fragment ligation involves the joining of two DNA fragments through the action of an 
enzyme (see Figure 2.2 for schematic). 
The transformed, cleaned and digested DNA fragments of PDE-HA and the pL6 repair template 
plasmid (sections 2.6.E) were incubated at room temperature for 2 hours in T4 ligase 
(enterobacteria phage T4), x10 ligase buffer (50 mM Tris-HCL, 10 mM MgCl2, 1 mM ATP, 10 mM 
DTT, pH 7.5 at 25 C̊) and PCR water to give a total volume of 10 µl. This was followed by an 
inactivation step at 65   C̊ for 10 minutes to inactivate the ligase.  
 
  
Figure 2.2: Schematic showing PDE-Delta-HA and PL6 plasmid digest and fragment ligation 
 
2.6.F. Infusion cloning with oligos 
Oligos (see appendix A2 for sequences) were firstly annealed. Both were diluted in PCR grade 
H2O to prepare a stock concentration of 100 µM. 10 µM was made in a total volume of 100 µl 
annealing reaction (10 µl of each oligo, 10 µl buffer (NE buffer D70025 10x Bio labs) and 70 µl 
PCR H2O). The reaction was incubated at 95   C̊ for 5 minutes to annealed oligos. 
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Infusion cloning was carried out by Avnish Patel, (LSHTM) using the pre-infusion cloning pL6 
repair plasmid containing PDEδ-HA synthetic gene insert. The infusion cloning reaction was 
prepared on ice to result in a 5 µl total reaction as follows: 1 µl 5x enzyme mix, 5 µl cut plasmid, 
1.5 µl of 0.5 M annealed oligos and 1.5 µl PCR grade H2O. The reaction was incubated at 50   C̊ 
for 15 minutes.  
 
2.6.G. Maxi prep 
Maxi prep on PL6 containing PDEδ HA plasmid sample 2b post-infusion cloning. 
The post infusion cloning sample was put into LB broth. A Maxi kit (Qiagen plasmid plus maxi kit, 
cat 12963) was used to extract the DNA as indicated in the manufacturer’s instructions. The DNA 
content of the Maxi prep product was measured by nanodrop. 1 µl of sample was loaded onto 
the nanodrop to measure DNA content. 
A restriction digest was carried out by Christian Flueck, LSHTM. This sample was used for 
transfection. 
 
2.6.H. Transfection 
Genetic manipulation of a P. falciparum NF54 parasite line (with good gametocyte producing 
capabilities) was achieved using a standard ring stage transfection protocol. In short, parasites 
were prepared as indicated in section 2.3.C. The co-precipitation was prepared using 85 μl of 
precipitated PL9 high fidelity Cas9 blasticidin + gRNA DNA (measured as 176 ng/ μl using a 
nanodrop, and  26 μl of pL6 repair template containing the PDEδ-HA insert. 500 μl 100 % EtOH 
was added and 60 μl sodium acetate. Samples were incubated at - 80 C̊ for 30 minutes then 
pelleted at 15300 xg in a cold centrifuge for 15 minutes. The supernatant was removed and the 
sample washed in 70 % EtOH. Samples were briefly pelleted and left to air dry.  
DNA co-precipitation was resuspended in 10 μl 1x TE buffer (1 mM Na2EDTA, 10 mM Tris-HCL 
(pH 8)). This was followed by addition of 100 μl PE primary cell solution. Samples were mixed 
well.  
Parasite samples were pelleted at 8000 rpm for 30 seconds and all of the supernatant removed. 
The DNA-cytomix preparation was added to the parasite pellet and immediately transferred to 
a 0.2 cm cuvette (Bio-Rad). Cells were transferred gently using a pipette. The sample was 
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electoporated using a Lonza 4D-NucleofectorTM at 0.31 kilovolts (KV) and 950 microfarad (F). 
Parasites were gently transferred to 10 ml pre-warmed CM (section 2.1.A) in a 25 ml culture 
flask with 0.5 ml very fresh blood (< 2 days old). Parasites were incubated at 37  C̊ / 5 % CO2 
(BOC) as indicated in section 2.1.A. 2.5 g/ml blasticidin was added for 10 days and the parasites 
regularly monitored by Giemsa stained blood film (section2.1.C) until parasites were detectable 
by microscopy. A PCR analysis of parasites (section 2.6.K) was carried out and samples analysed 
by SDS PAGE (section 2.7.A) and western blot (section 2.7.B) to confirm integration. 
 
2.6.I. Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) is a technique that uses a method of thermal cycling in order 
to exponentially amplify a segment of DNA. This involves an initial denaturation step at a high 
temperature (94 ̊C to 96 C̊) to break apart the double stranded DNA. This is followed by a 
decrease in temperature to allow annealing of specific primers to each strand of the DNA (this 
is usually 40-60  C̊ and varies depending on the optimal temperature required for the primer 
used). The last step involves a further increase in temperature to 72  C̊ to allow for elongation 
of the complementary strand of DNA which enables an enzyme, polymerase, to add nucleotides 
to the primer sequence. This extends both complementary strands, resulting in two segments 
of double stranded DNA. This cycle is repeated on average around 30 times leading to an 
amplification of the sequence of interest.  
PCR to determine integration of the HA-tagging plasmid into the PfPDE locus 
To confirm integration of the HA-tagging plasmid (NF54-PfPDE-HA) into the correct locus, the 
following PCR protocol was followed: DNA was extracted from whole blood from predominantly 
schizont stage cultures of the NF54-PfPDE-HA line using a Qiagen, DNeasy Blood & tissue kit, 
(Qiagen, cat 09504). Wildtype NF54 line parasites were used as a control. DNA was measured 
using a nanodrop giving a quantity of 43.2 ng/µl for NF54 sample and 134.1 ng/µl for the NF54-
PfPDE-HA line DNA.  A master mix was prepared using 100 l BIOMixTM Red DNA polymerase 
(Bioline) and 100 l PCR grade H2O. Primer pairs (1 l each primer) were added to 8 tubes as 
indicated as follows: tubes 1 and 2: WT specific (p1 + p2), tubes 3 and 4: Integration specific (p3 
+ p4), tubes 5 and 6: Episome and integrated specific (p4 + p5) and tubes 7 and 8: a DNA control 
(13’PKG-BC1F + PKG-CRD). See appendix A2 for primer sequences. 0.5 l parasite DNA (NF54-
PfPDE-HA line or NF54 control for each primer set) was added to primer pairs. 22.5 l of master 
mix was added to each tube. The PCR reactions were cycled as follows: 94  C̊ for 3 minutes, 60 
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 C̊ for 30 seconds, 65   C̊ for 30 seconds, 94   C̊ For 30 seconds, 60   C̊ for 30 seconds, 65   C̊ for 30 
seconds, steps 4-6 cycles 30 times, then 65   C̊ for 3 minutes. 
Samples were run on an agrose gel ((1g agrose in 100 ml TAE), 100v/13w/137ma for 1 hour). 
 
2.7. PfPDEδ-HA line assays 
 
2.7.A. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)  
 
Polyacrylamide gel electrophoresis is a method used to separate proteins based on their charge, 
size, electrophoretic mobility and conformation. In this project SDS-PAGE was used to separate 
proteins based on size by denaturing proteins leading to linearization. The SDS in the buffer 
results in an overall negative charge of the protein. Smaller proteins will travel further along the 
gel and sizes of proteins can be estimated based on comparison to proteins with an already 
known molecular weight. The molecular weight ladder used was Precision Plus proteinTM 
Standards (BioRad, cat 161-0373). A tris/glycrine based gel (Bio Rad mini-protean®TGX stain-
FreeTM gel) was placed in a gel tank with 1x SDS-PAGE running buffer. 15ul of each sample was 
loaded into the wells and the gel run for 40 minutes at 200V.  
 
2.7.B. Western blotting 
After completion of SDS-PAGE (section 2.7.A), the gel was blotted onto a nitrocellulose 
membrane (Bio Rad Trans-Blot® turboTM mini sized transfer stacks) at 2.5 amps, 25V for 20 
minutes. Once transfer had occurred, the nitrocellulose membrane was blocked in 5 % milk 
powder (Marvel dried skimmed milk in 1x PBS with 0.1 % Tween (Sigma Aldrich)) for an hour 
while shaking gently. The blot was then incubated with a 1:2000 dilution primary antibody (-
HA high affinity rat monoclonal 100μg/ml, clone 3F10, Roche) overnight while gently shaking. 
Samples were washed twice for 15 minutes in 1x PBS with 0.1 % Tween and stained with a 
secondary antibody (polyclonal rabbit -rat Alexa Fluor 595 (Dako) 1.3 g/l stock, lot: 00076525, 
diluted in milk block to 1:6000) for 1 hour at room temperature while shaking. The blot was 
washed twice for 15 minutes in 1x PBS with 0.1 % Tween. SupersignalTM West Femto maximum 
sensitivity substrate (Thermo Scientific, cat 34095, enhanced chemiluminescent (ECL) substrate 
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with horseradish peroxidase) was added to the blot and ECL hyper film (GE healthcare) and the 
protocol followed according to the manufacturer’s instructions.  
 
2.7.C. Immunoprecipitation of PfPDEδ-HA 
An immunoprecipitation assay was carried out on the HA-tagged PfPDEδ line using an anti-HA 
affinity matrix composed of immobilised anti-HA high affinity rat monoclonal antibodies (clone 
3F10) (Roche, Diagnostics, Lot 10167700) to pull down PfPDEδ protein from mature gametocyte 
samples (see section 2.3 A for gametocyte sample preparation). Parasite pellets were 
resuspended in 250 μl ice cold PDE lysis buffer (150mm NaCl, 0.5 % Nonidet P-40, 10 mM Tris-
HCL pH 7.5 and EDTA-free protease inhibitors) per 50 μl of sample. Samples were incubated on 
ice for 30 minutes with occasional mixing followed by a 20 minute centrifugation step at 16000 
xg/4 ° C. The supernatant was transferred to a pre-cooled tube and the pellet discarded. A 15 μl 
sample of supernatant was removed for immunoblotting and labelled ‘undiluted input’. The 
volume of the remaining supernatant sample was adjusted to 500 μl with PDE dilution buffer 
(150mM NaCl, 10 mM Tris-HCL pH 7.5 and EDTA-free protease inhibitors) to give a final 
detergent concentration of < 0.2 %. A sample of supernatant was saved for immunoblotting and 
labelled ‘diluted input’. To equilibrate the anti-HA affinity matrix, 20 μl was transferred to an 
eppendorf tube containing 500 μl PDE dilution buffer. This was centrifuged at 8000 rpm for 30 
seconds. The supernatant was removed and this wash step was repeated. After the second wash 
the supernatant was removed from the beads and discarded. The supernatant sample (all 500 
μl) was added to the equilibrated anti-HA affinity matrix and incubated at room temperature for 
2 hours with constant mixing. After incubation, the anti-HA affinity matrix was pelleted by 
centrifugation at 8000 rpm for 30 seconds. The supernatant was removed to a new tube and a 
40 μl sample saved for immunoblotting and labelled as ‘wash 1’. 500 μl ice cold PDE dilution 
buffer was added to the pelleted Anti-HA affinity matrix and a 1000 μl sample removed for 
immunoblotting and labelled ‘bound beads’. The Anti-HA affinity matrix and the sample labelled 
‘bound beads’ were then pelleted by centrifugation at 8000 rpm for 30 seconds. Tubes were 
then turned with the opposite side facing into the centrifuge and the matrix was centrifuged 
again at 8000 rpm for 30 seconds. The supernatant from the Anti-HA affinity matrix sample was 
removed to a new tube and a 40 μl sample saved for immunoblotting and labelled as ‘wash 2’. 
The remaining beads were saved for analysis by PDE assay (see section 2.5.G p88).  
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Compound 
name 
Molecular 
weight 
Structure 
IC50 on 
Asexual 
stages 
(μM) 
IC50 on 
gametocytes 
stages (μM) 
Cellular 
Target 
references 
Compound 
2 
362.41 
 
2.70  ±  
0.17  
unknown PKG 
Gurnett et 
al, 2001 
McRobert 
et al, 2008 
KT5720 537.61 
 
 
2.5 
 
unknown PKA 
(Christian 
Flueck, 
unpublished) 
Zaprinast 271.27 
 
3.0 ± 1.2 33.7 ± 1.3 PDE 
McRobert 
et al, 2008 
PF9  
Pfizer compound. 
Restricted access to 
information. 
0.14 
  
0.052  ± 0.41 
 
PDE 
(Laura 
Drought, PhD 
Thesis) 
XA 205.17 
 
N/A 
IC50 
Unknown 
active on 
gametocytes 
above 3 μM. 
Working 
conc used:   
3 μM to      
30 μM  
unknown 
Bilker et al, 
1998. 
 Garcia et 
al, 1998 
 
Table 2.1. An overview of the properties of C2, KT5720, zaprinast, PF9 and XA.    
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Chapter 3 
Investigation into the relationship between cGMP signalling and Ca2+ release in 
Plasmodium falciparum 
 
3.1. Introduction 
 
PfPKG plays an essential role in asexual blood stage schizogony. This tightly regulated process 
can be blocked by the PfPKG inhibitors C1 and C2 with merozoites unable to egress[160]. PfPKG 
is known to regulate the discharge of PfSUB1 from the exonemes required for the proteolytic 
processing of proteins required for egress and invasion[173].  PfPKG inhibition also leads to 
subsequent block in the release of proteins from the micronemes[173]. The PDE inhibitor 
zaprinast can induce premature egress of merozoites and does so in a PfPKG-dependent 
manner[173]. This evidence suggests that the natural trigger for egress is likely to involve a signal 
that leads to elevated levels of cGMP. PfPKG is also essential for XA-induced gametogenesis and 
this process can be blocked at the very earliest stages by addition of C1 and C2[159] with 
gametocytes unable to round up. In the absence of XA, zaprinast can stimulate gametogenesis 
and does so in a PfPKG-dependent manner[159].  
The mobilisation of Ca2+ into the cytosol from as yet unidentified internal stores plays a key role 
in many cellular processes within the parasite. In asexual blood stages a steady increase in Ca2+ 
occurs prior to blood stage merozoite egress[224]. This rise in cytosolic Ca2+ is an essential 
signalling event required for egress to occur and chelation of intracellular Ca2+ results in a block 
in egress[224]. Ca2+ mobilisation from internal stores is required for the secretion of microneme 
and rhoptry proteins[265], and for the activation of a Ca2+-dependent protein kinase, CDPK5, 
which is critical for merozoite egress and evidence suggests it acts downstream of PfPKG 
regulated proteolytic processing[175].  
Ca2+ is also an important signalling molecule in gametocyte stages where a rapid rise in cytosolic 
Ca2+ occurs in response to XA (and a concomitant decrease in temperature)[210]. In P. berghei 
gametocytes, this Ca2+ response occurs within 20 seconds of XA addition and is essential for 
exflagellation[260],[210]. In gametocytes, Ca2+ mobilisation leads to the activation of a Ca2+ -
dependent protein kinase, CDPK4, which is required for male gametocyte cell cycle 
progression[210]. In P. berghei, Ca2+ activates a myristoylated isoform of CDPK4 enabling it to 
control two important events in male gametogenesis, which occur within the first 30 seconds of 
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gametocyte activation. Firstly, phosphorylation of the substrate SOC1 (substrate of CDPK4-1) 
leading to replication of the parasite genome from a haploid state enabling entry into the S 
phase. This involves recruitment of a complex to the origin of replication required to initiate the 
first genome replication and secondly, mitotic spindle assembly and formation, enabling 
chromosome segregation allowing duplicated genetic material to be separated into new cells. 
This involves phosphorylation of the CDPK4 substrate SOC2[215]. In addition to these two roles, 
a non-myristoylated isoform of CDPK4 plays a third role in male gametogenesis, by 
phosphorylating a third substrate SOC3, which acts downstream of genome replication, mitotic 
spindle assembly and axoneme assembly to activate flagella motility[215]. Interestingly, Ca2+ is 
required for all constituent events of gametogenesis in P. berghei and this has been explored in 
detail[210], but evidence using pharmacological inhibition of PfPKG using C1 and chelation of 
Ca2+ using BAPTA-AM suggests that Ca2+ is only required for the later stages of gametogenesis in 
P. falciparum[159]. This may reflect possible species-specific differences. 
 
There is a clear symmetry between the role of PfPKG at various stages of the Plasmodium 
lifecycle and the role of Ca2+ in merozoite egress[175] and gametogenesis[210],[215] as 
mentioned here, but also in merozoite invasion[207], ookinete gliding motility[209],[208] and 
more recently, P. berghei sporozoite invasion of hepatocytes[218] . Zaprinast presumably 
bypasses the natural trigger for merozoite egress by elevating levels of cGMP through cGMP-
PfPDE inactivation. In gametocytes the natural trigger for gametogenesis (XA) is already known 
and in 2001, Muhia et al identified that XA could induce elevated levels of cGMP in gametocyte 
membrane preparations[126], suggestion that zaprinast and XA may act through the same 
pathway, but that zaprinast likely bypasses the initial XA signal.  
 
In Plasmodium species phosphatidylinositol lipids are important secondary messengers in 
signalling cascades and also play an important role in vesicle trafficking[266]. Their synthesis is 
controlled by PfPKG which targets the lipid kinases (PIP4K and PIP5K) that mediate their 
phosphorylation[174]. The regulation of phosphoinositide synthesis mediated by PfPKG, 
specifically the production of IP3 which occurs through activation of phospholipase C (PLC) 
results in the release of Ca2+ [174]. In gametocytes of the murine malaria parasite P. berghei, XA 
triggers the hydrolysis of PIP2 which results in IP3 production[200]. Two global analyses by mass 
spectrometry of the P. berghei phosphoproteome in ookinetes were carried out[174]. The first 
approach looked at the effect on the proteome of altered cGMP signalling using a PbGC-ko 
mutant cell line and the second study used PbPKG inhibition by C2 of both the wildtype and 
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gatekeeper mutant cell lines to determine changes in phosphorylation of proteins when PbPKG 
was inhibited. Both of these approaches revealed several signalling pathways, which appear to 
operate downstream of PbPKG. Interestingly, one of these was phosphoinositide metabolism 
and given the already identified link between XA stimulation and IP3 production in gametocytes, 
this pathway was selected for further validation. Phosphoinositide lipid analysis on P. berghei 
ookinetes revealed that inhibition of PbPKG led to a marked increase in levels of phosphatidyl-
ID-myo-inositol (PI) and a concomitant increase in phosphatidylinositol 4-phosphate (PI4P) and 
phosphatidylinositol (4,5)-bisphosphate (PI(4,5)P2) in gliding ookinetes. Indicating that PbPKG 
controls lipid kinases to regulate phosphoinositide synthesis in motile ookinetes of P. berghei. 
Further studies showed that PbPKG is also required to raise levels of cytosolic Ca2+ in both P. 
berghei ookinetes and P. berghei gametocytes (in response to XA stimulation). 
In collaboration with the authors as part of this publication[174], we sought to investigate this 
link between PfPKG, phosphotidylinositide synthesis and Ca2+ mobilisation in blood mature 
stages. As this has already been identified for P. berghei[174], we sought to identify whether 
this association between Ca2+ and cGMP signalling was conserved in the human parasite P. 
falciparum.  
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3.2. Results 
 
3.2.1. Zaprinast-induced Ca2+ release in P. falciparum schizonts 
 
Zaprinast induces Ca2+ release in segmented schizonts in a dose-dependent manner. 
 
The PfPKG inhibitor C2 and the C2-insensitive PfPKGT618Q line were used in Ca2+ release assays as 
tools to determine firstly whether the PDE inhibitor zaprinast can stimulate Ca2+ release in P. 
falciparum late schizonts, and secondly, to determine whether zaprinast-induced Ca2+ 
mobilisation is PfPKG specific. Ca2+ levels were measured in Fluo-4-loaded schizonts over time 
both prior to and after addition of test compounds.  
In the wildtype 3D7a line, the PDE inhibitor zaprinast induced Ca2+ mobilisation in mature, 
segmented schizonts in a dose-dependent manner (Figure 3.1). Elevation of Ca2+ levels was 
measurable at a zaprinast concentration of as low as 6.25 μM and was detectable within 20 
seconds of addition of zaprinast to cells, indicating a rapid mobilisation of Ca2+ from internal 
stores in response to addition of this PDE inhibitor. No Ca2+ release was detected using this assay 
when cells were treated with 3.125 μM zaprinast, the lowest concentration tested. At the 
highest concentration tested (100 μM), Ca2+ release reached ~30 % of the ionophore control 
(A23187). The results imply that elevated cGMP levels induced by zaprinast stimulate Ca2+ 
release. 
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Figure 3.1. Ca2+ release in Fluo-4-AM-loaded 3D7a segmented schizonts stimulated with 
zaprinast. Data are presented as Ca2+ release measured as relative fluorescent units (RFU) 
minus the baseline fluorescence and fluorescence of the DMSO control sample. The 
ionophore (A23184) was used as a positive control. The bar chart was generated in GraphPad, 
Prism and shows the mean of 3 experiments each carried out in triplicate. Error bars represent 
SD. 
 
 
 
In mature, segmented schizonts of the PfPKGT618Q line, zaprinast induced Ca2+ release in a dose-
dependent manner (Figure 3.2) as was seen in the 3D7a line (Figure 3.1). Ca2+ release was 
detected at the lowest concentration of zaprinast tested (3.125 μM). At the highest 
concentration tested (100 μM), zaprinast induced Ca2+ mobilisation to ~ 27 % of the ionophore-
treated control, a comparable level to that induced by 100 μM zaprinast in the 3D7a line (~ 30 
%). As seen in the 3D7a wildtype line, 100 μM zaprinast induced Ca2+ release within 20 seconds 
of addition to schizonts of the PfPKGT618Q line (Figure 3.6). Zaprinast stimulation of the PfPKGT618Q 
line therefore exhibits a comparable pattern of Ca2+ mobilisation to that seen in the 3D7a 
wildtype line confirming that the genetically manipulated line does not have a reduced ability to 
release calcium in response to zaprinast. 
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Figure 3.2. Ca2+ release in Fluo-4-AM-loaded PfPKGT618Q segmented schizonts stimulated with 
zaprinast. Data are presented as Ca2+ release measured as relative fluorescent units (RFU) minus the 
baseline fluorescence and fluorescence of the DMSO control sample. The ionophore (A23184) was used 
as a positive control. The bar chart was generated in GraphPad, Prism and shows the mean of 3 
experiments each carried out in triplicate. Error bars represent SD.  
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Zaprinast-induced Ca2+ release in segmented schizonts is PfPKG dependent 
 
To investigate whether PfPKG plays a role in zaprinast-induced calcium release, the previous 
experiments were repeated in the presence of the PKG inhibitor C2. 
In segmented schizonts of the wildtype 3D7a line induced with 100 μM zaprinast, a dose-
dependent decrease in fluorescence was measured with increasing concentrations of C2 (Figure 
3.3: data shown as percentage of ionophore control and Figure 3.4: data shown as change in 
Ca2+ levels over time). Zaprinast induced Ca2+ release was completely reversed by 8 μM C2 (P = 
0.0434, Welch’s unpaired t test). Zaprinast treatment in the presence of 4 μM C2 reduced Ca2+ 
levels by ~85 % compared to zaprinast treatment alone (normalised to 100 %). 2 μM C2 reduced 
zaprinast induced Ca2+ release by ~ 60 %. At the lowest C2 concentration (1 μM), zaprinast-
induced Ca2+ release was reversed by ~ 40 % compared to the zaprinast only sample (P = 0.0295, 
Welch’s unpaired t test). The data suggests that zaprinast-induced Ca2+ release in schizonts is a 
PfPKG-dependent event. 
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Figure 3.3. The effects of C2 on zaprinast-stimulated Ca2+ levels in Fluo-4-AM-loaded 3D7a line 
schizonts. A zaprinast only sample (green) is compared to zaprinast-treated samples in combination with 
a serial dilution of C2 (light blue). All samples are compared to an ionophore control (A23187). Data are 
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presented as Ca2+ release measured as relative fluorescent units (RFU) minus the baseline fluorescence 
and fluorescence of the DMSO (0.05 %) control sample analysed in Excel. The bar chart was generated in 
GraphPad, Prism and shows the mean of 3 experiments each carried out in triplicate. Error bars represent 
SD. 
 
      
0
6
0
1
2
0
1
8
0
2
4
0
3
0
0
3
6
0
4
2
0
4
8
0
5
4
0
1 .0
1 .5
2 .0
2 .5
T im e  (S e c o n d s )
C
a
2
+
r
e
le
a
s
e
 (
R
F
U
)
Z a p + 8 µ M  C 2
Z a p + 4 µ M  C 2
Z a p + 2 µ M  C 2
Z a p + 1 µ M  C 2
Z a p r in a s t
A 2 3 1 8 7
D M S O
 
                          
Figure 3.4. Zaprinast-induced Ca2+ release in the presence of C2 in Fluo-4-AM-loaded 3D7a 
schizonts over time. A zaprinast only sample (light blue) is compared to zaprinast-treated 
samples in combination with a serial dilution of C2 (green). All samples are compared to an 
ionophore control (A23187). Data are Ca2+ release measured every 20 seconds and presented 
as relative fluorescent units (RFU). Compounds were added to cells at the 2 minute time point 
(purple star). Data are normalised to the first baseline read of each sample (0 second time 
point) and minus the buffer only control. The graph generated in GraphPad, Prism. The data 
are from 1 experiment carried out in triplicate.  
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To confirm the on-target effects of C2 on Ca2+ release, this experiment was repeated with the 
C2-insenstive gatekeeper mutant line. In PfPKGT618Q segmented schizonts, C2 was unable to 
reverse zaprinast-induced Ca2+ release at all four concentrations tested (Figure 3.5: data shown 
as  percentage of ionophore control and Figure 3.6: data shown as change in Ca2+ levels over 
time). Levels of fluorescence induced by 100 μM zaprinast remained at a similar level regardless 
of the concentration of C2 added. This confirms that zaprinast-induced Ca2+ mobilisation is 
indeed PfPKG dependent. 
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Figure 3.5. The effects of C2 on zaprinast-stimulated Ca2+ levels in Fluo-4-AM-loaded PfPKGT618Q line 
schizonts. A zaprinast only sample (green) is compared to zaprinast treated samples in combination with 
a serial dilution of C2 (light blue). All samples are compared to an ionophore control (A23187). Data are 
presented as Ca2+ release measured as relative fluorescent units (RFU) minus the baseline fluorescence 
and fluorescence of the DMSO (0.05 %) control sample analysed in Excel. The bar chart was generated in 
GraphPad, Prism and shows the mean of 3 experiments each carried out in triplicate. Error bars represent 
SD. 
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Figure 3.6. Zaprinast-induced Ca2+ release in the presence of C2 in Fluo-4-AM-loaded PfPKGT618Q line 
schizonts over time. A zaprinast-only sample (light blue) is compared to zaprinast-treated samples in 
combination with a serial dilution of C2 (green). All samples are compared to an ionophore control 
(A23187). Data are Ca2+ release measured every 20 seconds and presented as relative fluorescent units 
(RFU). Compounds are added to cells at the 2 minute time point (purple star). Data are normalised to the 
first baseline read of each sample (0 second time point). Minus the buffer only control. Data are analysed 
in Excel and the graph generated in GraphPad, Prism and shows the data from 1 experiment carried out 
in triplicate.  
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Use of a PfPKG-DD line further confirms that zaprinast-induced Ca2+ release in 
schizonts is PfPKG dependent 
 
To further confirm that zaprinast-induced Ca2+ mobilisation is PKG specific, a PfPKG conditional 
knockdown line (kindly provided by Dr Manoj Duraisingh and Jeffrey Dvorin) utilising a 
destabilising domain (DD) system was used to regulate the levels of PfPKG. In this line a DD 
protein is fused to the C-terminus of PfPKG. This fusion protein is rapidly degraded in the 
absence of the ligand shield-1 but is stabilised in its presence. Removal of shield-1 from cultures 
results in degradation of PfPKG essentially producing a knockdown line of PfPKG. Shield-1 was 
removed from cultures at the ring stage and parasites were allowed to develop to the 
segmented schizont stage. This was to ensure that, by the time the parasites reached the mature 
schizont stage, prior to egress, that most and if possible, all of the PfPKG protein was absent 
from samples.  
Zaprinast treatment induced Ca2+ release in the PfPKG-DD line in the presence of Shield-1 (Figure 
3.7 Purple bars). This sample is essentially the same as the wildtype line as PfPKG is present at 
presumably comparable levels to the wildtype and PfPKGT618Q lines indicating (although levels of 
PfPKG were not measured) that this genetically manipulated line has not affected its ability to 
release calcium in response to addition of zaprinast. Similarly to the results obtained with the 
wildtype 3D7a line, the zaprinast-induced Ca2+ release was reduced by ~ 85 % on addition of 2 
μM C2 to the PfPKG-DD line in the presence of Shield-1. This reduction in Ca2+ release on addition 
of C2 was shown to be significant (P = 0.0063, Welch’s unpaired t test). 
By contrast, in the absence of Shield-1 (Figure 3.7, blue bars) and therefore at reduced levels of 
PfPKG (where PfPKG has been degraded), much lower levels of fluorescence were measured in 
response to zaprinast treatment compared to the plus Shield-1 zaprinast-treated sample, 
indicative of much lower levels of Ca2+ release in this sample in response to zaprinast (Figure 
3.7). The difference in zaprinast-induced Ca2+ release in samples grown in the presence and 
absence of Shield-1 was significant (P = 0.0446, Welch’s unpaired t test). The levels of zaprinast-
induced Ca2+ release in the minus Shield-1 samples (blue bars) plus and minus C2 (~7 % and ~ 6 
% of ionophore control respectively), were comparable to C2 treatment of the plus shield-1 
sample in which PfPKG was present but inhibited (~ 4.5 % ionophore control). The small level of 
calcium release induced by zaprinast in the minus Shield-1 sample was not altered by addition 
of C2 (P= 0.9333, Welch’s unpaired t test). These data provides independent confirmation that 
in asexual blood stage schizonts, zaprinast-induced Ca2+ mobilisation is PfPKG dependent. 
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Figure 3.7. The effects of C2 on zaprinast-stimulated Ca2+ levels in Fluo-4-AM-loaded PfPKG-DD line 
schizonts. Plus Shield-1 samples (PfPKG stable: purple bars)  C2, compared to minus Shield-1 samples 
(PfPKG degraded: blue bars)  C2. Data are presented as Ca2+ release, measured as percentage of 
ionophore control (both +/- shield-1). Minus the baseline fluorescence and fluorescence in the DMSO 
(0.05 %) control sample (both +/- shield-1). Data are analysed in Excel and the graph generated in 
GraphPad, Prism and is the average of 3 experiments each carried out in triplicate. Error bars represent 
SD. 
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Zaprinast triggers a rapid depletion in phospholipids in a PfPKG-dependent manner 
 
Lipid extractions were carried out on zaprinast-treated purified schizonts of the 3D7a and 
PfPKGT618Q lines either pre-incubated with C2 or with no C2 treatment. This was followed by 
analysis of the schizont lipidome by Electrospray-mass spectrometry to look at changes in levels 
of phospholipids in relation to PfPKG inhibition (the mass spectrometry was carried out by Terry 
K Smith in schools of Biology and Chemistry, University of St Andrews). The relative abundance 
of the phospholipids PI, PIP, PIP2 and PIP3 were measured over time after addition of zaprinast 
to C2 pre-treated purified schizonts from the 3D7a and PfPKGT618Q lines. 
Addition of zaprinast to the PfPKGT618Q line pre-incubated with C2 (this sample should reflect 
what would occur in the wildtype line with no C2 treatment) resulted in a rapid depletion in both 
PIP2 and PIP3 compared to the C2-treated wildtype (3D7a) control in which PfPKG had been 
inhibited (Figure 3.8). This change in levels of phospholipids in zaprinast-induced PfPKGT618Q 
schizonts was accompanied by a reduction in levels of PIP and a concomitant increase in levels 
of PI (Figure 3.9). 3D7a schizonts treated with zaprinast showed no changes in levels of PI or PIP 
in the presence of C2. PfPKG inhibition therefore prevented zaprinast-induced changes in levels 
of PI, PIP, PIP2 and PIP3 in the 3D7a wildtype line but not in the PfPKGT618Q lines, indicative that 
regulation of phosphoinositide levels by zaprinast is a PfPKG-dependent event. These changes 
in levels of phospholipids occurred within 10 seconds of treatment. 
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Figure 3.8. Changes in levels of PIP2 and PIP3 over time in mature P. falciparum schizonts, in response to 
zaprinast treatment in the presence of C2 in the wildtype 3D7a line compared to the gatekeeper mutant 
PfPKGT618Q.  Cells were pre-incubated with C2 (1 µM) then treated with 100 µM zaprinast followed by lipid 
extraction using chloroform-methanol and relative levels measured by nanoelectrospray mass 
spectrometry. Data are 1 replicate. Graph was generated in Graphpad, Prism. This figure is a modified 
version of data presented in Brochet et al 2014[174]. 
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Figure 3.9. Changes in levels of PI and PIP over time in mature P. falciparum schizonts, in response to 
zaprinast treatment in the presence of C2 in the wildtype 3D7a line compared to the gatekeeper mutant 
PfPKGT618Q.  Cells were pre-incubated with C2 (1 µM) then treated with 100 µM zaprinast followed by lipid 
extraction using chloroform-methanol and relative levels measured by Nano electrospray mass 
spectrometry. Data are 1 replicate. The graph was generated in GraphPad, Prism. This figure is a modified 
version of data presented in Brochet et al 2014[174]. 
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3.2.2. Zaprinast-induced Ca2+ release in stage V gametocytes 
 
Both XA and zaprinast induce Ca2+ release in stage V gametocytes 
 
In stage V gametocytes of the 3D7a wildtype line, zaprinast induced Ca2+ release to ~ 38 % of the 
ionophore control (Figure 3.10). This was reversed to ~ 5 % of the ionophore control by addition 
of C2. C2 did not reverse the zaprinast-induced Ca2+ release fully, but levels were reduced by ~ 
85 % of zaprinast-treated samples and this was significant (P= 0.0155, Welch’s unpaired t test) 
indicating that the majority of zaprinast-induced Ca2+ mobilisation is likely to be PfPKG 
dependent. XA also induced Ca2+ levels to ~ 44 % of the ionophore control, levels comparable to 
that induced by zaprinast. This Ca2+ release was also reduced by addition of C2 but not fully 
(Figure 3.10), with levels of Ca2+ reduced by ~ 71 % compared to XA alone (normalised to 100 
%). This reduction in XA-induced Ca2+ release was also significant (P=0.0363, Welch’s paired t 
test). 
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Figure 3.10. Ca2+ release in Fluo-4-AM-loaded 3D7a stage V gametocytes. 
Parasites stimulated with XA (10 µM) and zaprinast (100 µM) in the presence and absence of 
2 μM C2. Data are presented as Ca2+ release measured as relative fluorescent units (RFU) 
minus the baseline fluorescence and fluorescence of the DMSO (0.05 %) control sample 
analysed in Excel. The ionophore (A23184) was used as a positive control. The bar chart was 
generated in GraphPad, Prism and shows the mean of 3 experiments each carried out in 
triplicate. Error bars represent SD. 
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Zaprinast induces Ca2+ release in stage V gametocytes in a PfPKG-dependent manner 
 
In order to investigate whether the reduction in Ca2+ release seen in both the zaprinast and XA-
treated gametocyte samples was due to an on-target effect of PfPKG inhibition by C2 (i.e. that 
Ca2+ release is PKG dependent), the PfPKGT618Q gatekeeper mutant line was used.  
In the PfPKGT618Q cell line, zaprinast-induced Ca2+ release was not reversed by addition of either 
C2 or a more specific inhibitor MRT00207065 (EC50 PfPKGT618Q/WT ratio in 72 h hypoxanthine 
incorporation assays = > 1,100. For C2 the ratio is 15 (Baker et al, NComms, in press)) indicating 
that in mature gametocytes zaprinast-induced Ca2+ mobilisation is likely to be a PKG-dependent 
event (Figure 3.11), A comparison of XA and zaprinast induced Ca2+ release in the wildtype and 
PfPKGT618Q gatekeeper mutant lines is presented in Figure 3.12. The difference between the Ca2+ 
release measured in zaprinast only samples compared to zaprinast samples also treated with C2 
or MRT00207065 was shown to be not significant using a Welch’s unpaired t-test with values of 
P=0.1470 and P=0.2103 respectively. This indicates that in contrast to the wildtype line, PKG 
inhibition in gametocyte samples treated with zaprinast did not significantly alter the level of 
zaprinast-induced Ca2+ release, therefore indicating that zaprinast-induced Ca2+ mobilisation in 
stage V gametocytes is likely to be a PfPKG-dependent event. 
 
XA-induced Ca2+ release appears to be by both a PfPKG-dependent and a non PfPKG-
dependent manner 
In the PfPKGT618Q gatekeeper mutant line, roughly half of the XA-induced Ca2+ release appeared 
to be reversed by addition of C2 with a ~ 54 % decrease in Ca2+ levels in C2-treated samples 
compared to the XA only sample (Figure 3.11). This was compared to a ~70 % decrease in Ca2+ 
levels in XA treated samples on addition of C2 to the wildtype line (Figures 3.10 and 3.12). This 
difference between the percentage decrease of Ca2+ levels in the wildtype line on addition of C2 
vs the percentage decrease in the PfPKGT618Q cell line was not significant (P=0.3199, Welch’s 
unpaired t test). This indicates that addition of C2 to the PfPKGT618Q gatekeeper mutant line does 
not significantly decrease the levels of Ca2+ induced by XA compared to the wildtype control, 
indicating that in the C2 resistant line, C2 can still reduce the Ca2+ levels and this may be 
explained by C2 targeting a different kinase that is not PfPKG.  (A comparison of XA and zaprinast 
induced Ca2+ release in the wildtype and PfPKGT618Q gatekeeper mutant lines is presented in 
Figure 3.12).  However, unlike the wildtype line in which the decrease in Ca2+ levels on addition 
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of C2 was shown to be significant, in the PfPKGT618Q cell line, the difference in Ca2+ levels between 
XA treatment alone compared to XA-treatment in the presence of C2 was shown to be not 
significant (P= 0.1706, Welch’s unpaired t test). Although these data are preliminary and require 
repeating, they indicate that the reduction in Ca2+ release in samples stimulated with XA in the 
presence of C2 in the PfPKGT618Q cell line is not significantly different to levels of Ca2+ in samples 
treated with XA alone. This preliminary data indicates that XA-induced Ca2+ release may be a 
PfPKG-dependent event as there is a significant decrease in Ca2+ levels with addition of C2 in the 
wildtype line but this difference is not significant in the gatekeeper line.  
Addition of MRT00207065 to XA- treated gametocytes of the PfPKGT618Q cell line appeared to 
reverse Ca2+ mobilisation less than C2. However, the difference between C2 and MRT00207065 
treatment in XA-stimulated samples of this line was shown to be not significant (Welch’s 
unpaired t test, P=0.7536). The difference in Ca2+ levels in XA treated samples compared to 
samples treated with both XA and MRT00207065 was shown to be not significant (Welch’s 
unpaired t test, P= 0.2861). This indicates that the more specific PKG inhibitor MRT00207065 
does not significantly reduce levels of XA-induced Ca2+ in stage V gametocytes. 
Overall, these data points towards a possibility that XA induces Ca2+ mobilisation in mature 
gametocytes is through more than one pathway: through both a PfPKG-dependent pathway and 
also through a pathway that is not PfPKG-dependent. Data on Zaprinast-induced Ca2+ release in 
gametocytes on the other hand, appears clearer, with Ca2+ mobilisation likely to be induced 
through a PfPKG-dependent pathway only. 
 
 
 
115 
 
                     
X
A
X
A
 +
 0
6
5
X
A
 +
 C
2
Z
a
p
Z
a
p
 +
0
6
5
Z
a
p
 +
 C
2
A
2
3
1
8
7
0
1
2
3
4
C
a
2
+
r
e
le
a
s
e
 (
R
F
U
)
p  =  0 .1 7 0 6
p  =  0 .2 8 6 1
p  =  0 .3 3 2 1
p  =  0 .7 9 1 7
                      
Figure 3.11. Ca2+ release in Fluo-4-AM-loaded PfPKGT618Q line stage V gametocytes. Parasites stimulated 
with XA (30 µM) and zaprinast (100 µM) in the presence and absence of 2 μM C2 or 1 µM MRT00207065 
(065). Data are presented as Ca2+ release measured as relative fluorescent units (RFU) minus the baseline 
fluorescence and fluorescence of the DMSO (0.05 %) control sample analysed in Excel. The ionophore 
(A23184) was used as a positive control. The bar chart was generated in GraphPad, Prism and shows the 
mean of two technical replicates from 1 experiment. Error bars represent SEM.  
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Figure 3.12. C2 reduction of zaprinast or XA-induced Ca2+ release in PfPKGT618Q gametocytes compared 
to gametocytes of the wildtype line. Data from figures 3.10 and 3.11 presented as percentage of either 
XA (light grey bars) or zaprinast (dark grey bars) with both XA and zaprinast normalised to 100 %. Data are 
the average of three repeats from three experiments for 3D7a and two repeats from 1 experiment for 
PfPKGT618Q. Error bars represent the SEM of the mean.  
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XA induces an immediate and rapid release of Ca2+ in 3D7a stage V gametocytes 
 
In an attempt to visualise Ca2+ release in real time, 3D7a stage V gametocytes were loaded with 
Fluo-4-AM and observed by confocal microscopy. XA was added and the resulting fluorescence 
viewed in real time. 
Prior to XA addition, Fluo-4-AM loaded gametocytes did not fluoresce (Figure 3.13 panel A). On 
addition of XA, a sudden and rapid increase in fluorescence was observed within milliseconds 
(ms) (Figure 3.13 panel B and Figure 3.14 and 3.15). This appeared to gradually decrease over a 
short period of time (~75 ms) with no fluorescence being observed after ~170 ms (Figure 3.14 
and 3.15). At the ~95 ms time point, there appeared to be another wave of fluorescence which 
increased in intensity then gradually decreased. This fluorescence lasted for ~75 ms (see Figure 
3.15 for schematic of these two peaks). 
Interestingly, the majority of fluorescence appeared to be concentrated in circular foci at the 
two tips of the gametocyte (Figure 3.13).  
 
Figure 3.13. Live confocal microscopy of Fluo-4-AM loaded 3D7a stage V gametocytes before (A) and 
directly after (B) XA addition. Focal points of fluorescence (circled in orange) were identified towards 
both ends of gametocytes (C). Green fluorescence.  
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Figure 3.14. Images from live confocal microscopy of fluo-4-AM loaded 3D7a stage V gametocytes. 
Images generated in Zeiss image browser taken 1ms apart. 
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Figure 3.15. Schematic showing predicted pattern of fluorescence seen in the live cell microscopy 
images represented in Figure 1.12. XA induces a rapid increase in fluorescence in mature gametocytes 
followed by a gradual decrease in intensity. This is followed by what appears to be another wave of 
fluorescence, which is less rapid but reaches similar levels to the first peak. Levels of fluorescence then 
gradually decrease. 
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3.3. Discussion 
 
The data obtained from these experiments have indicated that the PDE inhibitor zaprinast can 
induce Ca2+ mobilisation in both mature schizont stages and mature gametocyte stages of P. 
falciparum. The zaprinast Ca2+ response in both asexual and sexual stages appears to be a PfPKG-
dependent event. This supports data in the literature demonstrating that zaprinast is known to 
elevate cGMP levels in P. falciparum[159],[173]. This was determined using the PKG inhibitor C2 
(and a more potent and selective PKG inhibitor MRT00207065) on the wild type line and in 
combination with gatekeeper mutant PfPKGT618Q line, which is resistant to C2. An additional tool, 
a PKG conditional knockdown line, further confirmed the PKG specificity of the Ca2+ response in 
the blood stage schizonts. The data indicate that zaprinast induces Ca2+ mobilisation through the 
cGMP signalling pathway, by inhibition of cGMP hydrolytic PDE activity, which in turn leads to 
elevated levels of cGMP and subsequent activation of PfPKG (for schematic see Figures 3.16 and 
3.17). Zaprinast (a synthetic compound) is not the natural trigger of these events so it is not 
necessarily representative of what is happening in vivo. Indeed in gametocytes, the signalling 
events induced by XA do not appear as clear as those induced by zaprinast. There is evidence 
that XA may elevate cGMP levels in gametocyte stages[126] leading to the hypothesis that 
zaprinast  essentially bypasses the initial XA interaction. 
XA induced Ca2+ mobilisation in P. falciparum wildtype line stage V gametocytes. This is 
unsurprising as Ca2+ has been shown to be required for the late stages of male gametogenesis in 
P. falciparum[159]. The data presented here both in calcium assays and live cell imaging are 
consistent with the findings from studies in the literature which have shown that addition of XA 
to P. berghei gametocytes induces a rapid mobilisation of Ca2+ [210].  The data presented here 
also indicate that in P. falciparum, XA induces a Ca2+ response within 20 seconds of addition. In 
the wild type line, the Ca2+ response was reduced by addition of C2 but not fully reversed. The 
reason for this incomplete reversal of Ca2+ levels in the wild type line may be explained by the 
fact that both C2 and XA were added at the same time in this assay, so XA may be reaching its 
target to induce Ca2+ mobilisation before C2 can reach PKG to inhibit it fully. A small amount of 
residual Ca2+ was also measured in the zaprinast-treated wildtype line and this may be explained 
in the same way. This assay needs to be repeated with parasites pre-incubated with C2 to 
determine whether the residual Ca2+ levels seen in the C2-treated samples are due to 
experimental design. 
In gametocytes of the gatekeeper mutant line, C2 inhibition of XA-induced Ca2+ mobilisation was 
not significant. This taken with wildtype data, indicating that C2 inhibition of XA-induced Ca2+ 
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release is significant, suggests that in stage V gametocytes, XA-induces the release of Ca2+ in a 
PfPKG-dependent manner. However, although, data on the wildtype line are reproducible, initial 
data on the gatekeeper mutant line need to be interpreted with caution. This assay needs to be 
repeated as the data were from a single experiment carried out only in duplicate. Repeat 
experiments will be needed to confirm the PKG specificity of the XA response in gametocytes. 
The PKGT618Q gatekeeper mutant is a poor gametocyte producer and it is consistently a challenge 
to produce a high enough yield of purified gametocytes from this line to carry out Ca2+ release 
assays. It would therefore be useful to use gametocytes from the PfPKG-DD line plus and minus 
Shield-1 as an additional tool to look at the PKG specificity of the zaprinast and XA-induced Ca2+ 
responses in gametocytes. An alternative would be to make a new gatekeeper mutant using the 
NF54 line, which is a much more efficient gametocyte producer. It would also be beneficial to 
use the more PKG-specific inhibitor MRT00207065 in Ca2+ release assays on the wild type line as 
this would confirm that the decrease in Ca2+ levels seen with C2 inhibition of PfPKG are in fact 
on target. If MRT00207065 treatment reduced the XA-induced Ca2+ release in the wildtype line 
by less than C2, this would indicate that part of the Ca2+ response is due to a C2-sensitive protein 
kinase that is not PKG. However, this result needs to be taken with caution as this inhibitor was 
used at 1 M which may be too high a concentration to prevent an off target effect. 
The initial stage of gametogenesis, rounding up, is PKG dependent but in P. falciparum this event 
is not dependent upon Ca2+ since addition of BAPTA-AM to mature P. falciparum gametocytes 
does not prevent rounding up[159], whereas the later stages of male gametogenesis require 
Ca2+ and are blocked by BAPTA-AM. However, there is evidence to suggest that at least some of 
the later events of male gametogenesis (post rounding up) are PKG independent but still C2 
sensitive as exflagellation can be inhibited by C2 in both the wildtype and gatekeeper mutant 
lines[159], suggesting that another C2-sensitive protein kinase may regulate events required for 
exflagellation[159]. It was suggested that a likely candidate could be CDPK4[159] and in fact, not 
only does it have a small gatekeeper residue (conferring sensitivity to imidazopyridine (C2 + 065) 
and pyrrole (C1) PKG inhibitors)[267], this calcium-dependent protein kinase has been shown to 
be essential for the male specific events of genome replication, mitotic spindle assembly and 
flagella motility[215],[210] leading to exflagellation. Therefore, it’s essential that the PKG 
specificity of XA-induced Ca2+ release is determined and the additional and more in depth 
experiments listed above will be crucial for identifying whether this Ca2+ response is completely 
PKG dependent, or whether a proportion of the Ca2+ released in response to XA is PKG 
independent but C2 sensitive. If the latter is the case, this may indicate that another protein 
kinase such as CDPK4 could contribute to the Ca2+ response. Given the recent findings on CDPK4 
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in P. berghei by Fang et al[215], an interesting hypothesis would be that an initial PKG-
dependent increase in Ca2+ levels is required to activate the myristoylated form of CDPK4 which 
is required to regulate DNA replication and mitotic spindle assemble, events that occur within 
the first 30 seconds of activation. This then leads to another wave of Ca2+ mobilisation, which is 
induced either directly or indirectly through phosphorylation of substrates by the myristoylated 
form of CDPK4, which then leads to activation of the non-myristoylated isoform of CDPK4 
required for flagella motility about 9 minutes post activation. It may be possible to investigate 
this hypothesis using a knockout line of CDPK4, which uses the PfPKGT618Q gatekeeper mutant 
line as a background. This transgenic line could then be used in Ca2+ release assays in 
combination with PKG inhibition to determine whether levels of Ca2+ can be completely reversed 
by C2 when CDPK4 is absent. If part of the Ca2+ response in gametocytes is due to a PKG-
dependent pathway and the other part due to CDPK4 induced Ca2+ release, it would be expected 
that in the PfPKGT618Q gatekeeper mutant line, as seen in data presented here, Ca2+ levels would 
be reduced by C2 targeting CDPK4 but the PKG-dependent proportion of Ca2+ would not be 
altered compared to the 3D7a wildtype line in which both PKG and CDPK4-induced Ca2+ levels 
would be reduced significantly by C2. However, in the absence of CDPK4 in a PfPKGT618Q 
gatekeeper mutant line (i.e. if CDPK4 is absent from the line and the line is also resistant to C2 
targeting of PKG), it would be expected that the CDPK4 portion of Ca2+ release would be absent, 
therefore there should be no reduction in levels of Ca2+on addition of C2 because the two targets 
of C2, PKG, and CDPK4 would have been removed.  
The preliminary observations from live cell microscopy on P. falciparum stage V gametocytes 
were consistent with studies on P. berghei which showed that XA induced a rapid release of Ca2+ 
which appeared after a lag period of 10 seconds then peaked at the 10-12 second time 
point[210]. Addition of XA to live Fluo-4 loaded P. falciparum gametocytes resulted in a rapid 
release of Ca2+; however, it appeared to result in fluorescence almost immediately. This is 
slightly at odds to the 10 second lag phase seen in P. berghei strains expressing a GFP-Aequorin 
fusion protein[210]. This may represent differences in the species of Plasmodium, differences in 
experimental design or dynamics of the reporter system and acquisition and analysis of data. 
The data presented here are preliminary and were only achieved once. Attempts made to 
reproduce these data were unsuccessful because on subsequent attempts, fluorescence was 
already present in unstimulated gametocytes. As such, definitive conclusions were unable to be 
drawn from these data. There are a number of possible factors that may have contributed to 
this including Fluo-4 loading and cellular distribution (the fluo-4 may have entered cellular Ca2+ 
stores prior to activation), sample preservation leading to the unstimulated release of Ca2+, 
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namely challenges with maintaining unstimulated gametocytes at 37°C prior to activation and 
maintaining a temperature range sufficient for gametocyte activation to occur when stimulated 
(gametocyte samples may have cooled). This was due to the long distance required to transport 
the samples in order to image them using the confocal microscope and the very low temperature 
of the microscope room required for maintenance of equipment stored there. Although care 
was taken, unfavourable conditions for gametocytes during sample preparation may also be a 
contributing factor.  
Interestingly, the majority of fluorescence observed in XA-stimulated gametocytes appeared to 
be found in circular foci towards both ends of each gametocyte. This pattern of fluorescence 
was consistent in all gametocytes observed in the sample. This pattern may be a reflection of 
the cytosolic space available (the nuclear material and haemozoin are often concentrated in the 
centre of the gametocyte). Or may possibly indicate a more specific localisation of the site of 
Ca2+ response. Fluo-3, a labelled calcium indicator with similar properties to Fluo-4 (Fluo-4 is an 
analogue of Fluo-3, with two chlorines replaced by two fluorine’s resulting in higher fluorescent 
signals), is thought to concentrate mostly in the cytosol and this is likely to be the case for Fluo-
4 also[268]. However, Fluo-3 can also compartmentalise into internal organelles in some cases. 
The fact that this pattern of fluorescence was seen only after addition of XA indicates that the 
foci observed are unlikely to be representing compartmentalisation of Fluo-4 into a Ca2+store, 
but that it is likely to be a result of Ca2+ mobilisation from the store to elsewhere in the cell 
where the Fluo-4 is located on XA addition. Fluo-4-AM is able to cross membranes prior to 
esterification (this process removes the ester group preventing the Fluo-4 from crossing 
membranes and essentially traps the Fluo-4 within the cell’s cytoplasm where it can then bind 
to Ca2+ released from internal stores), however on losing the AM ester, it should get trapped 
within the cell and is unlikely to be able to cross further membranes and, for example, enter 
organelles such as the ER. It would be hypothesised that XA would induce release of Ca2+ from 
the ER into the cytosol where the majority of the Fluo-4 would be predicted to be concentrated. 
This hypothesis is based on evidence that the IP3 signalling pathway may be induced by XA 
stimulation in P. berghei gametocytes[200]  and that there is evidence that the ER is involved in 
Ca2+ mobilisation[198]. It was very interesting to observe a possible second wave of 
fluorescence. This may have been due to an artefact such as movement of liquid across the 
sample disrupting the focus. If this second wave of fluorescence is due to a second wave of Ca2+ 
mobilisation, this would be highly interesting and may support the hypothesis presented earlier 
which suggests that there may be a first wave of PKG-dependent Ca2+ mobilisation, followed by 
a second PKG-independent but C2-sensitive Ca2+ release, possible requiring CDPK4. It would be 
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very interesting to optimise the conditions for this live cell microscopy experiment to look at XA-
induced Ca2+ mobilisation in real time more closely. If conditions can be optimised, this possible 
second wave of fluorescence can be investigated more thoroughly and the use of both C2 which 
can inhibit both PKG and CDPK4 and MRT00207065 which will only target PKG (at low 
concentrations) in combination with the gatekeeper mutant line and a CDPK4-ko line, and 
possibly a CDPK4 gatekeeper mutant line, will all be useful tools in identifying if there is in fact 
another wave of Ca2+ release and whether there is a differing PKG-dependency for XA-induced 
Ca2+ mobilisation. This will also complement experiments suggested above which would aim to 
investigate the hypothesis that CDPK4 may be involved in the XA-induced Ca2+ response. 
Data presented here and published[174] show that in P. falciparum schizonts, PfPKG plays a role 
in regulating levels of phosphoinositol lipids. Zaprinast induced depletion of PIP2 and its 
precursor PIP only when PfPKG was inhibited indicating that phosphoinositide (lipid) levels can 
be regulated by activation of PfPKG through PDE-induced changes in levels of cGMP. This has 
also been shown to be the case in motile ookinetes of the murine species P. berghei[174]. In 
both P. berghei and P. falciparum phospholipid analysis studies, in conjunction with gatekeeper 
mutant lines, were used to show that this phosphoinositide metabolism was PKG dependent. 
It would be useful to measure IP3 levels in zaprinast-treated schizonts from both the 3D7a and 
PfPKGT618Q lines in the presence and absence of a PKG inhibitor and also in the presence and 
absence of a PLC inhibitor such as U73122. This would confirm what the data presented in this 
thesis indicates, that the changes in phospholipids induced by zaprinast lead to the hydrolysis of 
PIP2 to produce the secondary messenger IP3 and that this occurs via PLC in a PfPKG-dependent 
manner. This would provide a nice link to Ca2+ mobilisation. To complement this, it would also 
be of interest to repeat Ca2+ release assays using a PLC inhibitor.  
At a permissive temperature, XA has been shown to induce the hydrolysis of phosphoinositide 
(lipids) to produce IP3 in P. berghei gametocytes and inhibition of PLC using the inhibitor U73122 
reduced the initial XA-induced Ca2+ signal[200]. An analysis of the gametocyte lipidome by 
Electrospray-mass spectrometry to look at changes in levels of phospholipids in relation to 
PfPKG inhibition using MRT00207065 would be interesting. This would give us insight into 
whether phospholipid synthesis and IP3 production is involved in the generation of Ca2+ in 
mature P. falciparum gametocytes in response to zaprinast and XA stimulation. This would also 
complement work done in P. berghei gametocytes which showed that XA can trigger the 
hydrolysis of PIP2 which is accompanied by the production of IP3 and which results in a rapid 
release of Ca2+ [200]. The production of IP3 and subsequent Ca2+ mobilisation can be inhibited by 
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a the PLC inhibitor U73122 in P. berghei gametocytes[200]. It would be interesting to measure 
levels of IP3 in XA and zaprinast-induced P. falciparum gametocytes in the presence and absence 
of both C2 and MRT00207065 and also in the presence and absence of inhibitors of the IP3 
pathway including PI-PLC.  
XA stimulation of gametogenesis is an important event in the parasite lifecycle, enabling the 
parasite to undergo a transformation leading to fertilisation and subsequent establishment of 
infection within the mosquito. A drug that could disrupt this process would block transmission 
and would be a valuable tool in tackling this devastating disease. Similarly, asexual blood stage 
merozoites egress is essential for parasite proliferation as a block in egress prevents the 
liberation of free merozoites, which are required to invade new erythrocytes and continue the 
lifecycle in the human host. Unlike disruption of the transmission stages which will not alleviate 
clinical symptoms but will prevent the host from being infectious to feeding mosquitoes, 
disruption of the asexual blood stage life cycle can treat the symptoms of malaria and save lives. 
Understanding the signalling pathways leading to events such as Ca2+ mobilisation during crucial 
stages of the life cycle such as schizogony and gametogenesis will help us to identify drug targets 
and novel ways to disrupt these parts of the parasite life cycle. Although there have been several 
really important findings in terms of understanding the signalling systems involved in driving 
these processes, including the identification of XA, thought to be the natural trigger for 
gametogenesis, understanding of cell signalling in plasmodium is still in its infancy and much 
more needs to be learnt. Understanding how XA actually induces gametogenesis, whether it 
binds to a receptor or perhaps interacts directly with a component of the signalling cascade such 
as a PDE and the elucidation of the order of downstream signalling events will greatly benefit 
our understanding of gametogenesis and this in turn will facilitate drug discovery progress. 
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Figure 3.16. Schematic showing a model of signalling pathways induced by zaprinast involved in asexual 
blood stage merozoite egress. Zaprinast induces premature egress of merozoites (which are often non-
invasive). Zaprinast inhibits cGMP-PDE activity (red cross), which leads to increased levels of cGMP and 
subsequent activation of PKG (signalling cascades downstream of PKG can be blocked by addition of the 
PKG inhibitor C2: red cross). PKG is required for the discharge of the serine protease SUB1 from exonemes 
which is required for the proteolytic processing of proteins such as SERA proteases and components of 
the MSP complex needed for egress and invasion. Activation of PKG also induces Ca2+ mobilisation via the 
phosphoinositide synthesis pathway leading to subsequent IP3 production via PI-PLC by targeting the 
kinases that mediated the hydrolysis of phospholipids. Released Ca2+ activates CDPK5, which is 
independent of PKG-induced proteolytic processing but also required for egress. This can be blocked by 
addition of the Ca2+ chelator BAPTA-AM (red cross). The PKG inhibitor C2 inhibits both Ca2+ mobilisation 
and release of SUB1.  
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Figure 3.17. Schematic showing a model of signalling pathways activated by XA (orange arrows) and 
zaprinast (green arrows) that induce gametogenesis. Zaprinast induces rounding up of gametocytes by 
PDE inhibition (PDEδ and/or possibly PDEα) followed by an increase in cGMP, which activates PKG. This 
leads to rounding up of both male and female gametocytes in a non-Ca2+-dependent manner. Zaprinast 
induces Ca2+ mobilisation in gametocytes, which is required for exflagellation. This Ca2+ release is inhibited 
by C2 in the wildtype line but not by C2 or 065 in the gatekeeper mutant line PfPKGT618Q. Indicating that 
zaprinast likely induces Ca2+ mobilisation in a PfPKG-dependent manner. As seen in schizonts, zaprinast 
may induce Ca2+ mobilisation via phosphoinositide metabolism leading to IP3 production and subsequent 
Ca2+ release but this is currently not known. XA treatment increases levels of cGMP by a mechanism 
currently unknown (but may involve PDE inhibition or GC activation). This leads to PKG activation and 
PKG-dependent but non-Ca2+-dependent induction of rounding up. XA induces Ca2+ mobilisation via PKG 
and the phosphoinositide hydrolysis cascade leading to the production of IP3 via PI-PLC likely resulting in 
Ca2+ release from the ER. XA-induced Ca2+ mobilisation leads to the activation of two isoforms of CDPK4 
(myristoylated and non- myristoylated) which results in male exflagellation. A myristoylated isoform 
regulates genome replication and mitotic spindle assembly in the first 30 seconds of activation. A non-
myristoylated isoform regulates flagella motility 9 minutes post XA-activation. Blue dotted arrows 
represent the hypothetical induction of Ca2+ mobilisation by the already PKG-dependent Ca2+-activated 
myristoylated isoform of CDPK4, which then leads to the Ca2+- dependent activation of the non-
myristoylated isoform.  
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Chapter 4 
 
Investigation into the role of phosphodiesterases in distinct stages of gametocyte 
development using genetic and pharmacological approaches 
 
4.1. Introduction 
 
Gametocyte-infected erythrocyte deformability and gametogenesis are essential parts of the 
parasite lifecycle and a requirement for transmission from the human host to the mosquito 
vector. Although there has been some progress in understanding the signalling pathways 
involved in these cellular events, they are still not currently well understood. Increased 
knowledge and understanding of what signalling pathways are required for gametocytes to 
develop, survive in the host and to transmit to the mosquito vector where fertilisation takes 
place, and the role that signalling molecules play in these processes, will help to identify possible 
drug targets in gametocyte stages. Cyclic nucleotide signalling plays an important role in several 
key stages of the parasite life cycle. Regulation of cyclic nucleotide levels by ACs, guanylyl 
cyclases (GCs) and PDEs is essential to maintaining normal cellular functions. As such, these 
enzymes are attractive targets to explore further. Drugs developed against mammalian PDEs, in 
particular have been used successfully for a number of medical conditions. Although 
Plasmodium PDEs show some similarity to their human homologues, it is thought that they are 
divergent enough in the catalytic domain to be selectively targeted and although many PDE 
inhibitors that target mammalian PDEs also target apicomplexan PDEs (such as sildenafil citrate, 
tadalafil and zaprinast), these compounds could potentially be used as a starting point to design 
drugs that specifically target apicomplexan PDEs and not mammalian ones. This will enable 
treatment of malaria infection (or prevention of malaria transmission) without adverse side 
effects. There has recently been a surge of interest in the targeting of Plasmodium PDEs because 
disruption of cyclic nucleotide signalling pathways through inhibition of PfPDEs would be an 
important tool that can be used not only to treat clinical symptoms of malaria, but also to 
prevent transmission within a population and along with other interventions, will greatly aid the 
move towards malaria elimination. 
This chapter therefore seeks to understand more about the effects of PfPDE inhibition with the 
aim to determine the value of Plasmodium PDEs as drug targets in mature gametocyte stages. 
This will be achieved by using a combination of genetic and pharmacological approaches to 
investigate the impact of PfPDE inhibition on gametocyte infected erythrocyte deformability, 
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gamete egress from the host erythrocyte and the mobilisation of Ca2+ from internal stores, 
events that are all required for transmission from the human host to the mosquito vector. 
 
Mature P. falciparum gametocytes that have been released from sequestration in the bone 
marrow are able to avoid splenic clearance while circulating in the host blood stream. This is 
thought to be due to their ability to change from a stiff phenotype to a deformable one once 
they reach maturity at stage V. The mechanisms and cell signalling pathways mediating this 
switch are not fully understood; however, in collaboration with Catherine Lavazec (Institute 
Pasteur), deformability assays were carried out on a PfPDEδ-ko and a PfPDE-ko line. These data 
are presented below and formed part of a publication[25], the broader findings of which will be 
discussed in more detail in the discussion section. 
 
The known signal that initiates gametogenesis, XA[26],[258] has been shown to act through a 
PfPKG-dependent pathway[159], and this is thought to be mediated through the cGMP signalling 
pathway[126] to result in a rapid rise in cytosolic Ca2+ [210], which is required for the later stages 
of gametogenesis but not for the earlier stage of rounding up[159]. The effector protein, 
calcium-dependent protein kinase 4 (CDPK4) is essential for the later male specific stages of 
gametogenesis and this kinase is dependent upon the upstream mobilisation of Ca2+ [215],[210]. 
There is currently no identified receptor for XA and the mechanism by which XA induces 
gametogenesis is unknown. Studies on mammalian cells have shown that XA can cross 
membranes and enter the ER of lens epithelial cells and directly interact with ER proteins[269]. 
There is therefore a possibility that in P. falciparum, XA could cross the erythrocyte and parasite 
vacuole membranes freely to enable it to associate with signalling molecules or receptors either 
on the parasite surface or within the parasite itself.  
The cGMP PfPDE inhibitor zaprinast[159] and the PDE inhibitor sildenafil citrate (Cathy Taylor, 
PhD Thesis, 2007) can also induce gametogenesis independently of XA indicating that the 
pharmacological inhibition of cGMP-PfPDEs can lead to the induction of gametogenesis. The 
zaprinast-induced induction of gametogenesis, like XA, has also been shown to be PfPKG 
dependent[159] and to act upstream of Ca2+  [159]. In P. falciparum, the earlier stages of 
rounding up have therefore been shown to be PfPKG dependent (as XA or zaprinast-stimulated 
gametocytes will not round up in the presence of C1), but Ca2+ independent (gametes will still 
round up the presence of the Ca2+ chelator BAPTA-AM but emergence is greatly reduced and 
male gametes will not exflagellate[159]). This is interesting and could possibly indicate that XA 
may induce a similar or the same signalling pathways that zaprinast does. Work by Cathy Taylor 
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et al[130] indicated an essential role for PfPDEδ in gametogenesis, as a PfPDEδ-ko line was 
unable to emerge from the host erythrocyte in response to XA-stimulation. The published[25] 
work carried out on gametocyte infected erythrocyte deformability presented in this chapter 
revealed an unexpected role for PfPDEδ and PfPDE (the latter not included in the publication) 
in gametocyte deformability. This was linked to elevated levels of cAMP as a result of the 
absence of PfPDEδ leading to an inability of mature gametocytes to become deformable. In light 
of these findings, it was deemed important to re-evaluate the PfPDEδ-ko line phenotype 
observed by Cathy Taylor[130], (Cathy Taylor, PhD Thesis, 2007) because the theory was formed 
that perhaps this inability of the PfPDEδ-ko line to round up may be a consequence of cAMP-
induced stiffness due to the absence of PfPDEδ rather than a cGMP-dependent effect as 
concluded by Taylor et al[130]. Alternatively, PfPDEδ may be required for the initiation of 
gametogenesis in this line, but the deformability phenotype complicates the use of this line in 
determining a role for PfPDEδ in gametogenesis. This was an important question to answer in 
order to progress in dissecting the signalling pathways involved in gametogenesis.  
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4.2. Results 
 
4.2.1. Investigation into the effects of PDE inhibition on gametocyte deformability  
 
Stage V gametocytes of the PfPDE-ko and PfPDEδ-ko lines show deformability defects 
 
The role of PfPDE and PfPDE in host cell deformability was investigated. To achieve this, a 
nano-filtration technology was used in collaboration with Catherine Lavazec (Institute 
Pasteur)[25]. Purified samples of stage V gametocytes from the 3D7a, PfPDE-ko and PfPDE-ko 
lines were perfused through a microsphere matrix using a peristaltic pump in order to mimic 
splenic retention. Numbers of parasites in the flow through (deformable) were compared to 
numbers retained in the matrix (stiff) by light microscopy of paraformaldehyde-fixed samples 
(for more information see section 2.5.F of the methods).  
 
The majority of stage V gametocytes of the wildtype 3D7a line (~ 70 %) filtered through the 
microsphere matrix with ~ 30 % remaining inside (Figure 4.1 and Table 4.1). This indicates that 
the majority of 3D7a stage V gametocytes were deformable. 
 
By contrast, stage V gametocytes of the PfPDE-ko and PfPDE-ko lines were mostly retained 
with only ~ 10 % and ~20 % of parasites respectively being able to transverse the microsphere 
matrix (Figure 4.1 and Table 4.1). The difference in retention compared to the 3D7a wildtype 
control was significant for both PfPDE-ko (P = <0.0001) and PfPDE-ko (P = 0.0116) using a 
Welch’s unpaired t test). The majority of gametocytes from these two lines were therefore 
retained and were thus non deformable, suggesting a likely role for PfPDEs in gametocyte-
infected erythrocyte deformability. 
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Figure 4.1. Retention rates of PfPDEγ-ko and PfPDEδ-ko stage V gametocytes filtered through a 
microsphiltration matrix. Data are an average of 3 experiments for both wildtype and the PfPDEδ-ko line 
and two experiments for the PfPDEγ-ko line, all carried out in triplicate. Presented as percentage retention 
rate of gametocytes passed through a microsphere matrix. Graph generated in GraphPad, Prism. Error 
bars represent SD.  
 
 
 
Retention rate of stage V gametocytes ± SD 
3D7a PfPDEδ-ko PfPDEγ-ko 
23.65 ± 1.93 82.81 ± 11.89  89.50 ± 1.55  
 
Table 4.1. Percentage retention rate (± SD) of 3D7a, PfPDEδ-ko and PfPDEγ-ko stage V gametocytes 
passed through a microsphere matrix. Data are analysed in Excel and are an average of 3 experiments 
for both wildtype and PfPDEδ-ko lines and two experiments for PfPDEγ-ko line, all carried out in triplicate. 
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4.2.2. Investigation into the effect of phosphodiesterase inhibition on rounding up 
and emergence of P. falciparum gametocytes 
 
To re-evaluate the involvement of PfPDE-regulated cGMP signalling in mature gametocyte 
emergence from the host cell erythrocyte, stage V gametocytes of the 3D7a, PfPKGT618Q, PfPDE-
ko and PfPDEδ-ko lines were stimulated with the known inducer of gametogenesis; XA, in the 
presence and absence of the PfPKG inhibitor C2. The aim of this was to confirm previous work 
done by Cathy Taylor (Cathy Taylor, PhD Thesis, 2007), which showed that in the absence of 
PfPDEδ, rounding up of gametocytes was reduced and emergence of gametocytes from the host 
erythrocyte was greatly reduced. The work in this chapter will also aim to confirm work done by 
McRobert et al on the PfPKG-specificity of rounding up and emergence[159].  
Blood films were incubated with an antibody specific to a host erythrocyte membrane protein, 
Band 3, followed by incubation with an Alexa Fluor 594-conjugated secondary antibody and 
observation by confocal microscopy. Numbers of crescent-shaped (non-activated gametocytes) 
and rounded cells (activated gametocytes) were counted and staining of the host erythrocyte 
(non-emerged) and lack of staining (emerged) was recorded. 
 
XA induces rounding up and emergence of stage V gametocytes in a PfPKG-dependent 
manner 
 
3D7a stage V gametocytes rounded up and emerged in response to XA treatment in a PfPKG-
dependent manner (Figures 4.2 and 4.3) consistent with previous findings[130],[159]. Parasites 
in the control (DMSO) sample remained as crescent shaped gametocytes surrounded by the host 
erythrocyte membrane, which was stained with the Band 3 antibody, characteristic of non-
activated parasites (Figure 4.3). On addition of XA, ~90 % of parasites rounded up with no Band 
3 staining detected, indicative of gamete emergence from the host cell (Figures 4.2 and 4.3). 
Rounding up and emergence of XA-induced mature gametocytes in the 3D7a line was reversed 
by addition of C2 with parasites retaining their characteristic crescent shape and host 
erythrocyte staining of Band 3 detected as seen in the DMSO control sample. A small number of 
gametocytes (~10 %) still rounded up and emerged in C2 treated samples (Figure 4.2). 
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Figure 4.2. XA-induced rounding up and emergence in 3D7a gametocytes in the presence and absence 
of C2. XA-treated (100 μM) stage V gametocyte samples were incubated for 30 minutes at RT in the 
presence or absence of C2 (2 μM) and compared to an unstimulated control (0.05 % DMSO). Data are 
presented as percentage of total parasitemia and determined by counts of parasites from IFA samples 
prepared from blood films stained with Band 3 ab and imaged by confocal microscopy. Data are from a 
single count (~ 900cells counted per replicate) of one experiment analysed in Excel. The graph was 
generated in GraphPad, Prism.  
 
 
Figure 4.3. Confocal Images of XA-induced rounding up and emergence in the 3D7a line +/- C2 
XA-treated (100 μM) samples compared to an unstimulated control (0.05 % DMSO). Upper panels 
represent light image with Band 3 (red) and DAPI (blue) staining. Lower panels represent the same image 
with Band 3 staining only (red). Blue arrows indicate crescent shaped stage V gametocytes stained with 
Band 3 antibody (non-activated). Green boxes represent rounded up gametocytes with no Band 3 staining 
(activated). Purple boxes are parasites that appear round in morphology but have not emerged (Band 3 
staining present). 
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Stage V gametocytes of the PfPKGT618Q line also rounded up and emerged in response to XA but 
this could not be reversed by C2 (Figures 4.4 and 4.5). Parasites in the control (DMSO) sample 
remained as crescent-shaped gametocytes surrounded by the host erythrocyte membrane, 
which was stained with Band 3 antibody, characteristic of non-activated parasites (Figure 4.5). 
On addition of XA, ~90 % of parasites rounded up with no Band 3 staining detected, indicative 
of host cell emergence (Figures 4.4 and 4.5). 
On addition of C2 to XA-treated samples, unlike the 3D7a line, parasites did not retain their 
characteristic crescent shape and presented as rounded up cells with no Band 3 staining of the 
erythrocyte membrane, comparable to XA-treated samples (Figures 4.4 and 4.5). C2 could 
therefore not reverse XA activation of rounding up and emergence in this C2-resistant line 
indicating that XA induced rounding up and emergence are PfPKG-dependent events. 
               
C o n tro l X A X A + C 2
0
5 0
1 0 0
T
o
ta
l 
P
a
r
a
s
it
e
m
ia
 (
%
)
C re s e n t  s ta in e d
C re s c e n t  u n - s ta in e d
R o u n d  s ta in e d
R o u n d  u n -s ta in e d
 
Figure 4.4. XA induced rounding up and emergence in the PfPKGT618Q line in the presence and absence 
of C2  
XA-treated (100 μM) samples incubated for 30 minutes/RT in the presence or absence of C2 (2 μM) and 
compared to an unstimulated control (0.05 % DMSO). Data are presented as percentage of total 
parasitemia and determined by counts of parasites from IFA samples prepared from blood films stained 
with Band 3 ab and imaged by confocal microscopy. Data are a single count (~ 900cells counted per 
replicate) of one experiment analysed in Excel. Graph generated in GraphPad, Prism.  
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Figure 4.5. Confocal images of XA-induced rounding up and emergence in the PfPKGT618Q line +/- C2. XA-
treated (100 μM) samples compared to an unstimulated control (0.05 % DMSO). Upper panels represent 
light image with Band 3 (red) and Dapi (blue) staining. Lower panels represent the same image with Band 
3 staining only (red). Blue arrows indicate crescent shaped stage V gametocytes stained with Band 3 (non-
activated). Green boxes represent rounded up gametocytes with no Band 3 staining (activated). Purple 
boxes are parasites that appear round in morphology but have not emerged (Band 3 staining present).  
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PfPDE-ko line Stage V gametocytes round up and emerge normally in response to XA 
stimulation 
 
In light of the deformability data presented in section 4.2.1, It was of interest to attempt to 
reproduce emergence experiments carried out by Cathy Taylor (Cathy Taylor, PhD Thesis, 2007) 
on the PfPDE-ko line, the reason being that hypothetically, gametocytes that present with a 
stiff phenotype (as the data in section 4.2.1. suggests is the case for PfPDE-ko line gametocytes) 
are unlikely to be able to round up, and data presented by Cathy Taylor on gametocyte 
emergence is at odds with this and indicates that the PfPDE-ko line appears to round up 
normally in response to XA stimulation compared to a wildtype line (Cathy Taylor, PhD Thesis, 
2007). 
Stage V gametocytes of the PfPDE-ko line rounded up and emerged from the host erythrocyte 
in response to XA treatment in a PfPKG-dependent manner comparable to what was seen in the 
wild type 3D7a line (Figures 4.2 and 4.6) and consistent with the findings of Cathy Taylor (Cathy 
Taylor, PhD Thesis, 2007). Parasites in the control (0.05 % DMSO) sample remained as crescent-
shaped gametocytes surrounded by the host erythrocyte membrane, which was stained with 
the Band 3 antibody, characteristic of non-activated parasites (Figure 4.7). On XA addition, ~95 
% of parasites rounded up with no Band 3 staining of the host erythrocyte detected, indicative 
of host cell emergence (Figures 4.6 and 4.7). Rounding up and emergence of XA-induced mature 
gametocytes in the PfPDE-ko line was reversed by addition of C2 with parasites retaining their 
characteristic crescent shape and host erythrocyte staining with Band 3 detected as seen in the 
DMSO control samples indicating XA can induce rounding up in the absence of PfPDE and that 
this is a PfPKG-dependent event as seen in the wildtype 3D7a parasite line. In samples stimulated 
with XA in the presence of C2, a small number (~6 %) of parasites also appeared as crescent 
shaped gametocytes with no erythrocyte Band 3 staining detected (Figure 4.7, green ovals).  
These data mirror work carried out by Cathy Taylor (Cathy Taylor, PhD Thesis, 2007) 
demonstrating that PfPDE-ko line stage V gametocytes will round up and emerge from the host 
erythrocyte in response to XA stimulation in comparable levels to that of the control line and 
that this occurs in a PfPKG-dependent manner. This indicates that the absence of PfPDE has no 
impact on the ability of gametocytes to respond to XA by rounding up and emerging and puts 
into question the results presented in section 4.2.1, which suggest that PfPDE-ko line stage V 
gametocytes may present with a ‘stiff’ phenotype.    
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Figure 4.6. XA induced rounding up and emergence in the PfPDEγ-ko line in the presence and absence 
of C2. XA-treated (100 μM) samples incubated for 30 minutes/RT in the presence or absence of C2 (2 μM) 
and compared to an unstimulated control (0.05 % DMSO). Data are presented as percentage of total 
parasitemia and determined by counts of parasites from IFA samples prepared from blood films stained 
with Band 3 ab and imaged by confocal microscopy. Data are a single count (~ 900cells counted per 
replicate) of one experiment analysed in Excel. Graph generated in GraphPad, Prism.  
 
Figure 4.7. Confocal Images of XA-induced rounding up and emergence in the PfPDEγ-ko line +/- C2 
XA-treated (100 μM) samples were compared to an unstimulated control (0.05 % DMSO). Upper panels 
represent light image with Band 3 (red) and Dapi (blue) staining. Lower panels represent the same image 
with Band 3 staining only (red). Blue arrows indicate crescent shaped stage V gametocytes stained with 
Band 3 (non-activated). Green boxes represent rounded up gametocytes with no Band 3 staining 
(activated). Purple boxes are parasites that appear round in morphology but have not emerged (Band 3 
staining present). Green ovals represent crescent shaped stage V gametocytes that are not stained with 
Band 3. 
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PfPDEδ-ko line stage V gametocytes do not round up or emerge in response to XA 
stimulation 
 
In keeping with data produced by Cathy Taylor (Cathy Taylor, PhD Thesis, 2007) the majority of 
stage V gametocytes of the PfPDE-ko line do not emerge from the host erythrocyte in response 
to XA (Figures 4.8 and 4.9). DMSO treated parasites remained as crescent-shaped cells with host 
erythrocyte Band 3 staining detected. On addition of XA, ~85 % of cells retained their crescent 
shape and did not round up. Band 3 staining of the erythrocyte was still detected, indicative that 
these cells had not emerged from the host erythrocyte. This is slightly at odds with data 
presented by Cathy Taylor (Cathy Taylor PhD Thesis, 2007), which show that some cells do round 
up but that the majority of cells will not emerge, which suggests predominantly an emergence 
phenotype, whereas the data presented here indicates both a rounding up and emergence 
phenotype.   
A small number (~15 %) of cells both rounded up and emerged from the host erythrocyte in 
response to XA (again this is at odds to Cathy Taylor’s work). This was much lower than the ~ 90 
% that rounding up in response to XA in the 3D7a wildtype line. In samples treated with both XA 
and C2, ~100 % of gametocytes retained their crescent shape and erythrocyte membrane Band 
3 staining was still observed. Indicative that the small number of parasites that were able to 
round up and emerge in response to XA, did so in a PfPKG-dependent manner. This sample 
contained a proportion of asexual stages that remained surrounded by an erythrocyte 
membrane asexual stages were identified by the bright field image and the larger Dapi staining 
and were excluded from the final counts. 
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Figure 4.8. XA induced rounding up and emergence in the PfPDEδ-ko line in the presence and absence 
of C2.  XA-treated (100 μM) samples incubated for 30 minutes/RT in the presence or absence of C2 (2 μM) 
and compared to an unstimulated control (0.05 % DMSO). Data are presented as percentage of total 
parasitemia and determined by counts of parasites from IFA samples prepared from blood films stained 
with band 3 ab and imaged by confocal microscopy. Data are a single count of one experiment analysed 
in Excel. Graph generated in GraphPad, Prism.  
 
 
Figure 4.9. Confocal Images of XA-induced rounding up and emergence in the PfPDEδ -ko line +/- C2 
XA-treated (100 μM) samples compared to an unstimulated control (0.05 % DMSO). Upper panels 
represent light image with Band 3 (red) and Dapi (blue) staining. Lower panels represent the same image 
with Band 3 staining only (red). Blue arrows indicate crescent shaped stage V gametocytes stained with 
Band 3 (non-activated). Green boxes represent rounded up gametocytes with no Band 3 staining 
(activated). Purple boxes are parasites that appear round in morphology but have not emerged (Band 3 
staining present). Green ovals represent crescent shaped stage V gametocytes that are not stained with 
Band 3. 
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4.2.3. Investigation into a possible link between the ‘stiff’ phenotype of the PfPDEδ-
ko line and its inability to round up. 
 
In light of published data presented in this thesis showing that in the absence of PfPDEδ, stage 
V gametocytes exhibit a ‘stiff’ phenotype (section 4.2.1), it was of huge interest to investigate 
whether this lack of deformability contributes to the absence of XA-induced rounding up and 
emergence observed in the PfPDEδ-ko line (section 4.2.2). The absence of XA-induced 
emergence in the PfPDEδ-ko line, and greatly reduced ability to round up was first observed by 
Cathy Taylor (Cathy Taylor, PhD Thesis, 2007). Deletion of PfPDEδ was shown to increase levels 
of cGMP (~2-fold, corresponding to a ~2-fold decrease in cGMP-PDE activity) in 
gametocytes[130] indicating that the absence of PfPDEδ disrupted cGMP signalling. cAMP levels 
were also measured in this study but levels were very low and unchanged compared to the 
control and so it was not clear whether they were beyond the detection limit of the cAMP ELISA 
used[130]. Unregulated cGMP levels were deduced as the cause of the aberrant gametogenesis 
observed in the PfPDEδ-ko line. As mentioned elsewhere in this thesis, PfPDEδ is expressed at 
the protein level in mature gametocytes[144] and likely plays an important role in regulating 
cGMP levels, which are required for the process of gametogenesis. PfPDEδ was therefore 
previously thought to be a cGMP-specific PfPDE. However, data published by Ramdani et al[25] 
(in which the deformability data presented in this thesis are included), have linked P. falciparum 
gametocyte infected erythrocyte deformability to the absence of PfPDEδ and subsequent 
activation of PfPKA. In the Ramdani study, in contrast to work by Taylor et al[130], the total 
intracellular cAMP concentration in P. falciparum gametocyte was shown to be elevated in the 
PfPDEδ-ko line compared to 3D7a in both immature and mature gametocytes[25]. These data, 
along with those linking the absence of PfPDEδ to cAMP-regulated gametocyte deformability, 
suggests that PfPDEδ may be dual specific (however, data presented in this thesis (Chapter 6, 
Section 6.2.5) and data from Cathy Taylor’s work suggests otherwise). Alternatively, the 
apparent influence of PfPDEδ on cAMP levels may be indirect. However this needs to be 
confirmed (see chapter 5 for data presented on PfPDEδ cyclic nucleotide specificity). It must be 
noted that the host erythrocyte PKA may be contributing wholly or partly to the deformability 
phenotype. The PKA-induced stiff phenotype of the PfPDEδ-ko line complicates investigations 
into the role of PfPDEδ in gametogenesis because a premature spike in cAMP/PKA signalling may 
have rendered the PDE-δ gametocytes unable to respond later to cGMP/PKG signalling that 
triggers rounding up and emergence. Therefore, in order to attempt to dissect the two questions 
of the role of PfPDEδ in deformability and the role of PfPDEδ in inducing rounding up and 
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emergence, PKA was inhibited in the PfPDEδ-ko line using three concentrations of the PKA 
inhibitor KT5720. This is a specific, cell permeable inhibitor of both human and parasite PKA 
(assumed) that does not target PKG (Sigma product information). In mammalian cells it is known 
to inhibitor PKA by competitively binding to the ATP binding site on the PKA catalytic subunit 
preventing PKA from phosphorylating  target proteins[270]. It is important to note that PKA 
inhibition in this assay may affect the host-derived PKA, the parasite-derived PKA or both. PKA-
inhibitor treated PfPDEδ-ko samples were observed for rounding up events in both non-
stimulated (no PF9) and stimulated (plus PF9) samples. Samples were compared to a PKA-
inhibitor treated wildtype control. PF9 is a potent PDE inhibitor that stimulates gametogenesis 
(see chapter 6).  
 
At the highest concentration of KT5720 tested (10 μM), a small proportion (~ 9 % of the no PKA 
inhibitor control) of stage V gametocytes of the PfPDEδ-ko line rounded up in the absence of 
PF9 stimulation (Figure 4.10, control). This was completely reversed by the addition of the 
specific PKG inhibitor MRT00207065 indicating that the rounding up observed in this line when 
incubated with 10 μM KT5720 is PfPKG dependent. Addition of PF9 to samples pre-incubated 
with 10 μM KT5720 (Figure 4.10, PF9) resulted in ~ 25 % of gametocytes rounding up compared 
to the non-PKA inhibitor-treated control. This was reversed almost completely by pre-incubation 
with MRT00207065 with only ~ 3 % of parasites rounding up, indicating that at this 
concentration of KT5720, gametocytes lacking PfPDEδ are able to respond to PF9 stimulation by 
rounding up in a PfPKG-dependent manner. The data demonstrate that at this concentration, 
inhibition of PKA can reverse the inability of PfPDEδ-ko gametocytes to round up and that this 
may be due to reversing the deformability phenotype observed in this line. Not only this, but a 
small proportion (~ 9 %) of PKA-inhibited parasites lacking PfPDEδ can also round up un-
stimulated. 
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Figure 4.10. Rounding up of PfPDEδ-ko stage V gametocytes treated with 10 μM KT5720. Samples were 
pre-incubated with KT5720 (10 μM) in the presence and absence of MRT00207065 (1 μM). After 3 hours 
incubation, samples were split and incubated for 20 minutes in the presence or absence of PF9 (10 μM). 
Data are presented as percentage of the DMSO (0.05 %) control (no PKA inhibitor treatment see Figure 
4.13 green star) generated by counts (number of parasites per 900 RBC’s) of Giemsa stained blood films. 
Data are the average of 2 counts from 2 individual experiments. Graph generated in GraphPad, Prism. 
Error bars represent SD.       
 
 
At 5 μM KT5720, as seen with 10 μM KT5720, a proportion of stage V gametocytes of the PfPDEδ-
ko line rounded up unstimulated (Figure 4.11, control). Numbers of rounded up parasites were 
comparable to that of 10 μM KT5720 treatment with ~ 9 % appearing as rounded up forms. The 
number of non-stimulated rounded-up parasites was completely reversed by PfPKG inhibition 
(Figure 4.11, control + 065) indicating that treatment with 5 μM KT5720 can lead to rounding up 
of mature gametocytes in a PfPKG-dependent manner. This was also the case for PF9-stimulated 
mature gametocytes treated with 5 μM KT5720 (Figure 4.11, PF9), which showed ~ 30 % 
rounding up compared to the non-PKA inhibited control. This was completely reversed by pre-
incubation with MRT00207065. 
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Figure 4.11. Rounding up of PfPDEδ-ko stage V gametocytes treated with 5 μM KT5720.  Samples were 
pre-incubated with KT5720 (5 μM) in the presence and absence of MRT00207065 (1 μM). After 3 hours 
incubation, samples were split and incubated for 20 minutes in the presence or absence of PF9 (10 μM). 
Data are presented as percentage of the untreated DMSO (0.05 %) control (no PKA inhibitor treatment 
see Figure 4.13 green star) generated by counts (number of parasites per 900 RBC’s) of Giemsa stained 
blood films. Data are the average of 2 counts from 2 individual experiments. Graph generated in 
GraphPad, Prism. Error bars represent SD.       
 
 
 
 
 
Pre-incubation of PfPDEδ-ko line parasites with 1 μM KT5720 did not result in un-stimulated 
rounding up as seen with 5 μM and 10 μM KT5720, although a very small number (~ 1 % of the 
non-PKA inhibited control) did round up (Figure 4.12). However, when stimulated with PF9, ~30 
% of gametocytes rounded up compared to the DMSO control. This was completely reversed by 
pre-incubation with MRT00207065 (Figure 4.12) demonstrating that at the lowest concentration 
tested, although PfPDEδ-ko line gametocytes did not appear to round up un-stimulated as seen 
at the two higher PKG inhibitor concentrations, they were able to round up in a PfPKG-
dependent manner when stimulated with PF9. 
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Figure 4.12. Rounding up of PfPDEδ-ko stage V gametocytes treated with 1 μM KT5720.  Samples were 
pre-incubated with KT5720 (1 μM) in the presence and absence of MRT00207065 (1 μM). After 3 hours 
incubation, samples were split and incubated for 20 minutes in the presence or absence of PF9 (10 μM). 
Data are presented as percentage of the untreated DMSO (0.05 %) control (no PKA inhibitor treatment 
see Figure 4.13 green star) generated by counts (number of parasites per 900 RBC’s) of Giemsa stained 
blood films. Data are the average of 2 counts from 2 individual experiments. Graph generated in 
GraphPad, Prism. Error bars represent SD.       
 
 
 
Control samples (no PKA inhibition) of the PfPDEδ-ko line showed no un-stimulated rounding up 
(Figure 4.13). This demonstrates that in samples inhibited with KT5720, un-stimulated rounding 
up was likely to be due to PKA inhibition. These samples also showed ~15 % PF9-stimulated 
rounding up (Figure 4.13). However this was lower than seen in PKA inhibitor-treated samples 
and comparable levels to numbers seen in other experiments carried out on PfPDEδ-ko line 
parasites using PF9 (chapter 6 section 6.2.4.1). Again this indicated that the majority of PF9-
induced rounding is likely to be a result of PKA inhibition. Some abnormal forms were observed 
in PF9-treated samples of the non-PKA-inhibited control but not in any of the KT5720-treated 
samples.  
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Figure 4.13. Rounding up of PfPDEδ-ko stage V gametocytes with no PKA inhibition.  Samples were pre-
incubated with DMSO (0.05 %) in the presence and absence of MRT00207065 (1 μM). After 3 hours 
incubation, samples were split and incubated for 20 minutes in the presence or absence of PF9 (10 μM). 
Data are presented as percentage of the untreated DMSO (0.05 %) control (green star) generated by 
counts (number of parasites per 900 RBC’s) of Giemsa stained blood films. Data are the average of 2 
counts from 2 individual experiments.  Graph generated in GraphPad, Prism. Error bars represent SD. 
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Addition of KT5720 to the 3D7a wildtype line does not affect gametocyte numbers or 
lead to un-induced rounding up. 
 
To make sure that the PKA inhibitor KT5720 did not lead to any adverse effects on gametocytes, 
and to ensure that the rounding up seen in PfPDEδ-ko line gametocytes was due to the reversing 
of the stiff phenotype rather that rounding up induced by addition of the PKA inhibitor, 
Increasing concentrations of KT5720 were incubated with 3D7a stage V gametocytes and 
samples observed for rounding up events or changes in total parasitemia. 
Addition of 10 M, 5 M or 1 M KT5720 to wild type 3D7a stage V gametocytes did not result 
in un-stimulated rounding up as seen in the PfPDEδ-ko line (Figure 4.14). Stage V gametocyte 
numbers did not differ from the non-treated control when KT5720 was added. This indicates 
that KT5720 does not act to induce rounding up in the wildtype line. These data also indicate 
that all concentrations of KT5720 tested do not affect parasite numbers after 3 hours of 
incubation and are therefore unlikely to result in a toxic effect under the conditions of the assay. 
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Figure 4.14. Addition of KT5720 to stage V gametocytes of the 3D7a line. Samples pre-incubated with 10 
M, 5 M or 1 M KT5720 for 3 hours. Data are presented as percentage of the untreated DMSO (0.05 
%) control generated by counts (number of parasites per 900 RBC’s) of Giemsa stained blood films. Data 
are the average of 2 counts from 1 experiment. Graph generated in GraphPad, Prism.  Error bars represent 
SD.   
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XA was also able to induce an increase in round forms in KT5720-treated samples 
 
Addition of XA to stage V gametocytes of the PfPDE-ko line resulted in only a very small 
proportion (~ 5 %) of parasites rounding up from a crescent shaped to a rounded form (Figure 
4.15). This proportion was increased when PfPDE-ko line gametocytes were treated for 12 
hours with the PKA inhibitor KT5720 (Figure 4.16). ~25 % gametocytes rounded up in response 
to XA when PKA was inhibited. A small proportion (~ 9 %) of gametocytes of the PfPDE-ko line 
appeared to have rounded up in samples that had been incubated for 20 minutes with KT5720 
but which had not been stimulated by XA (Figure 4.16). This proportion of rounded up cells was 
~ 2.5 times lower than in XA treated samples, but was not seen in PfPDE-ko line samples not 
treated with KT5720 indicating that a small proportion of PKA-inhibited gametocytes can round 
up unstimulated. The XA response in the PfPDE-ko line was compared to that in the 3D7a 
wildtype line not treated with PKA inhibitors. ~ 51 % of 3D7a stage V gametocytes rounded up 
in response to XA (Figure 4.17).  
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Figure 4.15. XA stimulation of PfPDEδ-ko gametocytes. PfPDEδ-ko line stage V gametocytes were 
incubated with XA (30 μM) or 0.05 % DMSO (control) at RT for 30 minutes. Numbers of stage V (crescent) 
and rounded up parasites were counted from Giemsa stained blood films. Data are the average of 3 counts 
(parasites per ~900 RBC’s counted) from 1 experiment. Graph generated in GraphPad, Prism. Error bars 
represent SD.   
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Figure 4.16. XA-stimulation of PfPDEδ-ko gametocytes in the presence of KT5720. PfPDEδ-ko line 
stage V gametocytes pre-incubated with 5 M KT5720 for 12 hours were then incubated with XA (30 μM) 
or 0.05 % DMSO (control) at RT for 30 minutes. Numbers of stage V (crescent) and rounded up parasites 
were counted from Giemsa stained blood films. Data are the average of 3 counts (parasites per ~900 RBC’s 
counted) from 1 experiment. Graph generated in GraphPad, Prism.  Error bars represent SD.   
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Figure 4.17. XA-stimulated 3D7a stage V gametocytes. 3D7a stage V gametocytes were incubated with 
XA (30 μM) or 0.05 % DMSO (control) at RT for 30 minutes. Numbers of stage V (crescent) and rounded 
up parasites were counted from Giemsa stained blood films. Data are the average of 3 counts (parasites 
per ~900 RBC’s counted) from 1 experiment. Graph generated in GraphPad, Prism. Error bars represent 
SD.   
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These data indicate that PKA inhibition of PfPDE-ko line gametocytes results in some non-
induced rounding up and, more strikingly, an increase in both XA and PF9-induced rounding up. 
This suggests that if PKA-induced ‘stiffness’ is reversed, parasites are able to round up. However, 
this line still appears to exhibit greatly reduced XA-induced (and PF9) rounding up as previously 
described[130], suggesting that as previously hypothesised, PfPDE may play an important role 
in the processes of gametogenesis. In light of this it was of interest to investigate whether the 
absence of PfPDE could affect another important part of the gametogenesis process, the 
release of Ca2+ from internal stores, which is required for the later stages of gametogenesis. 
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4.2.4. Investigation into the effect of genetic and pharmacological phosphodiesterase 
disruption on Ca2+ mobilisation 
 
XA-induced Ca2+ mobilisation in stage V gametocytes requires the presence of PfPDEδ.  
 
It is known that gametogenesis involves Ca2+ release. It was therefore of interest to explore the 
role of PfPDEs that are potentially expressed in mature gametocyte stages at this crucial event 
of gametogenesis and to determine a possible link between Ca2+ mobilisation and cyclic 
nucleotide regulation through PfPDEs.  As seen in chapter 3 (section 3.3.1), both XA and 
zaprinast can induce Ca2+ mobilisation in wild type stage V gametocytes and for zaprinast this is 
a PfPKG-dependent event, whereas in XA-induced Ca2+ mobilisation, although there is evidence 
of some PfPKG specificity, a proportion of the XA induced Ca2+ response appears not to be PfPKG 
dependent (chapter 3). The PfPDE-ko, PfPDEγ-ko and PfPDEδ-ko lines were used in calcium 
release assays (see methods section 2.4.A) to determine the PKG specificity of the XA and 
zaprinast-induced Ca2+ responses in the absence of PfPDE, PfPDEγ or PfPDEδ. The aim of this 
was to investigate the impact that the absence of these PfPDEs would have on the Ca2+ signalling 
response in mature gametocytes in the presence and absence of the PKG inhibitor C2.  
Purified stage V gametocytes were loaded with Fluo-4-AM then treated with XA or zaprinast. In 
order to look at the PKG specificity of the Ca2+ response in these knockout lines, samples were 
treated in the presence or absence of C2. Levels of Ca2+ release from test samples were 
compared to an ionophore control that facilitates the transport of Ca2+ across membranes and 
therefore induced a rapid rise in intracellular Ca2+. 
 
 
 
 
 
 
 
 
 
 
 
 
151 
 
There is no evidence that deletion of PfPDEγ alters the XA or zaprinast-induced Ca2+ 
response 
 
Although data are preliminary and need repeating, the PfPDEγ-ko line (Figure 4.18) appeared to 
behave as the wildtype line (Chapter 3, section 3.2.2, Figure 3.10 and also see Figure 4.21 for a 
comparison of the Ca2+ response in all parasite lines tested). In the absence of PfPDEγ, parasites 
responded to both XA and zaprinast by releasing Ca2+. Ca2+ release induced by zaprinast was fully 
reversed by addition of C2. However, C2 only reversed XA induced Ca2+ mobilisation by ~50 % in 
XA-treated samples indicating that half of the XA-induced Ca2+ release is likely to be PfPKG-
dependent but the other half of the Ca2+ response is likely to be induced through a signalling 
pathway that is not dependent upon PfPKG as C2 inhibition of PfPKG in this line does not fully 
reverse the Ca2+ release as previously observed (Chapter 3). This experiment is only one replicate 
and needs to be repeated and with an ionophore control. 
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Figure 4.18. Ca2+ release in purified stage V gametocytes of the PfPDEγ-ko line. Parasites were stimulated 
with 3 µM XA and 100 µM zaprinast in the presence and absence of 2 μM C2. Fluorescence levels are 
presented as relative fluorescence units (RFU) minus the baseline fluorescence and fluorescence of the 
DMSO (0.05 %) control sample analysed in Excel. Graph generated in GraphPad, Prism. Data are from one 
experiment carried out in triplicate.  
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PfPDE-ko gametocytes are unable to respond to XA stimulation but can release Ca2+ 
in response to zaprinast 
 
Interestingly, stage V gametocytes of the PfPDE-ko line appeared completely unresponsive to 
XA-stimulation. No Ca2+ was detected at all in XA treated or XA + C2 samples and this result was 
reproducible (Figure 4.19).  
Zaprinast induced ~20 % Ca2+ release in relation to the ionophore control (normalised to 100 %). 
All of the Ca2+ release seen in the zaprinast-treated sample was reversed by the addition of C2. 
This indicates that in the absence of PfPDE, Gametocytes cannot undergo Ca2+ release in 
response to XA stimulation. They can however respond to zaprinast stimulation and do so in a 
PfPKG-dependent manner. 
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Figure 4.19. Ca2+ release in stage V PfPDE-ko gametocytes. Parasites were stimulated with XA (3 µM) 
and zaprinast (100 µM) in the presence and absence of 2 μM C2. Fluorescence levels are presented as 
percentage of ionophore control (A23187, 5 µM) minus the baseline fluorescence and fluorescence of the 
DMSO (0.05 %) control sample analysed in Excel and are the average of 2 separate experiments each 
carried out in triplicate. Graph generated in GraphPad, Prism. Error bars represent SD.  
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Absence of PfPDEα appears to reduce the PfPKG dependence of both the XA and 
zaprinast induced Ca2+ responses  
 
Both XA and zaprinast stimulated Ca2+ release in parasites in which PfPDE had been knocked 
out (Figure 4.20). This indicates that in the absence of PfPDE, parasites can still respond to both 
XA and zaprinast stimulation to release Ca2+. Addition of C2 reduced the XA-induced Ca2+ 
response by only ~ 30 %. This reduction in the Ca2+ levels was shown to be not significant 
(Welch’s unpaired t test, P = 0.0636). 
Addition of C2 to the PfPDE-ko line reduced the zaprinast-induced Ca2+ response by ~ 60 %. 
This decrease in Ca2+ levels was also not significant (Welch’s unpaired t test, P = 0.0763). 
However, the more specific PKG inhibitor MRT00702065 appeared to reduce both XA and 
zaprinast-induced Ca2+ release more than C2 with a ~ 60 % and a ~ 70 % decrease reduction 
compared to non-PKG inhibition, respectively. The decrease in Ca2+ release observed with 
addition of MRT00702065 was shown to be significant for both XA induced Ca2+mobilisation 
(Welch’s unpaired t test, P = 0.0440) and for zaprinast-induced Ca2+mobilisation (Welch’s 
unpaired t test, P = 0.0202). The data, although preliminar152y, suggest that when PfPDE is 
absent, the Ca2+ released in response to both XA and zaprinast is likely to be less PKG dependent 
compared to the wildtype 3D7a line (See figure 4.21 for a comparison) as C2 does not 
significantly reverse levels of Ca2+ compared to that stimulated by XA or zaprinast alone. 
However, the reduction in Ca2+ levels on addition of MRT00702065 is a significant decrease. 
However, this may be due to an off target effect at the concentration used.  
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Figure 4.20. Ca2+ release in stage V PfPDEα-ko gametocytes. Parasites pre-incubated in the presence and 
absence of 2 μM C2 or 1 μM MRT00207065 were stimulated with XA (30 µM) and zaprinast (100 µM). 
Data are presented as Ca2+ release measured as percentage A23187 (positive control) minus the baseline 
fluorescence and fluorescence of the DMSO (0.05 %) control sample analysed in Excel. Bar chart was 
generated in GraphPad, Prism and shows the data from 1 experiment carried out in duplicate. 
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Figure 4.21. Comparison between parasite lines of the PfPKG-specificity of the XA and zaprinast-induced 
Ca2+ responses. 
Data are from Figures 3.10, 3.11, 4.16, 4.17 and 4.18 collated and presented as percentage reduction of 
XA (30 µM-PfPDEα-ko and PfPKGT618Q, 3 µM all other lines) or zaprinast (100 µM) induced Ca2+ levels on 
addition of C2. (Note, no XA-induced Ca2+ data included for PfPDEδ-ko). XA and zaprinast-induced Ca2+ 
release in the absence of C2 is normalised to 100 %. Bar chart was generated in GraphPad, Prism and 
shows the data from 3 experiments carried out in triplicate for 3D7a, 1 experiment carried out in duplicate 
for PfPDEα-ko and PfPKGT618Q, 2 experiments carried out in triplicate for PfPDE-ko and 1 experiment 
carried out in triplicate for PfPDEγ-ko line. Error bars represent SD.  
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4.3. Discussion 
 
Data presented in this chapter, although requiring further work, strongly indicate that PfPDEs 
play an important role in regulating levels of cyclic nucleotides required for essential stages of 
gametogenesis including rounding up, emergence and Ca2+ mobilisation and also for gametocyte 
infected erythrocyte deformability, which is required for the circulation in the host blood stream 
of gametocytes primed for transmission and ready to be taken up in a blood meal. 
There is evidence to suggest that PfPDEδ may be essential for the process of gametogenesis 
(Cathy Taylor, PhD Thesis, 2007)[159]; however, the role of PfPDEδ in gametocyte infected 
erythrocyte deformability complicates the use of this line in studies into the role of PfPDEδ in 
subsequent processes such as rounding up and emergence from erythrocytes. 
 
In gametocyte infected erythrocyte deformability assays, unlike the wildtype line that exhibited 
a deformable phenotype, stage V gametocytes of both the PfPDEγ-ko and PfPDEδ-ko lines were 
unable to pass through the microsphiltration matrix. This demonstrates that these parasites 
were not deformable and likely exhibited a stiff phenotype. Accompanying data in this 
publication[25] indicated that this stiff phenotype was a result of increased levels of cAMP in 
the PfPDEδ-ko line. Supporting this, authors showed that the overall concentration of cAMP in 
gametocyte infected erythrocytes decreases as parasites mature from early gametocytes to 
mature stage V gametocytes and that this correlates with increased deformability of these cells. 
In this study, a role for PDEs in deformability was shown in this process, with the PDE inhibitors 
sildenafil citrate and zaprinast elevating levels of cAMP in mature gametocytes and rendering 
them stiff. Cyclic GMP levels were also shown to be slightly elevated with these compounds. 
However, inhibition of PfPKG using C2 did not alter retention rates of stage III or Stage V 
gametocytes. However, this doesn’t rule out cross-talk between the cAMP and cGMP-signalling 
pathways which could lead to an indirect role for parasite cGMP signalling in gametocyte 
infected erythrocyte deformability. Cross talk between these two signalling pathways has been 
identified in mammalian systems and in human erythrocytes: levels of cAMP can be regulated 
by the cGMP-induced inhibition of the PDE that regulates cAMP, PDE3. Inhibition of PDE5, which 
regulates cGMP in these cells, leads to elevated levels of cAMP due to cGMP-induced inhibition 
of PDE3 and this leads to ATP release leading to vasodilation. This is interesting and as we predict 
that PfPDEδ is likely to be cGMP-specific rather than dual-specific (see chapter 6 section 6.25) 
(despite the outcome of this publication[25]), it is tempting to speculate that perhaps the 
elevated levels of cGMP known to be a result of the pharmacological or genetic removal of 
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PfPDEδ in mature gametocyte stages, could indirectly elevate levels of cAMP (either host or 
parasite derived) to induce gametocyte stiffness, rather than PfPDEδ directly regulating levels 
of cAMP.  
Data presented here on the deformability phenotype of the PfPDEγ-ko line were not included in 
the final manuscript[25]. These data suggest that the absence of PfPDEγ also impacts on the 
ability of gametocyte-infected erythrocytes to become deformable via direct or indirect 
regulation of cAMP levels. This was unexpected as PfPDEγ does not appear to be expressed at 
the mRNA level in gametocytes[25]. The ability of PfPDEγ to hydrolyse cAMP is not known, 
although there is evidence that PfPDEγ may hydrolyse cGMP. This was shown by a study on a 
transgenic line of P. yoelii in which PγPDEγ was absent. Sporozoites of this line exhibited elevated 
levels (~ 18 fold higher than wildtype) of cGMP[142]. However confirmation of the deformability 
phenotype of the PfPDEγ-ko line requires further clarification. It is possible that parasites used 
in the assay may have been too young and were already exhibiting a stiff phenotype as a result 
of not reaching sufficient maturity to become deformable. Data presented in this chapter 
showing gamete egress assays demonstrate that stage V gametocytes lacking PfPDEγ can still 
round up and emerge normally in response to XA stimulation. This brings into doubt the 
evidence presented here that indicates that these parasites also show a lack of deformability. If 
this were the case, PfPDEγ-ko line gametocytes would not be expected to be able to round up 
in response to XA stimulation. This assay needs to be repeated and the PfPDEγ-ko parasite line 
checked. 
 
Gamete egress assays confirmed Cathy Taylor’s work (Cathy Taylor, PhD Thesis, 2007) showing 
that gametocytes cannot respond to XA by emerging from the host erythrocyte when PfPDEδ is 
absent (and that rounding up is also reduced). However, these data presented here show some 
differences to that of Cathy Taylor’s work in that the majority of gametocytes (> 80 %) were 
unable to round up in response to XA. By contrast, data by Taylor et al[130], point towards an 
emergence phenotype rather than a rounding up phenotype (although rounding up is reduced) 
and show that depending on the day of induction and clonal line tested (three were tested), 
between ~50 % and ~80 % of PfPDEδ-ko line parasites will still round up in response to XA[130]. 
However, similarly to the results presented here, the same publication showed that the majority 
of gametes will not emerge[130]. This difference is interesting and may reflect the differences 
in the assays used to determine rounding up or possibly the clonal line or age of gametocytes 
used in these studies. However, despite the differences, both the work presented here and work 
carried out by Taylor et al, point towards a defect in emergence when PfPDEδ is absent. 
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Data presented in this chapter using the PKA inhibitor KT5720 have shown convincingly that if 
PKA is inhibited (inhibition by KT5720 is likely to target both host and parasite PKA, although, it 
is only assumed that it targets parasite PKA, this has not been confirmed experimentally) and it 
is not yet clear which is responsible for deformability) a greater proportion of the PfPDEδ-ko 
gametocytes can round up and emerge from the host erythrocyte in response to the PDE 
inhibitor PF9 and XA (although emergence is still greatly reduced). This suggests that the egress 
phenotype previously observed in this line is due in part to the inability of gametocytes to 
physically change their shape from a crescent to a rounded morphology and that this is due to 
PKA-induced stiffness as a result of the absence of PfPDEδ. Interestingly but unsurprisingly, a 
small proportion of PfPDEδ-ko mature gametocytes also rounded up un-stimulated when PKA 
was inhibited. This is unsurprising because given that PfPDEδ is absent in this line and it is known 
to have elevated levels of cGMP, it would be expected that the elevated levels of cGMP would 
lead to induction of gametogenesis and as a consequence, the phenotype of this line would be 
expected to be that of premature rounding up (with no induction) rather than no rounding up 
when induced with XA. Data showing induction of gametogenesis with pharmacological 
inhibition of PDEs (i.e. PF9 and zaprinast) support this and it has always been puzzling to observe 
a discrepancy between the phenotype of the PfPDEδ-ko line (no rounding up) and 
pharmacological PDE inhibition (induction of gametogenesis). This discrepancy may therefore 
be explained by these data presented here using PKA inhibition to prevent the ‘stiff’ phenotype, 
which suggests that when this block in deformability is removed, a proportion of PfPDEδ-ko 
stage V gametocytes can round up unstimulated. If the deformability phenotype resulting from 
the removal of PfPDEδ were not present, it may be expected that this line would round up 
unstimulated upon reaching maturity at stage V and perhaps it would be expected that a greatly 
reduced number of stage V gametocytes would be observed in cultures. It may also be expected, 
given other observations outlined in this report, that the absence of PfPDEδ would still exhibit a 
defect in the XA-induced response (see figure 4.22 for a schematic).  
The number of PfPDEδ-ko line parasites rounding up un-stimulated was low. This likely reflects 
an essential role for PfPDEδ in gametogenesis and the majority of parasites may be unable to 
round up due to the absence of PfPDEδ. It may also reflect the maturity of the parasites and the 
subsequent requirement for other components of the cellular signalling cascade to be present 
in order for the signalling cascade to be complete, so rounding up may not be able to occur until 
gametocytes have reached full maturity. Or it may simply reflect the result of unregulated 
elevated levels of cGMP (or cAMP), which have essentially disrupted the parasites. It would be 
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interesting to observe these un-stimulated PKA-inhibited parasites over time to see if numbers 
of parasites rounding up increases temporally as parasites mature.  It is important to note that 
although we know that KT5720 inhibits mammalian PKA[270]  there is no concrete evidence that 
it will also target Plasmodium PKA and there is also a possibility that this inhibitor could be 
targeting other kinases. In mammalian cells it is known to target amongst others, the serine-
threonine protein kinase Phosphoinositide-dependent kinase 1 (PDK1) which itself targets other 
kinases, and mitogen-activated protein kinase (MAPK)[270]. However, data presented here on 
the 3D7a line (Figure 4.14) indicate that this inhibitor will not induce rounding up in the wildtype 
line at the three concentrations tested. Therefore the rounding up that is seen in the PfPDEδ 
line is unlikely to be due to an off target effect but is likely to be a result of inhibitor-induced 
reversing of the ‘stiff phenotype’.  
 
Both un-stimulated and stimulated (XA and PF9) rounding up of PfPDEδ-ko gametocytes was 
reversed by pre-incubation with the PKG inhibitor MRT002070065. This indicates that both 
stimulated rounding up and un-stimulated rounding up in parasites devoid of PfPDEδ is a PfPKG-
dependent process. This was also observed in XA treated samples and supports evidence 
presented in this chapter (and in the literature[159]) on rounding up and emergence. 
MRT00207065, although more specific for PfPKG than C2, may have off target effects if used at 
a concentration that is too high. This inhibitor is extremely active and has a low EC50 value of 2.1 
nM, however, it’s EC50 value on the PfPKGT618Q parasite line (2.4 M), although much higher than 
the concentration required to inhibit the wildtype line, is still low and as such a concentration of 
1 M may target other kinases. C2 on the other hand, has an EC50 value of 6 M on the PfPKGT618Q 
parasite line so a concentration of 1 M C2 would be safer to use than 1 M MRT00207065. In 
light of this, it would be good to repeat these assays using a lower concentration of 
MRT00207065 to ensure that the potential PfPKG-specificity seen is real and not due to 
inhibition of another kinase.  
 
Addition of PF9 or XA to PKA-inhibited samples induced a higher level of rounding up than seen 
in non-treated samples. In Chapter 6 (section 6.2.4.1), data are presented to demonstrate that 
PF9 can induce a small proportion of PfPDEδ-ko parasites to round up. This is very likely to be 
due to inhibition of a PfPDE other than PfPDEδ. This is predicted to be PfPDEα and it is possible 
that activation of PKA in this line is not 100 % sufficient to cause all parasites to become stiff and 
this is seen by the retention rates of the PfPDEδ-ko which showed ~80 % retention 
demonstrating that ~ 20 % of the parasites are still deformable. It is likely that this population 
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of cells are the ones able to round up when induced with PF9 in a PKG-dependent manner, as 
they are unlikely to exhibit the structural restraints that the ‘stiff’ cells do. In KT5720-treated 
PfPDEδ-ko gametocytes, this proportion of rounded up parasites is higher, suggesting that PKA 
inhibition allows more parasites to become deformable and therefore able to be induced by 
PfPDE inhibition (and PKG activation) to round up. This proportion of parasites able to round up 
in the PKA-inhibited PfPDEδ-ko line is much lower than seen in the 3D7a wildtype line with the 
same treatment. This is likely due to the fact that the PfPDEδ protein is absent from this line and 
is likely to be the predominant PfPDE required for gametogenesis (although this needs to be 
clarified) therefore, absence of PfPDEδ still significantly lowers the rounding up efficiency of 
gametocytes. This supports data from Cathy Taylor (Cathy Taylor, PhD, 2007) and points towards 
an essential role for PfPDEδ in the initial stages of gametogenesis. The observation of stimulated 
rounding up (of a small proportion of gametocytes) in the PfPDEδ-ko line suggests that the 
presence of one or more other PfPDEs may play a slight compensatory role (although not enough 
to reverse the phenotype observed). It is possible, although speculative, that PfPDEα may be the 
only other PfPDE expressed in the PfPDEδ-ko line at the protein level (although again, this 
requires confirmation) and may be able to help regulate levels of cGMP. It cannot be ruled out 
that gametogenesis could be PfPDEδ-regulated and involve both cGMP and cAMP and there is 
evidence in the literature that both of these cyclic nucleotides are elevated in the PfPDEδ-ko line 
in mature gametocytes (although elevated cAMP levels may be host derived)[130],[25].  
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Figure 4.22. Schematic showing a model of the relationships between cyclic nucleotide signalling, 
PfPDEδ, gametocyte deformability and gametocyte rounding up and gamete emergence. 
(A) In a wildtype situation, early gametocytes exhibit a ‘stiff’ phenotype maintained by elevated levels of 
cAMP, which keep PfPKA activated. When gametocytes reach maturity at stage V cAMP levels go down 
and PfPKA is no longer activated resulting in gametocytes becoming deformable. This is thought to require 
PfPDEδ. These parasites round up and emerge in response to XA, which stimulates elevation of cGMP 
levels leading to PKG activation. (B) and (C) In the PfPDEδ-ko line in the presence of the PKA inhibitor 
KT5720, both cAMP and cGMP levels remain high in stage V gametocytes. However, PfPKA is non-
activated by the PKA inhibitor reversing the stiff phenotype. Elevated levels of cGMP leading to activation 
PfPKG as a result of the absence of the PfPDEδ lead to a small proportion of gametocytes rounding up 
unstimulated. A proportion of PfPDEδ-ko line gametocytes treated with KT5720 can also round up when 
stimulated with XA (C) or (B) PF9. PF9 likely inhibits PfPDEα, which may lead to rounding up via cAMP 
signalling. (D) In the PfPDEδ-ko line, PfPDEδ is absent leading to an increase in levels of both cAMP (by a 
PfPDEδ-mediated non-PKG-dependent pathway) and cGMP which do not go down once parasites reach 
maturity. Stage V gametocytes remain stiff and do not become deformable. This physical restriction 
prevents these parasites from rounding up in response to XA.  
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The relationship between cGMP signalling and Ca2+ mobilisation from internal stores in P. 
falciparum gametocytes is explored in chapter 3. The data presented in that chapter 
demonstrate that Ca2+ release in mature gametocytes can be stimulated by zaprinast in a PfPKG-
dependent manner (and this is also seen in zaprinast-induced Ca2+ mobilisation in schizont 
stages). However, data in chapter 3 also identified that XA stimulation of Ca2+ release in 
gametocytes is more complicated and may involve both a PfPKG-dependent and a non-PfPKG-
dependent component. On this basis, and particularly given the evidence that PfPDE inhibition 
by zaprinast leads to Ca2+ mobilisation, it was of interest to explore further the relationship 
between Ca2+ mobilisation and cGMP signalling by investigating the effect on Ca2+ release in 
mature gametocyte stages where the individual PfPDEs have been deleted. Observation of the 
absence of XA-induced Ca2+ mobilisation, but the presence of zaprinast-induced Ca2+ 
mobilisation in the PfPDEδ-ko line was very exciting. These data suggest that these two 
compounds may either act through different pathways or that XA may specifically require the 
presence of PfPDE to induce Ca2+ mobilisation in mature gametocytes and that zaprinast may 
bypass this initial interaction. Zaprinast is a broad spectrum PDE inhibitor, so in the absence of 
PfPDE, can induce Ca2+ release through inhibition of another PfPDE such as PfPDEα in a PfPKG-
dependent manner. There is a possibility that PfPDE-ko parasites could be disrupted due to 
prolonged elevated levels of cGMP. The fact that zaprinast can trigger calcium release in PfPDEδ-
ko means that the calcium release machinery is intact. However, if the proteomic data are 
considered, it is likely that PfPDEδ is only expressed at the protein level in mature gametocytes 
and not earlier. Therefore, if this is the case, levels of cGMP (in the PfPDEδ-ko line) would not 
likely have been elevated for long (or at all) prior to gametocytes reaching stage V. However, 
cAMP may be elevated for a prolonged period (possibly through synthesis by ACs) and it must 
be considered that parasites of the PfPDEδ-ko line may not be viable due to disruption. It would 
be of huge interest to test the viability of this line. It may be possible to do this using Alamar 
blue to determine whether the cells are metabolically active. It would also be of use to re-create 
this knockout line using a gametocyte luciferase expressing line as a background. Another 
interesting approach would be to make a conditional knock down line of PfPDEδ. This would 
hopefully decrease the length of time that parasite are exposed to unregulated elevated levels 
of cyclic nucleotides and may be a useful tool in investigating the role for PfPDEδ in gametocyte 
stages.  
 
Elevated levels of cGMP (~2 fold and ~0.5 fold cGMP-PDE activity) have been recorded in 
PfPDEδ-ko parasites[130]. It was therefore interesting to see that PfPDEδ-ko line gametocytes 
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could respond to zaprinast by releasing Ca2+. The presence of a zaprinast-induced Ca2+ response 
(which will elevate cGMP levels further) in this line indicates that these already elevated cGMP 
levels do not appear to affect the zaprinast response. The presence of another PfPDE such as 
the cGMP-PfPDE, PfPDEα, may reduce levels of cGMP to a low enough level that doesn’t exceed 
the threshold required to activate PfPKG. However, this is unlikely given that PfPDEδ-ko line 
gametocytes can round up un-stimulated in the presence of a PKA inhibitor (unless PKA 
suppresses PKG) But levels of cGMP may be reduced enough in the PfPDEδ-ko line that further 
increases in cGMP due to addition of zaprinast would still have an effect. In the PfPDEδ-ko line 
the zaprinast-induced Ca2+ mobilisation appeared to be PfPKG-dependent as it was completely 
reversed by C2. It would be interesting to measure levels of cGMP in this line in the presence 
and absence of stimuli such as PF9, zaprinast and XA. 
 
The absence of XA-induced Ca2+ mobilisation in the PfPDEδ-ko line is an exciting result but needs 
to be confirmed further. A serial dilution of XA addition to this line would identify whether this 
line may just require a higher concentration of XA than the wildtype line to induce a Ca2+ 
response. The concentration of XA used in this assay was very low (3 μM) and although this is 
the same concentration used to stimulate the wildtype line in which XA-induced 
Ca2+mobilisation was observed, it would be of benefit to test XA on the PfPDEδ-ko line at a higher 
concentration. XA has been shown to only stimulate gametogenesis above 3 μM[26] so the 
concentration used should have been higher. The contrast observed between zaprinast and XA-
induced Ca2+ release in the PfPDEδ-ko line was interesting and if further investigation does 
indeed confirm that the PfPDEδ-ko line cannot respond to XA-stimulation by releasing Ca2+, this 
would suggest that the signalling components or pathways used by XA and zaprinast to induce 
Ca2+ release may differ or as suggested earlier, zaprinast may bypass the initial XA response, 
which is the more likely scenario. Hypothetically it may be that XA interacts specifically with 
PfPDEδ to induced Ca2+ release so when PfPDEδ is absent XA can have no effect, whereas 
zaprinast can inhibit PfPDEs other than PfPDEδ also, leading to Ca2+ mobilisation in the absence 
of PfPDEδ. This would be an extremely interesting finding. It would be interesting to use 
immunoprecipitated PfPDEδ from gametocyte stages to carry out interaction studies with XA to 
determine whether there is a direct interaction between PfPDEδ and XA. It would be also be of 
interest to carry out Ca2+ release assays on the PfPDEδ-ko line in the presence of the PKA 
inhibitor KT5720. It could be possible that the elevated levels of cAMP in the PfPDEδ-ko line are 
somehow supressing the XA response. 
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As explored in other chapters in this thesis, the other PfPDE predicted to be present in stage V 
gametocytes is PfPDE. Both XA and zaprinast induced Ca2+ release in parasites in which PfPDE 
had been deleted. This indicates that unlike PfPDEδ, the presence of PfPDE is not required for 
the Ca2+ response induced by either of these compounds. Interestingly, both XA and zaprinast-
induced Ca2+ release was reduced much less by C2 when PfPDE was absent. This assay was only 
carried out once and needs to be repeated to confirm the result observed, however, this 
preliminary data indicates that when PfPDE is absent the XA and zaprinast induced Ca2+ 
responses appear to show less PfPKG dependence. This indicates that when the cGMP-specific 
PDE PfPDE is removed, so is most of the PKG-dependent Ca2+ response and that in the PfPDE-
ko line, the majority of the Ca2+ release is not likely to be PKG-dependent, therefore XA and 
zaprinast ‘inhibition’ of the remaining PfPDE (which is predicted to be PfPDEδ based on Plasmo 
DB data), does not result in Ca2+ release through a PKG-dependent pathway. This is unexpected 
as based on the literature[130] and data presented in this thesis (Chapter 6, section 6.2.5), it is 
predicted that PfPDEδ is likely to be cGMP-specific and as yet there is no evidence that it directly 
hydrolyses cAMP. It would be interesting if possible to create a line in which both PfPDE and 
PfPDEδ can be conditionally knocked down. In the PfPDE-ko line, the pattern of XA and 
zaprinast responses in regards to the effect of C2 addition were very comparable. This is 
interesting and may possibly reflect the differences in the way that zaprinast and XA induce 
gametogenesis. It would be interesting to speculate that zaprinast (which we believe likely 
inhibits all four PfPDEs) will inhibit whatever PDEs are expressed at the protein level in stage V 
gametocytes to induce Ca2+ mobilisation, whereas XA will only specifically inhibit PfPDEδ 
(assuming that the interaction with PfPDEδ is to inhibit it). This hypothesis would account for 
the observation that in the PfPDE-ko line, where both compounds may only be targeting 
PfPDEδ, the profile of XA and zaprinast-induced Ca2+ response is similar whereas in the PfPDEδ-
ko line where only zaprinast is targeting PfPDE the pattern is not comparable. MRT00207065 
did significantly reduce the XA or zaprinast-induced Ca2+ mobilisation in the PfPDE-ko line. 
However, as stated earlier, this concentration may have been too high and as a consequence, 
could have had off-target effects. This compound needs to be used at a lower concentration in 
order to confirm the PfPKG-specificity in this line. 
  
Overall, these data indicate that despite the deformability phenotype clouding efforts to 
determine the importance of PfPDEδ in rounding up of gametocytes, PfPDEδ is still likely to be 
essential for critical events of gametogenesis such as rounding up and emergence and Ca2+ 
release (although this does require further work). Partially reversing (or fully reversing, the 
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effect is unknown) the ‘Stiff’ phenotype induced by the activation of PKA, allows a small 
proportion PfPDEδ-ko line gametocytes to round up un-stimulated and increases the number of 
parasites that can round up when stimulated by either XA or PDE inhibition. However, a large 
number of parasites are still unable to round up in response to XA or PF9 treatment when 
PfPDEδ is absent. This suggests that PfPDEδ may be important for this event to occur. 
PfPDEs also appear to play an important role in Ca2+ mobilisation in mature gametocyte stages. 
This is particularly apparent with XA treatment and data point towards PfPDEδ playing an 
essential role in XA-induced Ca2+ release and interestingly, PfPDE, although dispensable for 
both XA and zaprinast-induced Ca2+ mobilisation, appears to contribute to most of the PfPKG 
specificity of the Ca2+ response. 
Although exciting data, much of this is speculative and more work needs to be done to dissect 
and understand more the role that PfPDEs play in the process of gametogenesis. However, this 
work has forced a spotlight onto PfPDEδ as a PfPDE that is worth investigating further. 
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Chapter 5 
 
 The mode of action of a gametocytocidal PDE inhibitor 
 
5.1. Introduction  
 
In the fight against malaria, it is essential that drug discovery efforts continue because although 
there are some promising clinical candidates undergoing testing, drug attrition rates are high. 
Understanding the biology of the parasites that cause malaria is essential to discovering new 
and unique drug targets that can result in production of new candidates to enter the drug 
discovery pipeline. The combined efforts of chemists, developing new compounds against these 
targets and of biologists, testing such compounds against the parasite, is an invaluable part of 
the drug discovery process. 
 
PDE inhibitors have been used successfully as drugs to treat a number of medical issues in 
humans such as roflumilast to treat severe chronic obstructive pulmonary disease[271], 
pentoxifylline to treat muscle pain in patients with peripheral vascular disease[272] and Viagra 
to treat erectile dysfunction[273]. This success and the increasing literature emphasising the 
importance of cyclic nucleotide signalling in Plasmodium species has sparked a growing interest 
in Plasmodium PDEs as potential drug targets. Several human PDE inhibitors have been used as 
tools in numerous malaria parasite biology studies. IBMX (3-isobutyl-1-methylxanthine), a 
broad-spectrum human PDE inhibitor, has been reported to enhance exflagellation events[274]. 
Caffeine another broad-spectrum PDE inhibitor has been shown to induce both 
gametogenesis[275],[276] and gametocytogenesis[277],[243]. Despite these observations in 
sexual stages, investigations into the inhibition of P. falciparum PDE enzyme activity in both 
asexual and sexual stage parasite lysates showed little or no activity for either of these 
compounds (Ross Cummings, PhD Thesis, 2005). The lack of IBMX activity on P. falciparum PDEs 
has been further confirmed using 3[H] incorporation assays on live parasites, with IBMX showing 
no activity (>100 μM) against asexual stages (Laura Drought, PhD Thesis, 2014). This confirmed 
previous data by Yuasa et al, who found no inhibition of parasite growth of P. falciparum by 
IBMX even at 100 μM[143]. Zaprinast was the first human PDE inhibitor identified as being active 
against malaria parasite PDEs and was shown to inhibit cGMP PfPDE activity in membrane 
fractions of mixed asexual stages with an IC50 of 4 μM[143]. This compound also showed good 
inhibitory properties against both cAMP PfPDE enzyme activity (IC50 12 μM) and cGMP PfPDE 
enzyme activity (IC50 3 μM) in schizont stages and good cGMP hydrolytic activity in ring stages 
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(3.5 μM)[143]. Unlike most other human PDE inhibitors tested, zaprinast also showed activity 
against P. falciparum gametocyte cGMP-PDE activity (34 µM) (Ross Cummings, PhD Thesis, 
2005).  
Since then, zaprinast has been shown to induce premature blood stage merozoite egress in P. 
falciparum[173]. It can also be used to induce gamete egress (gametogenesis) when added to P. 
falciparum stage V gametocytes with the whole process from rounding up and emergence to 
male exflagellation being observed, in the absence of XA[159]. Zaprinast also exhibits good 
inhibitory activity against PDEs of the related apicomplexan T. gondii[278]. From this collection 
of studies, zaprinast has emerged as a good PDE inhibitor that targets all blood stream stages of 
P. falciparum, and represents a good starting point to develop more effective Plasmodium PDE 
inhibitors.  
Sildenafil citrate (known by the commercial name Viagra) targets human PDE5[273] and was 
originally developed to treat pulmonary heart disease[137]. It is now widely used to treat male 
erectile dysfunction. This PDE inhibitor and related inhibitors such as tadalafil which is also used 
to treat pulmonary arterial hypertension[279],[280], have been shown to impact on P. 
falciparum gametocyte deformability?[25],[281]. However, these inhibitors are less active than 
zaprinast on native gametocyte PDE activity (Ross Cummings, PhD Thesis, 2005)[25]. Sildenafil 
citrate (SC) is less effective at inducing rounding up with only ~ 30 % rounding up in response to 
400 μM SC treatment and 800 μM SC required to induce 70 % of rounding up. In similar assays, 
400 μM of zaprinast induced ~ 100 % of the wildtype line to round up (Cathy Taylor, PhD Thesis, 
2007). Sildenafil citrate is also less effective at inducing egress in P. falciparum stage V 
gametocytes compared to XA (Cathy Taylor, PhD Thesis, 2007 and my data not included). 
The PDE inhibitor BIPPO (5-benzyl-3-isopropyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one)[282] 
was developed along with several others based on the structures of existing human PDE1 and 
PDE9 inhibitors as these human PDEs (hPDEs) show greatest homology to Plasmodium PDEs. 
BIPPO was found to inhibit recombinant PfPDEα with an IC50 value of 150 nM, a much more 
potent activity than the 5 μM IC50 of zaprinast. BIPPO was shown to have high activity (IC50 0.4 
μM) exceeding that of zaprinast on P. falciparum asexual blood stages. It also exhibited better 
inhibitory activity than zaprinast against tachyzoites of T. gondii with an IC50 of 2 μM[282]. As 
observed with zaprinast[283],[173], BIPPO also induced egress of T. gondii tachyzoites and P. 
falciparum blood stage schizonts[282]. This inhibitor is an effective and useful tool for 
investigating cell signalling pathways and the related cellular events in both P. falciparum and T. 
gondii. However, as BIPPO has a higher potency against human PDEs (hPDE1, hPDE5, hPDE6 and 
hPDE9) with an IC50 value of 30 nM against recombinant hPDE9 and inhibition of 42 %, 66 % and 
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64 % at 1 μM against recombinant hPDE1, hPDE5 and hPDE6 protein respectively[282], it cannot 
be used as a drug to treat patients with malaria. Nevertheless, the work carried out with 
zaprinast and BIPPO to identify their activity in apicomplexan parasites demonstrates that 
human PDEs are a good starting point for the design of drugs that specifically target 
apicomplexan PDEs. In fact, a good example of how compounds can be altered to develop similar 
compounds with slightly different properties is the work done by Beghyn et al, who altered the 
structure of tadalafil with the aim to produce new analogues with improved biochemical 
properties and selectivity for malaria parasites[284].   
 
A very large number of PDE inhibitors have been developed by chemists at Pfizer. Five of these 
were selected to be tested against P. falciparum blood stages and exhibited sub-µM inhibitory 
activity against asexual blood stages. One of these inhibitors exhibited potency of around 1000-
fold higher than that of zaprinast (Laura Drought, PhD Thesis, 2014) against mixed P. falciparum 
asexual blood stages.  
 
This chapter focuses on the testing of these five Pfizer PDE inhibitors against the gametocyte 
stages of P. falciparum. Elucidation of the mechanism of action against transmission stages, 
although not a priority for drug discovery in the past, has now emerged as an important focus 
of drug discovery efforts in the malaria elimination/eradication era. It has now been recognised 
that elimination/eradication cannot be seriously considered without breaking the cycle of 
transmission (also targeting the transmission stages). Currently available antimalarial drugs 
alleviate clinical symptoms of the disease by killing asexual blood stages. However, these drugs 
have no inhibitory effect on mature gametocytes, enabling these stages to continue the parasite 
life cycle through mosquitoes and back to a new human host, thus maintaining malaria 
transmission within the population. As noted in the introduction, primaquine is the only 
currently licenced antimalarial that targets mature gametocytes and use of this drug is limited 
due to its toxicity in people with G6PD deficiency[66] and its poor activity against P. falciparum 
blood stages[285].   
 
 
 
 
 
 
168 
 
 
5.2. Results 
 
5.2.1. The human PDE inhibitor PF9 shows potent activity against mature P. falciparum 
gametocytes 
 
The panel of five Pfizer human PDE inhibitors were tested against immature (stage II/III) and 
mature (IV/V) gametocytes from a 3D7a transgenic line (3D7elo1-pfs16-CBG99) expressing 
luciferase under the control of the sexual stage specific pfs16-gene promoter[264] in a 
gametocyte viability assay. Pfs16 is the earliest marker for the onset of gametocytogenesis and 
is expressed from the committed ring stage through to stage V gametocytes[286]. Separate 
assays were carried out on both purified stage II gametocytes and purified stage V gametocytes 
expressing luciferase. This luciferase (CBG99 from the click beetle Pyrophorus 
plagiophthalamus[264]) catalyses the oxidation of its substrate, D-luciferin, releasing photons 
in the visible light spectrum that can then be measured. As the luciferase expressed is dependent 
upon ATP to produce light, this assay can be used as an indicator of cell viability. This assay is 
further improved by the use of a D-luciferin substrate solution developed by L. Cevenini et 
al[264], which is nontoxic and does not cause cell lysis (see methods section 2.4.C for more 
details).  
EC50 values for inhibition of asexual blood stage replication had previously been determined for 
these compounds using a 72 hour 3[H] hypoxanthine assay which utilises incorporation of 3[H] 
into newly synthesised DNA in replicating cells[287] (Laura Drought, PhD Thesis, 2014). As 
gametocytes do not undergo DNA replication (until male gametogenesis in the mosquito), this 
gold standard assay, or any other assay based on DNA replication, cannot be used to determine 
gametocyte survival. Therefore, a luciferase expressing gametocyte-producing line[264] was 
used to determine possible gametocyticydal activity of these PDE inhibitors using measurement 
of luminescence (RLUs) as a quantitative indicator of cell survival.  
 
Table 5.1 shows the EC50 values (μM) of the 5 Pfizer compounds tested in the luciferase assay 
against both immature (II/III) and mature (IV/V) gametocyte stages. These values are compared 
in the table to the EC50 values of the same compounds tested on asexual erythrocyte stages in a 
previous 3[H] assay (Laura Drought, PhD Thesis, 2014).   
As shown in Figure 5.1, after 48 hours incubation, the compounds PF9, PF11, PF12 and PF14 
showed no inhibition of immature stage gametocyte viability even at the highest concentration 
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tested (10 µM). This indicates that PfPDEs are either not expressed, not active or their activity 
not essential in immature stage gametocytes or that these drugs do not target the PDE(s) that 
are expressed at these stages. PF10 appeared to show a small amount of inhibition of early 
gametocyte stage viability (12.8 %) at 10 μM (Figure 5.1 and Figure 5.2). However, this inhibition 
was only observed in one of the three experiments carried out on immature gametocyte stages. 
The only compound exhibiting inhibition of mature (stages IV/V) gametocyte viability was 
compound PF9 (Figures 5.3 and Figure 5.4). PF9 did not show any activity against immature 
stages but showed potent activity (EC50 ~ 60 nM) against mature gametocyte stages. 
Interestingly, this EC50 was almost three times lower than the EC50 against asexual stage 
parasites. 
 
Overall, the data indicate that PF9 targets a PfPDE that is essential in stages IV and/or V 
gametocytes. Both PfPDEα and PfPDEδ have been identified by proteomics in stage V 
gametocytes. Existing proteome data suggests that PfPDEα is the most abundant protein in late 
gametocyte stages, whereas, transcriptomic data[145] indicates that PfPDEδ is the most 
abundant isoform expressed in late gametocyte stages. However, as the proteomics are not 
absolutely quantitative, a higher spectral count does not necessarily imply that PfPDEα is more 
abundant and the presence of mRNA transcripts does not necessarily indicate that translation 
occurs and in fact, transcripts can be translationally repressed in gametocytes and this is 
particularly apparent in female gametocytes[144]. This suggests that one or both of these 
PfPDEs are the most likely targets of PF9 in mature sexual stages. The PfPDE target of PF9 will 
be investigated in the next section. 
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Table 5.1. EC50 values (μM) of 5 Pfizer PDE inhibitors in a gametocyte viability assay. These were tested 
against both immature (stage II/III) gametocytes and mature (IV/V) gametocytes (of the 3D7elo1-pfs16-
CBG99 parasite line) in a luciferase-based cell viability assay. The average of 3 technical replicates from 3 
experiments are shown ± SD). EC50 values were generated in GraphPad Prism and compared to EC50 (μM) 
values on asexual blood stages in a 3[H] incorporation assay (Laura Drought, PhD Thesis, 2014). The 
compound showing activity against mature gametocytes is highlighted in grey. 
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Figure 5.1. EC50 (μM) values of Pfizer PDE inhibitors tested against immature P. falciparum 3D7elo1-
pfs16-CBG99 gametocyte stages (II/III) in a gametocyte viability assay. EC50 values measured from a (1:3) 
serial dilution in complete media from a starting concentration of 10 μM (stock diluted in DMSO). Data 
are transformed and presented as percentage inhibition of 3D7elo1-pfs16-CBG99 (luciferase expressing) 
P. falciparum parasites by the compounds relative to a no inhibitor (DMSO 0.05 %) control from a single 
biological replicate assay performed in triplicate (a representative experiment is presented). Percentage 
inhibition values calculated in Excel. The graph was generated in GraphPad Prism. Error bars represent 
SEM. 
 
 
Pfizer PDE Inhibitors Luciferase Assay EC50 values (μM ) 
Compound 
Average EC50 
Asexual stages 
Average EC50 
Immature 
Gametocytes 
Average EC50 
Mature 
Gametocytes 
 μM μM μM 
PF-01273175 (PF9) 0.14 >10 0.0521  (± 0.412) 
PF-05184913 (PF10) 0.16 >10 >10 
PF-05225388 (PF11) 0.01 >10 >10 
PF-00394183 (PF12) 0.08 >10 >10 
PF-00388991 (PF14) 0.03 >10 >10 
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Figure 5.2. Representative image of a Giemsa-stained blood film taken prior to the start of an immature 
stage gametocyte luciferase assay. Parasites are the characteristic ‘half-moon’ shape of stage II. 
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Figure 5.3. EC50 (μM) values of Pfizer PDE inhibitors tested against mature P. falciparum 3D7elo1-pfs16-
CBG99 gametocyte stages (IV/V) in a gametocyte viability assay. EC50 values measured from a (1:3) serial 
dilution in complete media from a starting concentration of 10 μM (stock diluted in DMSO). Data are 
transformed and presented as percentage inhibition of 3D7elo1-pfs16-CBG99 (luciferase expressing) P. 
falciparum parasites by the compounds relative to a no inhibitor (DMSO 0.05 %) control from a single 
biological replicate assay performed in triplicate (a representative experiment is presented). Percentage 
inhibition values calculated in Excel. The graph was generated in GraphPad Prism. Error bars represent 
SEM. 
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Figure 5.4. Representative image of a Giemsa-stained blood film taken prior to the start of a mature 
stage gametocyte viability assay. Parasites appear as the characteristic ‘crescent’ shape of stage V 
gametocytes.  
 
 
 
5.2.2. Investigation of the PDE target of Pfizer 9 
 
Data from section 5.2.1 show that PF9 targets mature gametocyte stages specifically. This leads 
to the question of which PfPDE or PfPDEs, this inhibitor targets in mature gametocyte stages. 
PF9 is known to target human PDE9 and current data suggest it targets both PfPDEα and PfPDEβ 
in asexual blood stages (Laura Drought, PhD Thesis, 2014). These data were derived from 
comparing PDE inhibition data from the PfPDEα-ko and wild type blood stage parasites and also 
from a PfPDEβ conditional knockout line (Drought, Flueck et al., LSHTM, unpublished data), 
However, no experiments had been carried out to investigate the effects of PF9 on gametocyte 
stages from these lines or on gametocytes from the PDEδ-ko or PfPDEγ-ko lines and so the PfPDE 
target of PF9 in gametocytes is not known. Based on what we already know from the literature, 
we would hypothesise that the main target for PF9 in gametocytes is PfPDEδ. This is because we 
know that PfPDEδ is highly expressed in mature gametocytes at the mRNA level and more 
importantly, is detectable at the protein level[144] and there is evidence that PfPDEδ is required 
for the process of gametogenesis[130]. However, this needs confirmation and currently, the role 
of other PfPDEs in mature gametocyte stages cannot be ruled out. It has been shown that the 
PfPDE protein is present in gametocytes[144] and is known to specifically hydrolyse 
cGMP[141],[143]. However, gametocyte growth and development appear normal in a PfPDE 
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knock out line (my data, unpublished), indicative that PfPDE alone is not essential for 
gametogenesis or gametocytogenesis to occur. Therefore, PfPDE is unlikely to be the sole or 
main target of PF9 in mature gametocytes as PF9 targeting of PfPDE alone would not be 
expected to result in the level of inhibition of gametocyte viability seen in luciferase assays 
(section 5.2.1). But that is not to say that inhibition of PfPDE wouldn’t contribute to the overall 
inhibitory activity of PF9 in the gametocyte and it does not rule out a role for PfPDE in 
gametocyte stages. PfPDE is also dispensable for asexual blood stage growth[141]. Another 
possible, but less likely candidate is PfPDEγ. PfPDEγ mRNA but not protein has been detected at 
low levels in gametocytes[145] and gametocytogenesis and gametogenesis are not affected in 
a PfPDEγ-ko line (Cathy Taylor PhD Thesis, 2007), suggesting that PfPDEγ is not essential in 
gametocyte stages. However, PfPDEγ has been shown to be important for P. falciparum 
sporozoite motility[142], so it may well be a dominant target for PF9 in sporozoite stages. This 
would be interesting to investigate in the future.  
 
 
PF9 kills mature NF54 gametocytes in a PKG-dependent manner 
 
To investigate the PfPDE target of PF9 in sexual stages, PfPDE (Christian Flueck, LSHTM, 
unpublished), PfPDEδ and PfPDEγ knockout lines all with a 3D7a background (Cathy Taylor PhD 
Thesis, 2007) and an NF54 line were used in a PF9 dose response assay. Stage IV/V gametocytes 
were incubated for 12 hours with 0.2 μM, 2 μM and 20 μM PF9. The PfPKG dependence (and 
therefore the cGMP specificity) of PF9 activity was also investigated using the PfPKG inhibitor 
compound 2 (C2). Percentage parasitaemia was calculated by counts of Giemsa stained blood 
films. Test samples were compared to a DMSO control. 
 
In an NF54 control line, PF9 treatment resulted in an almost complete reduction in mature 
gametocyte numbers at the highest concentration of 20 μM (Figures 5.5 and 5.9) with less than 
5 % of stage V gametocytes counted when normalised to the DMSO control (Table 5.2). At a 
concentration of 2 μM PF9 also showed a good reduction of gametocyte numbers in the NF54 
line with an ~85 % reduction in gametocytemia after 12 hours (Figure 5.5 and Table 5.2). 
Remarkably, reduction in numbers of NF54 gametocytes at both 20 μM and 2 μM was almost 
completely reversed by adding the PKG inhibitor C2 (2 μM) (see Figure 5.9 for a comparison of 
PF9 treatment on the four lines tested). This indicates that PF9 activity on the NF54 line is PfPKG 
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dependent and strongly suggests that that PF9 inhibits cGMP-specific PfPDE activity in mature 
gametocytes to elevate cGMP levels and prematurely activate PfPKG.  
At the lower concentration of 0.2 μM, PF9 did not appear to reduce NF54 stage V 
gametocytemia, with comparable numbers of crescent shaped gametocytes in the no DMSO 
control (Figure 5.5, Table 5.2). This was initially surprising given the IC50 value of ~0.060 μM seen 
in luciferase assays. However, this may reflect strain specific differences or differences in 
experimental design i.e. length of exposure to the compound, but is likely to reflect the different 
read out of the two assays, i.e. cell viability in the luciferase assays by measurement of ATP 
verses the less sensitive method of quantification of counts of cells by microscopy which is not 
necessarily an indication of viability.  
In all samples, a population of cells exhibiting an abnormal morphology (Figure 5.5 red bars) 
were present. From here on, these will be referred to as abnormal cells. Numbers of these 
abnormal cells were higher in samples treated with 0.2 μM PF9 and 2 μM PF9 (Figure 5.5). The 
percentages of abnormal cells in these samples were ~30 % and ~75 % respectively. C2 
treatment appeared to reduce the numbers of abnormal cells observed. In samples treated with 
20 μM PF9, the % parasitaemia of abnormal cells was less than seen in samples treated with 
lower concentrations of PF9, but exceeded that of cells appearing with a normal morphology 
(stage IV/V gametocytes) with ~ 76 % of the total number of cells counted being abnormal. C2 
did not appear to reduce the number of abnormal cells counted in samples treated with 20 μM 
PF9. 
 
 
 
 
 
 
 
 
175 
 
                     
C
o
n
tr
o
l
C
o
n
tr
o
l+
 C
2
0
.2
µ
M
0
.2
µ
M
 +
 C
2
2
µ
M
2
µ
M
 +
 C
2
2
0
µ
M
2
0
µ
M
 +
 C
2
0
1
2
3
4
P
a
r
a
s
it
e
m
ia
 (
%
)
S ta g e  IV /V
A b n o rm a l
 
Figure 5.5. Parasitaemia of stage IV/V NF54 gametocytes treated with PF9. NF54 line samples incubated 
for 12 hours 37 °C/CO2 with 20 μM, 2 μM and 0.2 μM PF9 +/- C2 (2 μM). Data are presented as percentage 
parasitaemia of stage IV/V gametocytes compared to unusual shaped gametocytes (abnormal). Numbers 
of abnormal cells in the control sample are subtracted from all other samples. Data analysed in Excel is 3 
independent counts (900 cells counted per replicate) from one experiment. Graph is generated in 
GraphPad, Prism. Error bars represent SD.  
 
 
 
PF9 kills PfPDE-ko gametocytes in a PfPKG-dependent manner 
 
Addition of PF9 to mature PfPDEγ-ko gametocytes showed comparable results to those obtained 
with NF54 gametocytes (see Figure 5.9 for a comparison between lines). Both 20 μM and 2 μM 
concentrations of PF9 resulted in complete disappearance of stage V gametocytes from samples 
within 12 hours of incubation (Figure 5.6). 0.2 μM PF9 reduced the parasitaemia to ~ 70 % 
compared to the DMSO control. This is a higher reduction in parasitemia than seen in the NF54 
line (Table 5.2) and may reflect differences between parasite lines since the PfPDEγ-ko line is 
derived from a 3D7a background. PF9 inhibition in the PfPDEγ-ko was shown to be PfPKG 
dependent as gametocytes survived in the presence of PF9 if the PfPKG inhibitor C2 was also 
present (Figures 5.6 and 5.9). The difference between PF9 treatment in the presence and 
absence of C2 was shown to be significant at 20 μM, 2 μM and 0.2 μM using the Holm-Sidak 
method (GraphPad, Prism), which gave P values of P=0.00000015, P=0.000043 and P=0.01444 
respectively. This indicates that the absence of PfPDEγ in mature gametocyte stages appears to 
have no effect on PF9 activity and that PF9 is achieving its killing effect independently of PfPDEγ.  
A population of abnormal cells was observed in PfPDEγ-ko samples treated with PF9 (Figure 5.6 
red bars). Numbers of abnormal cells were much lower than seen in the NF54 line. In samples 
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treated with 0.2 μM PF9, numbers of abnormal cells constituted less that ~ 20 % of the total 
parasitaemia counted. In samples treated with 2 μM over half of cells counted were abnormal 
in morphology, constituting ~ 59 % of the total parasitaemia.  In samples treated with 20 μM 
PF9, the majority of cells counted were abnormal (~ 95 % of the total parasitaemia). In both the 
2 μM and 20 μM treated samples, C2 completely reversed the presence of cells exhibiting an 
abnormal morphology. In contrast, C2 did not appear to alter the numbers of abnormal parasites 
observed in samples treated with 0.2 μM. 
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Figure 5.6. Parasitaemia of stage IV/V PfPDEγ-ko line gametocytes treated with PF9. PfPDEγ-ko line 
samples incubated for 12 hours 37 °C/CO2 with 20 μM, 2 μM and 0.2 μM PF9 +/- C2 (2 μM). Data is 
presented as percentage parasitaemia of stage IV/V gametocytes compared to unusual shaped 
gametocytes (abnormal). Number of abnormal cells in the control sample are subtracted from all other 
samples. Data analysed in Excel is the average of two experiments each with 3 independent counts (900 
cells counted per replicate). Graph is generated in GraphPad, Prism. Error bars represent SD. 
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PfPDE-ko gametocytes are apparently more sensitive to PF9 than the PfPDE-ko line, 
the PfPDE-ko line and NF54  
 
Stage V gametocytes of the PfPDE-ko line showed high sensitivity to all concentrations of PF9 
tested (Figure 5.7 and 5.9). This was particularly apparent at the lowest concentration of 0.2 M 
PF9, which resulted in complete disappearance of crescent-shaped cells with a small proportion 
(~0.1 % parasitemia) of abnormal forms remaining. Gametocyte numbers were reversed back to 
control levels by addition of C2. 2 M PF9 also resulted in complete disappearance of crescent 
shaped gametocytes and as seen at 0.2 M, this was reversed back to control levels by addition 
of C2. At a concentration of 20 M, numbers of crescent shaped gametocytes were reduced 
almost completely. However, in contrast to the lower concentrations of PF9 tested, this 
reduction in parasitemia was not reversed back to control levels by C2 indicating a possible toxic 
effect at this concentration in this line. C2 treatment reversed gametocyte numbers to ~ 30 % 
of the control. 
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Figure 5.7. Parasitaemia of stage IV/V PfPDEα-ko line gametocytes treated with PF9. PfPDEα-ko line 
samples incubated for 12 hours 37 °C/CO2 with 20 μM, 2 μM and 0.2 μM PF9 +/- C2 (2 μM). Data is 
presented as percentage parasitaemia of stage IV/V gametocytes compared to unusual shaped 
gametocytes (abnormal). Number of abnormal cells in the control sample are subtracted from all other 
samples. Data analysed in Excel is 3 independent counts (900 cells counted per replicate) from one 
experiment. Graph is generated in GraphPad, Prism. Error bars represent SD. 
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PF9 does not alter the parasitemia or morphology of stage V gametocytes of the 
PfPDEδ knockout line 
 
Interestingly, in contrast to the results obtained with NF54 and PfPDEγ-ko cultures, mature 
PfPDEδ-ko gametocyte survival was very pronounced in the presence of PF9 (Figure 5.8, see 
Figure 5.9 for a comparison between lines). PF9 appeared to show some killing of PfPDEδ-ko 
gametocytes at both 20 μM and 2 μM (60 % and 70 % of parasites counted in PF9 treated 
samples respectively compared to the DMSO control normalised to 100 %). However, this 
decrease in parasitaemia in the PF9 treated samples was not significant in both cases using a 
Welch’s unpaired t test, which was used to compare the percentage parasitaemia of PF9-treated 
samples to the percentage parasitaemia of the DMSO control with P values of P=0.1161 and 
P=0.0809 respectively. As seen with the data obtained from the NF54 line, no reduction in 
gametocyte numbers was observed at a PF9 concentration of 0.2 μM (Figure 5.9). Very few 
gametocytes exhibiting an abnormal morphology were observed in PfPDEδ-ko line samples 
compared to the NF54 line and the PfPDEγ-ko line (Figure 5.9). The majority of all cells counted 
were normal looking crescent shaped gametocytes. Addition of C2 did not alter the parasitemia 
at any of the concentrations. Figure 5.9 shows a comparison of all lines at each concentration of 
PF9. 
 
Overall, these data suggests that PF9 is much less effective at reducing the parasitemia of 
gametocyte samples when PfPDEδ is absent. This indicates that the presence of PfPDEδ is likely 
required for the majority of PF9 activity and may be the main target of PF9. It also demonstrates 
that the absence of PfPDEγ does not alter PF9 activity at all whereas, in the absence of PfPDE, 
parasites become more sensitive to PF9. These data indicates that PF9 mediated killing of 
mature gametocytes is PfPKG-dependent.  
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Figure 5.8. Parasitaemia of stage IV/V PfPDEδ-ko line gametocytes treated with PF9. PfPDEδ-ko line 
samples incubated for 12 hours 37 °C/CO2 with 20 μM, 2 μM and 0.2 μM PF9 +/- C2 (2 μM). Data is 
presented as percentage parasitaemia of stage IV/V gametocytes compared to unusual shaped 
gametocytes (abnormal). Number of abnormal cells in the control sample are subtracted from all other 
samples. Data analysed in Excel is 3 independent counts (900 cells counted per replicate) from one 
experiment. Graph is generated in GraphPad, Prism. Error bars represent SD. 
 
 
 
 
Table 5.2. Counts of NF54, PfPDEγ-ko and PfPDEδ-ko gametocytes treated with PF9 ± C2. Data is the 
average and SD of 3 separate counts from one experiment presented as the percentage of the DMSO 
control normalised to 100 %. Values above 60 % of the control (little or no inhibition) represented in dark 
grey. Values below 20 % of the control (Good inhibition) represented in light grey.  
 
Stage V gametocytes (% of Control ±  SD) 
 NF54 PfPDEγ-ko PfPDEδ-ko PfPDEα-ko 
Average (SD)  
Control 100 100 100 100 
Control + C2 160.05 ± 
46.92 
82.96 ±  15.75 135.60 ± 20.93 
- 
PF9 0.2 μM 106.94 ± 
24.73 
73.52 ± 24.67 103.71 ± 26.96 
2.26 ± 3.92 
PF9 0.2 μM + C2 118.14 ± 
21.59 
130.61 ± 60.48 97.72 ± 18.60 
130.67 ± 6.84 
PF9 2 μM 14.32 ± 0.92 0 59.63 ± 18.54 2.06 ± 3.56 
PF9 2 μM + C2 151.24 ± 
11.45 
102.85 ± 20.93 59.17 ± 3.70 
88.01 ± 31.64 
PF9 20 μM 3.97 ± 4.77 0 72.29 ± 20.35 7.17 ± 1.89 
PF9 20 μM + C2 107.80 ± 
11.19 
119.50 ± 30.37 92.01 ± 7.14 
30.98 ± 4.46 
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Figure 5.9. Reduction in number of stage V gametocytes treated with PF9 in the presence and absence 
of C2. Stage IV/V gametocytes from the NF54, PfPDEα-ko, PfPDEγ-ko and PfPDEδ-ko lines incubated for 
12 hours 37 °C/5 % CO2 with 20 μM, 2 μM or 0.2 μM PF9 +/- 2 μM C2. Data presented as percentage 
parasitaemia of parasites relative to a no inhibitor (DMSO 0.05 %) control (normalised to 100 %). Data 
analysed in Excel is 3 independent counts from 1 experiment for NF54, PfPDEα-ko, and PfPDEδ-ko lines 
and 3 counts from 2 experiments for PfPDEγ-ko line. 900 cells counted per replicate. Graph generated by 
GraphPad, Prism. Error bars represent SD.  
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5.2.3. PF9 causes rounding up of mature gametocytes and acts within 5 minutes of 
addition 
 
In order to investigate the reduction in gametocyte numbers observed in the experiments above 
and to determine when the gametocytes disappear from samples, 3D7a stage V gametocytes 
were incubated in the presence or absence of PF9 for a 30-minute period and blood films 
prepared every 5 minutes. The numbers of stage V gametocytes (crescent shaped) in PF9 treated 
samples were counted from Giemsa-stained blood films and compared to the numbers of stage 
V gametocytes in DMSO-treated control samples. 
 
Parasites in PF9-treated samples appeared as mostly round shaped cells at all time points with 
only a small number of parasites remaining as crescent-shaped cells (Figures 5.10 and 5.11). The 
numbers of rounded cells remained relatively constant over the 30 minute period. These 
‘rounded’ forms were strikingly similar in morphology to that of gametocytes undergoing the 
initial stage of gametogenesis (rounding up) (Figure 5.11). This was a really interesting find and 
is investigated further in the next section. These data show that PF9 acts quickly and within 5 
minutes of addition to mature gametocytes. The percentage parasitaemia of stage V 
gametocytes in PF9-treated samples was decreased at all time points by approximately one third 
(Figure 5.10). As demonstrated by images of Giemsa stained samples in Figure 5.11, this was not 
due to the presence of a population of ‘abnormal’ cells, but parasites have disappeared from 
the culture. Interestingly, the cells that were present in the PF9-treated samples appeared 
morphologically changed, presenting as rounded up forms characteristic of XA-induced 
gametocytes. These data leads to the exciting question of whether PF9 acts by inducing 
gametogenesis. This question will be explored in the next section. 
Gametocytes in all DMSO-treated samples remained as crescent-shaped cells characteristic of 
non-induced stage V gametocytes (Figures 5.10 and 5.11). The numbers of crescent-shaped 
gametocytes in control samples remained relatively constant over the first 20 minutes. At the 
30 minute time point, a small increase in a population of rounded cells appeared in the control 
sample (Figure 5.10). This experiment was carried out at room temperature, a temperature not 
favourable to gametocyte growth and survival, so this increase in rounded cells at this time point 
is likely to be due to the length of time that the gametocytes were exposed to a drop in 
temperature below 37 °C, and would likely represent a reduced gametocyte viability causing 
them to adopt a rounded morphology. 
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Figure 5.10. Time course of PF9 treatment of stage V gametocytes from the 3D7a line. Presented as 
percentage parasitaemia of parasites treated with PF9 (10 M) over a 30 minute period compared to a 
no inhibitor (DMSO, 0.05 %) control. Counts are of crescent-shaped cells (blue) and rounded cells (orange) 
from Giemsa stained blood films. Data analysed in Excel is 3 independent counts from one experiment. 
Error bars represent SD. 
 
 
 
 
Figure 5.11. Images of Giemsa-stained blood films of 3D7a stage V gametocytes incubated ± PF9   
PF9 concentration was 10 M. Samples were taken over a period of 30 minutes at 5 minute time intervals.  
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5.2.4. Investigation into the mode of action of PF9  
 
Data in the previous sections have shown that PF9 acts very quickly (within 5 minutes), that it is 
apparently more active when PfPDEδ is present and less active when it is absent, and that the 
majority of PF9 inhibition in the wildtype line is PfPKG dependent. We know from the literature 
that the initial stage of gametogenesis (rounding up) is a PfPKG-dependent process[159], and 
that the cGMP-PDE inhibitor zaprinast can induce gametogenesis in vitro in the absence of 
XA[130], indicative that PfPDE inactivation and subsequent PfPKG activation are important parts 
of the signalling cascade required for gametogenesis to occur. This led to the hypothesis that 
PF9 may act on mature gametocytes by inducing premature gametogenesis. This would be 
achieved as follows; PF9 inhibits PfPDE activity in the mature gametocyte. Inhibition of cGMP-
specific PfPDEs (most likely from the evidence so far to be PfPDEδ) would abolish cGMP-PfPDE 
hydrolytic activity leading to elevated levels of cGMP. This in turn would activate PfPKG, which 
would then phosphorylate downstream protein targets leading to the initiation of 
gametogenesis (See Figure 5.28 in discussion section for schematic).  
 
 
5.2.4.1. Pfizer 9 induces rounding up of wildtype stage V gametocytes  
 
To determine whether PF9 can induce Stage V gametocytes to round up, the number of crescent 
shaped and round parasites were counted in Giemsa-stained blood smears from samples of 
wildtype (3D7a) parasites after treatment with PF9 and compared to a non-treated wildtype 
3D7a control and a PF9-treated PfPDEδ-ko line sample. 
 
After 15 minutes of incubation at room temperature, DMSO-treated wildtype (3D7a) parasites 
remained mostly crescent shaped, characteristic of non-activated gametocytes, with a small 
proportion appearing with a rounded morphology (~ 21 %) (Figure 5.12 and Table 5.3). PF9 
treatment of the same line resulted in the majority of parasites rounding up, with ~ 20 % 
remaining as crescent-shaped cells.  
By contrast, treatment of the PfPDEδ-ko line did not induce rounding up, with the majority of 
cells (~ 75 %) remaining crescent shaped reminiscent of the 3D7a non-treated control line 
(Figure 5.12 and Table 5.3). A relatively small proportion of PfPDEδ-ko line gametocytes (~25 %) 
did round up in response to PF9 treatment. But this is over 3 times less than seen in the 3D7a 
wildtype line.  
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Figure 5.12. Comparison of PF9 treatment in wildtype (3D7a) and PfPDEδ-ko gametocytes. Gametocytes 
were treated for 15 minutes with PF9 (10 M) and compared to a DMSO (0.05 %) control. The numbers 
of non-activated (crescent) or activated (round) parasites were counted (a total of 900 parasites counted 
per replicate) from Giemsa-stained blood films.  Data is the average of 3 counts from one experiment 
analysed in Excel and presented as percentage of total parasitaemia. Graph is generated in GraphPad, 
Prism. Error bars represent SD.  
 
 
 
% Total parasitaemia ± SD 
 Crescent Round 
3D7a control 78.93 ± 8.93 21.06  ± 8.93 
3D7a + PF9 20.47 ± 12.02 79.52 ± 12.02 
PfPDEδko + PF9 75.75 ± 1.77 24.24 ±  1.77 
 
Table 5.3. Comparison of PF9 treatment in wildtype (3D7a) and PfPDEδ-ko gametocytes. 
Gametocytes were treated for 15 minutes with PF9 (10 M) and compared to a DMSO (0.05 %) control. 
The numbers of non-activated (crescent) or activated (round) parasites were counted (a total of 900 
parasites counted per replicate) from Giemsa-stained blood films.  Data is the average of 3 counts from 
one experiment analysed in Excel and presented as percentage of total parasitaemia. Graph is generated 
in GraphPad, Prism. Error bars represent SD. 
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To investigate PF9-induced rounding up of stage V gametocytes further, 3D7a stage V 
gametocytes were incubated with PF9 for 1 minute or 3 minutes and compared to incubation 
with XA under the same conditions. Samples were compared to a DMSO control. Blood films 
were prepared immediately after incubation and counts of non-activated (crescent shaped cells) 
and activated (rounded-up cells) were carried out to determine percentage of parasites 
activated and non-activated in each sample. 
 
PF9 stimulated rounding up of wildtype 3D7a gametocytes (Figures 5.13 and 5.14). In the control 
sample (0.05 % DMSO) at both 1 minute and 3 minutes, cells remained crescent shaped (Figure 
5.14). After 3 minutes, ~ 65 % of parasites in PF9 treated samples appeared morphologically 
rounded up with ~ 30 % of parasites remaining crescent shaped (Figure 5.13 and Table 5.4). This 
was comparable to the numbers of rounded up cells recorded in the XA-treated samples treated 
sample after 3 minutes (~ 55 %). After 1 minute incubation with PF9, the majority (~100 %) of 
wildtype cells remained crescent shape indicating that PF9 does not induce rounding up before 
1 minute. This is comparable to XA-induced samples, which appeared mostly non-activated at 
the 1 minute time point with only ~10 % (Table 5.4) of parasites rounded up.  
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Figure 5.13. Comparison of XA and PF9 treatment of 3D7a stage V gametocytes. Samples treated for 1 
minute or 3 minutes at room temperature with either PF9 (10 M) or XA (30 M). Numbers of non-
activated (crescent) or activated (round) parasites counted from giemsa stained blood films. Data 
presented as percentage parasitemia and compared to a DMSO (0.05 %) control (incubated for 3 minutes). 
Data analysed in Excel is the average of 3 counts from one experiment (~900 cells counted per replicate). 
Error bars represent SD. 
 
186 
 
 
 
Figure 5.14. Morphology of 3D7a stage V gametocytes treated with either XA or PF9. Identified by 
Giemsa stained blood films. Samples treated for 1 minute or 3 minutes with 10 μM PF9 (column 2) or 30 
μM XA (column 3) compared to a DMSO (0.05 %) control (column 1). Crescent-shaped Stage V (V) 
gametocytes (non-activated) and rounded-up (R) gametocytes (activated) identified by light microscopy. 
 
 
 
Closer examination of Giemsa-stained blood films showed that the morphology of rounded-up 
gametocytes in the PF9-treated 3D7a gametocytes appear comparable to that following XA 
treatment (Figure 5.15). 
Parasites appear rounded in shape with dissipated haemozoin pigment. Nuclear staining (pink) 
indicates nuclear material is visible by microscopy in all cells. Most cells appeared emerged from 
the erythrocyte with no apparent Giemsa staining of the erythrocyte membrane although some 
cells appear to have remnants of erythrocyte membrane still associated with the parasite and a 
small number have staining indicative that they are still at least partially retained inside the host 
erythrocyte (Figure 5.15 and 5.16).  
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Figure 5.15: Comparison of morphology of PF9 (10 μM) treated and XA-treated (30 μM) 3D7a stage V 
gametocytes compared to a DMSO control (un-treated) after 3-min incubation at room temperature from 
a single experiment. Blood films stained with Giemsa. Note: sizes of individual parasites are not to scale 
in this figure.  
 
 
Figure 5.16. Features of rounded-up parasites (A) compared to non-activated parasites (B) identified in 
Giemsa-stained blood films from samples activated with XA or PF9 (A) or not treated (B). Nucleus (n) 
stained pink and cytoplasm stained pink/blue with Giemsa stain. In stage V female gametocytes, pigment 
usually relatively concentrated and close to the nucleus whereas in males, the pigment and nucleus is 
more diffuse. 
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PfPDEδ-ko line parasites treated with 0.05 % DMSO only had a comparable morphology to 
DMSO-treated 3D7a gametocytes (Figures 5.17 and 5.18) with ~100 % cells appearing crescent 
shaped after 3 minutes (Table 5.4). However, this line greatly differed in its response to both 
PF9 and XA compared to the 3D7a control line. 
Following both 1 minute and 3 minute incubations with 10 M PF9, the majority of gametocytes 
remained crescent shaped (~85 %, Table 5.4). A small number of PfPDEδ-ko parasites treated 
with PF9 rounded up (~ 15 %). This was the same number for both the 1-minute and 3-minute 
time points (Figures 5.17 and 5.18 and Table 5.4). At the 3 minute time point, the number of 
rounded-up cells was significantly lower in PfPDEδ-ko line samples treated with PF9 when 
compared to the 3D7a wildtype line (P= 0.0222, Welch’s paired t test). The numbers of rounded-
up gametocytes in PfPDEδ-ko cultures treated with XA was also less than seen in the 3D7a line 
treated with XA, with only ~ 20 % of PfPDEδ-ko gametocytes rounding up after 3 minutes of XA 
incubation compared to ~55 % (Table 5.4) in the 3D7a line. No-rounded up parasites were seen 
in XA-treated samples at the 1 minute time point (Figure 5.17 and Table 5.4). 
Overall, these data are in agreement with results presented in section 5.2.2 indicating that in 
the absence of PfPDEδ, PF9 is much less active. It also shows that in the 3D7a wildtype line, PF9 
acts more quickly than XA and that it induces stage V gametocytes to round up in a manner that 
appears morphologically comparable to that of XA stimulation. It may be that PF9 is able to 
bypass the XA ‘receptor’ steps leading to elevated cGMP levels more quickly.  
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Figure 5.17. Comparison of XA and PF9 treatment of PfPDEδ-ko line stage V gametocytes. Samples 
treated for 1 minute or 3 minutes at room temperature with either PF9 (10 M) or XA (30 M). Numbers 
of non-activated (crescent) or activated (round) parasites counted from Giemsa stained blood films. Data 
presented as percentage parasitemia and compared to a DMSO (0.05 %) control (incubated for 3 minutes). 
Data analysed in Excel is the average of 3 counts (~900 cells counted per replicate). Error bars represent 
SD. 
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Figure 5.18. Morphology of PfPDEδ-ko stage V gametocytes treated with either XA or PF9 identified by 
Giemsa stained blood films. Samples treated for 1 minute or 3 minutes with 10 μM PF9 (column 2) or 30 
μM XA (column 3) compared to a DMSO (0.05 %) control (column 1). Crescent-shaped stage V (V) 
gametocytes (non-activated) and rounded-up (R) gametocytes (activated) identified by light microscopy. 
 
 
 
Percentage of Total parasitaemia ± SD 
 3D7a PfPDEδ-ko 
 Stage V Round Stage V Round 
Control 100 0.00 100 0.00 
PF9 10 μM 
1min 
106.45  ± 
38.72 
0.00  ± 38.72 85.02  ± 14.16 14.98  ±  14.16 
XA 30 μM 
1min 
88.21  ± 20.62 11.79  ± 20.62 103.19  ± 
11.25 
0.00  ±  11.25 
PF9 10 μM 
3min 
32.63  ± 2.77 67.37  ± 2.77 85.15  ± 0.30 14.85  ±  0.30 
XA 30 μM 
3min 
45.04  ± 17.25 54.96  ± 17.25 76.82  ± 1.35 23.18  ± 1.35 
 
Table 5.4. Comparison of XA and PF9 treatment of 3D7a and PfPDEδ-ko line stage V gametocytes. Data 
as presented in Figures 5.13 and 5.17. Parasites incubated with PF9 (10 M) or XA (30 M) for 1 minute 
or 3 minutes and compared to a DMSO (0.05 %) control incubated for 3 minutes. Data presented as 
percentage of total number gametocytes (Including all crescent and rounded up cells but minus stages I-
IV). Date is the average of 3 individual counts (~900 cells counted per replicate) from one experiment ± 
SD. Values above 50 % of the control represented in dark grey, Values below 25 % of the control 
represented in light grey. Values between 50 % and 25 % of the control represented in white.  
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Pfizer 9 induces rounding up in the wildtype line in a PKG-dependent manner and more 
effectively than either zaprinast and XA  
 
The previous data in section 5.2.4 show that PF9 induces rounding up of mature gametocytes 
and that it does so very quickly. 
To investigate the PF9 activation of gametocytes further, PF9 treatment of 3D7a stage V 
gametocytes was compared to that of XA and zaprinast treatment. In section 5.2.2 the majority 
of PF9 activity was shown to be PfPKG dependent. To further confirm this, the PfPKG-specific 
inhibitor MRT00207065 was added to PF9-activated samples and compared to C2 treatment. 
Gametocyte activation was determined by counts (using Giemsa-stained blood films) comparing 
the number of crescent shaped parasites (non-activated) to the number of rounded up 
(activated) parasites in each sample. The same experiment was carried out on the PfPDEδ-ko 
line in parallel.  
 
In the 3D7a line, gametocytes in the DMSO control sample all remained as crescent-shaped cells 
with no rounded-up cells counted (Figure 5.19). This is the expected morphology for normal, 
non-activated gametocytes. After treatment with PF9, the majority (~90 %) of cells appeared to 
have rounded up, with only ~10 % remaining crescent shaped after 15 minutes of incubation 
(Figure 5.19). This is a higher proportion of rounded-up cells than was seen in the XA-treated 
samples (~70 % rounded up) and even more so for (100 M) zaprinast-treated samples (~20 % 
rounded up). This indicates that 10 µM PF9 induces higher levels of rounding up than 30 µM XA 
does in the same time period.  
PF9 treatment in combination with C2 confirmed earlier data that PF9 induced rounding up is a 
PfPKG-dependent process. This was further confirmed by the more potent (and more specific) 
PKG inhibitor MRT00207065 (1 M) (Baker et al., 2017), which also reversed the activity of PF9 
in a similar manner to C2. However a small number (~ 15 %) of parasites were still able to round 
up with PF9 stimulation in the presence of MRT00207065 (Figure 5.19). This was a similar level 
seen with C2 treatment. 
 
 
 
 
 
 
 
 
191 
 
                    
C
o
n
tr
o
l
X
A
 
Z
a
p
 
P
9
 
P
9
 +
C
2
 
P
9
+
0
6
5
 
0
2 0
4 0
6 0
8 0
1 0 0
%
 T
o
ta
l 
P
a
r
a
s
it
e
m
ia
C re s c e n t
R o u n d
 
Figure 5.19. Comparison of PF9 treatment of 3D7a stage V gametocytes to XA and zaprinast treatment. 
Parasites treated with PF9 (10 μM) in the presence and absence of C2 (2 μM) or MRT00207065 (1 μM). 
Compared to XA (30 μM) or zaprinast (100 μM) incubated at room temperature for 15 minutes. Data 
analysed in Excel are presented as percentage total parasitaemia from 3 separate counts from Giemsa 
stained blood films (~900 cells counted per replicate) from 1 experiment. Graph generated in GraphPad, 
Prism. Error bars represent SD.  
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The inactivity of PF9 against the PfPDEδ-ko line was further confirmed with only ~25 % of cells 
rounding up in response to PF9 compared to ~ 90 % in the 3D7a line (Figure 5.20). In the PfPDEδ-
ko line, the small level of PF9 activity observed appears to be PKG dependent as it was 
completely reversed to control levels by both C2 and MRT00207065.  
Only ~5 % of gametocytes rounded up in XA-treated samples in the PfPDEδ-ko line with ~90 % 
of parasites remaining crescent shaped (Figure 5.20). This is in agreement with data presented 
in Figure 5.17 and Table 5.4, which show that ~75 % of gametocytes from the PfPDEδ-ko line 
remain crescent shaped after 3 minutes of incubation with XA. 
Parasites of the PfPDEδ-ko line treated with zaprinast also remained mostly crescent shaped 
(~90 %), (Figure 5.20).  
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Figure 5.20. Comparison of PF9 treatment of PfPDEδ-ko line stage V gametocytes to XA and zaprinast 
treatment. Parasites treated with PF9 (10 μM) in the presence and absence of C2 (2 μM) or MRT00207065 
(1 μM), compared to XA (30 μM) or zaprinast (100 μM). All treatments were incubated at room 
temperature for 15 minutes. Data analysed in Excel is presented as percentage total parasitaemia from 3 
separate counts from Giemsa stained blood films (~900 cells counted per replicate) from 1 experiment. 
Graph generated in GraphPad, Prism. Error bars represent SD.  
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5.2.4.2. Pfizer 9 induces emergence of gametes from the host erythrocyte  
 
So far the data have shown convincingly that PF9 induces rounding up. However, this is only the 
first visible step of gametogenesis so it was important to determine whether PF9 could induce 
subsequent steps in the process of gametogenesis such as host erythrocyte emergence and male 
exflagellation. This would strengthen the data supporting the hypothesis that PF9 acts by 
inducing gametogenesis rather than just inducing a morphological change in the parasite which 
results in a phenotype resembling activated gametocytes. 
In the above section, the morphology of rounded-up parasites induced by PF9 appears to 
indicate emergence from the erythrocyte in Giemsa-stained blood films (Figures 5.14 to 5.16). 
However, Giemsa staining alone cannot confirm emergence. This must be achieved by analysis 
of samples in which the host erythrocyte cell membrane has been stained. This enables 
identification of emerged (no erythrocyte staining) or non-emerged (erythrocyte staining) 
parasites.  
To achieve this, live gametocyte samples were stained with an erythrocyte membrane stain 
conjugated to a fluorescent dye, Wheat Germ Agglutinin-Texas Red (WGA-TR). WGA is a lectin 
that specifically binds the sugars N-acetyl glucosamine and sialic acid and when conjugated to a 
fluorescent probe can be imaged by fluorescent microscopy. Gametocytes were also stained 
with a nuclear stain Hoechst 33342. Samples were then treated with PF9 in the presence and 
absence of C2 for 20 minutes after which they were immediately fixed in formaldehyde and 
imaged using a fluorescent microscope. This protocol was used to investigate whether the 
rounded-up gametocytes observed in Giemsa-stained blood films of PF9-activated samples have 
emerged from the host erythrocyte or not. This was done in the presence and absence of C2 to 
investigate the PfPKG-specificity of PF9-induced emergence.  
In control samples treated with DMSO, parasites remained crescent shaped, characteristic of 
non-activated gametocytes with positive erythrocyte staining (Figures 5.21 and 5.22). Addition 
of PF9 resulted in emergence of gametocytes from the host erythrocyte (Figures 5.21 and 5.22). 
Emerged parasites appeared rounded and lacking in erythrocyte membrane staining (Figure 
5.22). Addition of C2 to PF9-treated samples reversed the effects of PF9 but not fully, with the 
majority of cells remaining crescent shaped and with erythrocyte staining present (Figures 5.21 
and 5.22).                   
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Figure 5.21. Levels of emergence from host erythrocytes in 3D7a gametocytes treated with PF9 in 
the presence and absence of C2. 
WGA-Texas red (5 μg/ml) and Hoechst 33342 (20 μM) stained gametocytes incubated with PF9 (10 
μM) ± C2 (2 μM) for 20 minutes followed by formaldehyde fixation and imaged by fluorescent 
microscopy. (Data are presented as percentage of total number of gametocytes/gametes counted 
and are an average of 5 counts from a single experiment. Error bars represent SD. 
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Figure 5.22. Representative images of 3D7a stage V gametocytes stained with WGA coupled to Texas 
Red to detect emergence of parasites from erythrocytes.  
Nuclear material stained with Hoechst (blue), erythrocyte membrane stained with WGA-Texas Red (Red). 
Top panel is DMSO control (non-stimulated), middle panel is PF9-treated (10 μM) stage V gametocytes 
(activated) and the bottom panel is treatment with PF9 (10 μM) + MRT00207065 (1 μM). Green boxes 
represent zoomed-in images presented on the right along with bright field images. Images generated from 
formaldehyde-fixed samples in suspension on an EVOS FL cell imaging system x 1000 objective. 
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5.2.4.3. Pfizer 9 induces exflagellation of 3D7a male gametes  
 
The final stages of male gametogenesis involve, amongst other cellular events, the production 
of 8 highly motile flagella. This can be seen by light microscopy. Giemsa-stained blood films from 
PF9-treated samples of 3D7a stage V gametocytes were examined by light microscopy for 
exflagellation events.  
 
Exflagellating forms were observed in both PF9 and XA-treated samples (Figure 5.23). These 
events were apparent after 15 minutes of incubation with 10 μM PF9 and 30 μM XA (not shown) 
No exflagellation events were observed in control (DMSO) samples (not shown).  
 
 
Figure 5.23. Exflagellating male gametocytes following treatment with PF9. Blue arrows indicate 
exflagellation events in Giemsa stained dried blood films from samples incubated for 15 minutes with PF9 
(10 μM). Blue star indicates a detached flagellum.   
 
 
 
 
 
 
 
 
 
 
 
 
 
197 
 
5.2.4.4. Pfizer 9 induces PKG-dependent Ca2+ release in stage V gametocytes of the 
3D7a line. 
 
The mobilisation of Ca2+ from internal stores is essential for the later stages of gametogenesis 
to occur. XA has been shown to induce Ca2+ release[210] and Ca2+ is required for the late stages 
of both XA- induced and zaprinast-induced gametogenesis[159]. Given this information and the 
fact that PF9 can induce gametocyte activation and exflagellation, it was therefore of interest to 
investigate whether PF9 could induce Ca2+ mobilisation in mature gametocytes. In order to do 
this, Ca2+ release was measured in 3D7a stage V gametocytes loaded with a Fluo-4-AM, which 
fluoresces upon binding to free Ca2+ (for method see section 2.4.A). Samples were treated with 
PF9, XA or zaprinast and levels of fluorescence compared to an ionophore control (A23187). This 
ionophore selectively binds to Ca2+ forming complexes and thus increases permeability of Ca2+ 
across membranes resulting in a rapid release of Ca2+ into the cytosol. 
 
Treatment of 3D7a Stage V gametocytes with PF9 resulted in the release of Ca2+ (Figure 5.24). 
Levels of Ca2+ measured in the PF9-treated samples were comparable to those induced by the 
ionophore control and were much higher than the Ca2+ release measured in samples treated 
with both XA (~40 % of ionophore control) and zaprinast (~40 % of ionophore control). 
The majority of Ca2+ released in the PF9-treated samples (~80 %) was reversed by addition of C2. 
However ~20 % of the Ca2+ release measured in the PF9 treated sample was not reduced by C2 
treatment.  
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Figure 5.24. Ca2+ release in Fluo-4-AM-loaded 3D7a stage V gametocytes stimulated with PF9.  
Stage V gametocytes treated with PF9 (10 μM) in the presence and absence of C2 (2 μM). Compared to 
zaprinast (100 μM) and XA (10 μM) treatment. Data are analysed in Excel and presented as Ca2+ release 
measured in relative fluorescent units minus the baseline fluorescence and fluorescence of the DMSO 
(0.05 %) control. The ionophore (A23187, 10 μM) used as a positive control. Graph generated in GraphPad, 
Prism shows a single experiment carried out in triplicate.  
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5.3. Discussion 
 
5.3.1. PF9 inhibition of gametocyte viability 
 
Compounds that kill late gametocyte stages would be a valuable tool to reduce transmission of 
malaria and thus contribute to elimination efforts. To date, there is only one compound, 
primaquine that does this. However, this drug has safety issues and so there is a great need to 
develop additional drugs, which can target both asexual blood stages and gametocyte stages. 
PF9 was developed by Pfizer as an inhibitor of human PDE9. It has also been shown to have 
potent inhibitory activity against P. falciparum asexual blood stages (EC50 143 nM) (Laura 
Drought, PhD Thesis, 2014). 
 
Work carried out in this thesis further investigated the properties of PF9 on P. falciparum by 
focussing on its inhibition of gametocyte stages. This work has discovered that PF9 specifically 
targets mature gametocytes and not early gametocytes and that it exhibits potent activity 
against mature (stage V) gametocytes (EC50 value of ~0.060 μM) in a gametocyte viability assay. 
This EC50 value is ~ 2.5 times lower than that for asexual stages. This may reflect a difference in 
the types of assay used to measure viability, or more likely, it may indicate that this compound 
is more active in gametocytes than asexual stages, possibly in reflection of its mode of action. 
However, this assay needs to be repeated to confirm this result. None of the other four Pfizer 
compounds tested were active against gametocytes. It was previously shown that compounds 
PF11, PF12 and PF14 all specifically target PfPDEβ in asexual blood stages, whereas PF9 targets 
both PfPDEα and PfPDEβ (Laura Drought PhD Thesis, 2014) and it is predicted that it may target 
all PfPDEs. The potent activity of the Pfizer compounds against asexual blood stages is consistent 
with the fact that they all inhibit PfPDEβ, which is the only essential PfPDE at these stages (Laura 
Drought, PhD Thesis, 2014, Christian Flueck, LSHTM, unpublished data). The results are also 
consistent with the fact that none of the compounds, apart from PF9, showed inhibition of 
gametocyte stages, as PfPDEβ has not been detected in gametocyte stages[145] and does not 
appear to be required for sexual stage growth and development (my data unpublished). The lack 
of activity on early gametocyte stages suggests that perhaps PfPDEs are not expressed or are 
not required for early gametocyte stage growth and development. This is supported by the 
observations that gametocytes can grow and develop from stage I through to stage V in knock 
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out lines of PfPDEα (my data, unpublished), PfPDEγ [130] and PfPDEδ[130] and in a conditional 
knockdown line of PfPDE (my data unpublished). 
 
 
5.3.2. PfPDE target of PF9 in stage V gametocytes 
 
Since PF9 showed good inhibition against mature gametocyte stages in viability assays, it was 
then of interest to try to determine the PfPDE target of this compound in stage V gametocytes. 
If the prediction that PF9 targets all PfPDEs is assumed correct, then the PfPDE specificity of PF9 
would possibly give us insight into the PfPDEs required at this stage of the life cycle. Data using 
PF9 treatment on knock out lines of PfPDE, PfPDEγ and PfPDEδ and also a wild type NF54 line, 
indicate that in the absence of PfPDEδ, PF9 treatment reduces gametocyte numbers much less 
effectively compared to loss of stage V gametocytes in the NF54 line and the PfPDEγ-ko and 
PfPDE-ko lines. This was assessed by observation of numbers of stage V gametocytes exhibiting 
the characteristic crescent shape remaining after treatment compared to a non-treated DMSO 
control. In all lines, but particularly apparent in the NF54 line, a population of what has been 
referred to here as ‘abnormal’ forms were also counted. These were cells which did not present 
as having the normal stage IV or V gametocyte morphology or the characteristic morphology of 
rounded up cells. These abnormal forms were at higher numbers in PF9-treated samples and C2 
treatment reduced the proportion of such forms. This indicates that these abnormal forms are 
present as a result of a PKG-dependent effect of PF9 treatment. The overall general parasitemia, 
including abnormal forms was significantly reduced in the NF54, PfPDE-ko and PfPDEγ-ko lines 
in PF9-treated samples indicating that the general effect of this compound is by killing rather 
than inhibition of development because most parasites disappear from culture after 12 hours of 
incubation. Given that we now know that PF9 acts by inducing gametogenesis, it may be that 
the ‘abnormal’ forms observed are stages earlier than stage V which are affected by PF9 
treatment but which do not have the cell signalling capacity for gametogenesis to be induced so 
they remain in the culture but do not appear morphologically as normal, healthy gametocytes. 
It would be useful to determine the viability of gametocytes remaining in PF9-treated samples 
and in samples treated with both PF9 and C2, particularly in the absence of PfPDEδ. It may be 
possible to knockout PfPDEδ in the luciferase expressing line using a similar method to that used 
by Cathy Taylor (Cathy Taylor, PhD Thesis, 2007) to produce the PfPDEδ-ko line that I have used 
in these studies. Luciferase conversion of its substrate requires ATP, which is only present in 
viable cells so repeating these assays on a luciferase expressing line lacking PfPDEδ would 
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indicate whether the cells that are present by microscopy are viable. It also may be possible to 
look at the effect on gametocyte viability of PF9 in the NF54 and PfPDE-ko PfPDEγ-ko and 
PfPDEδ-ko lines by flow cytometry using a live-dead fluorescent stain such calcein-AM. 
The lack of PF9 activity in the PfPDEδ-ko line initially suggested that PF9 targets PfPDEδ in 
mature gametocyte stages, as PF9 is much more active in the NF54, PfPDE and PfPDEγ-ko lines 
where PfPDEδ protein is expected to be present based on proteomic data[144] compared to the 
knockout line where it is absent. The rationale being that if the target of PF9 is not present, then 
the inhibitor will be inactive. However as demonstrated in chapter 4 of this Thesis (section 4.2.3), 
the PfPDEδ-ko line appears unable to round up in response to PF9 due to its lack of deformability 
as a result of PfPDEδ-mediated cAMP/PfPKA activation and addition of a PKA inhibitor to this 
line can result in PF9-induced rounding up. This complicates work attempting to explore the role 
of PfPDEδ in gametogenesis and PfPDEδ as a target for PF9 as it may already be unable to 
undergo rounding up due to an earlier effect on deformability. A conditional knock down line of 
PfPDEδ would be a useful tool to look at the effect of PF9 on a line in which PfPDEδ is present 
until excision is induced. These data also suggest that the effects of PF9 appear to be PfPKG-
specific and on target because they are reversed by the PfPKG inhibitors C2 and MRT00207065. 
The relatively small effect of PF9 on PfPDEδ-ko gametocytes, was shown to be not significant 
using statistical analysis.  
 
Interestingly, the PfPDE-ko line appeared to be more sensitive to PF9 treatment. The lowest 
concentration of 0.2 M completely inhibited this line. This was in contrast to NF54 in which 
gametocyte numbers were unchanged at this concentration. The PfPDE-ko line also exhibited 
higher sensitivity at 0.2 M PF9 than the PfPDEγ-ko line. This indicates that in the absence of 
PfPDE, PF9 is more active. This result may reflect a scenario whereby PF9 is targeting PfPDEδ 
which is likely to be the predominant PfPDE present in stage V gametocytes and required for 
gametocyte activation, but that it is also targeting PfPDE, which is also present in mature 
gametocytes but is known not to play an essential role in the process of gametogenesis. It is not 
clear what the role of PfPDE is as no phenotype has been observed in blood stages or 
gametocyte development. It is perhaps present to compensate for the loss of PfPDEδ or it may 
play an important role in vivo or later on during mosquito stage development, but this has not 
yet been defined. In the absence of PfPDE, a lower concentration of PF9 is required to inhibit 
PfPDEδ and the compound is essentially more active. PF9 is predicted to bind both PfPDEα and 
PfPDEδ, therefore in the absence of PfPDEα there will be effectively more free PF9 to bind to 
PfPDEδ. In a wildtype situation where both PfPDEα and PfPDEδ are present, the presence of 
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PDEα provides an additional target for PF9 to bind to. The number of target molecules in a cell 
clearly influences the EC50 value and so if there are fewer target molecules the EC50 value will be 
lower and this appears to be what is seen in the PfPDE-ko line, which shows a much higher 
sensitivity to PF9 compared to the wildtype line. The similarity observed between the PF9 
responses in wildtype (3D7a) and PfPDEγ-ko line gametocytes may be due to the fact the PfPDEγ 
is not likely to be expressed at the protein level in mature gametocytes so as seen in the wildtype 
line, both targets, PfPDEα and PfPDEδ are present but PfPDEγ is absent. Therefore it is unlikely 
that PfPDEγ contributes to the EC50 of PF9 in gametocytes. 
The slight difference in sensitivity observed in the NF54 and PfPDEγ-ko lines may be due to strain 
specific differences as the background of the PfPDEγ-ko line is 3D7. Repeating this assay on the 
3D7a line would provide a more useful comparison to the knockout lines that NF54. 
The inability of C2 to reverse the effect of 20 M PF9 in the PfPDE-ko line may be due to a toxic 
(off target, PKG-independent) effect at this concentration. Or it may be that as PF9 shows more 
activity when PfPDE is absent (and therefore when the only PfPDE available for targeting is 
PfPDEδ), it may be reaching its PfPDE target more quickly than C2 is able to inhibit PfPKG so may 
therefore not be able to fully reverse the effects of PF9 at the higher concentration.  
 
PF9 appeared not to require the presence of PfPDEγ for activity (i.e. PfPDEγ does not contribute 
to the EC50 of PF9), as absence of the gene encoding PfPDEγ in the PfPDEγ-ko line did not alter 
PF9 activity on mature gametocytes when compared to the NF54 line. One explanation for this 
is that PfPDEγ is simply not a target for PF9. This is currently unknown. Another explanation is 
that PfPDEγ protein is absent from stage V gametocytes so it is not present as a target for PF9. 
PfPDEγ mRNA transcripts have been detected in P. yoelii sporozoites[142], but detected at only 
very low levels in gametocyte stages of P. falciparum[25],[145]; however, the presence of mRNA 
transcripts does not necessarily indicate that protein is present at these stages. A third 
explanation is that PfPDEγ protein is present in gametocyte stages but may not be active, so PF9 
targeting of PfPDEγ would not affect gametocyte viability. However, if this were to be the case, 
the absence of PfPDEγ would likely present an effect of PF9, which reflects what was seen in the 
PfPDE-ko line. PfPDEγ is not required for gametocyte or gamete development (Cathy Taylor, 
PhD Thesis, 2007) but it has been implicated as an essential PDE in P. yoelii sporozoite motility 
and subsequent infection of the mosquito salivary gland[142]. It may be that PF9 could affect 
parasite viability by targeting PfPDEγ at a later point in the insect stages of the life cycle. It would 
be interesting to test the activity of PF9 on sporozoite stages, or to test PF9 in native PDE 
inhibition assays using samples of epitope tagged PfPDEγ protein from pull down experiments 
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or from baculovirus expression studies. The most likely explanation for the PF9 activity seen in 
the PfPDEγ-ko line is that the enzyme is simply not present or not active in stage V gametocytes 
because activity of this PfPDE is not required until later in the life cycle for sporozoite motility 
and subsequent salivary gland invasion[142].  
 
 
5.3.3. PF9 mode of action on stage V gametocytes 
 
Following the discovery of PF9 killing of mature P. falciparum gametocytes, it was then of 
interest to determine how quickly this compound acted. A time course experiment 
demonstrated that PF9 acts within 5 minutes of PF9 addition and interestingly, parasites treated 
with PF9 at all time points appeared to exhibit a round morphology. This phenotype is the same 
as that seen when gametogenesis is initiated in stage V gametocytes using a drop in temperature 
in combination with either the compound XA or a permissive increase in pH. This led to an 
investigation into whether PF9 induced gametogenesis and this resulted in confirmation that 
PF9 does indeed act by initiating gametogenesis. This was confirmed by observing rounding up, 
erythrocyte emergence and exflagellation in PF9-treated parasites of the 3D7a line.  
 
PF9-activated gametocytes appeared morphologically indistinguishable by Giemsa staining from 
XA-activated gametocytes presenting as rounded-up forms. In both PF9 and XA-treated samples 
haemozoin pigment appeared dissipated in contrast to the concentrated area of haemozoin in 
non-activated gametocytes. In contrast to the 3D7a wild type line, gametocytes of the PfPDEδ-
ko line did not round up or emerge from the host erythrocyte when treated with PF9, but 
retained the characteristic crescent shape of non-activated stage V gametocytes. This is 
reminiscent of what is seen in XA-induced gametocytes of the PfPDEδ-ko line and the inability 
of this line to round up and emerge from the host erythrocyte has been investigated in chapter 
4 (section 4.2.3. p145). The inability of PfPDEδ-ko line gametocytes to round up in response to 
PF9 is likely to be largely due to PKA-mediated ‘stiffness’. This needs to be explored further and 
use of a conditional knockdown line of PfPDEδ or possibly a better way of inhibiting PKA in the 
PfPDEδ-ko line (or an additional pharmacological targeting of PKA) may aid to separate the two 
questions of PfPDEδ-mediated deformability and the role of PfPDEδ in gametocyte rounding up 
and emergence. It would be of interest to study images of PF9-induced rounded up gametocytes 
in both the wildtype line and the PfPDEδ-ko line and look at the comparison to XA-induced 
rounded up gametocytes by electron microscopy to further confirm that these rounded up 
parasites have the same morphology.  
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In the wildtype line, rounding up of gametocytes treated with PF9 was inhibited by both C2 and 
MRT00207065, indicating that PF9 induces gametogenesis through a PfPKG-dependent pathway 
(however, this experiment needs to be repeated with a lower concentration of MRT00207065 
as the 1 M used in this study may have been too high leading to a possibility of off target 
effects).  XA also initiates gametogenesis in a PfPKG-dependent manner[159] and it is likely that 
PF9 may be stimulating gametogenesis through the same pathway, by bypassing the interaction 
of XA with its receptor to stimulate elevation of cGMP levels (as is thought to be the case with 
zaprinast). It would be of interest to measure levels of cGMP in response to PF9 treatment in 
stage V gametocytes. In light of the data presented in this chapter, indicating that PF9 activity is 
PfPKG dependent, it would be expected that levels of cGMP would be elevated in response to 
PF9 treatment.  
 
Further investigation using WGA-Texas red to visualise the presence/absence of the erythrocyte 
membrane of gametocyte-infected erythrocytes of the 3D7a line confirmed that the rounded-
up parasites observed in PF9-treated samples had mostly emerged from the host erythrocyte. 
Observation that these morphologically-rounded parasites do in fact emerge from the host 
erythrocyte and that the rounded-up forms that are seen were not morphologically altered from 
the characteristic crescent shape due to another action of the compound, serves to further 
confirm that PF9 is acting by stimulating gametogenesis rather than by another inhibitory effect.  
 
The icing on the cake in terms of confirming that PF9 acts by inducing gametogenesis, was the 
observation of exflagellation events in PF9-treated 3D7a wildtype samples. This confirmed 
further that this compound acts by initiating gametogenesis and also indicating that PF9 can 
induce the whole process of gametogenesis from rounding up through to exflagellation. These 
data also indicates that PF9 is not likely to act in a sex-specific manner as it clearly stimulates 
male gametocytes as exflagellation has been observed and the number of gametocytes 
stimulated to round up in response to PF9 is not likely to account for only male gametocytes 
especially given that the predicted ratio of males to females is around 1:4 and the data indicating 
that PF9 could induce rounding up of >90 % of wildtype gametocytes. Exflagellation assays need 
to be carried out to quantify the number of exflagellation centres in PF9-treated samples 
compared to XA-treated samples (in the presence and absence of C2 and/or MRT00207065 and 
in the PfPKGT618Q gatekeeper mutant line) and EC50 values determined for induction of 
exflagellation and PfPKG-specificity of PF9-induced exflagellation (which was shown by 
McRobert et al[159], to be likely to be a non-PKG-dependent event). We have now available, 
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another PF9-like compound, which has shown higher potency than PF9 on asexual blood stages. 
It would be good to test this compound for its activity in gametocyte stages and to also identify 
whether this compound will induce events of gametogenesis. 
Interestingly, in the wildtype 3D7a line, ~ 15 % of parasites still rounded up in the presence of 
both PF9 and MRT00207065. This could mean that the majority of PF9 activity is PfPKG 
dependent but that in addition, this compound can also induce rounding up of gametocytes 
through a different non-PfPKG-dependent mechanism, which is not sensitive to PfPKG inhibition 
(which is hypothesised to be the case with XA treatment based on evidence on Ca2+ mobilisation 
presented in chapter 4). It is highly unlikely that an off target effect would be seen with 
MRT00207065; however, this compound needs to be used at low concentrations to avoid an off 
target effect. This inhibitor is highly specific for PfPKG and has an EC50 value of 2 nM in a 72-hour 
hypoxanthine incorporation assay and was used at 1 µM in this assay, which in hindsight may 
have been too high. It would be useful to repeat these assays using MRT00207065 at a lower 
concentration in the nM range. PF9 was used at 10 µM, which is well above the EC50 (143 nM) 
value of this compound. Another explanation is that it could be a product of experimental 
design. Both compounds were added simultaneously. It may be that PF9 is reaching its target 
more quickly than that of C2 in this assay, so a certain proportion of cells have rounded up before 
PfPKG has been inhibited. Or it may reflect different dynamics of the actual inhibition process. 
Data in this thesis have indicated that PF9 acts very quickly, faster than is seen in XA induction. 
It would be of interest to pre-incubate cells with C2 prior to addition of PF9. It would also be 
useful to test PF9 on the PfPKGT618Q line in both the presence and absence of C2 and 
MRT00207065. 
What is also interesting is that in the PfPDEδ-ko line, ~ 25 % of cells still rounded up in response 
to PF9 in the absence of PfPDEδ. This indicates PF9 can still induce rounding up in the absence 
of PfPDEδ (and in the presence of activated PfPKA leading to induced stiffness) but much less 
effectively than in the wildtype line. This activity in the PfPDEδ-ko line was completely reversed 
by both C2 and MRT00207065, indicating that this is a PfPKG-dependent event. An explanation 
for this is that PF9 is also targeting another PfPDE, such as PfPDEα that is present in mature 
gametocytes (though not essential) and that can hydrolyse cGMP. As the majority (two thirds) 
of activity is inhibited when PfPDEδ is absent, this indicates that this other PfPDE is unable to 
compensate fully for the loss of PfPDEδ. And that the inhibition of this PfPDE alone cannot 
induce gametocyte induction to levels as high as PfPDEδ inhibition. The fact that these cells can 
still undergo rounding up in the presence of PfPKA-induced stiffness likely indicates that absence 
of PfPDEδ does not result in all cells becoming stiff and that a small proportion remain 
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deformable and can undergo gametogenesis when stimulated. This is supported by the 
deformability data presented in chapter 4 in which ~ 20 % of parasites of the PfPDEδ-ko line 
transcend the matrix indicating that this proportion of parasites still exhibit deformability in the 
absence of PfPDEδ. Another explanation may be that PfPDEδ is only present in one of the sexes 
i.e. in male gametocytes (as we see exflagellation). It would be interesting to repeat some of 
these rounding up assays using sex-specific antibodies such as -tubulin II for male detection 
and Pfg377 for female detection. 
 
Ca2+ mobilisation has been shown to play an important role in the process of 
gametogenesis[260],[159],[210]. Ca2+ has been shown to be required for both XA and zaprinast-
induced exflagellation but not for rounding up[159]. It therefore appears not to be required for 
the initial step of gametogenesis and is thought to act downstream of PfPKG and PfPDEs[159]. 
As XA, zaprinast and PF9 have all been shown to stimulate gametogenesis in a PfPKG-dependent 
manner, it was therefore interesting to investigate whether PF9 also induces Ca2+ release in 
mature gametocytes.  
Interestingly, PF9 induced Ca2+ mobilisation in stage V gametocytes at levels much higher than 
either XA or zaprinast. The majority of Ca2+ release appeared to be PfPKG dependent as it was 
reversed by C2. However, just over 20 % of the total Ca2+ released in PF9 treated samples was 
not reversed by C2. This mirrors what was seen in PF9-induced rounding up of the same line 
with MRT00207065 (~ 15 % rounding up) and indicates that PF9, although mostly inducing Ca2+ 
through a PfPKG-dependent pathway, might also induce Ca2+ mobilisation through an additional 
pathway that is not sensitive to PfPKG inhibition. This is what is observed in Ca2+ release assays 
in wildtype parasites in chapter 3 (section 3.2.2, p120). Again, this result may be explained simply 
by experimental design, as C2 and PF9 were added simultaneously in this assay and repeating 
this experiment using cells pre-incubated with C2 may confirm whether this result is just a case 
of PF9 reaching its target much quicker than C2. In the absence of this confirmation, it would be 
useful to repeat this experiment both using the more specific PfPKG inhibitor MRT00207065 at 
a lower concentration than used in this thesis, and the gatekeeper mutant PfPKGT618Q, which is 
resistant to both C2 and MRT00207065. Based on work on other life cycle stages, zaprinast and 
XA are thought to induce Ca2+ mobilisation via PI-PLC induced release of IP3. It may be that PF9 
induces Ca2+ release through the same signalling pathways as both zaprinast and XA. It would be 
interesting to look at changes in levels of phosphoinositide lipids in PF9 treated gametocytes as 
we have done with zaprinast treated schizonts in chapter 3 (section 3.2, p116). It would be also 
of interest to look at changes in IP3 levels with PF9 treatment. If pre-treatment of gametocytes 
207 
 
with MRT00207065 in both the wildtype and PfPKGT618Q still results in a population of cells that 
response to PF9 in the presence of PfPKG inhibition, in terms of Ca2+ mobilisation and rounding 
up, it would be interesting to look at what other C2-sensitive protein (kinase) is responding to 
PF9-treatment in a PfPKG-independent manner. PfCDPK4 is a Ca2+-dependent protein kinase 
that is required for the late stages of gametogenesis[210]. An orthologue of PfCDPK4 in Eimeria 
and Toxoplasma (the orthologue is known as CDPK1) has been shown to be sensitive to 
C1[159],[181]. It is therefore likely that PfCDPK4 may be a secondary target of C2 in P. falciparum 
gametocytes. More work therefore needs to be done to confirm the specificity of the PfPKG-
dependent Ca2+ mobilisation induced by PF9. Data presented in chapter 4 (section 4.2.4, p157) 
indicate that the PfPDEδ-ko line does not release Ca2+ in response to XA stimulation at all but 
does in response to zaprinast stimulation and in a PfPKG-dependent manner. It would be 
interesting to test PF9 in a Ca2+ release assay on the PfPDEδ-ko line to compare PF9 stimulation 
of Ca2+ mobilisation in this line to that of XA and zaprinast. This may give us an indication of 
which profile PF9 closely resembles and would therefore identify whether PF9 requires the 
presence of PfPDEδ in order to stimulate Ca2+ release. 
Evidence in the literature has shown that the cGMP-PDE inhibitor zaprinast can stimulate 
gametogenesis in the absence of XA[159]. This led to the hypothesis for PF9 action, which is 
described and depicted in Figure 5.26. 
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Figure 5.26. Schematic of predicted PF9-induced signalling pathways leading to gametogenesis in stage 
V gametocytes.  
PF9 inhibits PfPDEs in mature gametocytes. It is likely to target PfPDEδ and PfPDE but with targeting of 
PfPDEδ having a greater impact on gametogenesis. Inhibition of these PfPDEs is likely to result in elevated 
levels of cGMP and activation of PfPKG. This leads to activation of mature gametocytes leading to 
rounding up and emergence followed by the male specific exflagellation. This later stage of gametogenesis 
is dependent upon Ca2+ mobilisation and PF9 induces Ca2+ release. The signalling components between 
the PF9 signal and Ca2+ release are currently unknown but they may involve phosphoinositide lipid 
synthesis via PKG activation of phospholipid kinases and IP3-mediated Ca2+ mobilisation (dotted lines) as 
this is the likely pathway leading to Ca2+ release in XA and zaprinast-activated parasites. Rounding up, 
emergence and Ca2+ mobilisation induced by PF9 require PfPKG activation. Inhibition of PfPKG with either 
C2 or MRT00207065 inhibits all of these events. XA-induced Ca2+ release activates CDPK4, which leads to 
the later stages of male gametogenesis. PF9 treatment leads to both Ca2+ mobilisation and exflagellation 
but as yet there has not been evidence to link the two. PF9 may also induce exflagellation through Ca2+ -
dependent activation of CDPK4 (dotted line) but this needs to be investigated. Rounding up of PF9-
induced gametocytes is likely to be independent of Ca2+ release as observed in zaprinast and XA-induced 
gametocytes, however, this needs to be confirmed. 
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5.3.4. Discussion summary 
 
Overall, the data described in this chapter were generated using a PDE inhibitor that targets 
both male and female mature gametocytes, by inducing gametogenesis in a PfPKG-dependent 
manner. The target is likely to be PfPDEδ, which is thought to be the predominant PfPDE active 
in stage V gametocytes. This compound also induces mobilisation of Ca2+ from internal stores, a 
signalling event, which has been shown to be essential for the later stages of 
gametogenesis[260], ,[215],[210], and an event which has been observed in PF9 induced 
gametocytes, indicating that this compound induces all the events of gametogenesis from 
rounding up through to exflagellation.  
This mode of action and the evident fast speed at which this compound acts would have 
relevance in a clinical setting, as the premature initiation of gametogenesis in the human host 
would render gametocytes non-transmissible. Gamete emergence from the host erythrocyte 
into the harsh environment of the host blood stream where they are no longer protected inside 
a host cell would lead to quick removal by the spleen or the host immune system. Gametes need 
to be in the environment of the mosquito midgut for fertilisation to occur and in the absence of 
fertilisation, development through the mosquito stages of the life cycle to infectious sporozoites 
primed for transmission to a new human host will not occur. Premature gametocyte activation 
would quickly result in death of gametocytes in the host blood stream and it is not thought to 
be possible that these activated parasites would survive in the host blood stream to be taken up 
in a mosquito blood meal. Such a compound, which also exhibits good activity against asexual 
blood stages, would act to alleviate the clinical symptoms of the disease while also inhibiting 
transmission to the mosquito vector. This compound is a very good starting point to develop a 
compound that shows good inhibition against both asexual blood stages and gametocyte stages 
while not targeting any human PDEs. Such a drug would be an invaluable pharmacological 
intervention to reduce morbidity and mortality while also reducing the spread of malaria and 
could well be a new weapon in the arms race against malaria.  
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Chapter 6 
Generation of a PfPDEδ-HA tagged transgenic line 
 
6.1. Introduction 
 
The putative metal ion-dependent 3’5’-cyclic nucleotide PDE PfPDEδ (PF3D7_1470500; located 
on chromosome 14) is a predicted 97.186 kDa (plasmodb.org) integral membrane protein as it 
contains 6 possible transmembrane helices. The membrane association of the P. falciparum PDE 
enzymes has been confirmed experimentally with PDE activity being associated with the 
membrane fractions of blood stage and gametocyte lysates but not the soluble fractions (Ross 
Cummings, PhD Thesis, 2005),[141],[130]. These transmembrane domains are predicted to be 
located towards the N-terminus followed by a catalytic domain[141]. The catalytic domains of 
human PDEs contain the metal-ion binding sites (Zn2+ and one other presumed to be Mg2+) 
required for activity and this domain is involved in cyclic nucleotide recognition and substrate 
binding. This domain is conserved in the four parasite PDEs. The functional importance of this 
domain suggests that it is likely to have most pharmacological relevance. Apart from its 
predicted membrane association, as yet there is no evidence regarding the specific cellular 
localisation of PfPDEδ. PfPDEδ mRNA transcripts have been detected in stage V gametocytes 
and ookinetes but only at low levels in other lifecycle stages[145] (see Figure 1.7, p49) of the 
Introduction for level of transcripts by Illumina sequencing), but this is not always an indication 
that the protein is expressed at a particular stage. This is a well-documented situation, female 
gametocytes transcribe many proteins which are translationally repressed until subsequent 
stages in the life cycle, usually in the insect stages when they are required[144]. However, 
PfPDEδ protein has been detected in stage V gametocyte lysates by proteome analysis of male 
and female gametocytes[144] and elevated levels of cGMP and correspondingly reduced cGMP-
PDE hydrolytic activity have been measured in a PfPDEδ-ko transgenic line (Cathy Taylor, PhD 
Thesis, 2007) indicative that PfPDEδ is likely to be required in mature gametocyte stages. The 
cyclic nucleotide specificity of PfPDEδ has not been confirmed directly; however, the fact that 
elevated levels of cGMP but not cAMP have been measured in a PfPDEδ-ko line[130] suggests 
that this enzyme may be cGMP specific.   
The aim of genetically modifying PfPDEδ with a triple (haemagglutinin) HA tag was to generate 
a tool to investigate further the role of PfPDEδ in gametocyte development and gametogenesis. 
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Such a line would be a useful tool firstly to confirm that the protein is present in gametocyte 
stages and also to determine its cellular localization and timing of expression. 
Immunoprecipitated protein would be pivotal to the study of protein-protein interactions and 
to determine the cyclic nucleotide specificity of PfPDEδ using a PDE assay. Observations of a 
defect in rounding up and emergence in the PfPDEδ-ko line originally pointed towards an 
essential role for PfPDEδ in gametogenesis. However, later work published on the PKA-regulated 
deformability of gametocyte infected erythrocytes[25] identified a role for PfPDEδ in 
maintaining a deformable phenotype to allow circulating mature gametocytes to avoid splenic 
clearance[25]. Interestingly, functional studies on P. berghei showed no phenotype in 
gametocytes or during gametogenesis in a PbPDEδ-ko line, but rather a role in ookinete stages 
where it regulates gliding motility. Work carried out in this thesis (chapter 4, p145) has identified 
that inhibition of PKA, (which becomes activated in the absence of PfPDEδ), can to some extent 
reverse the phenotype observed in PfPDEδ-ko parasites resulting in increased levels of XA and 
PF9-induced rounding up in this line. The observation that PfPDEδ-ko parasites will round up 
prematurely upon PKA inhibitor treatment is interesting and likely confirms that PfPDEδ does in 
fact play an important role in gametogenesis. However, more work needs to be done to 
investigate this further and the availability of a PfPDEδ-HA line will hopefully be a valuable tool 
to understand the role of this protein further.  
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6.2. Results 
 
6.2.1. The design and generation of a transgenic PfPDEδ-HA tagged line using the CRISPR-Cas9 
gene editing system. 
 
The CRSPR-Cas9 gene editing system uses a small RNA sequence known as a guide RNA (gRNA), 
which specifically binds to the target sequence of interest and in doing so guides the enzyme 
bacterial CRISPR-associated protein-9 nuclease (Cas9) to the target sequence where it cuts at 
the desired site inducing a double strand break. This technique can be used to make precise 
changes to the parasite genome such as an insertion or deletion (see section 2.6.A to 2.6.J for a 
more detailed method). In collaboration with Christian Flueck (LSHTM) this technique was used 
to introduce a triple haemagglutinin (HA) tag at the C terminal end of PfPDEδ (Figure 6.1). In 
short, a ~700 bp synthetic repair template (ThermoFisher Scientific, see appendix (A1) for 
sequence) corresponding to a partly recodonised 3' end of PfPDEδ, a triple HA tag, and PfPDEδ 
3' untranslated region (UTR) was inserted into the parental pL6_eGFP repair plasmid to yield 
pL6_ PfPDEδ-HA. pL6_PfPDEδ-HA was verified by restriction digest and Sanger sequencing 
(Figure 6.2).  
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Figure 6.1. Schematic showing the strategy to introduce a C-terminal triple HA tag into the PfPDEδ locus. 
Representation of the pL9 cas9 high fidelity plasmid and the PL6 repair template plasmid before and after 
integration. A 700 bp synthetic repair template corresponding to a partly recodonised (grey) 3’ end of 
PfPDEδ (blue), a triple HA tag (yellow) and a 3’ UTR inserted into the pL6_GFP repair plasmid. The resulting 
pL6_PfPDEδ-HA plasmid was transfected simultaneously with a PL9 Cas9 high fidelity plasmid containing 
the gRNA sequence and a blasticidin (BSD) marker. This gRNA targets the cas9 to the target sequence 
where it cuts (black dotted line) and the triple HA tag is inserted into the wildtype locus. The primer pairs 
for integration PCR analysis are indicated by blue triangles (see appendix (A2) for sequences). Pair P1-P2-
wildtype specific (expected size 226 bp), pair P3-P4 integration specific (expected size 761 bp) and P5-P4 
for detection of the episome and integration of the modified locus (expected size 400 bp). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
214 
 
Selection of site-specific guide RNA 
 
Selection of the most suitable guide RNA (gRNA) is crucial for efficient Cas9 targeting and 
subsequent repair using the provided repair template to introduce the triple HA tag. Poor guide 
RNA selection can lead to off target localisation of the Cas9 nuclease and induce a double strand 
break at the wrong location, which is potentially lethal. An initial attempt using a gRNA sequence 
predicted using the Protospacer software (http://www.protospacer.com), which predicts off-
target activity but not on-target activity was used. After transfection of P. falciparum NF54 
schizonts (Amaxa electroporation), a parasite population carrying both the pL6_ PfPDEδ-HA 
repair template plasmid (marker free, see Figure 6.1) containing the PfPDEδ-HA insert and the 
pUF1 Cas9 plasmid (selected for with DSM1) was selected, however, no modified PfPDEδ locus 
could be detected. The use of the Benchling software (https://benchling.com), which predicts 
both on-target and off-target gRNA activity revealed that the gRNA used exhibited poor on-
target activity (score of 0.6 out of 100). As a result, this was repeated with a new gRNA with a 
high on-target activity score (31 out of 100) that was selected using this software (see Figure 6.1 
for schematic) and a new transfection carried out as described below.  
 
 
Introduction of a triple HA tag into the PfPDEδ-HA wildtype locus  
The newly selected gRNA sequence was cloned into the pL9 Cas9-HF-bsd plasmid (Avnish Patel, 
LSHTM). For generation of a PfPDEδ-HA expressing line, P. falciparum NF54 ring stage parasites 
were transfected simultaneously with the circular pL6_PfPDEδ-HA repair template plasmid and 
the pL9-HF-bsd plasmid (Cas9 high fidelity plasmid) plasmid containing the gRNA sequence and 
a blasticidin marker for plasmid selection (see Figure 6.1). Transfected parasites were treated 
with 2.5 μg/ml blasticidin for 10 days and then monitored regularly until parasites were 
detectable by microscopy of Giemsa-stained blood films. Observations of parasite growth and 
development indicated that asexual blood stages of this transgenic line grow and develop 
normally through the cell cycle (data not included). 
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Confirmation of integration of the HA tagging plasmid into the PfPDEδ locus 
 
A comprehensive PCR analysis was carried out on DNA extracted from PfPDEδ-HA cultures 
(Figure 6.2). This showed successful integration of the HA-tagging plasmid into the PfPDEδ locus. 
A band size of ~ 700 bp was detected using primers specific for integration of PfPDEδ-HA only in 
PfPDEδ-HA samples and not in the Nf54 control (see appendix (A2) for primer sequences). This 
corresponded to the expected band size of 761 bp. The expected band size of 226 bp with 
wildtype-specific primers was detected only in the wildtype NF54 control sample and not in the 
PfPDEδ-HA sample showing that no wildtype parasites remained in the PfPDEδ-HA parasite 
population. 
Together the data indicated that successful integration had occurred (Figure 6.2). Primers 
specific for both integrated and episomal PfPDEδ-HA detected an expected band size of ~ 400 
bp. This was only detected in the PfPDEδ-HA sample and not the NF54 control. Primers specific 
for PKG were used as a DNA control and an expected band size of 711 bp was detected in both 
the PfPDEδ-HA and NF54 samples. 
 
 
Figure 6.2. PfPDEδ-HA integration PCR. (For primer sequences see appendix). Wildtype-specific 
primer pair (P1-P2) detected a band only in the wildtype NF54 sample (C), Integration-specific 
pair (P3-P4) detected a band only in the PfPDEδ-HA line sample (δ). Integration and episome 
specific pair (P4-P5) detected a band only in the PfPDEδ-HA line sample. The DNA control primer 
pair (PKG, P6-P7) detected bands in both the wildtype and PfPDEδ-HA line samples.  
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On initiation of gametocytogenesis, the PfPDEδ-HA transgenic appeared to exhibit good 
gametocyte-producing capabilities, with comparable numbers of gametocytes observed when 
compared to an NF54 control line (data not included). Gametocytes appeared to develop 
normally to stage V and rounding up assays indicated a normal (rounding up) response to XA 
(Figure 6.3).  
 
                        
Figure 6.3. XA-induced rounding up in the PfPDEδ-HA transgenic line. Stage V gametocytes treated with 
10 μM XA or 0.05 % DMSO (control) for 30 minutes at room temperature. Presented as percentage 
parasitemia from counts of Giemsa stained blood films. Data analysed in Excel is the average of 3 counts 
(900 RBCs counted per sample) from one experiment. Graph generated in GraphPad, Prism. Error bars 
represent SD. 
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6.2.2. PfPDEδ-HA gives a faint signal by immunofluorescence assay 
 
Determination of the localisation of a protein can provide information on its function. Detection 
of PfPDEδ-HA by immunofluorescence assay using a rat -HA antibody and an -rat Alexa Fluor 
594 secondary antibody, on 4 % formaldehyde-fixed and cold methanol-fixed dried blood 
smears was not initially successful when carried out in the absence of detergent (data not 
shown). High levels of background were seen in the wild type NF54 control samples. This 
experiment was carried out prior to the successful immunoprecipitation of PfPDEδ-HA. 
However, on achieving purified PfPDEδ-HA protein by pull down from samples of stage IV/V 
gametocytes (see section 6.2.4), it was clear that the tagged protein is present in mature 
gametocytes. It is possible that the HA tag is not easily accessible to the -HA antibody due to 
the folding of the protein or it may form part of a complex and this makes it harder for the 
antibody to access the HA tag. This assay was therefore repeated but including 0.05 % Tween 20 
with the aim to make the HA tag more accessible. Two different conditions were tested. Firstly, 
a rat -HA antibody followed by -rat Alexa Fluor 594 secondary antibody. Secondly, a rat -HA 
antibody followed by an -rat-biotin antibody followed by Alexa Fluor 488-conjugated 
streptavidin with the aim to increase sensitivity. Preliminary data revealed faint levels of 
fluorescence with both the conditions (Figures 6.4 and 6.5). At this stage (in the absence of 
negative controls using the antibodies individually) it is not clear whether the fluorescence seen 
represents the localisation of PfPDEδ-HA protein or whether it is background fluorescence. 
However, the fluorescence levels observed in the wild type NF54 control gametocyte samples 
(using both primary and secondary antibodies) were much lower than in the transgenic line 
(Figure 6.6). Fluorescence in NF54 samples appeared to be lower in the -rat-biotin antibody 
samples (Figure 6.5).  
The faint fluorescence appeared to show a punctate pattern. Interestingly, this pattern of 
fluorescence is similar to the pattern of localisation of osmiophilic bodies using a transgenic line 
expressing Pfg377 fused to a reporter protein[288]. This is intriguing as osmiophilic bodies are 
thought to be involved in egress of female gametocytes and PfPDEδ is also thought to be 
required for egress. The conditions of this assay need to be improved to visualise the HA-tagged 
PfPDEδ protein and to minimise any background fluorescence and unspecific binding resulting 
in a better signal to noise ratio. It will be important to investigate whether the fluorescence seen 
corresponds to specific binding of HA antibody to the tagged PfPDEδ rather than non-specific 
binding. 
218 
 
 
 
 
Figure 6.4. Immunofluorescence assay of PfPDE-HA mature gametocytes. Dried blood smears of 
PfPDE-HA stage V gametocytes were fixed with 4 % formaldehyde and incubated with -HA antibody 
(rat) followed by a -rat Alexa Fluor 594 secondary antibody (red), followed by addition of Vector shield 
containing DAPI (blue). Samples were imaged using an EVOS FL fluorescent cell imaging system. 
  
Phase DAPI αHA Merge 
PfPDEδ-HA 
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Figure 6.5. Immunofluorescence assay of PfPDE-HA mature gametocytes. Dried blood smears of 
PfPDE-HA stage V gametocytes fixed with 4 % formaldehyde and incubated with rat -HA antibody (and 
0.05 % Tween 20) followed by -rat biotin antibody coupled to Alexa Fluor 488 conjugated streptavidin 
(green) followed by addition of Vector shield containing DAPI (blue). Samples were imaged using an EVOS 
FL fluorescent cell imaging system. 
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Figure 6.6. Immunofluorescence assay of NF54 mature gametocytes. Control samples for figures 6.4 and 
6.5 (assays done in parallel). Dried blood smears of PfPDE-HA stage V gametocytes fixed with 4 % 
formaldehyde and incubated with -HA antibody (rat) (and 0.05 % Tween 20) followed by a -rat Alexa 
Fluor 594 secondary antibody (right) or with -rat biotin antibody coupled to Alexa Fluor 488 conjugated 
streptavidin (left), both followed by addition of Vector shield containing DAPI (blue). Samples were 
imaged using an EVOS FL fluorescent cell imaging system. 
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6.2.3. PfPDEδ-HA partially co-localises with the Golgi marker ERD2 
Given the interesting pattern of fluorescence in HA-tagged stage V PfPDE gametocytes (Figures 
6.4 and 6.5), which suggests a possible osmiophilic body localisation, it was of interest to 
determine whether the pattern of fluorescence seen would co-localise with a marker for the 
Golgi. This is because osmiophilic bodies are thought to be derived from the Golgi[288] and 
accumulate in female gametocytes reaching higher densities as gametocytes mature.  These 
data are very preliminary and the experiment needs to be repeated with the appropriate 
controls. However, a densely punctuate pattern was obtained in both cases and there appears 
to be some co-localisation of the -HA and -ERD2 antibodies, indicating that the location of 
PfPDE may overlap somewhat with the Golgi protein ERD2 (Figure 6.7). This partial overlap may 
reflect the location of osmiophilic bodies. It would be interesting to investigate this further. 
 
 
 
Figure 6.7. Immunofluorescence assay of PfPDE-HA mature gametocytes. Dried blood smears of 
PfPDE-HA stage V gametocytes fixed with 4 % formaldehyde. For detection of PfPDE-HA, samples 
incubated with -HA antibody followed by a -rat Alexa Fluor 588 secondary antibody (green). For 
detection of ERD2, samples incubated with a rabbit EDR2 (1:1000) antibody followed by -rabbit Alexa 
Fluor 549 secondary antibody (red). Vector shield containing DAPI (blue) was added to both samples. 
Samples were imaged using an EVOS FL fluorescent cell imaging system. 
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6.2.4. Purification of HA tagged PfPDEδ by immunoprecipitation from gametocyte lysates 
Immunoprecipitation (IP) assays were performed on stage IV/V gametocyte lysates from the 
PfPDEδ-HA transgenic line. An intense band size of ~ 90 kDa by western blotting was detected 
in the input sample, and also very strongly in the sample eluted from the anti-affinity matrix 
(Figure 6.8). This size is close to the expected size of PfPDEδ-HA, (97.168 kDa, plasmodb.org). 
The expected size of the triple HA tag is 3.17 kDa, making the whole protein size a predicted 
100.33 kDa; this likely indicates that the protein detected on the Western blot is full length 
PfPDEδ. A much fainter band corresponding to PfPDEδ-HA was detected in the unbound sample, 
but the majority of protein appeared to have been immunoprecipitated indicating that this 
protein can be pulled down very efficiently (Figure 6.8). This was in contrast to the positive 
control (PfPDEβ-HA from a P. falciparum blood stage culture) sample in which a strong band was 
still seen in the unbound sample indicative that not all of the PfPDEβ-HA protein was bound to 
the beads with a large amount of protein remaining in the unbound fraction. These data 
indicates that a large amount of PfPDEδ can be pulled down from stage IV/V gametocytes, 
consistent with proteomics data[144] indicating the presence of PfPDEδ protein at stage V by 
mass spectrometry. No protein was detected in the 3D7a negative control sample in any of the 
fractions, indicative that this assay only detected HA-tagged protein. 
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Figure 6.8: Western blot of immunoprecipitated PfPDEδ-HA from stage IV/V gametocyte 
lysates. PfPDEδ-HA compared to a positive control (PfPDEβ-HA from mature schizont lysates) 
and a negative control (3D7a schizont lysates). HA-tagged protein was pulled down using an Anti-
HA Affinity matrix. HA-tagged protein detected using an -HA high affinity rat monoclonal 
antibody. Undiluted input represents HA-tagged protein in parasite lysates prior to 
immunoprecipitation. Samples were diluted (diluted input) then detected in subsequent washes 
(unbound, wash 1 and wash 2). HA-tagged protein bound to the Anti-HA Affinity matrix 
(immunoprecipitated) and detected protein(bound beads).  
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6.2.5 cGMP (but not cAMP) hydrolytic activity is detected in immunoprecipitated PfPDEδ-HA 
protein from stage IV/V gametocyte lysate. 
The cyclic nucleotide specificity of native PfPDEδ has not been measured directly. However, 
elevated levels of cGMP have been measured in a PfPDEδ-ko line[130] and reduced cGMP but 
not cAMP hydrolytic activity has been measured in gametocyte lysates from the PfPDEδ-ko 
line[130]. As such, PfPDEδ is predicted to be a cGMP-specific PDE. 
To measure the cyclic nucleotide specificity of PfPDEδ directly, the immunoprecipitated protein 
eluted from the anti-affinity matrix (see Figure 6.8) was used to perform a PDE assay (see section 
2.5.G, p90 for more details of the method). The cyclic nucleotide hydrolysing activity of PfPDEδ 
was compared to that of PfPDE, which was shown to be dual specific in assays carried out by 
Laura Drought (Laura Drought, PhD Thesis, 2014).  
Data from the assay showed as expected that PfPDE hydrolyses both cAMP and cGMP and was 
therefore a good positive control for the assay (Figure 6.9). PfPDEδ on the other hand, showed 
only cGMP hydrolysing activity. No cAMP hydrolysing activity was detected. This is in keeping 
with data on gametocyte lysates, which showed cGMP hydrolysing activity but not cAMP activity 
and confirms that PfPDE-delta is a cGMP-specific PDE[130].  
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Figure 6.9:  Cyclic nucleotide hydrolysing activity of immunoprecipitated PfPDEδ protein. Assays were 
carried out on PfPDEδ and PfPDEβ protein pulled down by immunoprecipitation. Cyclic nucleotide 
hydrolytic activity was compared to that of PfPDE protein. Levels of tritiated labelled cAMP and cGMP 
were measured by scintillation counting. Means of triplicate wells are presented. Data were analysed in 
Excel and the graph generated in GraphPad, Prism. Error bars represent SD. 
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6.2.6  PDE inhibition reduces both cAMP and cGMP hydrolytic activity in mature 
gametocyte stages. 
 
Given the potent activity of the Pfizer PDE inhibitor PF9 on gametocytes (see chapter 5) and the 
observation that the PfPDEδ-ko line was unable to release Ca2+ in response to XA stimulation 
(chapter 4, section 4.24, p155), it was hypothesised that XA may interact with PfPDEδ either 
directly or indirectly to possibly turn off PfPDEδ leading to elevated levels of cGMP. It was of 
interest to test these compounds on immunoprecipitated (IP) HA-tagged PfPDEδ protein to 
determine whether they could inhibit cGMP hydrolytic activity. PF9 has already been tested on 
immunoprecipitated HA-tagged PfPDE protein and on asexual parasite lysates from a wildtype 
(3D7) and a PfPDE-ko line. This compound reduced both the cAMP and cGMP hydrolytic activity 
in blood stage parasite lysates and showed some activity against immunoprecipitated HA-tagged 
PfPDE protein. The interpretation was that PF9 is a broad specificity PDE inhibitor that targets 
both PfPDE and PfPDE  (Laura Drought, PhD Thesis, 2014).  
Addition of 5 M PF9 to purified HA-tagged PfPDEδ protein reduced cGMP hydrolysis by ~ 50 %, 
and this was shown to be significant (Welchs unpaired t test, P = 0.0287) (Figure 6.10). However, 
the lower concentration of 200 nM did not reduce levels of cGMP hydrolysis. Interestingly, 
addition of 1 M and 10 M XA to samples of PfPDEδ protein did not reduce the cGMP hydrolytic 
activity but appeared to increase it by 40-50 %. However, this was shown to be not significant 
(Welchs unpaired t test P=0.0878 and P = 0.3333 respectively). 
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Figure 6.10. The effect of PF9 and XA on PfPDE-HA cGMP hydrolysing activity. Immunoprecipitated HA-
tagged PfPDE protein incubated with PF9 (5 M and 200 nM) and XA (1 M and 10 M) presented as 
percentage of the control sample (1 in 10 dilution in PDE assay buffer) normalised to 100 %. Data is from 
one experiment carried out in triplicate and analysed in Excel. The graph was generated in GraphPad, 
Prism. Error bars represent SD. 
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PF9 is active against both PfPDE cAMP and cGMP hydrolysis 
Addition of the Pfizer inhibitor PF9 to immunoprecipitated PfPDE protein reduced both the 
cAMP and cGMP hydrolytic activity. Addition of 5 M PF9 almost completely abolished the cAMP 
hydrolysis by PfPDE protein with only ~ 7 % of activity remaining (P = 0.0024). The lower 
concentration of PF9 (200 nM) also reduced PDEβ cAMP hydrolysis by ~ 75 % (Figure 6.11) this 
was also shown to be significant (Welchs unpaired t test, P = 0.0004). 
PfPDE cGMP hydrolytic activity was also reduced by PF9 but only at the highest concentration 
of 5 M, which reduced the hydrolytic activity by ~ 70 %. This was shown to be significant 
(Welchs unpaired t test, P = 0.0287). However, levels of cGMP hydrolysis by PfPDE were not 
altered by addition of the lower concentration (200 nM) of PF9 (Figure 6.12).  
Interestingly, addition of 1 M XA appeared to reduced levels of cAMP hydrolysis by 
immunoprecipitated HA-tagged PfPDE protein by ~ 40 % (Figure 6.11),  this was shown to be 
significant (Welchs unpaired t test, P = 0.0033). Levels of cGMP hydrolysis did not appear 
reduced with XA addition (Figure 6.12), in fact, PfPDE cGMP hydrolytic activity appeared higher 
in XA-treated samples reflected by a ~ 50 % increase in activity. However, this was shown to be 
not significant (Welchs unpaired t test P = 0.1718). 
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Figure 6.11. The effect of PF9 and XA on PfPDE-HA cAMP hydrolysing activity. Immunoprecipitated HA 
tagged PfPDEβ protein incubated with PF9 (5 M and 200 nM) and XA (1 M) presented as percentage of 
the control sample (1 in 10 dilution in PDE assay buffer) normalised to 100 %. Data are from one 
experiment carried out in triplicate analysed in Excel. Graph generated in GraphPad, Prism. Error bars 
represent SD. 
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Figure 6.12. The effect of PF9 and XA on PfPDE-HA cGMP hydrolysing activity. Immunoprecipitated HA 
tagged PfPDEβ protein incubated with PF9 (5 M and 200 nM) and XA (1 M) presented as percentage of 
the control sample (1 in 10 dilution in PDE assay buffer) normalised to 100 %. Data are from one 
experiment carried out in triplicate analysed in Excel. Graph generated in GraphPad, Prism. Error bars 
represent SD. 
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6.3. Discussion 
 
The success of producing a HA-tagged PfPDEδ line was confirmed by a PCR with a diagnostic 
primer set that showed clearly that integration had occurred and that the population did not 
contain any wildtype parasites. The tagging of PfPDEδ did not to appear to affect the growth and 
development of asexual or sexual stages, indicating that this genetic modification did not disrupt 
normal growth and development.  
Interestingly the possible PfPDEδ-HA protein localisation showed similarity to the localisation of 
osmiophilic bodies, these are electron dense organelles mostly specific to female gametocyte 
stages. These organelles accumulate in female gametocytes where they localise under the 
gametocyte surface and are involved in female gamete egress[289],[288]. It would be interesting 
to repeat this assay with both the -HA antibody and an antibody against the female-specific 
protein Pfg377, as this protein has been shown to localise to the osmiophilic bodies[288]. This 
would help determine whether PfPDEδ is localised in osmiophilic bodies or not. It would also be 
of interest to test an antibody against the male specific -tubulin in parallel to determine 
whether male gametocytes exhibit this pattern of staining (or any staining). Osmiophilic bodies 
can also be found in male gametocytes but at a much lower number and it may be that in these 
cells no staining will be observed (as Pfg377 is not present and if PfPDEδ is also absent, so no 
staining for either proteins will be seen). Osmiophilic bodies are thought to be derived from the 
Golgi[288]  so it was of interest to see a degree of co-localisation of antibodies against  PfPDEδ 
and the Golgi protein ERD2. This was preliminary data but strengthens the hypothesis that 
PfPDEδ may be associated (or likely located within) osmiophilic bodies. In female gametocytes, 
the pattern of Pfg377 localisation changes as gametocytes emerge. If PfPDEδ is shown to co-
localise with Pfg377, It would be interesting to carry out rounding up experiments on the 
PfPDEδ-HA line using XA (and PF9) and staining with sex-specific antibodies (including Pfg377) 
and an -HA antibody to determine whether the localisation of PfPDEδ changes when egress 
occurs. 
The possible association of PfPDEδ to osmiophilic bodies is an interesting observation since 
PfPDEδ is thought to have a role in gametocyte rounding up and gamete 
emergence/egress[130]. The sex ratio of females to males differs between parasite lines. 
However, the ratio leans in favour of females with an average ratio of ~1:4[254].  Therefore if 
PfPDEδ were required for female egress only, the effect of deletion of PfPDEδ would still impact 
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significantly the egress/rounding up phenotype of a mixed culture as only ~ 25 % of parasites 
(depending on the sex ratio) would be expected to still be able to egress/round up in the absence 
of PfPDEδ and this could account for the male population. This appears to be reflected in egress 
assays presented in this thesis, carried out on the PfPDEδ-ko line, which in the presence of PKA 
inhibitors show that ~ 15/25 % of parasites can still round up in the absence of PfPDEδ. This may 
reflect the male population, with females still being unable to round up and egress in the 
absence of PfPDEδ despite the PKA inhibition, but males being able round up once the PKA-
induced stiff phenotype has been removed. Interestingly, Ca2+ assays carried out on mature 
gametocyte stages appeared to show both a PKG-dependent and PKG-independent response. 
This may also reflect a sex- specific difference in the XA and zaprinast induced Ca2+ response in 
this line and would be an interesting question to explore further.   
PfPDEδ-HA was successfully immunoprecipitated using an anti-HA affinity matrix. This method 
produced a good yield of PfPDEδ protein with very little protein remaining in the unbound 
fraction. This was a very welcomed result as large amounts of gametocyte material are hard to 
produce due to the long development time of gametocytes to stage V which takes up to 14 days, 
and the much lower parasitemias compared to asexual stages. The ability to pull down a good 
sized sample of PfPDEδ means that smaller starting gametocyte lysate samples can be used in 
the future, therefore saving a lot of time and resources. This yield also indicates that there is 
likely to be large amounts of PfPDEδ protein in stage IV/V gametocytes. The fact that there was 
a mixture of stage IV and V gametocytes in the sample used to produce the immunoprecipitated 
PfPDEδ protein may indicate that stage IV gametocytes also contain PfPDEδ. It would be 
interesting to carry out IFAs of gametocyte samples and Western blots from parasite lysates on 
all five stages of gametocytes to look at whether the PfPDEδ protein can be detected in stages 
other than stage V where it has been shown to be present by mass spectrometry. 
The immunoprecipitated PfPDEδ-HA protein was used to determine the cyclic nucleotide 
specificity of PfPDEδ. Although PDEδ has historically been thought to be cGMP specific, work by 
Ramdani et al, have identified a role for PfPDEδ in cAMP-regulated deformability[25] which had 
raised the possibility that this PDE could be dual specific. Authors in this paper measured 
elevated levels of both cAMP and cGMP in PfPDEδ-ko line gametocytes. However it was unclear 
whether cAMP levels were regulated by PfPDEδ directly or indirectly. Therefore confirmation of 
the hydrolytic activity was important. The PDE assay presented here was only carried out once 
in triplicate and this needs to be repeated to confirm the result. However, the data presented 
here mirrors previous findings[130]  and suggests that only cGMP hydrolytic activity is present 
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in the purified PfPDEδ protein samples, suggesting that any elevation of cAMP levels in the PDEδ 
knockout must be achieved indirectly.  
The observation that PF9 reduced cyclic nucleotide hydrolytic activity of purified PDEδ further 
confirmed our earlier observations that this PDE inhibitor has broad specificity in relation to the 
malaria parasite PDEs and further supports results presented in chapter 5 showing that PF9 
induces gametogenesis and that it is likely to target PDEδ. PF9 has previously been shown to 
reduce the cyclic nucleotide hydrolytic activity of HA-tagged PfPDE (Laura Drought, PhD, 2014).  
The HA-tagged PfPDEδ line is a useful tool that can be used in further studies to confirm the 
localisation of PfPDEδ and to answer the interesting question of a possible sex-specific function 
for this enzyme. It will also enable us to look at possible interactions of PfPDEδ with other 
proteins in a membrane-bound signalling complex and to pinpoint the role of PfPDEδ in the 
essential process of gametogenesis and gametocyte-infected erythrocyte deformability. This 
line may also prove useful in studies designed to determine the relationship between XA and 
PfPDEδ in the process of gametogenesis and to determine whether XA directly interacts with 
PfPDEδ. 
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Chapter 7 
 
General discussion 
 
7.1. Project overview 
 
PDEs are essential enzymes that function in cyclic nucleotide signalling events that govern many 
stages of the malaria parasite’s complex life cycle. These enzymes have been shown to be good 
drug targets in humans as several PDE inhibitors have been developed to successfully treat 
diseases. Plasmodium PDE catalytic domains show 24-28 % identity and ~50 % similarity to the 
11 member family of human homologues, however, they are thought to be sufficiently divergent 
in their catalytic domain to make selective inhibitor generation feasible. Cyclic GMP signalling 
has been shown in several studies to coincide with the release of Ca2+ from internal stores and 
c Ca2+-dependent protein kinase (CDPK) function, to regulate essential cellular processes in the 
parasite. CDPKs have been shown to be good potential drug targets in P. 
falciparum[290],[291],[292].  This project aimed to investigate the relationship between cGMP 
signalling and Ca2+ in blood stage schizonts and gametocytes and to also investigate the role of 
PDEs in the process of gametogenesis with particular focus on PfPDE which has been indicated 
in the literature to be essential in the process of gametogenesis. A small panel of human PDE 
inhibitors developed by Pfizer that showed good activity on asexual blood stages (Laura Drought, 
PhD Thesis, 2014) were tested as part of my PhD project for gametocytocidal properties. Data 
generated through the investigation into the biology of PfPDEs has emphasised the importance 
of PDEs as novel drug targets in the malaria parasite. Not only do these data reflect the value of 
targeting cyclic nucleotide signalling, (which will disrupt several parts of the parasite life cycle), 
but it demonstrates that since it is often closely associated with Ca2+ signalling, that this essential 
signalling pathways might also be blocked as a result of targeting cyclic nucleotide signalling 
pathways. 
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7.2. A relationship between cGMP signalling and calcium mobilisation  
 
In schizont stages the relationship between cGMP signalling and zaprinast-induced Ca2+ release 
appears to be clear and some of the evidence presented in this thesis has been published in 
collaboration with Mathieu Brochet[174]. Zaprinast induces an increase in Ca2+ levels and a 
concomitant depletion of key phospholipid intermediates in the generation of IP3. Using the PKG 
inhibitor C2 and the PfPKGT618Q transgenic line, both of these signalling events were shown to be 
PKG dependent. Although zaprinast is not the natural trigger of these events, these data strongly 
imply that the inhibition of PfPDE activity by zaprinast leads to increased levels of cGMP, which 
activate PfPKG. This results in Ca2+ mobilisation from internal stores through phosphorylation of 
phosphoinositides and activation of PI-PLC to produce the secondary messenger IP3. Although 
not included in this report, XA was also tested on schizont stages in a Ca2+ release assay at 
increasing concentrations and no increases in Ca2+ levels were detected (see appendix A3). 
 
In mature gametocyte stages, the relationship between zaprinast-induced Ca2+ release and 
cGMP signalling appears to mirror what is seen in schizont stages with zaprinast inducing Ca2+ 
mobilisation through a PKG-dependent pathway in P. falciparum gametocytes. Changes in levels 
of phospholipids were not investigated and this would be a useful question to address in future, 
to determine whether as seen in schizont stages, zaprinast (and XA) stimulates Ca2+ mobilisation 
through the IP3 signalling pathway. In P. berghei, XA has been shown to trigger PI(4,5)P2 
hydrolysis[200]. Again zaprinast is not the natural trigger of gametogenesis and it is clear from 
the data presented here that the relationship between cGMP and Ca2+ release is more 
complicated in XA-stimulated gametocytes. The fact that C2 reduces XA-induced elevated Ca2+ 
levels indicates that C2 is targeting a protein kinase involved in the Ca2+ response. The fact that 
C2 does not fully reverse levels of Ca2+ could either be a result of experimental design (XA 
reaching its target to induce Ca2+ release before C2 can reach its target to inhibit it), or that Ca2+ 
release in gametocytes is complicated and involves both a C2-sensitive response and a non-C2-
sensitive response. However, these assays need to be repeated to determine this. In a P. berghei 
transgenic line expressing the Ca2+-dependent photoprotein Aequorin, XA was shown to induce 
Ca2+ release in a PKG-dependent manner[174]. The difference may reflect species-specific 
differences or differences in experimental design.  
In the C2-resistant gatekeeper mutant line, the Ca2+ response was still reduced by ~ 50 % by C2. 
The likely explanation for this is that C2 can target another kinase the activation of which can 
also induce Ca2+ mobilisation but that the remaining 50 % of the Ca2+ response is still PKG 
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dependent (as it cannot be reversed by C2 in the PfPKGT618Q line). This is interesting and based 
on the literature, a likely candidate for this non-PKG-dependent Ca2+ release is CDPK4. This 
protein kinase also has a small gatekeeper residue and is sensitive to C1 and C2[172] and is 
essential for the later stages of male specific gametogenesis[210],[215]. This also raises the 
interesting question of whether this complicated Ca2+ response that we see could be a sex-
specific one. For example could XA stimulate female gametocytes to release Ca2+ through a PKG-
dependent pathway and males through a non-PKG-dependent pathway or vice versa? Or 
perhaps XA induces Ca2+ mobilisation in only one sex? The inhibitory effects of many new 
compound types have been shown to differ between male and female gametocytes with male 
gametocytes often exhibiting greater sensitivity. This may point to differences in metabolism 
and potentially sex-specific pathways in gametocyte stages[293]. It may be that only male 
gametocytes require Ca2+ for activation, as exflagellation is known to be Ca2+ dependent and is 
a male-specific event and there is currently no published data indicating a role for Ca2+ in female 
gametocytes. Data demonstrating that gametocytes will round up in the presence of the Ca2+ 
chelator BAPTA-AM but will not exflagellate supports this[159].  However, this does not rule out 
that female gametocytes (or gametes as emergence is not Ca2+ dependent) could release Ca2+ to 
activate male gametocytes once they are ready to be fertilised. This would be a very interesting 
question to answer but could only be achieved through separation of male and female 
gametocytes possibly using distinct colour reporters to differentiate the sexes in transgenic 
lines. This has been achieved in P. berghei[294]. Another possible theory is based on work done 
by Fang et al[215] who identified that in P. berghei, two forms of CDPK4 are responsible for the 
male specific events of gametogenesis. A myristoylated and non-myristoylated form. Both 
require Ca2+ for activation and are involved in distinct events leading to exflagellation. It may be 
possible that a first wave of Ca2+ activates the myristoylated form (which presumably is 
membrane bound) leading to the first events of male exflagellation and to a second wave of Ca2+ 
release, which may be through CDPK4 itself (so non-PKG dependent) that activates the non-
myristoylated form to induce flagella motility. Preliminary live cell imaging data presented in 
this thesis is suggestive of a possible double wave of Ca2+ release but this needs further 
investigation. Published data on the PKG specificity of exflagellation also indicate that this event 
is not likely to be fully PKG dependent as changes in levels of exflagellation with C1 inhibition 
did not differ between a wildtype line and PfPKGT618Q and it was suggested in this publication 
that a candidate for this could be CDPK4[159].  
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The fact that we don’t see any evidence of a non-PKG-dependent Ca2+ response in zaprinast-
treated stage V gametocytes suggests that zaprinast may be able to bypass the initial XA 
response including the non-PKG-dependent Ca2+ mobilisation but still induce all constitutive 
events of gametogenesis. The fact that zaprinast induces Ca2+ mobilisation in mature 
gametocytes implicates cGMP PDE activity in the Ca2+ response. This is supported by evidence in 
the literature demonstrating that zaprinast can induce gametogenesis in the absence of XA[159]. 
Data presented here measured clear and paralogue-specific changes in the Ca2+ response when 
individual PfPDEs were deleted. The most striking example of this was the absence of any XA-
induced Ca2+ response in a transgenic line in which PfPDE was absent due to gene deletion. This 
was an extremely exciting result and led to the hypothesis that XA-induced Ca2+ release requires 
the presence of PfPDE (however the concentration of XA used was low and this assay needs to 
be repeated with a higher concentration).  
However, zaprinast was able to induce a PfPKG-dependent Ca2+ response in the PfPDE-ko line 
(which was completely reversed by C2) indicative that this line could respond to zaprinast 
stimulation and release Ca2+ through inhibition of a cGMP-PDE that is not PfPDE. This was 
interesting given the concerns that this line may be disrupted due to dysregulated levels of cyclic 
nucleotides and the evidence that this line could respond to zaprinast and release Ca2+ is 
suggestive that parasites could respond to a signal leading to the induction of the cGMP 
signalling pathway and this provides evidence that the Ca2+ release machinery is at least partially 
intact. 
The absence of PfPDEγ appeared not to affect either the XA-induced or zaprinast-induced Ca2+ 
response (although these data is preliminary and needs confirmation). However, Ca2+ release 
assays carried out on a PfPDE-ko line revealed that the absence of this PDE resulted in a 
reduced PfPKG-dependent Ca2+ response to both XA and zaprinast. This suggests that PfPDE 
may contribute to (the majority of) the PfPKG-dependent response and this supports a 
hypothesis that the zaprinast-induced Ca2+ mobilisation seen in the PfPDE-ko line may be due 
to zaprinast inhibition of PfPDE.  
No receptor for XA has been identified in P. falciparum and the signalling events between entry 
of XA into the cell and providing the initial XA signal are unknown (XA may be able to diffuse into 
the cell or it may require a receptor binding interaction on the surface of the cell to either enter 
the cell or to initiate the pathway). Given the evidence we have for zaprinast outlined above and 
the inability of the PfPDE-ko line to respond to XA by releasing Ca2+ (or rounding up), it is 
tempting to speculate that PfPDE could be a receptor for XA. Or that XA could bind to PfPDE 
and directly inhibit it leading to elevated levels of cGMP (elevated cGMP levels have been 
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measured in this line[130]). Immunoprecipitation of the epitope-tagged PfPDE has been 
achieved in this project and the next step will be to determine whether XA can directly bind to 
PfPDE. Using radiolabelled XA and immunoprecipitated PfPDE protein it may be possible to 
carry out in vitro binding or association studies to determine whether there is an interaction 
between XA and PfPDE. Preliminary data, however, suggest that XA does not inhibit PDEδ 
activity and in fact showed a stimulatory effect. A model of the predicted PfPDE protein 
structure has been generated by a sequence alignment of PfPDE with the closest human 
homologue, PDE9A (appendix A4). The aim of this is to attempt to dock XA into the protein 
structure of PfPDE in order to predict whether XA can bind.  
There are several studies in the literature indicating a role for cyclic nucleotide signalling as well 
the release of Ca2+ from internal stores and activation of stage-specific Ca2+-dependent protein 
kinases (CDPKs) at several stages of the parasite life cycle. These are presented in Figure 7.1. 
This schematic demonstrates the importance of these two signalling pathways throughout the 
complex life cycle of the malaria parasite and emphasises the impact that targeting of these 
signalling pathways would have on disruption of the parasite through selective inhibition. 
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Figure 7.1. Schematic presenting the relationship between cyclic nucleotide signalling molecules and 
Ca2+-dependent signalling proteins throughout the parasite lifecycle. 
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7.3. Generation of a PfPDE haemagglutinin-tagged transgenic line for use as a tool to 
study the role of PfPDE in gametocyte stages 
 
Given the interest in PfPDE initiated by data produced by Cathy Taylor (Cathy Taylor, PhD 
thesis, 2007) suggesting that this PfPDE plays an essential role in gametogenesis, and evidence 
presented in this report further indicating its potential importance in gametocyte deformability, 
it was deemed worthwhile to investigate the role of this PfPDE in gametocyte stages further. 
The cellular localisation and cyclic nucleotide specificity of PfPDE has not been documented. In 
order to attempt to produce a tool to address these questions, a triple haemagglutinin (HA) tag 
was introduced at the C-terminal end of PfPDE using the CRISPR Cas9 system in a good 
gametocyte producing line (NF54). This double crossover event was successful and integration 
confirmed by locus-specific PCR.  
Preliminary results using this line to determine the cellular localisation have not shown strong 
staining with an -HA antibody and some background has been seen in control (NF54) samples, 
however fluorescence detected in the wildtype (NF54) -HA antibody control samples was much 
lower than seen in the PfPDEHA line. Interestingly, the faint staining pattern that was observed 
appeared to show similarity to the localisation of Pfg377 which is located in osmiophilic bodies 
which are membrane bound (derived from Golgi vesicles) [288]. PfPDE (which has six predicted 
transmembrane domains and has been detected in membrane fractions of gametocyte lysates, 
and so is predicted to be membrane associated) could be anchored to the membrane with its 
catalytic domain facing the cytosol rather than the lumen of the osmiophilic body, however 
more work needs to be done to confirm the cellular localisation of PfPDE. The use of an 
antibody against the female specific protein Pfg377, which is found in osmiophilic bodies, may 
determine whether the pattern that we see in the PfPDEδ tagged line corresponds with these 
organelles. Osmiophilic bodies are female-specific organelles (or at least very highly enriched in 
females) that increase in number as the gametocyte matures and are associated with the mature 
gametocyte subpellicular membrane and are involved in female gamete egress[288]. If co-
localisation were detected this would be a very exciting result and would indicate that PfPDE 
may play a predominantly female-specific role in gamete egress (as males may contain some 
PfPDEδ). The subpellicular membrane localisation would be interesting in terms of the role 
already established by Ramdani et al[25], for PfPDE in gametocyte infected erythrocyte 
deformability.  
The PfPDE-HA line was successfully used to immunoprecipitate PfPDE protein. This was an 
important result, because it confirmed that this protein is present in mature gametocyte stages 
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despite low levels of immunofluorescence detectable by IFA. It also demonstrated that a good 
amount of protein could be produced using this method. This parasite line is therefore useful 
for future studies requiring PfPDE protein such as XA interaction studies and also for pull down 
assays to determine whether PfPDE-delta exists as part of a signalling protein complex. 
Importantly, a PDE assay carried out on immunoprecipitated HA-tagged PfPDE protein 
demonstrated that PfPDE can only hydrolyse cGMP (this confirmed previous work by Cathy 
Taylor[130]), and provided the first direct measurement of cGMP specificity for this enzyme. No 
cAMP hydrolytic activity was detected in parallel assays which was also in keeping with previous 
work[130].  
 
The possibility of a relationship between XA and PfPDE is an interesting avenue for further 
study. XA showed no significant impact on PfPDE cGMP hydrolytic activity of the 
immunoprecipitated (IP) tagged PfPDE enzyme in a PDE assay. The PDE inhibitor PF9, however, 
reduced the cGMP hydrolytic activity of the IP tagged-PfPDE by ~ 50 %. This preliminary data 
could be suggestive that XA does not directly interact with PfPDE to prevent hydrolysis of cGMP 
(whereas PF9, as expected, does). This may point to an indirect (or one not involving PDE enzyme 
inhibition) association with PfPDE to induce events of gametogenesis and may explain the 
differences seen in XA and zaprinast in terms of the ability to trigger a Ca2+ response. However, 
this requires further investigation.  
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7.4. A role for PfPDE in gametocyte infected erythrocyte deformability 
 
Data presented in this report and in the literature[130], indicate that PfPDE is likely to be a 
cGMP-specific PDE rather than a dual specific enzyme (which is the case for PfPDEβ) as the HA-
tagged protein did not show detectable cAMP hydrolytic activity. Although confirming previous 
work that suggested PfPDEδ might be cGMP specific, this result raises questions concerning the 
published gametocyte-infected erythrocyte deformability data[25], which show elevated cAMP 
(and cGMP) levels in PfPDE-ko line parasite lysates and a role for PfPDE in the deformability 
phenotype. The authors of this study provide data that suggests that the changes in 
deformability are mediated by cAMP signalling and regulation of PKA and indicate using both 
pharmacological and genetic approaches that it is the parasite PKA that likely contributes to this 
response and not the host PKA. If PfPDE is not dual specific and can only hydrolyse cGMP (as 
suggested in this thesis), then it cannot contribute to the deformability response by directly 
hydrolysing cAMP. However, levels of cGMP have been shown by different groups to be elevated 
in this knock out line[25],[130] and it could be conceivable that PfPDE may induce elevated 
levels of cAMP indirectly. Cross talk between the cGMP and cAMP signalling pathways has been 
demonstrated in mammalian cells and there is evidence that in P. falciparum, PfAC is 
phosphorylated in a PKG-dependent manner at S1572[172]. In mature gametocytes of the 
PfPDE-ko line, there is evidence that the absence of PfPDE leads to elevated levels of 
cGMP[130]. It could be hypothesised that activated PKG (as a result of these elevated levels of 
cGMP), may phosphorylate AC leading to elevated levels of cAMP (elevated levels have been 
documented[25]), leading to activation of PKA which phosphorylates proteins involved in 
maintaining a stiff phenotype (see Figure 7.2 scenario B, grey arrows). In immature wildtype 
gametocytes, evidence suggests that PKG is not active (C2 will not block early gametocytes but 
will block gametogenesis in stage V gametocytes). Therefore, the maintenance of a stiff 
phenotype in immature wildtype gametocytes through elevated cAMP levels must be via a non-
PKG-dependent pathway leading to PKA activation. However, when these parasites reach 
maturity at stage V, PfPDE is involved in inducing deformability by indirectly lowering cAMP 
levels and ‘switching off’ PKA through cGMP hydrolysis subsequently reversing the stiff 
phenotype (see Figure 7.2 scenario A, grey arrows). In support of this hypothesis, data in chapter 
4 (section 4.2.3) indicates that a proportion of PfPDE-ko stage V gametocytes were able to 
round up unstimulated when treated with a PKA inhibitor (see Figure 7.2 scenario C, grey 
arrows) and this was reversed completely by PKG-inhibition (see Figure 7.2 scenario D, grey 
arrows). 
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It is thought that protein phosphatases are involved in the dephosphorylation of PKA targets to 
reverse the stiff phenotype of gametocytes when they reach maturity. In fact, the 
serine/threonine phosphatase inhibitor Calyculin A has been shown to prevent the action of 
phosphatases resulting in increased retention rates of mature gametocytes due to a lack of 
deformability[25].  
 
  
      
Figure 7.2. The predicted cell signalling pathways in gametocyte infected erythrocyte deformability and 
gametogenesis. (A). In a wildtype situation, in mature gametocytes, PfPDE is present and active, 
reducing cGMP levels by hydrolysis resulting in no PKG or PKA (indirect) activation (dark grey arrows) 
resulting in deformability. Phosphatases may act to dephosphorylate proteins phosphorylated by PKA to 
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induce stiffness in immature stages. When XA or PF9 is added (orange arrows) PfPDE is inhibited (possibly 
indirectly by XA) leading to elevated levels of cGMP and PKG activation leading to phosphorylation of 
downstream target proteins and the induction of gametogenesis. Downstream proteins still remain 
dephosphorylated maintaining the deformable phenotype. (B). In the PfPDE-ko line, mature 
gametocytes, PfPDE is absent, leading to prematurely elevated levels of cGMP and PKG activation. PKG 
phosphorylates AC leading to increased levels of cAMP and activation of PKA, which phosphorylates 
downstream target proteins, resulting in a stiff phenotype. Elevated levels of PKG, which would usually 
result in both stimulated and unstimulated rounding up in this line is unable to occur due to the lack of 
deformability. (C). When the PKA inhibitor KT5720 is added to PfPDE-ko line mature gametocytes, it 
partially reverses the stiff phenotype by preventing PKA from phosphorylating downstream proteins that 
result in structural events to make the gametocyte infected erythrocytes stiff. This leads to a deformable 
phenotype as seen in the wildtype situation. However, elevated levels of cGMP due to the absence of 
PfPDE in this line lead to PKG activation, which phosphorylates downstream target proteins leading to 
the unstimulated induction of gametogenesis. XA (and PF9) can also further increase numbers of parasites 
undergoing gametogenesis by leading to further elevated levels of cGMP and PKG activation. However, 
rounding up is greatly reduced in the absence of PfPDE, possibly as a result of only females being unable 
to round up in the absence of PfPDE (D). In PKA inhibited PfPDE-ko line parasites treated with the PKG 
inhibitor C2, cells are deformable due to the absence of PKA-induced stiffness (PKA is inhibited). Absence 
of PfPDE leads to elevated levels of cGMP. However PKG cannot phosphorylate downstream target to 
induce rounding up due to inhibition by C2. Gametocytes are therefore unable to round up unstimulated 
or stimulated.  
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7.5. A possible sex-specific role for PfPDE in gametogenesis 
One of the questions addressed in this thesis was whether the defect in rounding up and 
emergence seen in the PfPDE-ko line was due to a cGMP-dependent direct effect on 
gametogenesis (as predicted by Taylor et al[130]), or whether the PfPDE-ko line can simply not 
round up due to the physical restraints imposed on the parasite by PKA-induced stiffness or 
both.  
Studies presented in this report on PfPDE-ko mature gametocytes show that in PfPDE-ko line 
samples only ~ 5 % of parasites will round up in response to XA. This is increased to ~25 % with 
PKA inhibition. XA induction of rounding up in the wildtype line in this experiment was ~ 50 % 
(which was quite low and would normally be expected to be ~80 % in a culture containing mainly 
stage V gametocytes). This indicates that XA-induced rounding up is significantly increased when 
PKA is inhibited. This means that in the absence of PfPDE, ~ 25 % of parasites can still round up 
but that ~ 50 % less can round up compared to the wildtype line in which PfPDE is present. This 
does not rule out a rounding up phenotype in the PfPDE-ko line and an important role of PfPDE 
in gametogenesis, although the absence of PfPDE does not lead to a complete block in rounding 
up. It would be interesting to look at emergence of XA-induced/PKA inhibited PfPDE-ko line 
gametocytes to determine whether the phenotype is at the point of egress as observed by Cathy 
Taylor[130], rather than at the rounding up stage as observed here. It must be noted that these 
parasites may have been disrupted due to prolonged elevated levels of both cyclic nucleotides 
and as such are not competent to undergo gametogenesis. Viability assays would be required to 
determine this and a conditional knockout line of PfPDE would be a useful tool to investigate 
the function of PfPDE in gametogenesis without the issue of viability of the line. In such a line, 
excision of the gene encoding PfPDE both early (to look at deformability) and late (to look at 
gametogenesis) may help to dissect these two separate events and the involvement of PfPDE. 
It would also be of interest to look at other events of gametogenesis such as exflagellation and 
Ca2+ release in XA-induced/PKA inhibited PfPDE-ko line gametocytes. In addition to this, 
retention rates/deformability of the PfPDE-ko line in the presence and absence of KT5720 
would indicate the percentage change in retention (which is expected to reduce significantly as 
seen in KT5720 treated immature gametocytes[25] when PKA is inhibited. This will be important 
to check the reason that the remaining parasites that will not round up in response to XA, to 
eliminate the possibility that a large percentage of parasites still remain stiff.  
The fact that only 15 % - 25 % of PfPDE-ko line gametocytes treated with PKA will round up in 
response to XA or PF9 treatment may indicate a sex specific involvement. This is particularly 
interesting in light of the IFA results, which although preliminary, show a staining pattern that 
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exhibits similarity to the localisation of Pf377 in osmiophilic bodies. This would suggest a female-
specific role for PfPDE in egress and would account for the ~85 % to 75 % population of PKA-
treated PfPDE-ko line gametocytes that will still not round up in response to PF9 or XA (the 15 
% - 25 % of gametocytes that can round up would be expected to be males which presumably 
would not require the presence of PfPDE but are able to round up when the stiff phenotype is 
reversed by PKA inhibition). It would be very interesting to use antibodies to sex-specific 
proteins such as Pfg377 and -tubulin in these assays to investigate this. Interestingly, work on 
PfPKG carried out by Christine Hopp, LSHTM (Christine Hopp, PhD Thesis 2011) using a rabbit α-
human PKG antibody (that reacts strongly with PfPKG but not with human red cell PKG) showed 
that in gametocytes, PfPKG also exhibits a similar pattern of fluorescence to that of PfPDE 
presented in this thesis. This is extremely interesting and could indicate that PfPKG and PfPDE 
may form part of a complex that is localised to osmiophilic bodies in mature gametocyte stages. 
Interestingly, the protease subtilisin 2 (PfSUB2) has also been shown to localise to the 
osmiophilic bodies in female gametocytes[295]. In schizont stages the related PfSUB1, is a key 
player in merozoite egress[220] and is released from specialised organelles called exonemes in 
a PKG-dependent manner. It is tempting to speculate that PfSUB2 might be released from the 
osmiophilic bodies in a PKG-dependent manner in mature gametocytes to induce egress.  
 There may also be a sex-specific role in the release of Ca2+ in response to XA and zaprinast. This 
would be interesting to explore. It may be that the possible PKG specificity and non-PKG 
specificity of the Ca2+ response seen in gametocytes may reflect the different responses in male 
and female gametocytes. It would be very interesting to carry out Ca2+ release assays on 
separated male and female gametocytes to see whether the Ca2+ response to XA and zaprinast 
differs. Given the possibility that PfPDE may be specific to females, the lack of a XA-induced 
Ca2+ response in the PfPDE-ko line may be due to the fact that without PfPDE, female 
gametocytes are unable to respond to XA and as the concentration of XA used was very low, it 
may be that the male response (which may require PfPDEα) is undetectable in that assay. A 
caveat to the sex-specific theory is that the absence of PfPDE results in a greatly reduced 
number of exflagellation events in XA-treated samples[130]. This indicates that PfPDE is likely 
required for the majority of XA-induced exflagellation. However, exflagellation is a Ca2+-
dependent event and this may be explained possibly by a female involvement (through PfPDE) 
in the Ca2+ response required to initiate exflagellation.   
 
Given what we know about the involvement of cGMP and PKG in gametogenesis, the expected 
phenotype of PfPDEδ-ko mature gametocytes would be unstimulated or premature rounding 
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up/gametogenesis (rather than an absence of rounding up/gametogenesis). This is because, in 
the absence of PfPDEδ (presuming that there is no stiff phenotype preventing cells from 
physically rounding up), the elevated levels of cGMP induced by the absence of PfPDEδ would 
lead to activation of PKG and subsequent rounding up and emergence. The observation that a 
small proportion of parasites rounded up un-stimulated in PKA-treated PfPDEδ-ko gametocyte 
cultures is very interesting and supports this as in the absence of PKA inhibition, it is likely that 
parasites cannot physically round up due to PKA-induced stiffness. The fact that we don’t see 
this premature rounding up phenotype in the PfPDEδ-ko line (with no PKA inhibition) supports 
this. A conditional knockout line of PfPDE as suggested above would be a very useful tool to 
determine whether the real phenotype is one of premature rounding up/egress. In a conditional 
knockout line, removal of PfPDE at stage V (in the presence of a PKA inhibitor) may be expected 
to result in un-stimulated rounding up of gametocytes as soon as they reach maturity (when the 
appropriate cell signalling components are ready) and as such, greatly reduced numbers of stage 
V gametocytes would be expected to be observed in cultures (see Figure 7.2 for a schematic). 
This is what is seen with pharmacological inhibition of PDEs in wildtype mature gametocyte 
stages, for example the addition of PF9 (discussed below) will induce rounding up of mature 
gametocytes within 5 minutes of addition and this is what would be hypothesised to happen in 
the unstimulated PfPDE-ko line. This hypothesis presumes that PfPDE is the predominant PDE 
involved in gametogenesis (because if it is female specific so a larger proportion of the 
gametocyte population is dependent upon this protein for gametogenesis to occur). The 
observation that XA can induce rounding up (at low levels) in the PfPDE-ko line may reflect the 
male population that may be able to round up in response to XA stimulation in the absence of 
PfPDE (possibly through PfPDEα hydrolysis of cGMP).   
 
Data using the PDE inhibitor PF9 supports a theory for PfPDE being the predominant PDE 
involved in gametogenesis (discussed below). It may be that another PfPDE is involved or can 
partly compensate for the absence of PfPDE and respond to XA by inducing a small number of 
cells to round up or it may be that another PfPDE for example PfPDE (the only other PDE 
expressed at the protein level in gametocytes) may be required for male gametogenesis while 
PfPDE is required for female gametogenesis. This hypothesis suggesting a sex-specific role for 
PDEs in gametogenesis is supported by proteomic data, which detected more PfPDE protein in 
mature male gametocytes than mature female gametocytes[144] and this hypothesis would also 
be strengthened by confirmation of an osmiophilic body localisation for PfPDE. However, this 
hypothesis is very speculative and requires further experimental confirmation.  
247 
 
 
 
7.6. The Pfizer human PDE inhibitor, PF9, as a gametocytocidal compound 
Data presented in this thesis have shown gametocytocidal activity in a human PDE inhibitor 
obtained from Pfizer, PF9, and demonstrated that this compound specifically kills mature 
gametocyte stages and not immature stages. Further investigation revealed that PF9 acts by 
inducing gametogenesis. Furthermore, this compound was shown to act quickly (within 5 
minutes) and in a PfPKG-dependent manner and interestingly, appeared to not be active against 
PfPDE-ko line gametocytes (as assessed by their ability to round up, emerge and disappear over 
time) but showed greatest activity in the absence of PfPDE. The hypothesis generated for this 
result is that the main PDE required for the process of gametogenesis (possible in females only) 
is PfPDE (PF9 is predicted to target all PfPDEs). In a wildtype situation when both PfPDE and 
PfPDE are present in gametocytes, PF9 will bind to both PDEs. This leaves less available 
compound to target PfPDE. However, when PfPDE is absent, a lower concentration is required 
to inhibit the parasite, as the only target present is PfPDE. This initial interpretation of the data 
(that PfPDE was the primary target for PF9), was questioned by data in Chapter 4 that has 
strongly suggested that this transgenic line is unable to complete the physical action of rounding 
up due to PKA-induced stiffness and this led to a re-evaluation of the initial interpretation. The 
observations that a small (~ 25 %) number of PfPDE-ko line parasites could round up when 
stimulated with PF9 (with PKA inhibition) rather that a large number rounding up, and the 
possible localisation of PfPDE to the osmiophilic bodies suggests that this ratio of rounded up 
parasites may reflect the male population and that the majority of parasites cannot round up, 
not because PfPDE is the main target, but because the majority of gametocytes are female 
(reflecting a predicted sex ration of 4:1) and absence of PfPDE prevents this larger proportion 
of the population from rounding up. PF9 targeting of the PfPDE-ko line would presumably 
inhibit PfPDE (as it is predicted to target all PDEs) and this would lead to gametogenesis in male 
gametocytes. It would be interesting to use antibodies against sex specific markers in the 
PfPDE-ko line in the presence and absence of PKA inhibition to determine the sex specificity of 
gametocytes that will round up in the absence of PfPDE both in the presence and absence of 
PKA inhibitors.  
PF9 also induced Ca2+ mobilisation in 3D7a stage V gametocytes and induced high levels of Ca2+ 
compared to XA or zaprinast at the concentrations used. This coupled with the observation that 
exflagellation was also stimulated by PF9 in wildtype mature gametocytes was further 
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confirmation that this compound induced more than one essential event of gametogenesis and 
that its inhibitory effects were via stimulation of the pathway required for gametogenesis.  
 
 
The premature initiation of gametogenesis in the human host would be an excellent strategy to 
block transmission, as emerged gametes would not survive long in the host blood stream and as 
such the life cycle would be cut short with no progression through the insect stages. As predicted 
for zaprinast, it is thought that PF9 may bypass the natural trigger of gametogenesis. It is likely 
that XA induces gametogenesis via an upstream event that causes activation of GCs or inhibition 
of PDEs leading to elevated levels of cGMP and PKG activation. Data in this thesis point towards 
the inhibition of PDEs in the XA-induced response, rather than GC activation. 
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7.7. General summary of discussion 
Overall, data in this thesis strongly suggest that in line with previous work[130], PfPDE is still 
likely to be an important PDE involved in gametogenesis; however, more work needs to be done 
to confirm whether its absence impacts on two distinct events during sexual development (one 
in the human hosts and one in the insect vector).There is a possible indication that this PDE 
could play a sex-specific role in female gametogenesis. The discovery of a compound that will 
target PfPDEs and inhibit transmission stages by prematurely induce gametogenesis is an 
exciting result.  
One of the target product profiles outlined by MMV in a proposal to optimise malaria control 
efforts in 2013 was a product with activity against asexual blood stages in combination with a 
second product to target the transmission stages[68],[67]. PF9 is an example of a compound that 
can do both. PF9 can target asexual blood stage PDEs (PfPDE) to disrupt invasion and early ring 
stages (cell cycle progression) and transmission stage PDEs (PfPDE) to prevent the essential 
transmission event. Not only this, but it would be predicted to also prevent the deformability of 
mature gametocyte-infected erythrocytes increasing splenic clearance of circulating 
gametocytes. PfPDEα and PfPDEδ are both predicted, based on evidence in this thesis, to be 
involved in gametogenesis. PF9 is known to target both. This means that despite the predicted 
sex specificity of PfPDEδ, PF9 can kill both male and female gametocytes by inducing premature 
gametogenesis.  PfPDEs are novel targets because none of the current antimalarials target PDEs 
and so resistant parasite populations would be expected to be fully sensitive to a PDE inhibitor. 
Plans are currently underway in the Baker group at LSHTM (grant application submitted), partly 
based on data from this thesis, in partnership with Salvensis and MMV to optimise the PF9 
chemical series to provide in vivo proof of concept for PfPDEs as antimalarial targets.  
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